https://psychedelicinvest.com/ https://psychedelicinvest.com/news/ https://psychedelicinvest.com/public-psychedelic-companies/ https://psychedelicinvest.com/stock-index/ https://psychedelicinvest.com/thank-you/ https://psychedelicinvest.com/end-of-year-survey/ https://psychedelicinvest.com/psycedelics/ https://psychedelicinvest.com/mindshift/ https://psychedelicinvest.com/hotseat/ https://psychedelicinvest.com/disclaimer/ https://psychedelicinvest.com/next-titan-capital-event/ https://psychedelicinvest.com/hotseat-episode-1/ https://psychedelicinvest.com/sit-in-the-hotseat/ https://psychedelicinvest.com/register-for-the-investor-hot-seat/ https://psychedelicinvest.com/podcast/ https://psychedelicinvest.com/membership-join/ https://psychedelicinvest.com/pro/ https://psychedelicinvest.com/legal-landscape-report/ https://psychedelicinvest.com/research-organizations-report/ https://psychedelicinvest.com/educational-organizations-report/ https://psychedelicinvest.com/medicinal-treatments-report/ https://psychedelicinvest.com/public-companies-report/ https://psychedelicinvest.com/nonprofits-report-2/ https://psychedelicinvest.com/nonprofits-report/ https://psychedelicinvest.com/organizations-report/ https://psychedelicinvest.com/venture-capital-report/ https://psychedelicinvest.com/jobs-report/ https://psychedelicinvest.com/clinical-trials-report/ https://psychedelicinvest.com/showcase/ https://psychedelicinvest.com/coming-soon-podcast/ https://psychedelicinvest.com/subscribe/ https://psychedelicinvest.com/writer-analyst/ https://psychedelicinvest.com/educational-organizations/ https://psychedelicinvest.com/non-profits/update-details/ https://psychedelicinvest.com/non-profits/ https://psychedelicinvest.com/psychedelic-legalization-guide/ https://psychedelicinvest.com/most-influential-people-psychedelics-2021/ https://psychedelicinvest.com/psychedelic-law-firms/ https://psychedelicinvest.com/jobs/ https://psychedelicinvest.com/contact/ https://psychedelicinvest.com/private-companies/ https://psychedelicinvest.com/thank-you-for-downloading-our-investor-guidebook/ https://psychedelicinvest.com/terms-of-use/ https://psychedelicinvest.com/about/ https://psychedelicinvest.com/psychedelic-investors/ https://psychedelicinvest.com/events/ https://psychedelicinvest.com/privacy-policy/ https://psychedelicinvest.com/psychedelic-news/press/ https://psychedelicinvest.com/psychedelic-news/market-research/ https://psychedelicinvest.com/psychedelic-news/blog/ https://psychedelicinvest.com/psychedelic-news/lifestyle/ https://psychedelicinvest.com/psychedelic-news/news/ https://psychedelicinvest.com/psychedelic-news/interviews/ https://psychedelicinvest.com/psychedelic-news/health-science/ https://psychedelicinvest.com/psychedelic-news/podcast/ https://psychedelicinvest.com/psychedelic-news/video/ https://psychedelicinvest.com/psychedelic-news/pro/ https://psychedelicinvest.com/psychedelic-news/laws/ https://psychedelicinvest.com/psychedelic-news/business/ https://psychedelicinvest.com/psychedelic-news/mindshifting-moments/ https://psychedelicinvest.com/psychedelic-news/investor-hotseat/ https://psychedelicinvest.com/psychedelic-news/weekly-extractions/ https://psychedelicinvest.com/psychedelic-news/bullish-vs-bearish/ https://psychedelicinvest.com/psychedelic-news/showcase/ https://psychedelicinvest.com/companies/aion-therapeutic-inc/ https://psychedelicinvest.com/companies/albert-labs/ https://psychedelicinvest.com/companies/algernon-pharmaceuticals/ https://psychedelicinvest.com/companies/allied-corp/ https://psychedelicinvest.com/companies/atai-life-sciences/ https://psychedelicinvest.com/companies/awakn-life-sciences/ https://psychedelicinvest.com/companies/better-plant-sciences/ https://psychedelicinvest.com/companies/betterlife-pharma-inc/ https://psychedelicinvest.com/companies/biomind-labs/ https://psychedelicinvest.com/companies/blackhawk-growth-corp/ https://psychedelicinvest.com/companies/braxia-scientific/ https://psychedelicinvest.com/companies/bright-minds-biosciences/ https://psychedelicinvest.com/companies/captiva-verde/ https://psychedelicinvest.com/companies/clearmind/ https://psychedelicinvest.com/companies/compass-pathways/ https://psychedelicinvest.com/companies/core-one-labs/ https://psychedelicinvest.com/companies/creso-pharma-limited/ https://psychedelicinvest.com/companies/cure-pharmaceutical/ https://psychedelicinvest.com/companies/cybin-inc/ https://psychedelicinvest.com/companies/cypher-metaverse/ https://psychedelicinvest.com/companies/delic-corp/ https://psychedelicinvest.com/companies/egf-theramed-health/ https://psychedelicinvest.com/companies/ehave/ https://psychedelicinvest.com/companies/empower-clinics/ https://psychedelicinvest.com/companies/entheon-biomedical/ https://psychedelicinvest.com/companies/enveric-biosciences/ https://psychedelicinvest.com/companies/enveric-biosciences-2/ https://psychedelicinvest.com/companies/field-trip-health/ https://psychedelicinvest.com/companies/filament-health/ https://psychedelicinvest.com/companies/gh-research/ https://psychedelicinvest.com/companies/goodness-growth-holdings/ https://psychedelicinvest.com/companies/graph-blockchain/ https://psychedelicinvest.com/companies/havn-life-sciences/ https://psychedelicinvest.com/companies/high-fusion-inc/ https://psychedelicinvest.com/companies/hollister-biosciences/ https://psychedelicinvest.com/companies/irwin-naturals-inc/ https://psychedelicinvest.com/companies/lattice-biologics/ https://psychedelicinvest.com/companies/levitee-labs/ https://psychedelicinvest.com/companies/lobe-sciences/ https://psychedelicinvest.com/companies/m2bio-sciences-inc/ https://psychedelicinvest.com/companies/mind-cure-health-inc/ https://psychedelicinvest.com/companies/mindmed/ https://psychedelicinvest.com/companies/mindset-pharma/ https://psychedelicinvest.com/companies/mydecine/ https://psychedelicinvest.com/companies/mynd-life-sciences-inc/ https://psychedelicinvest.com/companies/neonmind-biosciences/ https://psychedelicinvest.com/companies/new-wave-holdings/ https://psychedelicinvest.com/companies/nirvana-life-sciences/ https://psychedelicinvest.com/companies/nova-mentis-life-science-corp/ https://psychedelicinvest.com/companies/novamind-inc/ https://psychedelicinvest.com/companies/numinus/ https://psychedelicinvest.com/companies/nutritional-high-international/ https://psychedelicinvest.com/companies/optimi-health/ https://psychedelicinvest.com/companies/optimind-pharma-corp/ https://psychedelicinvest.com/companies/origin-therapeutics-holdings-inc/ https://psychedelicinvest.com/companies/pasithea/ https://psychedelicinvest.com/companies/pharmadrug/ https://psychedelicinvest.com/companies/pharmala-biotech/ https://psychedelicinvest.com/companies/pharmather-inc/ https://psychedelicinvest.com/companies/psybio-therapeutics/ https://psychedelicinvest.com/companies/psyc-corporation/ https://psychedelicinvest.com/companies/psyched-wellness-ltd/ https://psychedelicinvest.com/companies/psyence-group/ https://psychedelicinvest.com/companies/red-light-holland/ https://psychedelicinvest.com/companies/relmada-therapeutics-inc/ https://psychedelicinvest.com/companies/reunion-neuroscience/ https://psychedelicinvest.com/companies/revitalist/ https://psychedelicinvest.com/companies/revive-therapeutics/ https://psychedelicinvest.com/companies/roadman-investments/ https://psychedelicinvest.com/companies/seelos-therapeutics/ https://psychedelicinvest.com/companies/silo-pharma/ https://psychedelicinvest.com/companies/silo-wellness-inc/ https://psychedelicinvest.com/companies/small-pharma/ https://psychedelicinvest.com/companies/thoughtful-brands/ https://psychedelicinvest.com/companies/tryp-therapeutics/ https://psychedelicinvest.com/companies/universal-ibogaine-inc/ https://psychedelicinvest.com/companies/wellbeing-digital/ https://psychedelicinvest.com/companies/wesana-health/ https://psychedelicinvest.com/companies/wuhan-general-group/ https://psychedelicinvest.com/companies/yourway-cannabis-brands/ https://psychedelicinvest.com/algernon-to-acquire-nobrainer-imaging-centers-inc-plans-to-establish-alzheimers-diagnostic-and-treatment-medical-clinics-featuring-new-pet-scan-technology/2025-07-07T20:43:44.000Z https://psychedelicinvest.com/atai-life-sciences-announces-first-patient-dosed-in-phase-2-study-of-emp-01-for-the-treatment-of-social-anxiety-disorder/2025-07-07T20:42:13.000Z https://psychedelicinvest.com/revive-therapeutics-provides-update-on-research-study-evaluating-bucillamine-for-nerve-agent-exposure-4/2025-07-07T20:40:31.000Z https://psychedelicinvest.com/scisparc-clearmind-collaboration-leads-to-publication-of-european-patent-for-psychedelic-based-combination-therapy-for-cocaine-addiction/2025-07-07T20:38:29.000Z https://psychedelicinvest.com/optimi-health-corp-obtains-u-s-fda-drug-establishment-registration/2025-07-07T20:37:05.000Z https://psychedelicinvest.com/neural-therapeutics-announces-serfor-permit-renewal-submission-and-extension-of-loi-with-hanf-com/2025-07-07T20:35:26.000Z https://psychedelicinvest.com/filament-health-announces-first-quarter-2025-financial-results-and-operational-highlights/2025-07-07T19:26:16.000Z https://psychedelicinvest.com/cybin-announces-additional-u-s-patent-supporting-its-cyb003-breakthrough-therapy-program-in-phase-3-development-for-major-depressive-disorder/2025-07-07T19:24:35.000Z https://psychedelicinvest.com/optimi-health-completes-largest-to-date-mdma-export-to-australia-for-ptsd-therapy/2025-07-07T19:22:55.000Z https://psychedelicinvest.com/compass-pathways-announces-first-quarter-2025-financial-results-and-business-highlights/2025-06-05T18:13:50.000Z https://psychedelicinvest.com/mindbio-issues-restricted-stock-units/2025-06-05T18:12:01.000Z https://psychedelicinvest.com/optimi-health-obtains-u-s-fda-drug-establishment-registration/2025-06-05T18:08:38.000Z https://psychedelicinvest.com/mydecine-innovations-group-provides-update-on-annual-financial-statements/2025-05-28T20:48:42.000Z https://psychedelicinvest.com/psyence-biomed-announces-effective-date-for-1-for-7-97-reverse-stock-split/2025-05-28T20:25:21.000Z https://psychedelicinvest.com/cybin-to-participate-at-the-28th-annual-milken-institute-global-conference/2025-05-28T20:23:08.000Z https://psychedelicinvest.com/silo-pharmas-sp-26-ketamine-implant-meets-all-endpoints-in-fibromyalgia-study/2025-04-30T19:12:35.000Z https://psychedelicinvest.com/pharmala-issues-q2-financial-statements/2025-04-30T19:11:09.000Z https://psychedelicinvest.com/compass-pathways-establishes-strategic-collaboration-with-healthport-to-inform-the-potential-delivery-of-comp360-synthesized-psilocybin-treatment-in-underserved-communities/2025-04-30T19:08:37.000Z https://psychedelicinvest.com/scisparc-clearmind-collaboration-leads-to-filing-of-international-patent-application-for-novel-treatment-of-anorexia-bulimia-and-other-eating-disorders/2025-04-30T19:05:09.000Z https://psychedelicinvest.com/clearmind-medicine-completes-the-initiation-of-its-alcohol-use-disorder-phase-i-iia-clinical-trial-at-all-current-clinical-sites/2025-04-23T17:56:33.000Z https://psychedelicinvest.com/cybin-announces-additional-strategic-clinical-site-partnerships-to-support-paradigm-a-multinational-phase-3-program-evaluating-cyb003/2025-04-23T17:54:48.000Z https://psychedelicinvest.com/revive-therapeutics-announces-proposed-shares-for-debt-transaction/2025-04-23T17:53:02.000Z https://psychedelicinvest.com/clearmind-medicine-to-host-live-webinar-gazing-through-the-crystal-ball-featuring-leading-psychedelic-experts/2025-04-23T17:49:10.000Z https://psychedelicinvest.com/awakn-life-sciences-provides-update-on-rd-programs-progressing-novel-therapeutics-for-alcohol-use-disorder-and-ptsd/2025-04-23T17:46:06.000Z https://psychedelicinvest.com/cybin-partners-with-osmind-to-accelerate-commercial-preparation-for-its-clinical-stage-psychiatry-programs/2025-04-23T17:28:12.000Z https://psychedelicinvest.com/psyence-biomed-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency/2025-04-23T17:26:04.000Z https://psychedelicinvest.com/psyence-group-announces-share-consolidation/2025-04-23T17:20:49.000Z https://psychedelicinvest.com/clearmind-medicine-receives-notice-of-allowance-for-united-states-patent-covering-binge-behavior/2025-04-23T17:19:01.000Z https://psychedelicinvest.com/clearmind-medicine-launches-first-u-s-clinical-site-for-its-fda-approved-clinical-trial-to-combat-alcoholism/2025-04-23T17:16:50.000Z https://psychedelicinvest.com/psyence-biomed-announces-usd500000-follow-on-investment-in-psylabs-and-global-ibogaine-supply-agreement/2025-04-23T17:15:08.000Z https://psychedelicinvest.com/mindmed-announces-first-patient-dosed-in-phase-3-emerge-study-of-mm120-in-major-depressive-disorder-mdd/2025-04-23T17:12:41.000Z https://psychedelicinvest.com/neural-therapeutics-strengthens-ip-portfolio-with-a-patent-application/2025-04-23T17:10:28.000Z https://psychedelicinvest.com/mindbio-therapeutics-corp-announces-private-placement-and-debt-settlements/2025-04-23T17:02:16.000Z https://psychedelicinvest.com/clearmind-medicine-announces-first-u-s-clinical-site-initiation-for-cmnd-100-clinical-trial-in-patients-with-alcohol-use-disorder/2025-04-23T16:59:09.000Z https://psychedelicinvest.com/revive-therapeutics-to-investigate-bucillamines-potential-in-cancer-treatment/2025-04-23T16:49:07.000Z https://psychedelicinvest.com/tryptamine-therapeutics-to-launch-groundbreaking-trial-for-binge-eating-disorder-treatment/2025-04-23T16:45:16.000Z https://psychedelicinvest.com/filament-health-announces-fda-authorization-of-phase-2-clinical-trial-studying-pex010-the-companys-botanical-psilocybin-drug-candidate-in-opioid-use-disorder/2025-04-23T16:43:17.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-receives-notice-of-allowance-from-european-patent-office-for-repirinast-for-kidney-disease/2025-04-15T19:16:49.000Z https://psychedelicinvest.com/clearmind-medicine-announces-the-publication-of-international-patent-application-for-next-gen-psychedelic-compounds-to-treat-mental-health-disorders/2025-04-15T19:14:52.000Z https://psychedelicinvest.com/psyence-biomed-signs-loi-with-southern-star-research-to-expand-phase-iib-clinical-trial-in-australia/2025-04-15T19:04:36.000Z https://psychedelicinvest.com/mindbio-issues-warrants-to-haywood-securities/2025-04-15T18:36:05.000Z https://psychedelicinvest.com/mindbio-adopts-new-equity-incentive-plan/2025-04-03T13:41:06.000Z https://psychedelicinvest.com/revive-therapeutics-announces-acquisition-of-molecular-hydrogen-program/2025-04-03T13:37:59.000Z https://psychedelicinvest.com/clearmind-launches-its-edc-system-to-support-its-phase-i-ii-clinical-trial-of-its-meai-based-treatment/2025-04-03T13:35:03.000Z https://psychedelicinvest.com/corporate-update-psyence-biomedical-ltd-redefines-psychedelic-medicine-with-a-multi-asset-strategy-advancing-clinical-trials-and-scalable-manufacturing/2025-04-03T13:33:32.000Z https://psychedelicinvest.com/filament-health-reports-q4-and-year-end-2024-financial-results-and-operational-highlights/2025-04-03T13:29:20.000Z https://psychedelicinvest.com/neural-therapeutics-commences-trading-on-frankfurt-stock-exchange/2025-04-03T13:26:05.000Z https://psychedelicinvest.com/mindbio-acquires-life-ai-corp-pty-ltd/2025-04-03T13:19:59.000Z https://psychedelicinvest.com/mydecine-innovations-group-announces-strategic-board-and-management-changes/2025-04-03T13:18:12.000Z https://psychedelicinvest.com/pharmala-contracts-with-partner-to-act-as-us-distributor/2025-04-03T13:15:16.000Z https://psychedelicinvest.com/clearmind-medicines-fda-approved-clinical-trial-for-cmnd-100-moves-forward-as-drug-arrives-in-the-u-s-advancing-toward-key-milestones/2025-04-03T13:11:48.000Z https://psychedelicinvest.com/pharmala-completes-shipment-of-laneo-mdma-to-the-university-of-washington/2025-03-27T16:59:15.000Z https://psychedelicinvest.com/revive-therapeutics-announces-results-of-annual-shareholder-meeting/2025-03-27T16:28:34.000Z https://psychedelicinvest.com/clearmind-to-evaluate-intranasal-delivery-of-its-psychedelic-drug-combination/2025-03-27T16:27:27.000Z https://psychedelicinvest.com/red-light-holland-appoints-michael-galloro-to-board-of-directors/2025-03-27T16:25:22.000Z https://psychedelicinvest.com/psyence-biomed-further-strengthens-scientific-advisory-board-with-appointment-of-dr-dan-j-stein/2025-03-27T16:24:05.000Z https://psychedelicinvest.com/clearmind-medicine-announces-initiation-of-first-in-human-clinical-trial-with-cmnd-100-in-alcohol-use-disorder-patients/2025-03-27T16:20:22.000Z https://psychedelicinvest.com/atai-life-sciences-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-corporate-highlights/2025-03-27T16:18:05.000Z https://psychedelicinvest.com/numinus-approved-as-a-state-certified-natural-medicine-training-program-in-colorado/2025-03-27T16:13:22.000Z https://psychedelicinvest.com/neural-therapeutics-commences-trading-provides-update-on-growth-initiatives-and-engages-investor-relations-consultants/2025-03-20T20:41:15.000Z https://psychedelicinvest.com/mindmed-appoints-matt-wiley-as-chief-commercial-officer/2025-03-20T20:37:55.000Z https://psychedelicinvest.com/filament-health-announces-positive-data-from-phase-2-study-of-pex010-in-patients-with-alcohol-use-disorder/2025-03-20T20:36:09.000Z https://psychedelicinvest.com/psyched-wellness-provides-comprehensive-investor-update/2025-03-20T20:32:59.000Z https://psychedelicinvest.com/polyrizon-signs-non-binding-loi-to-expand-its-innovative-intranasal-drug-delivery-platform-for-psychedelic-based-treatments/2025-03-20T20:31:43.000Z https://psychedelicinvest.com/optimi-health-provides-corporate-update-2/2025-03-20T20:30:30.000Z https://psychedelicinvest.com/atai-life-sciences-announces-first-patient-dosed-in-elumina-the-phase-2-clinical-trial-of-vls-01-for-treatment-resistant-depression/2025-03-20T20:27:30.000Z https://psychedelicinvest.com/clearmind-medicine-announces-publication-of-patent-for-cocaine-addiction-psychedelic-combination-treatment-in-south-korea/2025-03-20T20:24:56.000Z https://psychedelicinvest.com/pharmala-signs-duchefa-farma-as-exclusive-distributor-in-netherlands/2025-03-20T20:21:40.000Z https://psychedelicinvest.com/psyence-groups-nasdaq-listed-associate-psyence-biomedical-names-albert-p-garcia-romeu-ph-d-as-chair-of-its-newly-created-scientific-advisory-board/2025-03-11T20:43:11.000Z https://psychedelicinvest.com/netcapital-to-host-planned-reg-a-offering-by-algernon-neuroscience/2025-03-11T18:10:45.000Z https://psychedelicinvest.com/mindmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-updates/2025-03-11T18:09:05.000Z https://psychedelicinvest.com/algernon-neuroscience-engages-netcapital-securities-for-planned-regulation-a-financing/2025-03-11T18:06:42.000Z https://psychedelicinvest.com/pharmala-completes-shipment-of-laneo-mdma-to-ucla-for-schizophrenia-study/2025-03-11T18:04:29.000Z https://psychedelicinvest.com/revive-therapeutics-announces-loi-to-acquire-diagnameds-molecular-hydrogen-program/2025-03-11T18:02:20.000Z https://psychedelicinvest.com/pharmala-to-supply-strong-star-at-ut-health-san-antonio-with-novel-dosage-form-of-laneo-mdma/2025-03-11T18:00:44.000Z https://psychedelicinvest.com/enveric-biosciences-ceo-issues-letter-to-shareholders/2025-03-11T17:58:23.000Z https://psychedelicinvest.com/psyence-biomed-names-albert-p-garcia-romeu-ph-d-as-chair-of-its-newly-created-scientific-advisory-board/2025-03-11T17:56:20.000Z https://psychedelicinvest.com/numinus-wellness-inc-announces-cfo-transition/2025-03-11T17:47:03.000Z https://psychedelicinvest.com/revitalist-announces-filing-of-audited-financial-statements-for-the-year-ended-december-31-2022-and-provides-update-on-cease-trade-order/2025-03-11T17:39:26.000Z https://psychedelicinvest.com/atai-life-sciences-announces-completion-of-enrollment-in-phase-2b-clinical-trial-evaluating-bpl-003-for-treatment-resistant-depression/2025-03-08T20:20:11.000Z https://psychedelicinvest.com/numinus-wellness-inc-announces-strategic-wind-down-of-non-operating-subsidiaries/2025-02-14T22:15:14.000Z https://psychedelicinvest.com/atai-life-sciences-announces-proposed-public-offering-of-common-shares/2025-02-12T21:54:03.000Z https://psychedelicinvest.com/algernon-neuroscience-appoints-globally-recognized-dmt-researcher-and-clinician-dr-sandor-nardai-as-principal-investigator-for-planned-phase-2a-dmt-human-stroke-study/2025-02-12T21:53:01.000Z https://psychedelicinvest.com/cybin-reports-third-quarter-fiscal-year-2025-financial-results-and-recent-business-highlights/2025-02-12T21:51:37.000Z https://psychedelicinvest.com/clearmind-medicine-announces-publication-of-patent-for-binge-behavior-psychedelic-combination-treatment-in-mexico/2025-02-07T16:02:10.000Z https://psychedelicinvest.com/algernon-neuroscience-appoints-validcare-as-cro-for-its-phase-2a-dmt-human-stroke-trial-and-announces-validcares-usd-170k-equity-investment/2025-02-07T15:58:41.000Z https://psychedelicinvest.com/pharmala-signs-advisory-agreement-with-mr-matthew-azrieli/2025-02-07T15:56:08.000Z https://psychedelicinvest.com/revive-therapeutics-announces-update-on-rd-focus-on-bucillamine-for-infectious-diseases-and-medical-countermeasures/2025-02-07T15:52:47.000Z https://psychedelicinvest.com/mindmed-announces-first-patient-dosed-in-panorama-the-second-pivotal-phase-3-study-of-mm120-in-generalized-anxiety-disorder/2025-01-31T20:55:28.000Z https://psychedelicinvest.com/enveric-biosciences-receives-notice-of-allowance-for-lead-drug-candidate-eb-003-from-united-states-patent-and-trademark-office/2025-01-31T20:53:48.000Z https://psychedelicinvest.com/numinus-wellness-announces-cease-trade-order-and-provides-corporate-update/2025-01-31T20:52:23.000Z https://psychedelicinvest.com/optimi-health-completes-largest-mdma-capsule-batch-to-date-expands-stability-program/2025-01-31T20:50:34.000Z https://psychedelicinvest.com/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-execute-agreement-for-27-million-funding-transaction-for-hope-clinic-acquisition/2025-01-31T20:49:04.000Z https://psychedelicinvest.com/optimi-health-announces-closing-of-non-brokered-private-placement-and-debt-settlement/2025-01-31T20:46:49.000Z https://psychedelicinvest.com/mindbio-announces-successful-outcome-of-mandatory-independent-safety-audit-in-phase-2b-clinical-trials/2025-01-28T18:40:25.000Z https://psychedelicinvest.com/atai-life-sciences-announces-positive-topline-results-from-beckley-psytechs-bpl-003-intranasal-5-meo-dmt-benzoate-phase-2a-open-label-study-for-alcohol-use-disorder/2025-01-28T18:38:57.000Z https://psychedelicinvest.com/entheon-announces-agreement-to-acquire-mentis-ai/2025-01-24T19:08:02.000Z https://psychedelicinvest.com/numinus-wellness-announces-corporate-update/2025-01-24T19:05:42.000Z https://psychedelicinvest.com/red-light-holland-appoints-keith-li-as-chief-financial-officer-and-provides-corporate-updates/2025-01-24T19:03:37.000Z https://psychedelicinvest.com/mindbio-announces-major-diagnostic-speech-discovery/2025-01-24T18:59:57.000Z https://psychedelicinvest.com/filament-health-announces-shipment-of-botanical-psilocybin-to-the-university-of-wisconsin-madison/2025-01-24T18:54:06.000Z https://psychedelicinvest.com/rua-bioscience-announces-support-for-clinical-study-that-harnesses-the-potential-of-psilocybin-containing-mushrooms-to-treat-methamphetamine-addiction/2025-01-24T18:45:32.000Z https://psychedelicinvest.com/awakn-announces-positive-outcome-of-pre-ind-meeting-with-fda-for-awkn-002-in-alcohol-use-disorder/2025-01-24T18:44:02.000Z https://psychedelicinvest.com/pharmala-to-supply-merhavim-mental-health-centre-clinical-trial-in-exchange-for-full-data-license-in-partnership-with-maps-israel/2025-01-20T17:54:44.000Z https://psychedelicinvest.com/mindbio-provides-update-on-multiple-phase-2b-clinical-trials-and-technological-developments/2025-01-17T20:25:51.000Z https://psychedelicinvest.com/optimi-health-reports-first-patients-dosed-in-landmark-natural-psilocybin-study-in-new-zealand/2025-01-17T20:24:29.000Z https://psychedelicinvest.com/magdalena-biosciences-a-joint-venture-between-jaguar-health-and-filament-health-to-present-january-12-at-the-annual-neuroscience-innovation-forum/2025-01-17T20:22:35.000Z https://psychedelicinvest.com/clearmind-medicine-announces-shareholders-meeting-results-3/2025-01-17T19:56:28.000Z https://psychedelicinvest.com/revive-therapeutics-provides-update-on-research-study-evaluating-bucillamine-for-nerve-agent-exposure-3/2025-01-17T19:50:36.000Z https://psychedelicinvest.com/silo-pharma-awarded-us-patent-for-groundbreaking-ptsd-treatment-and-prepares-for-spc-15-clinical-trial/2025-01-17T19:43:37.000Z https://psychedelicinvest.com/cybin-launches-strategic-clinical-site-partnerships-to-support-paradigm-a-multinational-pivotal-phase-3-program-evaluating-cyb003-for-the-adjunctive-treatment-of-major-depressive-disorder/2025-01-17T19:38:35.000Z https://psychedelicinvest.com/atai-life-sciences-announces-key-leadership-appointments-as-it-advances-its-pipeline-of-novel-psychedelic-therapeutics-for-mental-health/2025-01-13T17:26:33.000Z https://psychedelicinvest.com/the-psychedelic-industry-in-2025-key-trends-and-opportunities/2025-01-06T20:17:08.000Z https://psychedelicinvest.com/the-psychedelics-industry-hit-major-highs-and-lows-in-2024/2025-01-06T19:41:27.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-receives-notice-of-allowance-from-uspto-for-repirinast-in-kidney-disease-patent/2025-01-06T19:18:32.000Z https://psychedelicinvest.com/optimi-health-completes-second-mdma-shipment-to-australia-and-expands-2025-production-forecast-to-support-over-5000-patients-globally/2025-01-06T19:16:14.000Z https://psychedelicinvest.com/scisparc-clearmind-medicine-collaboration-announces-the-publication-of-european-patent-application-for-binge-behavior-psychedelic-combination-treatment/2025-01-06T19:14:08.000Z https://psychedelicinvest.com/enveric-biosciences-to-present-at-and-participate-in-panel-discussion-at-sachs-associates-8th-annual-neuroscience-innovation-forum-during-j-p-morgan-week-2025/2025-01-06T19:11:33.000Z https://psychedelicinvest.com/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-announce-kadima-neuropsychiatry-institute-as-the-expected-first-acquisition-for-its-international-network-of-interventional-psychiatry-clinics/2025-01-04T02:56:41.000Z https://psychedelicinvest.com/clearmind-medicine-granted-patent-for-binge-behavior-treatment-by-the-macau-international-intellectual-property-office/2025-01-02T17:17:44.000Z https://psychedelicinvest.com/silo-pharma-issues-letter-to-shareholders-detailing-development-progress-and-potential-for-lead-assets-targeting-ptsd-and-chronic-pain/2025-01-02T17:16:27.000Z https://psychedelicinvest.com/numinus-provides-bi-weekly-update-on-annual-filings-2/2025-01-02T17:15:05.000Z https://psychedelicinvest.com/clearmind-medicine-looks-to-move-forward-with-its-novel-psychedelic-meai-based-alcohol-substitute/2024-12-26T19:59:41.000Z https://psychedelicinvest.com/clearmind-medicine-receives-irb-approval-for-its-fda-regulated-clinical-trial/2024-12-26T19:58:01.000Z https://psychedelicinvest.com/psyence-biomedical-regains-full-compliance-with-all-nasdaq-continued-listing-requirements/2024-12-23T17:19:25.000Z https://psychedelicinvest.com/psyence-biomed-announces-2-0-million-private-placement/2024-12-23T17:17:51.000Z https://psychedelicinvest.com/pharmala-issues-audited-financial-statements-completes-continuance-to-ontario-and-closes-private-placement/2024-12-23T17:15:49.000Z https://psychedelicinvest.com/jaguar-health-announces-import-of-coca-leaf-from-peru-by-joint-venture-magdalena-biosciences-for-research-in-treating-mental-health-indications/2024-12-20T15:34:57.000Z https://psychedelicinvest.com/psyence-biomedical-biomed-highlights-recent-progress-on-active-phase-iib-clinical-trial-form-6k/2024-12-19T16:20:17.000Z https://psychedelicinvest.com/awakn-life-sciences-announces-credit-facility/2024-12-18T19:48:26.000Z https://psychedelicinvest.com/silo-pharma-initiates-pharmacokinetic-and-tolerability-study-for-sp-26-targeting-chronic-pain-and-fibromyalgia/2024-12-18T19:43:08.000Z https://psychedelicinvest.com/numinus-wellness-closes-sale-of-clinics-and-launches-initiative-to-increase-access-to-mental-health-care/2024-12-17T22:47:33.000Z https://psychedelicinvest.com/optimi-health-to-supply-gmp-certified-psilocybin-for-psyence-biomeds-phase-iib-palliative-care-trial/2024-12-17T22:45:23.000Z https://psychedelicinvest.com/filament-health-announces-import-of-coca-leaf-from-peru-by-joint-venture-magdalena-biosciences/2024-12-17T22:42:13.000Z https://psychedelicinvest.com/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-generalized-anxiety-disorder-gad/2024-12-17T22:36:08.000Z https://psychedelicinvest.com/clearmind-medicine-and-dr-glitter-pty-ltd-sign-term-sheet-for-mutual-development-of-novel-psychedelic-meai-based-alcohol-substitute-in-activcrystal-format/2024-12-17T22:03:53.000Z https://psychedelicinvest.com/numinus-provides-bi-weekly-update-on-annual-filings/2024-12-17T22:01:47.000Z https://psychedelicinvest.com/awakn-life-sciences-enters-into-binding-letter-of-intent-for-acquisition-of-awakn-by-graft-polymer-uk-plc/2024-12-17T21:58:11.000Z https://psychedelicinvest.com/pharmala-announces-private-placement/2024-12-13T18:28:01.000Z https://psychedelicinvest.com/mindbio-announces-arrangements-to-address-mailing-delays-resulting-from-canada-post-strike/2024-12-12T20:20:01.000Z https://psychedelicinvest.com/awakn-announces-promising-results-from-aminoindane-new-chemical-entity-pre-clinical-program/2024-12-11T18:25:47.000Z https://psychedelicinvest.com/cybin-announces-poster-presentations-at-the-2024-american-college-of-neuropsychopharmacology-annual-meeting-including-cyb003-12-month-efficacy-results/2024-12-10T17:37:30.000Z https://psychedelicinvest.com/psyence-biomed-executes-binding-agreements-with-optimi-health-corp/2024-12-10T17:33:14.000Z https://psychedelicinvest.com/mindbio-announces-completion-of-private-placement-and-issuance-of-listed-securities/2024-12-09T17:29:34.000Z https://psychedelicinvest.com/bionomics-publishes-the-positive-results-from-the-phase-2-attune-study-of-bnc210-in-patients-with-post-traumatic-stress-disorder-in-nejm-evidence/2024-12-09T17:24:55.000Z https://psychedelicinvest.com/psyence-group-enters-into-agreements-with-its-nasdaq-listed-associate-psyence-biomedical-to-settle-outstanding-obligations/2024-12-06T20:56:47.000Z https://psychedelicinvest.com/mindmed-awarded-innovation-passport-designation-by-the-united-kingdom-uk-innovative-licensing-and-access-pathway-ilap-steering-group-for-mm120-orally-disintegrating-tablet-odt-for-generalized-an/2024-12-06T20:55:06.000Z https://psychedelicinvest.com/mindmed-appoints-javier-muniz-m-d-as-vice-president-of-research-and-development-strategy/2024-12-06T20:53:55.000Z https://psychedelicinvest.com/va-awards-1-5m-to-study-mdma-for-ptsd/2024-12-03T17:55:17.000Z https://psychedelicinvest.com/silo-pharma-enters-joint-development-agreement-for-sp-26-ketamine-implant-device-targeting-pain-management/2024-12-02T17:30:13.000Z https://psychedelicinvest.com/revitalist-releases-benefits-program-giving-access-to-all-for-ketamine-therapies-changing-the-narrative-of-mental-health-to-risk-mitigation/2024-11-25T18:25:18.000Z https://psychedelicinvest.com/betterlife-obtains-favourable-cardiac-safety-data-for-betr-001/2024-11-25T18:22:50.000Z https://psychedelicinvest.com/cannabis-for-ptsd-maps-mjp2-trial-approved/2024-11-21T17:37:32.000Z https://psychedelicinvest.com/psyence-biomedical-announces-favorable-result-of-nasdaq-listing-qualifications-hearing/2024-11-20T16:07:50.000Z https://psychedelicinvest.com/psyence-biomedical-announces-effective-date-for-1-for-75-share-consolidation/2024-11-20T16:05:55.000Z https://psychedelicinvest.com/braxia-scientific-announces-change-in-directors-and-ceo/2024-11-19T16:51:39.000Z https://psychedelicinvest.com/lobe-sciences-and-alera-pharma-announce-notice-of-allowance-for-second-u-s-patent-for-conjugated-psilocin/2024-11-19T16:49:19.000Z https://psychedelicinvest.com/mindmed-appoints-gregg-pratt-ph-d-as-chief-regulatory-and-quality-assurance-officer/2024-11-18T17:23:42.000Z https://psychedelicinvest.com/cybin-reports-positive-phase-2-data-for-cyb003-demonstrating-breakthrough-12-month-efficacy-in-treating-major-depressive-disorder/2024-11-18T17:17:26.000Z https://psychedelicinvest.com/silo-pharma-announces-positive-results-for-novel-spc-15-treatment-targeting-stress-related-disorders/2024-11-18T17:14:12.000Z https://psychedelicinvest.com/numinus-applies-for-management-cease-trade-order/2024-11-18T17:11:32.000Z https://psychedelicinvest.com/pharmadrug-announces-issuance-of-debenture-units/2024-11-18T17:08:32.000Z https://psychedelicinvest.com/numinus-wellness-announces-sale-of-clinics-and-unique-data-partnership-to-increase-access-to-mental-health-care/2024-11-15T21:35:29.000Z https://psychedelicinvest.com/filament-health-announces-third-quarter-2024-financial-results-and-operational-highlights/2024-11-15T21:31:40.000Z https://psychedelicinvest.com/cybin-to-present-12-month-phase-2-data-for-cyb003-in-major-depressive-disorder-on-november-18-2024/2024-11-14T16:37:32.000Z https://psychedelicinvest.com/pharmala-reaches-agreement-in-principle-to-supply-mdma-to-clinical-trial-in-exchange-for-full-data-license/2024-11-14T16:35:12.000Z https://psychedelicinvest.com/psyence-biomedical-announces-results-from-annual-and-special-general-meeting-share-consolidation-and-receipt-of-additional-staff-determination-from-nasdaq-form-6-k/2024-11-13T15:10:49.000Z https://psychedelicinvest.com/cybin-initiates-paradigm-a-multinational-pivotal-phase-3-program-evaluating-cyb003-for-the-adjunctive-treatment-of-major-depressive-disorder-and-reports-second-quarter-financial-results/2024-11-13T15:08:08.000Z https://psychedelicinvest.com/atai-life-sciences-reports-third-quarter-2024-financial-results-and-provides-corporate-updates/2024-11-13T15:05:30.000Z https://psychedelicinvest.com/revive-therapeutics-announces-publication-demonstrating-novel-therapeutic-approach-of-psilocybin-in-stroke/2024-11-12T18:24:39.000Z https://psychedelicinvest.com/how-the-eudemonia-summit-has-already-improved-my-life/2024-11-12T18:21:38.000Z https://psychedelicinvest.com/psilocybin-applications-are-available-in-colorado-what-exactly-does-that-mean/2024-11-11T18:17:32.000Z https://psychedelicinvest.com/compass-pathways-streamlines-operations-with-workforce-reduction-and-shift-in-research-focus/2024-11-08T20:23:54.000Z https://psychedelicinvest.com/mindmed-reports-third-quarter-2024-financial-results-and-business-updates/2024-11-07T22:18:19.000Z https://psychedelicinvest.com/pharmadrugs-sairiyo-therapeutics-announces-successful-completion-of-stability-study-of-pd-001-patented-reformulated-cepharanthine-to-support-use-in-phase-1-study-for-viral-infectious-diseas/2024-10-31T17:18:25.000Z https://psychedelicinvest.com/psyence-group-announces-closing-of-previously-announced-disposal-of-its-stake-in-psylabs/2024-10-31T17:16:42.000Z https://psychedelicinvest.com/revive-therapeutics-provides-update-on-research-study-evaluating-bucillamine-for-nerve-agent-exposure-2/2024-10-31T17:11:26.000Z https://psychedelicinvest.com/silo-pharma-reports-positive-results-in-sterilization-and-dissolution-testing-of-sp-26-ketamine-implant/2024-10-31T16:08:39.000Z https://psychedelicinvest.com/psyence-biomedical-announces-closing-of-previously-announced-acquisition-of-psyence-groups-stake-in-psylabs/2024-10-31T16:06:10.000Z https://psychedelicinvest.com/mindbio-reports-a-72-reduction-in-severity-of-depression-sustained-six-months-after-treatment-in-clinical-trials/2024-10-31T16:03:46.000Z https://psychedelicinvest.com/cybin-to-participate-at-the-2024-milken-institute-future-of-health-summit/2024-10-31T16:01:38.000Z https://psychedelicinvest.com/intra-cellular-therapies-reports-third-quarter-2024-financial-results-provides-corporate-update-and-raises-2024-caplyta-sales-guidance/2024-10-31T15:56:43.000Z https://psychedelicinvest.com/cybin-announces-grant-of-first-u-s-composition-of-matter-patent-in-support-of-its-cyb005-phenethylamines-program/2024-10-24T16:28:53.000Z https://psychedelicinvest.com/psyence-biomed-announces-recruitment-of-second-clinical-trial-site-for-ongoing-phase-iib-clinical-trial-of-nature-derived-psilocybin-for-adjustment-disorder-in-palliative-care/2024-10-24T16:27:50.000Z https://psychedelicinvest.com/mindbio-announces-clinical-trial-milestone-in-phase-2b-microdosing-trials-targeting-existential-distress-depression-anxiety-in-advanced-stage-cancer/2024-10-24T16:26:36.000Z https://psychedelicinvest.com/optimi-health-announces-first-ptsd-patients-treated-with-mdma-capsules-in-australia/2024-10-23T14:49:44.000Z https://psychedelicinvest.com/awakn-announces-opening-of-four-additional-awkn-001-phase-3-trial-sites/2024-10-22T17:28:28.000Z https://psychedelicinvest.com/mindbio-completes-final-post-treatment-milestone-in-phase-2a-microdosing-depression-clinical-trial/2024-10-22T17:26:51.000Z https://psychedelicinvest.com/optimi-health-announces-leadership-transition/2024-10-21T18:43:39.000Z https://psychedelicinvest.com/pharmala-to-supply-mt-sinai-hospital-with-laneo-mdma/2024-10-21T18:39:47.000Z https://psychedelicinvest.com/psylabs-eu-good-manufacturing-practices-certified-active-pharmaceutical-ingredient-development/2024-10-18T06:46:21.000Z https://psychedelicinvest.com/mindbio-announces-proposed-issuance-of-listed-securities/2024-10-17T04:49:11.000Z https://psychedelicinvest.com/firefly-neuroscience-collaborates-with-bright-minds-biosciences-to-analyze-the-data-from-its-positive-phase-1-study-using-its-artificial-intelligence-fda-cleared-bna-technology/2024-10-17T04:47:02.000Z https://psychedelicinvest.com/atai-life-sciences-to-participate-in-the-2024-maxim-healthcare-virtual-summit/2024-10-17T04:43:55.000Z https://psychedelicinvest.com/awakn-partners-with-the-university-of-nottingham-for-in-vivo-testing-of-aminoindane-new-chemical-entity-nce-pre-clinical-program/2024-10-16T05:27:20.000Z https://psychedelicinvest.com/bright-minds-is-unaware-of-any-material-changes/2024-10-16T04:20:15.000Z https://psychedelicinvest.com/psyence-group-enters-into-debt-for-equity-swap-agreement-with-its-nasdaq-listed-associate-psyence-biomedical/2024-10-15T04:51:26.000Z https://psychedelicinvest.com/clearmind-medicine-announces-irb-approval-for-fda-first-in-human-clinical-trial-of-cmnd-100-at-second-clinical-site/2024-10-10T20:22:52.000Z https://psychedelicinvest.com/braxia-scientific-announces-voting-results-from-the-annual-general-and-special-meeting-of-shareholders-2/2024-10-10T20:21:34.000Z https://psychedelicinvest.com/clearmind-medicine-fda-approval-for-the-ind-submission-to-conduct-its-trial-already-secured-form-6k/2024-10-10T20:19:12.000Z https://psychedelicinvest.com/pharmala-to-supply-the-university-of-texas-san-antonio-with-novel-dosage-form-of-laneo-mdma/2024-10-09T04:31:12.000Z https://psychedelicinvest.com/mindbio-develops-long-term-shelf-stable-microdosing-formulation-and-is-progressing-in-multiple-phase-2b-clinical-trials/2024-10-09T04:28:54.000Z https://psychedelicinvest.com/bionomics-issues-shareholder-letter-highlighting-recent-achievements-and-strategic-vision/2024-10-07T16:31:00.000Z https://psychedelicinvest.com/filament-health-announces-issuance-of-common-shares-to-negev-capital-investments-limited-pursuant-to-advisory-agreement/2024-10-07T16:28:30.000Z https://psychedelicinvest.com/psyence-biomed-provides-update-on-previously-announced-acquisition-of-clairvoyant/2024-10-04T20:26:58.000Z https://psychedelicinvest.com/awakn-selects-eurofins-discovery-for-pharmacology-testing-in-new-chemical-entity-nce-pre-clinical-program/2024-10-04T16:33:52.000Z https://psychedelicinvest.com/stonegate-initiates-coverage-on-incannex-healthcare-inc-ixhl/2024-10-02T21:07:20.000Z https://psychedelicinvest.com/lobe-sciences-and-alera-pharma-announce-issuance-of-u-s-patent-for-conjugated-psilocin/2024-10-02T18:26:37.000Z https://psychedelicinvest.com/pharmala-to-supply-harvard-medical-schools-maclean-hospital-with-laneo-mdma/2024-10-02T18:22:41.000Z https://psychedelicinvest.com/cybin-expands-clinical-team-to-support-cyb003-phase-3-program/2024-10-01T21:20:10.000Z https://psychedelicinvest.com/incannex-healthcare-inc-reports-fiscal-full-year-2024-financial-results-and-business-updates/2024-09-30T20:24:15.000Z https://psychedelicinvest.com/cybin-to-participate-in-the-td-cowen-4th-annual-novel-mechanisms-in-neuropsychiatry-summit/2024-09-25T16:43:53.000Z https://psychedelicinvest.com/red-light-holland-announces-ncib-update-and-live-qa-with-ceo-todd-shapiro-and-cfo-jon-szczur-on-september-26th/2024-09-25T16:41:58.000Z https://psychedelicinvest.com/mindbio-therapeutics-enrolls-25th-participant-into-landmark-take-home-microdosing-depression-trial/2024-09-25T16:40:03.000Z https://psychedelicinvest.com/compass-pathways-to-participate-in-cowen-psychedelics-and-novel-mechanisms-in-neuropsychiatry-summit/2024-09-25T16:36:24.000Z https://psychedelicinvest.com/psyence-group-enters-into-agreement-to-dispose-of-stake-in-psylabs/2024-09-20T17:29:14.000Z https://psychedelicinvest.com/psyence-biomed-enters-into-agreement-to-acquire-stake-in-psylabs/2024-09-19T15:28:30.000Z https://psychedelicinvest.com/cybin-announces-completion-of-previously-announced-share-consolidation/2024-09-19T15:26:06.000Z https://psychedelicinvest.com/pharmadrugs-sairiyo-therapuetics-announces-initiation-of-study-start-up-activities-and-design-for-clinical-trial-of-pd-001-patented-reformulated-cepharanthine-for-viral-infectious-diseases/2024-09-19T15:24:17.000Z https://psychedelicinvest.com/shortwave-life-sciences-reports-positive-drug-safety-results/2024-09-19T15:21:56.000Z https://psychedelicinvest.com/awakn-life-sciences-announces-upsizing-and-closing-of-tranche-of-private-placement-financing/2024-09-18T20:32:50.000Z https://psychedelicinvest.com/psyence-groups-nasdaq-listed-associate-psyence-biomed-issues-shareholder-update-recapping-recent-progress-and-previewing-key-upcoming-data-milestones/2024-09-18T20:30:47.000Z https://psychedelicinvest.com/revive-therapeutics-announces-strategic-focus-on-bucillamine-for-infectious-diseases-and-medical-countermeasures/2024-09-18T20:26:38.000Z https://psychedelicinvest.com/psyence-biomed-issues-shareholder-update-recapping-recent-progress-and-previewing-key-upcoming-data-milestones/2024-09-16T16:30:12.000Z https://psychedelicinvest.com/psyence-biomedical-ltd-announces-receipt-of-staff-delisting-determination-from-nasdaq/2024-09-16T16:28:15.000Z https://psychedelicinvest.com/psyence-biomed-announces-the-signing-of-a-conditional-binding-term-sheet-for-the-acquisition-of-psilocybin-based-drug-developer-clairvoyant/2024-09-12T17:57:08.000Z https://psychedelicinvest.com/psyence-biomed-announces-initiation-of-first-trial-site-in-australia-for-its-phase-iib-study-of-nature-derived-psilocybin-as-a-potential-treatment-for-adjustment-disorder-in-palliative-care/2024-09-12T17:53:50.000Z https://psychedelicinvest.com/revitalist-announces-strategic-partnership-with-sama-therapeutics-to-advance-digital-human-ai-agents-for-precision-mental-health/2024-09-12T17:51:08.000Z https://psychedelicinvest.com/clearmind-medicine-announces-publication-of-international-patent-application-for-innovative-mdma-based-combination-treatment/2024-09-12T17:45:52.000Z https://psychedelicinvest.com/braxia-announces-annual-general-and-special-meeting/2024-09-12T16:32:20.000Z https://psychedelicinvest.com/pharmala-to-supply-johns-hopkins-medicine-for-clinical-trial/2024-09-12T16:29:05.000Z https://psychedelicinvest.com/bright-minds-biosciences-initiates-the-breakthrough-study-a-phase-2-trial-of-bmb-101-in-absence-epilepsy-and-developmental-epileptic-encephalopathy/2024-09-12T16:26:30.000Z https://psychedelicinvest.com/clearmind-medicine-and-yissum-file-international-patent-application-for-revolutionary-psychedelic-compounds-for-ptsd-treatment/2024-09-12T15:11:23.000Z https://psychedelicinvest.com/silo-pharma-announces-completion-of-fda-pre-ind-meeting-to-advance-development-of-spc-15-for-treatment-of-ptsd/2024-09-10T20:11:36.000Z https://psychedelicinvest.com/incannex-healthcare-announces-strategic-financing-for-up-to-60-million-with-arena-investors/2024-09-10T20:08:25.000Z https://psychedelicinvest.com/revitalist-lifestyle-and-wellness-ltd-partners-with-wake-network-to-launch-lions-brain-supplements-for-enhanced-mental-clarity-and-wellbeing/2024-09-05T20:11:18.000Z https://psychedelicinvest.com/mindmed-to-participate-in-september-investor-conferences/2024-09-04T15:10:41.000Z https://psychedelicinvest.com/atai-life-sciences-to-participate-in-the-h-c-wainwright-26th-annual-global-investment-conference/2024-09-04T15:07:14.000Z https://psychedelicinvest.com/psyence-biomed-announces-worldwide-exclusive-licensing-agreement-with-psylabs-to-supply-nature-derived-psilocybin-to-be-evaluated-as-a-potential-treatment-for-alcohol-use-disorder-aud-and-other-subs/2024-09-04T15:05:14.000Z https://psychedelicinvest.com/cybin-to-participate-in-the-h-c-wainwright-26th-annual-global-investment-conference/2024-09-04T15:02:30.000Z https://psychedelicinvest.com/red-light-holland-launches-farmcare-health-to-revolutionize-healthcare-with-farm-fresh-food-prescriptions/2024-09-03T17:34:06.000Z https://psychedelicinvest.com/scisparc-clearmind-medicine-collaboration-leads-to-publication-of-application-for-innovative-ketamine-based-combination/2024-08-30T17:30:19.000Z https://psychedelicinvest.com/clearmind-medicine-announces-publication-of-its-patent-application-for-innovative-ketamine-based-combination-treatment/2024-08-30T17:27:13.000Z https://psychedelicinvest.com/psyence-biomed-announces-registration-statement-on-form-f-1-for-up-to-25-million-equity-line-of-credit-with-white-lion-capital-llc-declared-effective-by-sec/2024-08-30T17:23:57.000Z https://psychedelicinvest.com/maps-awards-grant-for-pilot-mdma-assisted-massed-exposure-therapy-trial/2024-08-29T19:00:29.000Z https://psychedelicinvest.com/red-light-holland-reports-first-quarter-2025-results/2024-08-29T18:56:03.000Z https://psychedelicinvest.com/nrx-pharma-subsidiary-hope-therapeutics-secures-30m-to-buy-ketamine-clinics/2024-08-29T18:52:32.000Z https://psychedelicinvest.com/mindbio-ceo-provides-video-update-to-shareholders-on-progress-of-world-first-government-approved-microdosing-clinical-trials/2024-08-29T18:45:47.000Z https://psychedelicinvest.com/psyence-biomed-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference-september-9th-11th-2024/2024-08-28T15:49:18.000Z https://psychedelicinvest.com/cybin-announces-results-of-annual-and-special-meeting-of-shareholders-and-share-consolidation/2024-08-28T15:45:49.000Z https://psychedelicinvest.com/revive-therapeutics-provides-yet-another-update-on-bucillamine-for-nerve-agent-exposure/2024-08-28T15:40:39.000Z https://psychedelicinvest.com/awakn-announces-key-progress-in-its-aminoindane-pre-clinical-program/2024-08-28T15:37:08.000Z https://psychedelicinvest.com/optimi-health-atma-receive-no-objection-letter-from-health-canada-for-phase-2-clinical-trial/2024-08-28T15:32:39.000Z https://psychedelicinvest.com/pharmadrugs-sairiyo-therapuetics-provides-strategic-plans-to-advance-pd-001-patented-reformulated-cepharanthine-for-viral-infectious-diseases/2024-08-28T15:29:37.000Z https://psychedelicinvest.com/clinical-trial-design-has-never-been-more-important-for-psychedelics/2024-08-27T18:04:45.000Z https://psychedelicinvest.com/psilera-receives-positive-preclinical-in-vivo-data-for-frontotemporal-dementia-ftd-candidate-psil-006/2024-08-27T17:57:03.000Z https://psychedelicinvest.com/nova-mentis-assigns-intellectual-property/2024-08-27T17:52:41.000Z https://psychedelicinvest.com/betterlife-highlights-advantages-of-non-hallucinogenic-lsd-derivative-betr-001-and-publication-of-its-methods-to-treat-mood-disorders-patent/2024-08-27T17:47:16.000Z https://psychedelicinvest.com/revitalist-lifestyle-and-wellness-ltd-sponsors-the-american-legion-105th-national-convention-to-combat-veteran-suicide/2024-08-23T18:04:02.000Z https://psychedelicinvest.com/pharmadrugs-sairiyo-therapuetics-announces-independent-screening-identifying-cepharanthines-potential-to-bind-to-monkeypox-mpox-proteins/2024-08-23T18:02:44.000Z https://psychedelicinvest.com/the-role-of-psilocybin-in-inner-healing-depression/2024-08-22T17:11:14.000Z https://psychedelicinvest.com/pharmala-launches-mdma-clinical-trial-tool-for-researchers/2024-08-22T16:55:09.000Z https://psychedelicinvest.com/clearmind-medicine-granted-u-s-patent-approval-for-binge-behavior-treatment/2024-08-22T16:52:20.000Z https://psychedelicinvest.com/bright-green-embarks-on-major-partnership-with-benuvia-pharmaceuticals-will-supply-pharma-expert-with-american-made-raw-materials-from-its-industry-leading-and-dea-approved-sch-i-ii-drug-facilit/2024-08-22T16:10:17.000Z https://psychedelicinvest.com/mindbio-therapeutics-corp-announces-sustained-antidepressant-response-3-months-post-treatment-in-microdosing-depression-clinical-trials/2024-08-20T17:11:02.000Z https://psychedelicinvest.com/pharmadrugs-sairiyo-therapuetics-receives-approval-to-initiate-phase-1-clinical-trial-of-patented-reformulated-cepharanthine/2024-08-20T17:08:09.000Z https://psychedelicinvest.com/clearmind-medicine-and-yissum-expand-collaboration-with-international-patent-application-for-generation-3-0-psychedelic-compounds-to-treat-mental-disorders/2024-08-20T17:02:47.000Z https://psychedelicinvest.com/mindbio-reports-promising-phase-2a-results-for-depression-treatment-with-lsd/2024-08-19T18:53:20.000Z https://psychedelicinvest.com/psychedelic-news-roundup-august-16th-2024/2024-08-16T19:34:25.000Z https://psychedelicinvest.com/who-is-the-ketamine-queen/2024-08-16T19:11:52.000Z https://psychedelicinvest.com/after-last-weeks-fda-decision-everyones-talking-about-whats-next/2024-08-16T18:47:34.000Z https://psychedelicinvest.com/hempacco-co-inc-announces-board-and-committee-appointments/2024-08-16T16:28:59.000Z https://psychedelicinvest.com/optimi-health-completes-inaugural-export-of-mdma-capsules-to-australia-for-ptsd-treatment/2024-08-16T16:20:37.000Z https://psychedelicinvest.com/filament-health-announces-second-quarter-2024-financial-results-and-operational-highlights/2024-08-15T15:36:59.000Z https://psychedelicinvest.com/silo-pharma-expands-development-agreement-with-sever-pharma-for-novel-ketamine-implant-therapeutic/2024-08-15T15:34:41.000Z https://psychedelicinvest.com/uc-davis-scientists-introduce-tool-to-reveal-psychedelics-effects-on-neurons/2024-08-14T20:59:13.000Z https://psychedelicinvest.com/want-to-work-in-the-psychedelics-the-industry-needs-more-screeners/2024-08-14T20:17:21.000Z https://psychedelicinvest.com/optimi-health-and-psyence-biomedical-sign-non-binding-letter-of-intent-to-advance-global-psilocybin-drug-development/2024-08-13T19:39:59.000Z https://psychedelicinvest.com/atai-life-sciences-reports-second-quarter-2024-financial-results-and-provides-corporate-updates/2024-08-13T19:36:20.000Z https://psychedelicinvest.com/cybin-announces-completion-of-fda-type-b-initial-breakthrough-therapy-meeting-and-plans-for-cyb003-phase-3-program-in-major-depressive-disorder/2024-08-13T19:20:03.000Z https://psychedelicinvest.com/mindmed-reports-second-quarter-2024-financial-results-and-business-updates/2024-08-13T18:02:37.000Z https://psychedelicinvest.com/filament-health-announces-major-intellectual-property-expansion/2024-08-13T17:59:33.000Z https://psychedelicinvest.com/atai-life-sciences-announces-positive-preliminary-results-from-phase-1b-trial-of-vls-01-buccal-film-dmt/2024-08-13T17:57:04.000Z https://psychedelicinvest.com/denial-of-lykos-mdma-assisted-ptsd-therapy-followed-by-retraction-of-related-studies/2024-08-12T17:31:48.000Z https://psychedelicinvest.com/pharmala-comments-on-usfda-decision-regarding-mdma-assisted-therapy-and-announces-patent-granting-for-ala-002/2024-08-12T17:14:36.000Z https://psychedelicinvest.com/fda-denies-lykos-and-requests-another-trial/2024-08-09T23:41:33.000Z https://psychedelicinvest.com/awakn-announces-first-patient-screened-in-phase-3-clinical-trial-of-awkn-001-for-severe-alcohol-use-disorder/2024-08-09T21:15:13.000Z https://psychedelicinvest.com/medbright-ai-issues-clarifying-news-release-on-continuous-disclosure-record/2024-08-09T21:11:20.000Z https://psychedelicinvest.com/cybin-reports-first-quarter-fiscal-year-2025-financial-results-and-recent-business-highlights/2024-08-09T21:00:39.000Z https://psychedelicinvest.com/optimi-health-announces-non-brokered-private-placement/2024-08-08T02:46:12.000Z https://psychedelicinvest.com/silo-pharma-announces-partnership-with-global-cro-for-central-nervous-system-homing-peptide/2024-08-08T02:43:19.000Z https://psychedelicinvest.com/intra-cellular-therapies-reports-second-quarter-2024-financial-results-provides-corporate-update-and-raises-2024-caplyta-sales-guidance/2024-08-07T19:03:30.000Z https://psychedelicinvest.com/cybin-to-participate-in-the-canaccord-genuity-44th-annual-growth-conference/2024-08-07T16:33:13.000Z https://psychedelicinvest.com/atai-life-sciences-to-participate-in-the-canaccord-genuity-44th-annual-growth-conference/2024-08-07T16:30:57.000Z https://psychedelicinvest.com/oregon-grants-first-psychedelic-edibles-manufacturer-license/2024-08-07T02:45:01.000Z https://psychedelicinvest.com/clearmind-medicine-new-scientific-publication-shows-meais-potential-as-a-novel-weight-loss-drug/2024-08-07T02:33:43.000Z https://psychedelicinvest.com/scisparcs-collaboration-with-clearmind-medicine-continues-to-bear-fruit-with-new-scientific-article-showing-meai-potential-as-a-novel-weight-loss-drug/2024-08-07T02:30:36.000Z https://psychedelicinvest.com/psyched-wellness-announces-supply-chain-disruption-in-the-us/2024-08-06T21:36:22.000Z https://psychedelicinvest.com/elaine-elisabetsky-phd-member-of-jaguar-healths-mental-health-entheogen-therapeutics-initiative-to-speak-august-2nd-about-plant-based-medicines-used-to-manage-schizophrenia/2024-08-06T04:59:14.000Z https://psychedelicinvest.com/braxia-scientific-announces-cease-trade-order/2024-08-06T04:57:01.000Z https://psychedelicinvest.com/mindbio-therapeutics-appoints-haywood-securities-to-conduct-strategic-investment-advisory/2024-08-02T16:48:42.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-announces-closing-of-private-placement-2/2024-08-02T16:45:58.000Z https://psychedelicinvest.com/tryptamine-therapeutics-limited-appoints-david-castle-to-its-scientific-advisory-board/2024-08-02T16:38:08.000Z https://psychedelicinvest.com/the-potential-of-psilocybin-for-alcohol-addiction-treatment/2024-08-01T18:40:13.000Z https://psychedelicinvest.com/psyence-biomed-enters-into-25-million-common-stock-purchase-agreement-with-white-lion-capital-llc/2024-08-01T18:32:20.000Z https://psychedelicinvest.com/revitalist-lifestyle-and-wellness-ceo-kathryn-a-walker-to-speak-at-the-aana-annual-congress-on-psychedelics-in-anesthesia/2024-07-31T16:53:57.000Z https://psychedelicinvest.com/awakn-life-sciences-announces-closing-of-tranche-of-private-placement-and-warrant-extension/2024-07-31T16:52:04.000Z https://psychedelicinvest.com/clearmind-medicine-concludes-the-successful-participation-in-the-psychedelic-medicine-israel-2024-conference-presented-industry-leaders-its-groundbreaking-research/2024-07-31T16:50:07.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-announces-increase-to-private-placement-2/2024-07-31T16:47:48.000Z https://psychedelicinvest.com/how-state-level-psychedelic-policies-balance-safety-and-access/2024-07-30T17:44:07.000Z https://psychedelicinvest.com/incannex-healthcare-dosing-completed-in-115-participant-bioavailability-bioequivalence-clinical-trial-for-proprietary-sleep-apnea-drug-candidate-ihl-42x-form-8-k/2024-07-30T17:34:48.000Z https://psychedelicinvest.com/pharmala-provides-comprehensive-investor-update-following-release-of-q3-financial-statement/2024-07-30T17:06:23.000Z https://psychedelicinvest.com/optimind-pharma-closes-second-tranche-of-private-placement/2024-07-29T18:26:31.000Z https://psychedelicinvest.com/mindmed-appoints-stephanie-fagan-as-chief-corporate-affairs-officer/2024-07-29T18:23:32.000Z https://psychedelicinvest.com/psyence-groups-nasdaq-listed-associate-psyence-biomedical-announces-export-of-nature-derived-psilocybin-to-australia-and-provides-update-on-upcoming-phase-iib-trial/2024-07-26T15:45:58.000Z https://psychedelicinvest.com/silo-pharma-to-present-at-h-c-wainwright-annual-global-investment-conference/2024-07-26T15:43:03.000Z https://psychedelicinvest.com/braxia-scientific-provides-update-on-application-for-management-cease-trade-order/2024-07-26T15:38:38.000Z https://psychedelicinvest.com/the-many-use-cases-for-psilocybin-assisted-therapy/2024-07-25T18:35:14.000Z https://psychedelicinvest.com/psyence-biomedical-ltd-provides-update-on-upcoming-phase-iib-trial/2024-07-25T18:24:10.000Z https://psychedelicinvest.com/enveric-biosciences-announces-preclinical-results-confirming-potential-of-eb-003-to-be-dosed-orally/2024-07-25T18:21:00.000Z https://psychedelicinvest.com/psyence-biomed-announces-export-of-nature-derived-psilocybin-to-australia-and-provides-update-on-upcoming-phase-iib-trial/2024-07-24T20:34:27.000Z https://psychedelicinvest.com/heres-how-lsd-can-treat-depression/2024-07-24T14:57:43.000Z https://psychedelicinvest.com/optimi-health-to-enter-asian-market-with-psilothai-collaboration-on-psilocybin-research/2024-07-23T15:39:35.000Z https://psychedelicinvest.com/psilocybins-impact-on-brain-activity/2024-07-23T15:35:31.000Z https://psychedelicinvest.com/awakn-life-sciences-provides-update-on-aminoindane-new-chemical-entity-patent-portfolio/2024-07-23T15:27:27.000Z https://psychedelicinvest.com/reunion-neuroscience-inc-announces-first-patient-dosed-in-phase-2-clinical-trial-of-re104-for-the-treatment-of-postpartum-depression/2024-07-23T15:24:37.000Z https://psychedelicinvest.com/therapeutic-potential-of-psychedelics-for-older-adults/2024-07-22T18:14:47.000Z https://psychedelicinvest.com/hytn-completes-acquisition-of-prism-scientific-labs-enhancing-psychedelic-compound-manufacturing-capabilities/2024-07-20T15:48:17.000Z https://psychedelicinvest.com/silo-pharma-announces-2-1-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules/2024-07-20T15:41:42.000Z https://psychedelicinvest.com/clearmind-medicine-signs-an-agreement-to-source-manufacturers-and-distributors-for-its-alcohol-substitute-beverage-product/2024-07-20T15:38:05.000Z https://psychedelicinvest.com/silo-pharma-and-resyca-bv-partner-on-device-and-cmc-development-for-intranasal-ptsd-drug-spc-15/2024-07-20T15:35:08.000Z https://psychedelicinvest.com/mindmed-announces-issuance-of-new-patent-for-mm120-orally-disintegrating-tablet-odt/2024-07-17T16:06:39.000Z https://psychedelicinvest.com/psyched-wellness-adds-harmons-to-list-of-retail-partners-engages-unfi-for-distribution-and-announces-appointment-of-kyle-nazareth-as-chief-financial-officer/2024-07-17T15:48:57.000Z https://psychedelicinvest.com/psilocybin-offers-promising-relief-for-cluster-headaches/2024-07-16T17:18:04.000Z https://psychedelicinvest.com/clearmind-medicine-obtains-ind-approval-from-the-fda-to-start-the-phase-i-iia-clinical-trial/2024-07-16T17:10:45.000Z https://psychedelicinvest.com/braxia-scientific-announces-application-for-a-management-cease-trade-order-for-late-filing-of-audited-annual-financial-statements/2024-07-16T17:08:37.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-reports-results-of-study-showing-93-cough-suppression-with-ifenprodil/2024-07-16T17:06:43.000Z https://psychedelicinvest.com/silo-pharma-secures-exclusive-global-license-for-alzheimers-therapeutic/2024-07-16T17:02:31.000Z https://psychedelicinvest.com/clearmind-medicine-announces-submission-of-us-patent-application-for-treating-metabolic-syndrome-and-weight-loss/2024-07-16T16:58:27.000Z https://psychedelicinvest.com/scisparc-announces-u-s-patent-application-for-treating-metabolic-syndrome-and-weight-loss/2024-07-16T16:45:35.000Z https://psychedelicinvest.com/matt-zemon-educates-about-the-impact-of-psychedelics-podcast-episode-50/2024-07-16T16:35:22.000Z https://psychedelicinvest.com/braxia-scientific-corp-delays-financial-report-amid-management-changes/2024-07-16T16:14:43.000Z https://psychedelicinvest.com/clearmind-medicine-to-present-groundbreaking-research-at-psychedelic-medicine-israel-2024-conference/2024-07-12T15:58:27.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-announces-private-placement-2/2024-07-12T15:54:43.000Z https://psychedelicinvest.com/oregons-psilocybin-industry-a-year-of-growth-and-challenges/2024-07-11T16:17:20.000Z https://psychedelicinvest.com/the-popularity-of-microdosing-psilocybin-continues-to-surge/2024-07-11T16:00:58.000Z https://psychedelicinvest.com/numinus-to-host-q3-fiscal-2024-results-conference-call-on-july-11-2024/2024-07-11T15:52:46.000Z https://psychedelicinvest.com/psilocybins-effects-on-the-auditory-cortex-in-mice/2024-07-10T18:18:17.000Z https://psychedelicinvest.com/cybin-inc-stands-strong-as-a-remaining-force-to-prove-benefits-of-psychedelic-therapeutics-cybn/2024-07-10T16:46:11.000Z https://psychedelicinvest.com/optimind-pharma-closes-first-tranche-of-private-placement/2024-07-09T19:38:15.000Z https://psychedelicinvest.com/red-light-holland-ctio-to-unveil-groundbreaking-imicroapp-research-findings-to-prestigious-drug-science-consortium/2024-07-09T19:16:33.000Z https://psychedelicinvest.com/mindbio-therapeutics-ceo-issues-letter-to-shareholders/2024-07-09T18:56:28.000Z https://psychedelicinvest.com/a-swell-of-insider-purchases-follow-cybin-inc-s-positive-year-end-update/2024-07-08T18:53:14.000Z https://psychedelicinvest.com/silo-pharma-announces-exclusive-global-license-for-lead-candidate-spc-15-targeting-ptsd-and-stress-induced-anxiety-disorders/2024-07-08T18:49:17.000Z https://psychedelicinvest.com/psyence-biomedical-ltd-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency/2024-07-08T18:46:33.000Z https://psychedelicinvest.com/optimind-pharma-private-placement/2024-07-08T18:41:02.000Z https://psychedelicinvest.com/mydecine-innovations-group-inc-annual-and-q1-financial-statements/2024-07-08T18:37:23.000Z https://psychedelicinvest.com/clearmind-medicine-inc-announces-advancement-in-its-proprietary-meai-based-binge-behaviors-treatment/2024-07-08T18:31:45.000Z https://psychedelicinvest.com/revive-therapeutics-provides-update-on-research-study-evaluating-bucillamine-for-nerve-agent-exposure/2024-07-03T15:07:28.000Z https://psychedelicinvest.com/analysis-reveals-the-most-significant-improvements-from-psychedelic-use-apply-to-single-individuals/2024-07-02T16:24:57.000Z https://psychedelicinvest.com/lykos-therapeutics-responds-to-icers-critique-of-mdma-assisted-psychotherapy-for-ptsd/2024-07-02T16:03:31.000Z https://psychedelicinvest.com/university-of-colorado-denver-unveils-psychedelic-research-center/2024-07-02T15:56:07.000Z https://psychedelicinvest.com/clearmind-medicine-granted-patent-approval-in-hong-kong-for-its-binge-behaviors-treatment/2024-07-01T16:47:54.000Z https://psychedelicinvest.com/the-therapeutic-potential-of-psychedelics-in-brain-health-and-aging/2024-06-27T19:24:40.000Z https://psychedelicinvest.com/mindbio-therapeutics-corp-reports-durability-data-from-phase-2a-clinical-trials-in-depressed-patients-testing-mb22001/2024-06-27T17:19:06.000Z https://psychedelicinvest.com/optimi-health-and-mind-medicine-australia-launch-optimed-prescriber-portal-for-australian-psychiatrists/2024-06-27T17:17:16.000Z https://psychedelicinvest.com/silo-pharma-partners-with-amplifybio-to-advance-spc-15-for-ptsd-and-anxiety/2024-06-26T17:23:56.000Z https://psychedelicinvest.com/cybin-reports-fiscal-year-2024-financial-results-and-recent-business-highlights/2024-06-26T17:22:13.000Z https://psychedelicinvest.com/atai-life-sciences-to-participate-in-the-h-c-wainwright-5th-annual-neuro-perspectives-conference/2024-06-26T17:20:24.000Z https://psychedelicinvest.com/mexico-might-be-legalizing-magic-mushrooms/2024-06-25T21:09:45.000Z https://psychedelicinvest.com/how-might-psychedelics-help-with-stuttering/2024-06-25T21:02:22.000Z https://psychedelicinvest.com/enveric-biosciences-provides-strategic-outlook-and-pipeline-update-elevating-eb-003-to-lead-development-candidate/2024-06-25T16:44:45.000Z https://psychedelicinvest.com/health-canada-issues-three-export-permits-to-optimi-to-supply-patients-under-australias-authorised-prescriber-scheme/2024-06-25T16:42:34.000Z https://psychedelicinvest.com/hypha-labs-inc-reveals-new-patent-applications-for-novel-artificial-intelligence-a-i-driven-in-home-mycelium-production/2024-06-24T21:46:24.000Z https://psychedelicinvest.com/numinus-wellness-announces-resignation-of-director/2024-06-24T21:44:00.000Z https://psychedelicinvest.com/what-mindblooms-ketamine-study-could-mean-for-the-psychedelics-industry/2024-06-21T19:20:29.000Z https://psychedelicinvest.com/psychedelics-and-their-potential-to-alleviate-death-anxiety/2024-06-20T20:37:05.000Z https://psychedelicinvest.com/psychedelic-legislative-trends-in-2024-a-detailed-overview/2024-06-20T20:29:53.000Z https://psychedelicinvest.com/numinus-wellness-announces-strategic-acquisition-of-medbright-ai/2024-06-20T15:51:34.000Z https://psychedelicinvest.com/mindmed-announces-constructive-end-of-phase-2-meeting-with-u-s-fda-for-mm120-in-generalized-anxiety-disorder-gad/2024-06-20T15:49:03.000Z https://psychedelicinvest.com/atai-life-sciences-announces-update-on-beckley-psytechs-phase-1-2a-trial-of-ele-101-iv-psilocin-for-major-depressive-disorder-with-initial-results-from-phase-1-and-first-patients-dosed-in/2024-06-20T15:46:56.000Z https://psychedelicinvest.com/clearmind-medicine-secured-exclusive-global-rights-to-innovative-psychedelic-compounds-for-ptsd-treatment/2024-06-20T15:43:35.000Z https://psychedelicinvest.com/cybin-to-participate-in-the-h-c-wainwright-5th-annual-neuro-perspectives-virtual-conference/2024-06-19T21:11:38.000Z https://psychedelicinvest.com/relmada-therapeutics-announced-publication-of-results-from-the-phase-3-reliance-i-study-of-rel-1017-in-the-journal-of-clinical-psychiatry/2024-06-21T19:34:36.000Z https://psychedelicinvest.com/psychedelic-retreats-market-set-to-cross-1-trillion-by-2027/2024-06-14T19:18:20.000Z https://psychedelicinvest.com/uc-berkeleys-groundbreaking-study-exploring-psilocybins-effects-on-perception/2024-06-14T19:07:01.000Z https://psychedelicinvest.com/lykos-therapeutics-addresses-concerns-over-mdma-treatment-for-ptsd/2024-06-14T18:59:16.000Z https://psychedelicinvest.com/largest-study-of-psychedelic-medicine-with-11441-mindbloom-clients-demonstrates-effectiveness-and-safety-of-guided-at-home-ketamine-therapy/2024-06-14T18:45:47.000Z https://psychedelicinvest.com/filament-health-announces-closing-of-warrant-exercise-note-conversion-and-concurrent-private-placement-of-common-shares/2024-06-13T17:12:45.000Z https://psychedelicinvest.com/psyched-wellness-developing-amanita-muscaria-gummies-for-sale-in-the-usa/2024-06-13T17:09:03.000Z https://psychedelicinvest.com/mindbio-therapeutics-reports-secondary-data-improvement-of-psychological-outcomes-safety-results-in-depressed-patients-from-phase-2a-depression-trial/2024-06-12T15:55:54.000Z https://psychedelicinvest.com/revive-therapeutics-provides-update-on-fda-type-c-meeting-for-clinical-study-of-bucillamine-to-treat-long-covid/2024-06-12T15:54:30.000Z https://psychedelicinvest.com/cybin-appoints-dr-atul-mahableshwarkar-m-d-as-senior-vice-president-clinical-development/2024-06-11T16:28:36.000Z https://psychedelicinvest.com/revive-therapeutics-provides-update-from-fda-meeting-for-long-covid-diagnostic-product/2024-06-11T16:26:21.000Z https://psychedelicinvest.com/clearmind-medicine-revolutionizes-the-13-billion-nonalcoholic-beverages-market-with-its-psychedelic-based-drink/2024-06-11T16:23:36.000Z https://psychedelicinvest.com/optimi-health-completes-first-international-shipment-of-mdma-to-israel-and-secures-cbsa-exporters-authorization-id/2024-06-11T16:20:10.000Z https://psychedelicinvest.com/effective-psychedelic-treatment-for-long-covid-symptoms-a-case-study/2024-06-07T17:47:23.000Z https://psychedelicinvest.com/numinus-wellness-comments-on-fda-advisory-committee-meeting-for-investigational-mdma-assisted-therapy-for-ptsd/2024-06-07T16:01:36.000Z https://psychedelicinvest.com/silo-pharma-announces-successful-production-of-its-sp-26-ketamine-implant-for-fibromyalgia/2024-06-07T15:58:42.000Z https://psychedelicinvest.com/red-light-holland-announces-completion-of-full-psilocybin-extraction-report-with-pharmala/2024-06-07T15:55:56.000Z https://psychedelicinvest.com/pharmala-biotech-ceo-letter-to-shareholders-2/2024-06-07T15:49:48.000Z https://psychedelicinvest.com/psych-capital-changes-name-to-shortwave-life-sciences/2024-06-07T15:45:27.000Z https://psychedelicinvest.com/lobe-sciences-announces-update/2024-06-05T17:34:51.000Z https://psychedelicinvest.com/silo-pharma-announces-2-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules/2024-06-05T17:32:04.000Z https://psychedelicinvest.com/proposal-to-approve-mdma-for-ptsd-treatment-fails/2024-06-05T17:27:58.000Z https://psychedelicinvest.com/awakn-life-sciences-announces-closing-of-tranche-of-private-placement-2/2024-06-04T17:40:59.000Z https://psychedelicinvest.com/silo-pharma-submits-pre-investigational-new-drug-application-to-fda-for-spc-15-as-a-treatment-for-ptsd-and-anxiety/2024-06-04T17:39:10.000Z https://psychedelicinvest.com/filament-health-announces-warrant-exercise-and-note-conversion-by-negev-capital-and-concurrent-private-placement-of-common-shares-to-benjamin-lightburn-chief-executive-officer/2024-06-03T17:50:59.000Z https://psychedelicinvest.com/filament-health-announces-authorization-of-phase-2-clinical-trial-for-pex010-in-the-treatment-of-methamphetamine-use-disorder/2024-06-03T17:47:22.000Z https://psychedelicinvest.com/wesley-ramjeet-to-join-lobe-sciences-board-of-directors-bringing-decades-of-strategic-financial-expertise/2024-06-03T17:44:02.000Z https://psychedelicinvest.com/optimi-health-awarded-drug-establishment-licence-from-health-canada/2024-06-03T17:41:27.000Z https://psychedelicinvest.com/mydecine-innovations-group-inc-provides-bi-weekly-status-report/2024-06-03T17:38:10.000Z https://psychedelicinvest.com/numinus-wellness-announces-voting-results-from-its-annual-general-meeting-of-shareholders/2024-06-03T17:35:27.000Z https://psychedelicinvest.com/atai-life-sciences-to-participate-in-the-jefferies-2024-global-healthcare-conference/2024-05-31T18:57:22.000Z https://psychedelicinvest.com/fsd-pharma-triumphs-in-legal-dispute-against-former-ceo-dr-raza-bokhari/2024-05-31T18:55:26.000Z https://psychedelicinvest.com/ftcs-final-rule-amendment-to-the-health-breach-notification-rule-and-its-implications/2024-05-31T18:50:03.000Z https://psychedelicinvest.com/optimi-health-announces-closing-of-fully-subscribed-1500000-financing/2024-05-31T18:39:53.000Z https://psychedelicinvest.com/lobe-sciences-announces-frederick-d-sancilio-ph-d-to-join-board-of-directors/2024-05-31T18:37:50.000Z https://psychedelicinvest.com/us-fda-staff-flags-concerns-on-mdma-assisted-ptsd-treatment/2024-05-31T18:34:51.000Z https://psychedelicinvest.com/webinar-analyzing-the-fda-advisory-committee-review-of-mdma-assisted-therapy-for-ptsd/2024-06-07T16:23:33.000Z https://psychedelicinvest.com/numinus-and-cybin-embark-on-a-groundbreaking-journey-pioneering-phase-3-trials-for-major-depressive-disorder/2024-05-30T17:50:26.000Z https://psychedelicinvest.com/brightgreens-update-from-the-ceo/2024-05-30T17:48:37.000Z https://psychedelicinvest.com/numinus-wellness-charts-path-to-profitability-while-strengthening-community-ties/2024-05-30T17:39:03.000Z https://psychedelicinvest.com/patient-dosing-commenced-in-reposa-phase-2-3-clinical-trial-protocol-to-assess-ihl-42x-drug-in-patients-with-obstructive-sleep-apnea/2024-05-30T17:34:10.000Z https://psychedelicinvest.com/former-merck-director-and-vanderbilt-vice-chancellor-dr-harry-jacobson-to-join-lobe-sciences-board-of-directors/2024-05-30T17:31:14.000Z https://psychedelicinvest.com/numinus-wellness-receives-health-canada-approval-for-study-into-group-model-for-mdma-assisted-therapy/2024-05-30T17:24:33.000Z https://psychedelicinvest.com/red-light-holland-initiates-psilocybin-extraction-phase-with-pharmala-following-successful-testing-and-preparation-by-ccrest-labs-2/2024-05-29T20:07:03.000Z https://psychedelicinvest.com/optimi-health-secures-import-permit-from-mind-medicine-australia-for-mdma-and-psilocybin-capsules/2024-05-29T17:39:06.000Z https://psychedelicinvest.com/cybin-to-participate-at-the-pathways-to-access-summit-and-the-interdisciplinary-conference-on-psychedelic-research-2024/2024-05-29T17:35:27.000Z https://psychedelicinvest.com/anumas-groundbreaking-mental-health-solutions/2024-05-24T17:38:19.000Z https://psychedelicinvest.com/reunion-neuroscience-announces-publication-of-results-from-early-preclinical-studies-demonstrating-the-potential-of-re104-for-development-in-depressive-disorders/2024-05-24T15:36:01.000Z https://psychedelicinvest.com/atai-life-sciences-strengthens-board-with-appointment-of-two-new-independent-directors/2024-05-23T19:56:00.000Z https://psychedelicinvest.com/pharmadrugs-securedose-announces-loi-with-canadian-controlled-drug-substance-licensed-dealer-for-patent-pending-pharmaceutical-grade-cocaine/2024-05-23T19:52:18.000Z https://psychedelicinvest.com/pharmala-ceo-nick-kadysh-pens-op-ed-mental-health-in-crisis-mdma-may-be-the-prescription/2024-05-23T19:50:03.000Z https://psychedelicinvest.com/kimberly-chew-helps-physicians-and-researchers-manage-legal-risks-podcast-episode-49/2024-05-22T17:37:05.000Z https://psychedelicinvest.com/optimi-health-atma-sign-letter-of-intent-to-advance-phase-ii-clinical-trial-group-and-individual-administration-protocol-for-major-depressive-disorder/2024-05-22T17:07:49.000Z https://psychedelicinvest.com/alaska-prepares-for-potential-federal-legalization-of-psychedelic-therapies/2024-05-21T16:54:52.000Z https://psychedelicinvest.com/is-compass-pathways-poised-for-success/2024-05-21T16:44:37.000Z https://psychedelicinvest.com/questions-about-mdma-for-ptsds-potential-fda-approval/2024-05-21T16:34:03.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-engages-icp-securities-inc-for-automated-market-making-services/2024-05-21T16:21:51.000Z https://psychedelicinvest.com/silo-pharma-announces-positive-results-from-study-for-depression-treatment-remission-and-relapse-prevention/2024-05-21T16:19:37.000Z https://psychedelicinvest.com/terran-biosciences-announces-the-development-of-terxt/2024-05-20T17:26:16.000Z https://psychedelicinvest.com/how-to-participate-in-psychedelic-clinical-trials/2024-05-20T17:04:53.000Z https://psychedelicinvest.com/psyched-wellness-announces-grant-of-options/2024-05-17T21:02:07.000Z https://psychedelicinvest.com/researchers-poised-for-breakthroughs-if-psychedelics-are-deregulated/2024-05-16T21:04:10.000Z https://psychedelicinvest.com/new-study-suggests-childhood-trauma-doesnt-cause-challenging-trips/2024-05-16T20:59:31.000Z https://psychedelicinvest.com/atai-life-sciences-ceo-stepping-down/2024-05-16T20:52:54.000Z https://psychedelicinvest.com/filament-health-announces-first-quarter-2024-financial-results-and-operational-highlights/2024-05-15T17:51:33.000Z https://psychedelicinvest.com/enveric-biosciences-reports-first-quarter-2024-financial-and-corporate-results/2024-05-15T17:48:38.000Z https://psychedelicinvest.com/atai-life-sciences-reports-first-quarter-2024-financial-results-and-corporate-updates/2024-05-15T17:46:38.000Z https://psychedelicinvest.com/pharmadrugs-sairiyo-therapeutics-submits-clinical-trial-application-for-phase-1-study-of-patented-reformulated-cepharanthine/2024-05-15T17:43:21.000Z https://psychedelicinvest.com/cybin-to-participate-in-the-alliance-global-partners-healthcare-company-showcase/2024-05-14T19:22:45.000Z https://psychedelicinvest.com/optimi-health-receives-certificate-of-analysis-for-mdma-40mg-and-60mg-gmp-capsules/2024-05-14T19:17:35.000Z https://psychedelicinvest.com/betterlife-obtains-excellent-animal-cardiopulmonary-safety-data-for-oral-betr-001/2024-05-14T17:59:05.000Z https://psychedelicinvest.com/enveric-biosciences-signs-66-5-million-non-binding-term-sheet-with-mindbio-therapeutics-to-out-license-novel-psilocin-prodrug-candidate-for-mental-health-disorders/2024-05-14T17:56:47.000Z https://psychedelicinvest.com/silo-pharma-to-participate-in-fda-meeting-exploring-emerging-therapeutic-interest-in-ketamine/2024-05-14T17:53:33.000Z https://psychedelicinvest.com/pharmadrug-provides-forward-plan-to-move-its-patent-pending-process-and-formulation-of-pharmaceutical-grade-biosynthetic-cocaine-through-development-into-commercialization/2024-05-13T18:01:21.000Z https://psychedelicinvest.com/abbvie-abbv-and-gilgamesh-pharmaceuticals-announce-collaboration-and-option-to-license-agreement-to-develop-next-generation-therapies-for-psychiatric-disorders/2024-05-13T17:55:13.000Z https://psychedelicinvest.com/clearmind-medicine-synthetic-alchohol-product/2024-05-10T15:40:18.000Z https://psychedelicinvest.com/optimi-health-provides-corporate-update/2024-05-10T15:36:23.000Z https://psychedelicinvest.com/new-studies-presented-at-the-international-society-for-health-economics-and-outcomes-research-meeting-ispor-24-show-growing-burden-and-impact-of-generalized-anxiety-disorder-gad-in-the-us/2024-05-09T16:03:42.000Z https://psychedelicinvest.com/optimi-health-receives-export-permit-from-health-canada-to-ship-mdma-to-tel-aviv-universitys-institute-for-psychedelic-research/2024-05-09T15:56:48.000Z https://psychedelicinvest.com/mdma-is-set-for-fda-panel-review-on-june-4th/2024-05-08T21:06:20.000Z https://psychedelicinvest.com/mindmed-reports-first-quarter-2024-financial-results-and-business-updates/2024-05-08T20:57:45.000Z https://psychedelicinvest.com/clearmind-medicine-secures-exclusive-global-rights-to-breakthrough-psychedelic-compounds-for-ptsd-treatment/2024-05-08T20:54:32.000Z https://psychedelicinvest.com/incannex-complete-successful-pre-ind-meeting-with-the-fda-for-cannquit-o-for-treatment-of-opioid-use-disorder/2024-05-08T20:52:13.000Z https://psychedelicinvest.com/numinus-wellness-focused-on-boosting-profitability-and-expanding-community-support/2024-05-08T20:49:54.000Z https://psychedelicinvest.com/enveric-biosciences-announces-signing-of-non-binding-term-sheet-with-undisclosed-licensee-for-exclusive-license-to-patented-methods-of-treating-breast-and-other-cancers-using-cannabinoids/2024-05-08T15:27:54.000Z https://psychedelicinvest.com/oprah-dailys-comprehensive-guide-to-psychedelics-a-milestone-for-industry-acceptance/2024-05-07T18:28:50.000Z https://psychedelicinvest.com/the-onion-pokes-fun-at-psychedelics/2024-05-07T18:13:03.000Z https://psychedelicinvest.com/mindmed-at-american-psychiatric-association-apa-annual-meeting-in-new-york/2024-05-06T17:08:40.000Z https://psychedelicinvest.com/lophos-pharmaceuticals-corp-enters-into-letter-of-intent-to-acquire-the-assets-of-magicactus-com/2024-05-06T17:04:46.000Z https://psychedelicinvest.com/cybin-provides-corporate-update-and-highlights-upcoming-clinical-milestones/2024-05-14T19:21:25.000Z https://psychedelicinvest.com/mindbio-therapeutics-scientists-present-landmark-womens-health-trials-company-to-release-phase-2a-depression-trial-secondary-data-this-month/2024-05-03T21:06:10.000Z https://psychedelicinvest.com/pharmala-launches-prescribers-portal-for-medical-professionals-focused-on-mdma-therapy/2024-05-03T21:02:54.000Z https://psychedelicinvest.com/reunion-neuroscience-inc-announces-103-million-series-a-financing-co-led-by-mpm-bioimpact-and-novo-holdings/2024-05-03T04:01:33.000Z https://psychedelicinvest.com/compass-pathways-establishes-research-collaboration-with-mindful-health-solutions-to-inform-the-development-of-a-scalable-and-cost-effective-delivery-model-for-investigational-comp360-psilocybin-treat/2024-05-03T03:58:25.000Z https://psychedelicinvest.com/mindbio-therapeutics-announces-landmark-womens-health-cns-drug-trials/2024-05-03T03:55:12.000Z https://psychedelicinvest.com/pharmadrug-announces-director-appointment-and-resignation/2024-05-03T03:51:46.000Z https://psychedelicinvest.com/awakn-life-sciences-discusses-filing-of-financial-statements/2024-05-03T03:48:10.000Z https://psychedelicinvest.com/mydecine-receives-management-cease-trade-order/2024-05-03T03:44:14.000Z https://psychedelicinvest.com/pharmadrugs-sairiyo-therapeutics-completes-clinical-and-regulatory-package-for-phase-1-study-of-patented-reformulated-cepharanthine/2024-05-02T04:30:31.000Z https://psychedelicinvest.com/freedom-biosciences-announces-fda-approval-of-ind-application-for-free001-in-patients-with-treatment-resistant-depression/2024-04-30T20:00:26.000Z https://psychedelicinvest.com/are-ketamine-bros-ruining-it-for-everyone-else/2024-04-30T19:52:58.000Z https://psychedelicinvest.com/fsd-pharma-inc-enters-agreement-to-conduct-clinical-trial-to-assess-safety-efficacy-of-unbuzzd/2024-04-30T19:37:48.000Z https://psychedelicinvest.com/behold-a-new-mushroom-emoji-has-arrived/2024-04-30T19:32:54.000Z https://psychedelicinvest.com/compass-pathways-and-journey-clinical-establish-research-collaboration-agreement-to-inform-the-training-of-healthcare-providers-and-delivery-model-for-comp360-psilocybin-treatment-if-approved-for-tre/2024-04-29T17:54:54.000Z https://psychedelicinvest.com/lophos-pharmaceuticals-corp-expands-peyote-cultivation-with-the-successful-planting-of-3000-seeds/2024-04-29T17:51:39.000Z https://psychedelicinvest.com/cybin-to-participate-at-the-27th-annual-milken-institute-global-conference/2024-04-29T17:48:53.000Z https://psychedelicinvest.com/mindmed-to-present-at-upcoming-may-medical-conferences/2024-04-29T17:46:26.000Z https://psychedelicinvest.com/mindbio-landmark-sleep-research-published-in-prestigious-nature-portfolio-journal-translational-psychiatry/2024-04-24T16:02:41.000Z https://psychedelicinvest.com/algernon-neuroscience-and-the-centre-for-human-drug-research-to-present-dmt-phase-1-stroke-clinical-data-at-the-interdisciplinary-conference-on-psychedelic-research-june-6-8th-2024/2024-04-24T15:58:42.000Z https://psychedelicinvest.com/atai-life-sciences-announces-dosing-of-first-patient-in-part-2-of-beckley-psytechs-phase-2a-study-exploring-bpl-003-adjunctive-to-ssris-in-patients-with-treatment-resistant-depression/2024-04-24T15:55:10.000Z https://psychedelicinvest.com/legal-battle-intensifies-the-fight-for-psilocybin-use-in-terminal-care/2024-04-23T18:40:33.000Z https://psychedelicinvest.com/revive-therapeutics-announces-type-c-meeting-request-granted-by-fda-for-clinical-study-of-bucillamine-to-treat-long-covid/2024-04-23T18:33:29.000Z https://psychedelicinvest.com/silo-pharma-announces-positive-results-for-intranasal-ptsd-treatment/2024-04-23T18:31:15.000Z https://psychedelicinvest.com/red-light-holland-initiates-psilocybin-extraction-phase-with-pharmala-following-successful-testing-and-preparation-by-ccrest-labs/2024-04-23T18:27:11.000Z https://psychedelicinvest.com/optimi-health-and-kwantlen-polytechnic-university-applied-genomics-centre-partner-to-advance-mushroom-science-and-research/2024-04-23T18:22:42.000Z https://psychedelicinvest.com/fsd-pharma-provides-another-update-on-celly-nus-anticipated-launch-of-unbuzzdtm/2024-04-23T18:18:47.000Z https://psychedelicinvest.com/what-is-bicycle-day/2024-04-20T01:53:35.000Z https://psychedelicinvest.com/psychedelics-can-offer-more-than-therapy-on-its-own/2024-04-20T01:47:24.000Z https://psychedelicinvest.com/pharmala-closes-private-placement-and-concurrent-debt-settlement/2024-04-19T21:23:04.000Z https://psychedelicinvest.com/revive-therapeutics-announces-fda-acceptance-of-meeting-request-for-long-covid-diagnostic-product/2024-04-18T20:48:35.000Z https://psychedelicinvest.com/cybin-announces-publication-of-research-manuscript-in-the-journal-of-medicinal-chemistry/2024-04-18T20:44:27.000Z https://psychedelicinvest.com/clearmind-medicine-announces-exclusive-licensing-agreement-for-generation-3-0-psychedelic-compounds-for-the-treatment-of-mental-disorders/2024-04-17T17:43:01.000Z https://psychedelicinvest.com/awakn-life-sciences-announces-closing-of-tranche-of-private-placement/2024-04-17T17:06:59.000Z https://psychedelicinvest.com/atai-life-sciences-announces-the-publication-of-beckley-psytechs-phase-1-study-of-bpl-003-in-the-journal-of-psychopharmacology/2024-04-17T17:03:34.000Z https://psychedelicinvest.com/cedar-clinical-research-selected-as-clinical-research-site-for-cybins-phase-3-study-of-cyb003/2024-04-17T17:00:04.000Z https://psychedelicinvest.com/cybin-announces-grant-of-additional-u-s-patent-in-support-of-its-cyb003-breakthrough-therapy-program-for-major-depressive-disorder/2024-04-16T17:46:14.000Z https://psychedelicinvest.com/incannex-healthcare-inc-quarterly-update-q1-2024/2024-04-16T17:44:16.000Z https://psychedelicinvest.com/pharmadrugs-securedose-announces-the-advancement-of-process-development-of-its-biosynthetic-formulation-of-pharmaceutical-grade-cocaine/2024-04-16T17:41:55.000Z https://psychedelicinvest.com/psyence-groups-nasdaq-listed-associate-psyence-biomedical-partners-with-fluence-and-ingenu-cro-to-train-research-therapists-for-phase-iib-psilocybin-trial/2024-04-16T17:39:07.000Z https://psychedelicinvest.com/optimi-health-signs-psilocybin-supply-agreement-with-new-zealand-based-matai-medical-research-institute/2024-04-16T16:49:28.000Z https://psychedelicinvest.com/numinus-wellness-provides-corporate-update-2/2024-04-15T19:48:08.000Z https://psychedelicinvest.com/the-eus-plan-for-a-e6-5m-study-of-psychedelics-to-treat-mental-disorders/2024-04-12T18:06:08.000Z https://psychedelicinvest.com/exploring-psilocybins-potential-in-diabetes-management/2024-04-12T17:52:29.000Z https://psychedelicinvest.com/theres-a-new-way-to-measure-the-potency-of-magic-mushrooms/2024-04-12T17:44:00.000Z https://psychedelicinvest.com/indiana-advances-psilocybin-research-with-new-funding-initiative/2024-04-15T19:57:43.000Z https://psychedelicinvest.com/testing-psilocybin-as-a-treatment-for-alcohol-use-disorder/2024-04-12T17:33:14.000Z https://psychedelicinvest.com/all-about-the-new-ketamine-trial-at-the-university-of-otago/2024-04-12T17:27:23.000Z https://psychedelicinvest.com/red-light-hollands-largest-psilocybin-shipment-received-by-ccrest-labs-in-montreal-with-health-canada-approved-import-permit/2024-04-12T17:07:02.000Z https://psychedelicinvest.com/pharmala-announces-private-placement-and-concurrent-debt-settlement/2024-04-11T20:24:40.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-ceo-christopher-j-moreau-to-be-featured-on-radius-researchs-pitch-deep-dive-and-qa-webinar-on-april-16th-2024/2024-04-11T20:21:34.000Z https://psychedelicinvest.com/cybin-to-present-at-the-2024-bloom-burton-co-healthcare-investor-conference/2024-04-10T20:28:06.000Z https://psychedelicinvest.com/silo-pharma-set-to-acquire-exclusive-licensing-for-promising-alzheimers-disease-therapeutic/2024-04-10T20:25:39.000Z https://psychedelicinvest.com/seaport-therapeutics-launches-with-100-million-oversubscribed-series-a-financing-round-to-advance-novel-neuropsychiatric-medicines/2024-04-10T20:23:41.000Z https://psychedelicinvest.com/clearmind-medicine-files-u-s-patent-application-for-psychedelic-based-treatment-for-eating-disorders/2024-04-10T20:18:19.000Z https://psychedelicinvest.com/red-light-holland-launches-its-largest-psilocybin-shipment-to-canada-with-health-canada-approved-import-permit-debenture-offering-successfully-closed/2024-04-09T19:19:32.000Z https://psychedelicinvest.com/clearmind-medicine-ceo-issues-letter-to-shareholders/2024-04-09T19:16:40.000Z https://psychedelicinvest.com/numinus-to-host-q2-fiscal-2024-results-conference-call-on-april-15-2024/2024-04-09T19:13:14.000Z https://psychedelicinvest.com/missouri-considers-10-million-from-opioid-settlements-for-psilocybin-research/2024-04-08T16:14:09.000Z https://psychedelicinvest.com/psilocybin-clinical-trial-sponsored-by-clairvoyant-therapeutics-reaches-90-randomization/2024-04-05T18:20:06.000Z https://psychedelicinvest.com/cortexa-commences-manufacturing-gmp-laneo-mdma-in-australia/2024-04-05T18:15:32.000Z https://psychedelicinvest.com/webinar-launching-and-protecting-your-ketamine-practice/2024-04-17T17:43:41.000Z https://psychedelicinvest.com/filament-health-nets-2-1m-in-revenue-in-2023/2024-04-04T19:48:35.000Z https://psychedelicinvest.com/fsd-pharma-cuts-annual-losses-to-18million-will-need-more-capital-to-develop/2024-04-04T19:10:43.000Z https://psychedelicinvest.com/alberta-blue-cross-inches-closer-to-covering-psychedelic-assisted-therapy/2024-04-04T18:49:31.000Z https://psychedelicinvest.com/hpdd-what-is-persistent-hallucinogenic-perception-disorder/2024-04-08T16:51:08.000Z https://psychedelicinvest.com/red-light-holland-partners-with-professor-david-nutt-and-drug-science-to-analyze-imicroapp-data-and-promote-responsible-regulations-for-psilocybin-microdosing/2024-04-04T18:25:48.000Z https://psychedelicinvest.com/filament-health-to-discuss-its-drug-development-platform-in-fireside-chat-with-water-tower-research-on-april-4-2024-at-12pm-et/2024-04-03T15:07:06.000Z https://psychedelicinvest.com/awakn-life-sciences-announces-launch-of-licensing-partnership-agreement-with-oklahoma-based-clinic/2024-04-03T15:03:23.000Z https://psychedelicinvest.com/reunion-neuroscience-inc-announces-upcoming-presentations-at-the-anxiety-and-depression-association-of-america-adaa-2024-conference/2024-04-03T14:59:18.000Z https://psychedelicinvest.com/betterlife-announces-closing-of-1-168-million-convertible-debentures-to-further-advance-ind-enabling-studies-of-its-non-hallucinogenic-lsd-based-drug-candidate-betr-001/2024-04-03T14:53:04.000Z https://psychedelicinvest.com/mindmed-shifts-focus-to-nasdaq/2024-04-02T21:20:14.000Z https://psychedelicinvest.com/compass-pathways-lost-its-co-founders-now-what/2024-04-02T20:56:40.000Z https://psychedelicinvest.com/buftoad-a-meme-coin-for-psychedelics/2024-04-02T20:50:18.000Z https://psychedelicinvest.com/psycan-welcomes-expansion-of-insurance-coverage-for-psychedelic-assisted-therapy-in-alberta/2024-04-02T20:37:08.000Z https://psychedelicinvest.com/compass-pathways-to-participate-in-upcoming-23rd-annual-needham-virtual-healthcare-conference/2024-04-02T20:34:13.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-to-move-forward-with-psychedelic-drug-dmt-stroke-research-program-as-its-lead-asset/2024-04-01T20:43:13.000Z https://psychedelicinvest.com/psyc-names-daniel-jaros-as-interim-ceo-retires-300k-debt/2024-04-01T20:40:26.000Z https://psychedelicinvest.com/patent-allowance-granted-for-ala-002-composition-by-us-patent-and-trademark-office/2024-03-28T16:12:48.000Z https://psychedelicinvest.com/psilera-welcomes-biopharma-executive-dr-magali-haas-to-its-board-of-directors/2024-03-28T16:08:26.000Z https://psychedelicinvest.com/atai-life-sciences-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-corporate-and-clinical-highlights/2024-03-28T16:02:04.000Z https://psychedelicinvest.com/optimi-health-confirms-presenting-sponsorship-at-the-4th-annual-psychedelic-therapeutics-and-drug-development-conference/2024-03-28T15:57:10.000Z https://psychedelicinvest.com/filament-health-announces-appointment-of-michael-messinger-to-its-board-of-directors/2024-03-28T15:47:06.000Z https://psychedelicinvest.com/preparing-for-the-horizons-perspectives-on-psychedelics-event-in-new-york/2024-03-27T20:44:10.000Z https://psychedelicinvest.com/atai-life-sciences-applauds-breakthrough-in-depression-treatment-with-beckley-psytechs-dmt-study/2024-03-27T18:00:31.000Z https://psychedelicinvest.com/beckley-psytech-announces-positive-initial-data-from-phase-iia-study-of-novel-5-meo-dmt-formulation-bpl-003-for-treatment-resistant-depression/2024-03-27T17:52:32.000Z https://psychedelicinvest.com/enveric-biosciences-reports-financial-results-and-provides-corporate-update-for-fourth-quarter-and-fiscal-year-ended-2023/2024-03-26T21:22:23.000Z https://psychedelicinvest.com/optimi-health-to-supply-mdma-for-psychedelic-research-at-tel-aviv-university/2024-03-26T21:19:27.000Z https://psychedelicinvest.com/pharmala-biotech-signs-sale-agreement-with-numinus/2024-03-26T21:09:05.000Z https://psychedelicinvest.com/psyence-group-announces-the-closing-of-the-previously-announced-strategic-restructuring-of-its-non-clinical-business/2024-03-26T21:05:12.000Z https://psychedelicinvest.com/pharmala-biotech-holdings-inc-announces-joint-venture-with-cortexa-pty-ltd/2024-03-25T18:22:39.000Z https://psychedelicinvest.com/insurance-coverages-to-help-bring-psychedelic-treatments-to-market/2024-03-22T16:56:25.000Z https://psychedelicinvest.com/robert-ansin-builds-bridges-to-healing-podcast-episode-48/2024-03-21T17:19:55.000Z https://psychedelicinvest.com/studying-the-effects-of-natural-psilocybin-versus-synthetic-versions/2024-03-21T16:52:12.000Z https://psychedelicinvest.com/psilocybin-study-reveals-the-brain-suppresses-reactions-to-angry-faces/2024-03-21T16:43:12.000Z https://psychedelicinvest.com/mindbio-therapeutics-corp-begins-phase-2b-take-home-microdosing-clinical-trial-in-patients-with-major-depressive-disorder/2024-03-20T20:15:09.000Z https://psychedelicinvest.com/silo-pharma-exercises-option-for-exclusive-license-agreement-for-first-in-class-ptsd-and-stress-induced-anxiety-therapeutic/2024-03-20T20:13:13.000Z https://psychedelicinvest.com/numinus-wellness-submits-clinical-trial-application/2024-03-20T20:11:10.000Z https://psychedelicinvest.com/psyence-biomedical-ltd-announces-results-of-recent-study-highlighting-benefits-of-nature-derived-psilocybin-vs-synthetic-psilocybin/2024-03-20T20:09:15.000Z https://psychedelicinvest.com/gilgamesh-receives-grant-to-combat-opioid-dependency/2024-03-20T20:04:59.000Z https://psychedelicinvest.com/filament-health-announces-shipments-of-botanical-psilocybin-to-four-countries-for-clinical-investigation/2024-03-19T18:42:00.000Z https://psychedelicinvest.com/breakthrough-in-wellness-clearmind-medicines-psychedelic-treatment-granted-divisional-patent-approval-in-china/2024-03-19T18:37:50.000Z https://psychedelicinvest.com/elon-musk-continues-to-defend-ketamine/2024-03-18T18:44:52.000Z https://psychedelicinvest.com/red-light-holland-announces-happy-caps-mushroom-home-grow-kits-now-available-in-over-270-retail-stores-across-canada/2024-03-18T18:21:43.000Z https://psychedelicinvest.com/silo-pharma-files-patent-for-groundbreaking-ketamine-implant-therapeutic-to-target-fibromyalgia-and-chronic-pain/2024-03-18T18:17:45.000Z https://psychedelicinvest.com/cybin-to-present-at-public-ventures-discovery-day-on-march-19th-in-dallas/2024-03-18T18:15:37.000Z https://psychedelicinvest.com/cybin-inc-announces-oversubscribed-private-placement-of-u-s-150-million/2024-03-14T19:25:56.000Z https://psychedelicinvest.com/clearmind-medicine-obtains-clearance-for-its-psychedelic-based-alcoholism-clinical-trial/2024-03-14T19:24:46.000Z https://psychedelicinvest.com/atma-cena-psychedelic-healthcare-solutions-opens-psychedelic-assisted-therapy-clinic-in-calgary-and-provides-update-of-its-clinic-network/2024-03-14T19:23:23.000Z https://psychedelicinvest.com/cybin-inc-announces-positive-end-of-phase-2-meeting-with-fda-for-cyb003-in-major-depressive-disorder-and-phase-3-program-design/2024-03-14T19:21:28.000Z https://psychedelicinvest.com/cybin-receives-fda-breakthrough-therapy-designation-for-its-novel-psychedelic-molecule-cyb003-and-announces-positive-four-month-durability-data-in-major-depressive-disorder/2024-03-13T20:32:24.000Z https://psychedelicinvest.com/pharmadrugs-securedose-announces-filing-of-us-provisional-patent-for-manufacturing-method-for-biosynthetic-pharmaceutical-grade-cocaine/2024-03-13T20:30:18.000Z https://psychedelicinvest.com/maps-and-the-city-of-denver-make-psychedelic-history/2024-03-13T20:27:54.000Z https://psychedelicinvest.com/numinus-wellness-provides-corporate-update/2024-03-13T20:16:58.000Z https://psychedelicinvest.com/clearmind-medicine-received-approval-for-a-voluntary-delisting-of-its-common-shares-from-the-canadian-securities-exchange/2024-03-13T20:14:03.000Z https://psychedelicinvest.com/revive-therapeutics-provides-corporate-update/2024-03-19T18:43:54.000Z https://psychedelicinvest.com/investments-in-studying-solid-tumors-could-increase-in-2024/2024-03-12T17:55:17.000Z https://psychedelicinvest.com/psyence-groups-nasdaq-listed-associate-psyence-biomedical-receives-human-research-ethics-committee-hrec-approval-to-initiate-phase-iib-study/2024-03-12T17:47:20.000Z https://psychedelicinvest.com/atai-life-sciences-advances-vls-01-for-treatment-resistant-depression/2024-03-12T17:44:05.000Z https://psychedelicinvest.com/psyence-group-provides-corporate-update-following-successful-spac-spin-out-of-therapeutic-division/2024-03-11T17:58:27.000Z https://psychedelicinvest.com/survey-shows-publics-growing-acceptance-of-magic-mushrooms/2024-03-11T17:14:27.000Z https://psychedelicinvest.com/cleveland-clinic-launches-nationwide-clinical-trial-for-magic-mushrooms/2024-03-11T17:02:43.000Z https://psychedelicinvest.com/red-light-holland-commences-experimental-research-on-psilocybin-truffles-to-develop-process-for-commercial-manufacturing-of-natural-source-active-pharmaceutical-ingredient/2024-03-08T17:33:57.000Z https://psychedelicinvest.com/alex-atwood-is-a-psychedelic-integration-coach-podcast-episode-47/2024-03-07T22:29:14.000Z https://psychedelicinvest.com/the-uae-is-exploring-the-rollout-of-psychedelic-assisted-therapies/2024-03-07T19:06:18.000Z https://psychedelicinvest.com/the-bluesky-wellness-and-lucy-scientific-deal-is-a-no-go/2024-03-07T18:22:30.000Z https://psychedelicinvest.com/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder/2024-03-07T18:13:23.000Z https://psychedelicinvest.com/the-rising-curiosity-in-psilocybin-gummies/2024-03-05T21:11:36.000Z https://psychedelicinvest.com/the-state-of-advertising-psychedelics-online/2024-03-05T20:46:06.000Z https://psychedelicinvest.com/mindbio-therapeutics-receives-final-regulatory-approval-to-conduct-phase-2b-randomized-controlled-trial-microdosing-mb22001-in-patients-diagnosed-with-major-depressive-disorder/2024-03-05T20:35:02.000Z https://psychedelicinvest.com/mushrooms-inc-otcmsrm-launches-new-health-supplements-progresses-with-german-partnership-and-boosts-engagement-initiatives/2024-03-05T20:30:15.000Z https://psychedelicinvest.com/atai-life-sciences-announces-first-participant-dosed-in-phase-1b-trial-of-vls-01/2024-03-04T21:43:23.000Z https://psychedelicinvest.com/betterlifes-2-bromo-lsd-for-treatment-of-depression-highlighted-by-carleton-university/2024-03-04T21:39:59.000Z https://psychedelicinvest.com/ketamines-short-and-long-term-effects-on-depression/2024-03-01T18:13:57.000Z https://psychedelicinvest.com/braxia-scientific-corp-shows-resilience-amid-financial-challenges/2024-03-01T18:02:41.000Z https://psychedelicinvest.com/silo-wellness-announces-extension-of-kaya-nugl-loi-annual-filings-delay/2024-02-29T17:31:16.000Z https://psychedelicinvest.com/mindmed-reports-2023-financial-results-and-business-updates/2024-02-29T17:28:26.000Z https://psychedelicinvest.com/incannex-announces-positive-topline-results-from-phase-2-psi-gad1-clinical-trial-of-psilocybin-in-generalised-anxiety-disorder/2024-02-29T17:25:28.000Z https://psychedelicinvest.com/optimi-announces-closing-of-first-tranche-of-non-brokered-private-placement/2024-02-29T17:23:12.000Z https://psychedelicinvest.com/silo-pharma-completes-successful-dose-ranging-study-of-spc-15-intranasal-therapeutic-for-ptsd/2024-02-29T17:20:00.000Z https://psychedelicinvest.com/atai-life-sciences-to-participate-in-the-upcoming-td-cowen-44th-annual-health-care-conference/2024-02-29T17:17:17.000Z https://psychedelicinvest.com/revive-therapeutics-ltd-announces-closing-of-the-second-and-final-tranche-of-its-private-placement-for-gross-proceeds-of-1187110/2024-02-27T22:59:33.000Z https://psychedelicinvest.com/pharmadrug-appoints-current-board-member-dr-david-kideckel-as-chairman/2024-02-27T22:56:01.000Z https://psychedelicinvest.com/psychedelic-focused-firm-clearmind-medicine-submits-three-new-international-patent-applications-for-mdma-ibogaine-and-ketamine-compounds/2024-02-27T22:53:11.000Z https://psychedelicinvest.com/cybin-to-present-at-the-td-cowen-44th-annual-health-care-conference/2024-02-27T22:42:46.000Z https://psychedelicinvest.com/red-light-holland-to-export-its-largest-batch-of-psilocybin-to-cgmp-lab-in-canada-under-a-5th-health-canada-approved-psilocybin-import-permit-to-partner-ccrest-labs/2024-02-27T19:39:21.000Z https://psychedelicinvest.com/fsd-pharma-inc-subsidiary-enter-agreement-for-clinical-trial-of-proprietary-blend-beverage/2024-02-26T20:33:22.000Z https://psychedelicinvest.com/clearmind-medicine-receives-approval-to-commence-its-phase-i-iia-clinical-trial-of-cmnd-100-for-alcohol-use-disorder/2024-02-23T18:18:26.000Z https://psychedelicinvest.com/psychedelics-effects-on-sexual-functions/2024-02-22T17:18:22.000Z https://psychedelicinvest.com/avesta-partners-with-veterans-affairs-va-to-offer-free-ketamine-therapy-to-eligible-veterans/2024-02-21T16:26:06.000Z https://psychedelicinvest.com/fsd-pharma-inc-nasdaq-huge-enters-market-offering-agreement/2024-02-21T16:22:52.000Z https://psychedelicinvest.com/illinois-embarks-on-a-legalization-journey-for-psilocybin-therapy/2024-02-20T17:20:45.000Z https://psychedelicinvest.com/clearmind-medicine-submits-three-international-patent-applications-for-next-generation-classic-psychedelic-based-compounds/2024-02-20T16:55:09.000Z https://psychedelicinvest.com/save-the-date-psychedelic-science-returns-in-2025/2024-02-20T16:51:11.000Z https://psychedelicinvest.com/robin-arnott-sandeep-prakash-are-building-meditative-states-through-sound-podcast-episode-46/2024-02-15T22:24:23.000Z https://psychedelicinvest.com/similarities-between-ai-and-psychedelics/2024-02-15T19:27:31.000Z https://psychedelicinvest.com/mindbio-therapeutics-completes-world-first-take-home-phase-2a-microdosing-depression-trial/2024-02-15T19:16:20.000Z https://psychedelicinvest.com/silo-pharmas-sp-26-ketamine-implant-demonstrates-successful-drug-delivery/2024-02-15T19:11:46.000Z https://psychedelicinvest.com/unveiling-the-mysteries-of-the-mind-a-landmark-event-in-new-orleans/2024-02-14T20:28:19.000Z https://psychedelicinvest.com/new-mexico-takes-bold-steps-towards-psilocybin-therapy-research/2024-02-14T18:56:03.000Z https://psychedelicinvest.com/cybin-reports-third-quarter-financial-results-and-recent-business-highlights/2024-02-14T17:03:46.000Z https://psychedelicinvest.com/a-doctor-is-suing-the-dea-to-treat-terminally-ill-patients-with-psilocybin/2024-02-12T18:00:43.000Z https://psychedelicinvest.com/fda-accepts-mdma-for-ptsd-therapys-new-drug-application/2024-02-12T20:17:53.000Z https://psychedelicinvest.com/rebecca-nicholson-is-advancing-the-field-of-wellness-for-all-podcast-episode-45/2024-02-09T18:55:29.000Z https://psychedelicinvest.com/pharmadrug-inc-announces-successful-closing-of-non-brokered-private-placement/2024-02-09T18:17:22.000Z https://psychedelicinvest.com/pharmala-and-red-light-holland-to-collaborate-on-medical-psilocybin-development/2024-02-09T18:13:41.000Z https://psychedelicinvest.com/optimi-announces-non-brokered-private-placement/2024-02-09T05:30:45.000Z https://psychedelicinvest.com/mydecine-innovations-group-receives-two-notice-of-allowances-from-uspto-for-its-myco-005-and-myco-006-family-of-compounds/2024-02-09T05:28:22.000Z https://psychedelicinvest.com/atai-life-sciences-appoints-anne-johnson-as-chief-financial-officer/2024-02-07T16:51:41.000Z https://psychedelicinvest.com/cybin-announces-grant-of-two-additional-patents-in-japan-in-support-of-its-dmt-program/2024-02-07T16:47:43.000Z https://psychedelicinvest.com/newsom-moves-california-toward-psychedelic-therapy/2024-02-06T18:18:12.000Z https://psychedelicinvest.com/police-seizures-of-psilocybin-are-up-369-since-2017/2024-02-06T18:10:57.000Z https://psychedelicinvest.com/clearmind-medicine-announces-exclusive-long-term-licensing-agreement-with-birad/2024-02-06T17:55:08.000Z https://psychedelicinvest.com/clearmind-medicine-receives-patent-approval-for-its-psychedelic-based-treatment-of-binge-behaviors-in-china/2024-02-06T17:51:54.000Z https://psychedelicinvest.com/awakn-life-sciences-announces-conditional-approval-of-cse-listing/2024-02-06T17:48:07.000Z https://psychedelicinvest.com/alto-neurosciences-inc-begins-trading-at-16-per-share/2024-02-02T17:46:04.000Z https://psychedelicinvest.com/numinus-wellness-inc-raises-6-million/2024-02-02T17:40:42.000Z https://psychedelicinvest.com/silo-pharma-announces-pipeline-prioritization-for-2024-targeting-mental-health-chronic-pain-and-neurology/2024-02-02T17:32:35.000Z https://psychedelicinvest.com/numinus-wellness-inc-announces-6-million-bought-deal-public-offering-with-leads-orders-from-maps-and-integrated-v-c/2024-02-02T17:30:25.000Z https://psychedelicinvest.com/clearmind-medicine-announces-exclusive-long-term-licensing-agreement-with-leading-israeli-research-center/2024-02-02T17:28:27.000Z https://psychedelicinvest.com/pharmadrug-inc-announces-proposed-non-brokered-private-placement/2024-02-02T17:26:02.000Z https://psychedelicinvest.com/numinus-wellness-divests-of-holdings-in-co-investment-feeder-fund-3/2024-02-02T17:23:22.000Z https://psychedelicinvest.com/revive-therapeutics-ltd-announces-closing-of-the-first-tranche-of-its-private-placement-for-gross-proceeds-of-913500/2024-02-02T17:20:47.000Z https://psychedelicinvest.com/pharmala-releases-profitable-q1-interim-financial-statement-and-business-update-2/2024-02-02T17:17:33.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-receives-notice-of-intention-to-grant-from-chinese-patent-office-for-repirinast-to-treat-ckd/2024-01-31T18:30:55.000Z https://psychedelicinvest.com/magdalena-biosciences-a-joint-venture-between-jaguar-health-and-filament-health-study-indicates-psychoactive-activity-of-medicinal-plant-utilized-for-centuries-by-indigenous-peoples-in-tropical-regi/2024-01-31T18:25:41.000Z https://psychedelicinvest.com/filament-health-announces-fda-opening-of-investigational-new-drug-application-for-substance-use-disorders/2024-01-31T18:24:03.000Z https://psychedelicinvest.com/pharmala-releases-profitable-q1-interim-financial-statement-and-business-update/2024-01-31T17:57:51.000Z https://psychedelicinvest.com/fsd-pharma-announces-dr-sanjiv-chopra-is-elected-to-fsd-pharma-board-of-directors-and-corporate-updates/2024-01-30T18:54:16.000Z https://psychedelicinvest.com/huxley-health-inc-provides-corporate-update-appoints-bruce-linton-as-chairman/2024-01-30T18:48:45.000Z https://psychedelicinvest.com/mindbio-therapeutics-corp-announces-completion-of-landmark-phase-2a-lsd-microdosing-clinical-trial-in-distressive-disorder/2024-01-30T18:44:32.000Z https://psychedelicinvest.com/nirvana-life-sciences-inc-announces-receipt-of-first-north-american-production-of-sosa-a-patented-who-approved-herbal-treatment-for-opiate-addiction/2024-01-29T20:13:09.000Z https://psychedelicinvest.com/psyence-biomedical-ltd-approved-to-list-on-nasdaq-following-completion-of-business-combination-agreement-with-newcourt-aquisition-corp/2024-01-26T20:48:02.000Z https://psychedelicinvest.com/pharmala-granted-a-controlled-drugs-and-substances-dealers-licencse-by-health-canada/2024-01-26T20:28:12.000Z https://psychedelicinvest.com/2023-the-psychedelic-industry-report-pro-report/2024-01-26T20:50:39.000Z https://psychedelicinvest.com/the-psychedelic-education-market-in-2023-pro-report/2024-01-26T19:15:05.000Z https://psychedelicinvest.com/5-risks-while-operating-in-the-psychedelics-industry-in-2024/2024-01-26T18:56:17.000Z https://psychedelicinvest.com/psychedelic-medicine-year-end-analysis-pro-report/2024-01-26T18:47:53.000Z https://psychedelicinvest.com/red-light-holland-announces-strategic-changes-and-launch-of-sr-wholesale-north-america-a-fresh-mushroom-sale-division/2024-01-25T17:14:24.000Z https://psychedelicinvest.com/revive-therapeutics-ltd-announces-offering-of-up-to-3-million/2024-01-24T23:36:35.000Z https://psychedelicinvest.com/incannex-commences-dosing-in-phase-2-clinical-trial-assessing-ihl-675a-in-patients-with-rhemetoid-arthritis/2024-01-24T23:26:29.000Z https://psychedelicinvest.com/cory-firth-is-committed-to-a-career-empowering-wellbeing-podcast-episode-44/2024-01-24T22:45:13.000Z https://psychedelicinvest.com/pharmala-biotech-receives-new-mdxxf-ticker-from-finra-for-otcqb-listing/2024-01-24T18:48:29.000Z https://psychedelicinvest.com/silo-pharma-announces-positive-results-in-alzheivers-disease-study/2024-01-24T18:45:20.000Z https://psychedelicinvest.com/awakn-life-sciences-completes-successful-investigative-study-to-establish-dissociative-effect-of-a-proprietary-sublingual-s-ketamine-oral-thin-film-formulation-in-harmful-drinkers/2024-01-24T18:42:01.000Z https://psychedelicinvest.com/red-light-hollands-homogenized-psilocybin-microdosing-capsules-complete-product-specification-document-by-cgmp-pharmaceutical-company-ccrest-laboratories-provided-to-nubu-pharmaceuticals-in-australasi/2024-01-23T17:38:14.000Z https://psychedelicinvest.com/cybin-announces-fda-clearance-to-initiate-a-phase-2a-study-of-cyb004-in-generalized-anxiety-disorder/2024-01-23T17:27:59.000Z https://psychedelicinvest.com/newcourt-acquisition-corp-announces-continuation-of-business-combination-close-process/2024-01-23T17:22:57.000Z https://psychedelicinvest.com/review-of-the-psychedelic-industry-in-2023-a-year-of-toil-torment-and-triumph/2024-01-19T21:05:44.000Z https://psychedelicinvest.com/optimi-health-secures-amendment-to-increase-quantities-of-mdma-mda-and-2cb-under-controlled-drugs-and-substance-dealers-license/2024-01-19T19:05:00.000Z https://psychedelicinvest.com/marik-hazan-invests-in-healthcares-biggest-blindspots-podcast-episode-43/2024-01-18T22:12:29.000Z https://psychedelicinvest.com/incannex-completes-dosing-and-therapy-in-phase-2-psigad-clinical-trial-assessing-psilocybin-assisted-therapy-psychotherapy-for-generalized-anxiety-disorder-data-analysis-commences/2024-01-18T19:11:14.000Z https://psychedelicinvest.com/clearmind-medicine-announces-aigis-captial-corp-bookrunner-for-private-placement/2024-01-19T19:36:54.000Z https://psychedelicinvest.com/filament-health-completes-the-first-export-of-botanical-psilocybin-to-australia/2024-01-17T19:27:30.000Z https://psychedelicinvest.com/incannex-receives-irb-approval-for-the-reposa-phase-2-3-clinical-trial-protocol-to-assess-ihl-42x-drug-in-patients-with-obstructive-sleep-apnea/2024-01-17T18:00:35.000Z https://psychedelicinvest.com/maps-unveils-improved-fiscal-sponsorship-program-empowering-innovators-in-the-psychedelic-movement/2024-01-17T17:55:25.000Z https://psychedelicinvest.com/update-provided-on-gbb-drink-lab-inc-litigation-and-safety-shot/2024-01-17T17:51:48.000Z https://psychedelicinvest.com/webinar-healing-october-7th-using-mdma-for-ptsd-in-israel-presented-by-maps-israel/2024-01-26T03:34:59.000Z https://psychedelicinvest.com/psyence-group-inc-subsidiary-psyence-biomedical-ltd-announces-signing-of-definitive-agreement-for-a-convertible-note-in-connection-with-planned-business-combination/2024-01-16T17:41:32.000Z https://psychedelicinvest.com/numinus-wellness-inc-announces-first-quarter-fiscal-2024-results/2024-01-16T17:34:58.000Z https://psychedelicinvest.com/red-light-holland-receives-building-permit-for-aem-farms-80000-square-mushroom-farm-adding-substantial-future-production-capacity/2024-01-16T17:19:00.000Z https://psychedelicinvest.com/psyc0ceo-provides-detailed-update-on-the-state-of-the-company-in-newly-released-podcast-recording/2024-01-11T21:45:28.000Z https://psychedelicinvest.com/cybin-announces-positive-topline-data-from-phase-1-studies-of-proprietary-deuterated-dmt-molecules-cyb-004-and-spl-028/2024-01-11T21:38:09.000Z https://psychedelicinvest.com/clearmind-medicine-completed-type-a-meeting-with-the-fda/2024-01-11T21:26:12.000Z https://psychedelicinvest.com/mindmed-announces-business-update-and-anticipated-milestones-for-2024/2024-01-11T21:17:21.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-announces-notice-of-allowance0for-ifenprodil-patent-in-japan-for-idiopathic-pulmonary-fibrosis/2024-01-11T21:12:32.000Z https://psychedelicinvest.com/pharmala-1-molecule-receives-us-patent-prosecution-highway-acceptance/2024-01-11T21:07:45.000Z https://psychedelicinvest.com/clearmind-medicine-inc-announces-pricing-of-2-4-million-registered-direct-and-private-placement/2024-01-11T21:03:26.000Z https://psychedelicinvest.com/brainweek-2024-to-feature-three-nationally-acclaimed-energizing-keynote-speakers-who-will-address-the-fields-most-relevant-topics-on-brain-health/2024-01-11T20:59:42.000Z https://psychedelicinvest.com/anuma-pioneering-psychological-wellbeing-technology-for-serious-disease-care-and-beyond/2025-06-29T17:48:04.000Z https://psychedelicinvest.com/maps-public-benefit-corporation-announces-oversubscribed-series-a-financing-and-renames-to-lykos-therapeutics/2024-01-05T17:37:00.000Z https://psychedelicinvest.com/allegations-of-sexual-abuse-in-the-psychedelic-industry-how-to-address-and-prevent-misconduct/2024-01-04T22:29:05.000Z https://psychedelicinvest.com/silo-pharma-successfully-completes-first-phase-of-dose-ranging-study-of-spc-15-an-intranasal-treatment-for-ptsd/2024-01-04T18:28:02.000Z https://psychedelicinvest.com/cybin-highlights-recent-topline-results-and-outlines-key-upcoming-milestones-across-its-clinical-development-programs/2024-01-04T18:25:12.000Z https://psychedelicinvest.com/scisparc-and-clearmind-medicine-reflect-on-successful-collaboration-in-2023-aiming-to-upgrade-wide-range-of-psychedelic-based-treatments/2024-01-04T18:18:39.000Z https://psychedelicinvest.com/optimi-health-granted-precursor-licence-to-formulate-mdma-and-completes-encapsulation-of-40mg-and-60mg-dosage-formats/2024-01-04T18:14:30.000Z https://psychedelicinvest.com/the-current-landscape-of-psychedelic-therapist-training/2025-06-29T17:48:04.000Z https://psychedelicinvest.com/atai-life-sciences-announces-strategic-investment-in-beckley-psytech-to-accelerate-the-clinical-development-of-short-duration-psychedelics/2024-01-04T17:56:22.000Z https://psychedelicinvest.com/webinar-neuroplasticity-and-psychedelics/2024-01-25T16:05:03.000Z https://psychedelicinvest.com/filament-health-announces-change-to-board-of-directors/2024-01-03T18:31:33.000Z https://psychedelicinvest.com/atai-life-sciences-announces-positive-topline-results-from-single-ascending-dose-phase1-study-with-emp-01-r-mdma/2024-01-02T17:40:07.000Z https://psychedelicinvest.com/better-life-announces-closing-of-convertible-debentures-for-further-development-of-betr-001/2024-01-02T17:33:45.000Z https://psychedelicinvest.com/pharmala-files-audited-financials-for-year-ending-august-31-2023/2024-01-02T17:29:53.000Z https://psychedelicinvest.com/silo-pharma-and-partner-receive-regulatory-approval-to-begin-development-of-ketamine-implant-for-fibromyalgia/2024-01-02T17:22:15.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-announces-closing-of-private-placement/2024-01-02T17:16:05.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-announces-increase-to-private-placement/2024-01-02T17:12:58.000Z https://psychedelicinvest.com/psychedelic-search-trends-in-2023/2025-06-29T17:48:04.000Z https://psychedelicinvest.com/here-are-the-champions-our-top-performing-stories-in-2023/2025-06-29T17:48:04.000Z https://psychedelicinvest.com/clarion-clinics-receives-ethics-board-endorsement-for-the-first-dedicated-psychedelic-assisted-therapy-clinic-in-australia/2023-12-22T16:16:36.000Z https://psychedelicinvest.com/gv-freeman-helps-leaders-find-inspiration-podcast-episode-42/2023-12-21T16:19:52.000Z https://psychedelicinvest.com/revive-therapeutics-announces-results-of-annual-general-and-special-meeting-of-shareholders/2023-12-21T15:24:37.000Z https://psychedelicinvest.com/filament-health-announces-termination-of-proposed-business-combination-with-jupiter-acquisition-corp/2023-12-20T18:08:23.000Z https://psychedelicinvest.com/the-main-ethical-issues-in-psychedelic-therapy/2025-06-29T17:48:04.000Z https://psychedelicinvest.com/filament-health-announces-termination-of-shareholder-meeting-and-engagement-of-donohoe-advisory-for-compliance-expertise/2023-12-19T17:08:52.000Z https://psychedelicinvest.com/sunstone-therapies-announces-publication-of-positive-phase-2-study-results-in-cancer/2023-12-18T14:43:17.000Z https://psychedelicinvest.com/mydecine-innovations-group-recieves-notice-of-allowance-from-uspto-for-its-myco-005-compound/2023-12-18T14:37:53.000Z https://psychedelicinvest.com/numinus-wellness-cedar-clinical-research-selected-as-clinical-research-site-for-beckley-psychtech-phasee-2-study/2023-12-15T17:49:12.000Z https://psychedelicinvest.com/beckley-academy-welcomes-new-faculty-for-2024-psychedelic-therapy-practitioners-course/2023-12-14T15:49:10.000Z https://psychedelicinvest.com/clearmind-medicine-announces-it-is-in-compliance-with-all-applicable-nasdaq-listing-standards/2023-12-14T15:45:56.000Z https://psychedelicinvest.com/mindmed-announces-positive-topline-results-from-2b-trial-of-mm-120-in-generalized-anxiety-disorder/2023-12-14T15:40:33.000Z https://psychedelicinvest.com/a-step-in-the-chaotic-journey-towards-fda-approval-of-psychedelic-assisted-therapy/2023-12-14T16:26:19.000Z https://psychedelicinvest.com/sunstrone-therapies-celebrates-three-year-anniversary-with-more-than-100-psychedelic-treatments-completedtherapy/2023-12-14T15:11:45.000Z https://psychedelicinvest.com/kyle-buller-educates-the-future-of-psychedelic-professionals-podcast-episode-41/2023-12-13T21:58:11.000Z https://psychedelicinvest.com/pharmadrug-ceo-provides-vision-for-securedose-acquisition/2023-12-13T15:23:16.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-announces-private-placement/2023-12-13T15:15:19.000Z https://psychedelicinvest.com/maps-pbc-announces-submission-of-new-drug-application-to-the-fda-for-mdma-assisted-therapy/2023-12-12T18:23:26.000Z https://psychedelicinvest.com/rose-hill-and-acs-labratory-join-forces-to-pioneer-psilocybin-testing-standards/2023-12-12T14:39:06.000Z https://psychedelicinvest.com/psyched-wellness-calm-first-legal-amanita-muscaria-extract-arrives-at-pop-up-grocer-in-nyc/2023-12-12T14:35:37.000Z https://psychedelicinvest.com/filament-health-announces-adjournment-of-special-meeting/2023-12-12T15:38:31.000Z https://psychedelicinvest.com/an-interview-with-psychedelic-investor-cody-shandraw/2023-12-12T14:26:38.000Z https://psychedelicinvest.com/beckley-retreats-annoucnes-expanded-scholarship-program-alongside-new-specialty-programs-for-underserved-communities/2023-12-11T17:12:22.000Z https://psychedelicinvest.com/red-light-hollands-gmp-manufactured-psilocybin-microdosing-capsules-aimed-to-be-distributed-in-emerging-markets-pass-five-month-stability-testing-by-ccrest-laboratories-in-montreal-canada/2023-12-11T17:09:21.000Z https://psychedelicinvest.com/tryp-therapeutics-inc-announces-signing-of-definitive-agreement-with-exopharm-limited/2023-12-11T17:00:21.000Z https://psychedelicinvest.com/the-state-of-psychedelic-reform-in-the-uk-and-eu/2025-06-29T17:48:05.000Z https://psychedelicinvest.com/optimi-health-and-sunshine-earth-labs-ltd-forge-strategic-supply-agreement/2023-12-07T17:01:19.000Z https://psychedelicinvest.com/tyler-zakovich-is-growing-a-clinic-focused-real-estate-portfolio-podcast-episode-40/2023-12-06T21:31:03.000Z https://psychedelicinvest.com/filament-health-announces-signing-of-definitive-agreement-for-convertible-note-financing-closing-of-c900000-non-brokered-private-placement-financing-founder-led-note-offering-and-other-updates-relat/2023-12-06T18:40:29.000Z https://psychedelicinvest.com/cybin-announces-grant-of-additional-us-patent-in-support-of-its-cyb003-deuterated-psilocybin-analog-program/2023-12-06T18:17:32.000Z https://psychedelicinvest.com/fsd-pharma-closes-non-brokered-private-placement/2023-12-06T18:04:12.000Z https://psychedelicinvest.com/numinus-releases-2023-financial-year-results/2025-06-29T17:48:05.000Z https://psychedelicinvest.com/clearmind-medicine-achieved-positive-results-in-cocaine-addiction-treatment/2023-12-05T19:46:45.000Z https://psychedelicinvest.com/mental-health-psychedelic-apps-market-is-booming-and-expected-to-grow-at-a-cagr-of-19-2-to-2031/2023-12-05T19:27:10.000Z https://psychedelicinvest.com/psychedelic-education-market-size-and-analysis/2025-06-29T17:48:05.000Z https://psychedelicinvest.com/weightloss-meai-clearmind-medicines-novel-obesity-drug-showed-positive-results-in-a-preclinical-trial/2023-12-01T19:54:39.000Z https://psychedelicinvest.com/cybin-inc-reports-positive-topline-data-from-phase-2-of-cyb003-in-major-depressive-disorder-with-79-of-patients-in-remission-after-two-12mg-doses/2023-12-01T17:50:34.000Z https://psychedelicinvest.com/braxia-scientific-reports-q2-2024-financial-results-and-provides-corporate-update/2023-11-30T22:41:10.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-recieves-notice-of-intention-to-grant-from-chinese-patent-office-for-repirinast-to-treat-nash-and-nafld/2023-11-30T22:31:02.000Z https://psychedelicinvest.com/global-cns-therapeutics-strategic-report-2023-market-to-reach-199-billion-by-2030-developing-market-to-drive-the-market-momentum-asia-pacific-to-exhibit-fastest-growth/2023-11-30T22:06:47.000Z https://psychedelicinvest.com/numinus-wellness-inc-announces-fourth-quarter-and-full-year-fiscal-2023-results/2023-11-30T22:00:39.000Z https://psychedelicinvest.com/incannex-healthcare-announces-completion-of-its-redomiciliation-to-the-us/2023-11-30T21:50:31.000Z https://psychedelicinvest.com/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-development-of-glycosylated-psilocybin-derivatives/2023-11-29T18:37:50.000Z https://psychedelicinvest.com/wesana-health-announces-restructuring-of-promissory-not-receivable/2023-11-29T18:30:32.000Z https://psychedelicinvest.com/mydecine-announces-update-regarding-the-special-access-program/2023-11-29T18:26:33.000Z https://psychedelicinvest.com/update-provided-on-gbb-drink-lab-inc-litigation-and-safety-shot-previously-known-as-jupiter-wellness/2023-11-29T18:22:16.000Z https://psychedelicinvest.com/beckley-retreats-launches-signature-program-for-personal-discovery-and-transformation/2023-11-29T18:16:28.000Z https://psychedelicinvest.com/clearmind-medicine-announes-positive-results-from-its-weight-loss-and-metabolic-disorder-program-with-its-proprietary-psychedelic-based-treatment/2023-11-29T18:09:09.000Z https://psychedelicinvest.com/optimi-health-achieves-genetics-milestone-and-completes-psilocybin-extract-validation-and-stability-testing/2023-11-29T17:56:22.000Z https://psychedelicinvest.com/irwin-naturals-reports-q3-2023-financial-results/2023-11-28T21:08:08.000Z https://psychedelicinvest.com/clearmind-medicine-to-participate-in-traditional-vs-novel-psychedelics-virtual-event-with-leading-industry-figures/2023-11-28T20:40:07.000Z https://psychedelicinvest.com/filament-health-signs-non-binding-term-sheet-for-convertible-note-in-connection-with-planned-business-combination/2023-11-28T21:25:16.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-announces-loi-for-the-acquisition-of-its-chronic-cough-research-program-by-u-s-based-seyltx-for-usd-2m-and-a-20-equity-position/2023-11-28T00:18:40.000Z https://psychedelicinvest.com/clearmind-medicine-announces-1-for-30-reverse-share-split/2023-11-21T15:22:51.000Z https://psychedelicinvest.com/silo-pharma-enters-into-exclusive-license-agreement-with-medspray-bv-for-intranasal-technology-used-in-spc-15-treatment-for-ptsd/2023-11-21T15:15:55.000Z https://psychedelicinvest.com/revive-therapeutics-provides-update-of-novel-becillamine-formulation/2023-11-21T15:10:24.000Z https://psychedelicinvest.com/optimi-health-november-2023-shareholder-update/2023-11-20T20:52:10.000Z https://psychedelicinvest.com/psyence-group-announces-resignation-of-board-member/2023-11-20T20:39:48.000Z https://psychedelicinvest.com/cybin-to-host-cyb003-topline-depression-study-review-and-rd-briefing-on-november-30-2023-in-new-york-city/2023-11-20T20:31:07.000Z https://psychedelicinvest.com/clearmind-medicine-announces-receipt-of-nasdaq-delisting-notice-and-plan-for-immediate-recompliance/2023-11-20T02:02:51.000Z https://psychedelicinvest.com/fsd-pharma-announces-distribution-date-for-distribution-of-celly-shares-pursuant-to-plan-of-arrangement/2023-11-20T01:57:58.000Z https://psychedelicinvest.com/federal-court-of-australia-approves-incannexs-re-domiciliation-and-lodgement-of-court-orders-with-asic/2023-11-16T19:15:34.000Z https://psychedelicinvest.com/psyence-group-announces-sec-effectiveness-of-f-4-for-proposed-businesscombination-between-subsidiary-and-nasdaq-listed-newcourt-acquisition-corp/2023-11-16T19:08:24.000Z https://psychedelicinvest.com/pharmala-biotech-and-filament-health-announce-release-of-second-batch-of-gmp-mdma-capsules/2023-11-16T19:01:15.000Z https://psychedelicinvest.com/pharmadrug-inc-completes-debt-restructuring/2023-11-16T18:52:56.000Z https://psychedelicinvest.com/us-patent-and-trademark-office-publishes-betterlife-comprehensive-patent-for-betr-001-and-other-lsd-derivatives/2023-11-16T18:44:42.000Z https://psychedelicinvest.com/clearmind-medicine-announces-shareholders-meeting-results-2/2023-11-16T18:38:16.000Z https://psychedelicinvest.com/compass-pathways-initiates-uk-components-of-global-phase-3-study-of-psilocybin-treatment-in-treatment-resistant-depression-and-launches-new-research-center/2023-11-16T18:32:29.000Z https://psychedelicinvest.com/matthew-helt-is-a-certified-integration-coach-podcast-episode-39/2023-11-16T18:25:37.000Z https://psychedelicinvest.com/filament-health-announces-third-quarter-2023-financial-results-and-operation-highlights/2023-11-16T17:58:17.000Z https://psychedelicinvest.com/wonderland-miami-psychedelic-conference-marks-a-shift-in-the-strategy-of-the-psychedelic-industry/2025-06-29T17:48:26.000Z https://psychedelicinvest.com/cybin-second-quarter-financial-results-recent-business-highlights-and-pipeline-updates/2023-11-15T16:12:10.000Z https://psychedelicinvest.com/cybin-announces-closing-of-offering-of-units-led-by-one-of-the-companys-largest-institutional-shareholders/2023-11-14T20:24:43.000Z https://psychedelicinvest.com/atai-life-sciences-reports-third-quarter-2023-financial-results-and-pipeline-update/2023-11-14T16:36:47.000Z https://psychedelicinvest.com/red-light-holland-psilocybin-microdosing-capsules-aimed-to-be-distributed-in-emerging-markets-pass-four-month-stability-testing-by-c-crest-laboratories-in-montreal-canada/2023-11-13T17:45:16.000Z https://psychedelicinvest.com/the-virtual-trip-showcases-veterans-sessions-from-psychedelic-science-in-honor-of-veterans-day/2023-11-13T16:58:54.000Z https://psychedelicinvest.com/cybin-announces-up-to-us64-million-offering-of-units/2023-11-10T16:12:03.000Z https://psychedelicinvest.com/optimi-health-resolves-dispute/2023-11-10T16:08:40.000Z https://psychedelicinvest.com/pharmala-partners-with-clariti-strategic-advisors/2023-11-09T23:00:10.000Z https://psychedelicinvest.com/psycs-ceo-to-moderate-panel-at-the-cannabis-psychedelics-investment-summit-hosted-by-kahner-global/2023-11-09T22:44:27.000Z https://psychedelicinvest.com/silo-pharma-to-initiate-dose-ranging-study-of-novel-intranasal-therapeutic-spc-15-for-the-treatment-of-ptsd/2023-11-09T22:34:15.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-receives-japanese-patent-notice-of-allowance-for-treatment-of-nash-with-repirinast/2023-11-09T22:24:32.000Z https://psychedelicinvest.com/darryl-hudson-is-developing-psilocybin-based-therapeutics-podcast-episode-38/2023-11-09T03:16:02.000Z https://psychedelicinvest.com/interview-with-therapsil-psychedelic-access-and-education/2023-11-08T15:07:59.000Z https://psychedelicinvest.com/pharmala-completes-historic-first-shipment-of-mdma-and-psilocybin-to-cortexa/2023-11-07T16:05:04.000Z https://psychedelicinvest.com/pharmadrug-inc-closes-acqusition-of-securedose-synthetics/2023-11-07T14:24:47.000Z https://psychedelicinvest.com/optimi-health-welcomes-dr-preston-a-chase-as-new-chief-science-officer/2023-11-07T14:19:08.000Z https://psychedelicinvest.com/revive-therapeutics-enters-into-worldwide-exclusive-agreement-with-lawson-health-research-institute-to-develop-and-commercialize-a-novel-long-covid-rapid-test/2023-11-06T15:51:29.000Z https://psychedelicinvest.com/sunstone-therapies-announces-start-of-first-study-of-multimple-doses-of-psilocybin/2023-11-06T15:35:14.000Z https://psychedelicinvest.com/dea-announces-major-increase-to-2023-production-quotas-for-psilocybin-thc-and-ibogaine/2023-11-06T15:30:44.000Z https://psychedelicinvest.com/red-light-holland-engages-dr-taras-nahirny-as-advisor-to-help-with-distribution-of-company-homogenized-psilocybin-microdosing-capsules/2023-11-06T15:26:26.000Z https://psychedelicinvest.com/media-blames-magic-mushrooms-for-pilots-attemptto-bring-down-plane-full-of-passengers-what-really-happened/2025-06-29T17:48:26.000Z https://psychedelicinvest.com/optimi-health-announces-third-and-final-tranche-of-cad-1000000-secured-for-debt-financing/2023-11-03T18:01:07.000Z https://psychedelicinvest.com/psyence-production-expands-psilocybin-production-capabilies/2023-11-03T17:54:00.000Z https://psychedelicinvest.com/mydecine-innovations-group-files-prospectus-supplement-announces-closing-under-share-subscription-agreements/2023-11-03T17:43:49.000Z https://psychedelicinvest.com/reset-pharma-receives-notice-of-safe-to-proceed-from-fda-for-investigational-new-drug-ind-application-for-oral-psilocybin-rstp1000/2023-11-02T19:16:57.000Z https://psychedelicinvest.com/cybin-provides-corporate-update-and-highlights-key-upcoming-milestones/2023-11-02T19:11:54.000Z https://psychedelicinvest.com/complete-guide-to-wonderland-maimi-2023/2025-06-29T17:48:26.000Z https://psychedelicinvest.com/christi-myers-believes-in-the-power-of-dissociative-therapy-podcast-episode-37/2023-11-01T20:08:57.000Z https://psychedelicinvest.com/cybin-announces-positive-phase-2-interim-data-for-cyb003-in-major-depressive-disorder/2023-11-01T13:50:02.000Z https://psychedelicinvest.com/psychedelic-laws-in-alabama/2023-10-30T18:31:22.000Z https://psychedelicinvest.com/the-peyote-predicament-a-controversial-debate-in-the-psychedelic-industry/2025-06-29T17:48:26.000Z https://psychedelicinvest.com/pharmadrug-inc-enters-definitive-agreeent0to-acquire-securedose-synthetics/2023-10-27T15:11:53.000Z https://psychedelicinvest.com/beckley-waves-acquires-nue-life/2023-10-26T14:40:34.000Z https://psychedelicinvest.com/cybin-announces-grant-of-european-patent-protecting-its-proprietary-deuterated-dmt-analogs/2023-10-26T14:34:02.000Z https://psychedelicinvest.com/safe-supply-streaming-co-ltd-announces-appointment-of-ronan-levy-as-president/2023-10-26T14:25:55.000Z https://psychedelicinvest.com/mydecine-provides-q4-2023-business-update/2023-10-26T14:17:31.000Z https://psychedelicinvest.com/hearings-commence-for-lawsuit-denying-psilocybin-rescheduling-request/2023-10-26T14:05:04.000Z https://psychedelicinvest.com/atma-welcomes-dr-scott-shannon-maps-mdma-phase-3-principal-investigator-to-expand-its-clinical-training-expertise-in-mdma-assisted-therapy/2023-10-25T17:17:11.000Z https://psychedelicinvest.com/first-patient-dosed-in-beckely-psytechs-international-phase-iib-study-of-bpl-003-a-novel-synthetic-intranasal-formulation-of-5-meo-dmt-for-treatment-resistant-depression/2023-10-25T17:05:09.000Z https://psychedelicinvest.com/the-healing-companys-chopra-and-swan-hellenic-announce-exclusive-multi-year-partnership-with-launch-of-well-being-travel-experience-explore-restore/2023-10-25T16:28:25.000Z https://psychedelicinvest.com/cybin-announces-grant-of-two-new-united-states-patents-protecting-its-deuterated-dmt-program/2023-10-25T14:57:46.000Z https://psychedelicinvest.com/colorado-natural-medicine-division-listening-session-part-1/2023-10-25T14:48:25.000Z https://psychedelicinvest.com/fsd-pharma-inc-announces-filing-in-connection-with-proposed-arrangement-with-celly-nu/2023-10-23T18:30:16.000Z https://psychedelicinvest.com/navigating-the-psychedelic-landscape-q3-industry-report/2023-10-24T18:45:22.000Z https://psychedelicinvest.com/cybin-completes-acquisition-of-small-pharma-inc-to-create-international-clinical-stage-leader-in-novel-psychedelic-therapeutics/2023-10-23T15:19:14.000Z https://psychedelicinvest.com/pharmadrug-announces-share-consolidation-and-change-to-chief-financial-officer/2023-10-20T20:56:33.000Z https://psychedelicinvest.com/small-pharma-reports-fiscal-second-quarter-2024-highlights/2023-10-20T17:04:21.000Z https://psychedelicinvest.com/brain-and-behavior-research-foundation-awards-10-2-million-in-young-investigator-grants-to-150-mental-health-scientists/2023-10-20T16:56:27.000Z https://psychedelicinvest.com/roland-griffiths-and-extraordinary-life-and-legacy-in-psychedelic-research/2023-12-08T01:49:06.000Z https://psychedelicinvest.com/red-light-holland-fully-owned-subsidiary-radix-motion-granted-patent-for-3d-movement-and-ai-innovations/2023-10-19T15:15:50.000Z https://psychedelicinvest.com/pioneers-and-innovators-in-psilocybin-treatments-and-how-big-pharma-want-in-on-the-psychedelic-sector/2023-10-19T14:48:20.000Z https://psychedelicinvest.com/democratic-presidential-candidate-wants-psychedelics-covered-by-health-insurance/2023-10-18T19:48:38.000Z https://psychedelicinvest.com/mushrooms-inc-announces-full-patent-filing-for-groundbreaking-mycelium-technology-providing-bacterial-detection-and-nutrient-delivery/2023-10-18T19:37:47.000Z https://psychedelicinvest.com/jennifer-chesak-writes-about-psilocybin-and-women-podcast-episode-36/2023-10-18T18:28:26.000Z https://psychedelicinvest.com/lucy-scientific-discoverys-alternative-mental-health-treatments-to-provide-opportunity-to-improve-mental-health/2023-10-18T13:41:39.000Z https://psychedelicinvest.com/mydecine-innovations-group-gearing-up-for-human-trials-after-completing-aquis-listing/2023-10-18T13:37:12.000Z https://psychedelicinvest.com/diamond-therapeutics-announces-first-patient-enrolled-in-fda-authorized-psilocybin-trial/2023-10-17T18:24:44.000Z https://psychedelicinvest.com/revive-therapeutics-enters-into-agreement-with-defence-research-and-development-canada-for-evaluating-bucillamine-for-nerve-agent-exposure/2023-10-17T18:18:44.000Z https://psychedelicinvest.com/silo-pharmas-spu-21-peptide-shows-positive-results-against-rheumatoid-arthritis/2023-10-16T13:58:37.000Z https://psychedelicinvest.com/q3-overview-the-state-of-the-psychedelic-sector/2025-06-29T17:48:26.000Z https://psychedelicinvest.com/cybin-shareholders-vote-overwhelmingly-for-acquisition-of-small-pharma/2023-10-13T20:22:02.000Z https://psychedelicinvest.com/small-pharma-announces-voting-results-in-favor-of-cybin-acquisition/2023-10-13T20:13:14.000Z https://psychedelicinvest.com/optimind-pharma-announces-entry-into-acquisitions-agreement-with-wolf-acquisitions/2023-10-13T19:59:56.000Z https://psychedelicinvest.com/revive-therapeutics-provides-update-of-novel-bucillamine-formulation-formulation-development/2023-10-12T14:36:14.000Z https://psychedelicinvest.com/silo-pharma-initiates-human-factor-study-of-spc-15-for-the-treatment-of-ptsd/2023-10-12T14:23:01.000Z https://psychedelicinvest.com/psychedelics-education-training-what-operators-educators-need-to-know-for-a-successful-practice/2023-10-11T19:31:55.000Z https://psychedelicinvest.com/james-gilligan-is-leading-the-next-wave-of-psilocybin-podcast-episode-35/2023-10-11T18:44:00.000Z https://psychedelicinvest.com/red-light-holland-fires-mia-khalifaa-for-tweets-condoning-hamas-attack-on-israel/2023-10-10T16:33:56.000Z https://psychedelicinvest.com/lophos-secures-game-changing-controlled-substance-dealers-license/2023-10-10T16:09:00.000Z https://psychedelicinvest.com/filament-health-announces-health-canada-authorization-for-phase-2-psilocybin-trial/2023-10-10T18:09:39.000Z https://psychedelicinvest.com/mindbio-therapeutics-corp-begins-selection-of-participants-for-its-phase-ii-trial/2023-10-10T15:54:22.000Z https://psychedelicinvest.com/mydecine-innovations-group-announces-admission-to-the-aqse/2023-10-10T15:43:05.000Z https://psychedelicinvest.com/origin-therapeutics-announces-results-of-annual-general-and-special-meeting-2/2023-10-10T15:35:40.000Z https://psychedelicinvest.com/safe-supply-and-origin-therapeutics-receive-conditional-approval-for-cse-listing/2023-10-10T14:56:29.000Z https://psychedelicinvest.com/medicinal-mushroom-market-anticipated-to-reach-usd-62-billion-by-2032-with-8-7-cagr/2023-10-09T17:24:39.000Z https://psychedelicinvest.com/atai-life-sciences-to-participate-in-the-jefferies-inaugural-biotech-cns-neuro-summit/2023-10-09T17:18:39.000Z https://psychedelicinvest.com/cybin-to-present-an-abstract-and-moderate-a-psychedelic-workshop-at-the-6th-annual-neuropsychiatric0-drug-development-summit/2023-10-09T17:12:31.000Z https://psychedelicinvest.com/building-a-supportive-infrastructure-for-the-emerging-psychedelic-industry/2025-06-29T17:48:27.000Z https://psychedelicinvest.com/mydecine-innovations-group-announces-listing-on-the-canadian-securities-exchange/2023-10-05T21:27:17.000Z https://psychedelicinvest.com/fsd-pharma-and-celly-nu-enter-into-arrangement-agreement/2023-10-05T21:23:43.000Z https://psychedelicinvest.com/clearmind-medicine-to-present-at-the-8th-annual-dawson-james-conference/2023-10-05T21:14:21.000Z https://psychedelicinvest.com/reunion-neuroscience-inc-to-participate-in-october-investor-conference/2023-10-05T21:04:30.000Z https://psychedelicinvest.com/fsd-pharma-wins-2-8-million-dollar-award-plus-accruing-interest-from-dr-raza-bokhari/2023-10-05T20:59:44.000Z https://psychedelicinvest.com/california-psychedelic-reform-bill-quickly-approaches-the-end-of-the-road/2023-12-08T01:50:03.000Z https://psychedelicinvest.com/safe-supply-streaming-co-to-begin-trading-on-the-cse-october-3-2023/2023-10-04T15:17:32.000Z https://psychedelicinvest.com/psycs-psychedelic-spotlight-to-be-media-partner-for-2023-remind-psychedelic-business-forum/2023-10-04T14:18:17.000Z https://psychedelicinvest.com/enveric-biosciences-announces-its-psybrary-portfolio-with-over-1000-psychedelic-inspired-drug-candidates/2023-10-04T14:05:50.000Z https://psychedelicinvest.com/atai-life-sciences-announces-completion-of-phase-1-study-of-vls01-in-healthy-participants/2023-10-03T16:43:37.000Z https://psychedelicinvest.com/cybin-completes-dosing-in-phase-2-study-of-cyb003-for-treatment-of-mdd/2023-10-03T16:01:43.000Z https://psychedelicinvest.com/psycan-releases-white-paper-examining-regulatory-options-for-psychedelics-in-canada/2023-10-03T15:50:36.000Z https://psychedelicinvest.com/sunstone-therapies-announces-expansion-of-innovative-mdma-study/2023-10-03T15:40:31.000Z https://psychedelicinvest.com/numinus-announces-psychedelic-program-for-mental-distress/2023-10-03T15:31:17.000Z https://psychedelicinvest.com/disposition-of-common-shares-of-small-pharma-inc/2023-10-03T15:25:08.000Z https://psychedelicinvest.com/jupiter-acquisition-files-investor-presentation-on-filament-health-deal/2023-10-03T15:20:50.000Z https://psychedelicinvest.com/atai-life-sciences-announces-completion-of-phase-1-study/2023-10-02T20:28:42.000Z https://psychedelicinvest.com/gh-research-provides-updates-and-guidance-on-its-clinical-development/2023-10-02T01:53:49.000Z https://psychedelicinvest.com/filament-health-corp-announces-non-brokered-private-placement/2023-10-02T16:01:52.000Z https://psychedelicinvest.com/psychedelics-aliens-fiction-vs-facts/2025-06-29T17:48:27.000Z https://psychedelicinvest.com/atai-life-sciences-to-participate-in-the-2023-cantor-fitzgerald-global-healthcare-conference/2023-09-28T22:27:32.000Z https://psychedelicinvest.com/pharmaala-recieves-first-office-action-for-pharmala-1-pct-filing/2023-09-28T22:16:58.000Z https://psychedelicinvest.com/psyched-wellnesss-is-pleased-to-announce-sponsorship-of-miami-wonderland/2023-09-28T22:06:42.000Z https://psychedelicinvest.com/mydecine-innovations-group-announces-expected-uk-listing-admission-date/2023-09-28T18:53:26.000Z https://psychedelicinvest.com/michigan-lawmaker-revives-efforts-to-legalize-psychedelics/2023-09-28T18:47:45.000Z https://psychedelicinvest.com/psychedelic-search-trends-and-traffic-analysis-q3/2025-06-29T17:48:27.000Z https://psychedelicinvest.com/canadian-veteran-recieves-approval-for-apex-psylocybin-therapy-through-special-access-program/2023-09-27T15:57:03.000Z https://psychedelicinvest.com/pharmather-announces-fda-acceptance-of-drug-application-for-ketarx/2023-09-27T14:49:36.000Z https://psychedelicinvest.com/gilgamesh-pharmaceuticals-successfully-completes-phase1-sad-mad-clinical-trial/2023-09-26T15:49:30.000Z https://psychedelicinvest.com/numinus-wellness-inc-announces-at-the-market-offering-equity-program/2023-09-26T15:43:14.000Z https://psychedelicinvest.com/small-pharma-reports-positive-top-line-data-from-spl-026-dmt-ssri-drug-drug-interaction-study/2023-09-26T15:38:03.000Z https://psychedelicinvest.com/interview-with-kernel-ceo-ryan-field/2023-09-25T17:22:18.000Z https://psychedelicinvest.com/psychedelic-education-is-adapting-to-meet-the-needs-of-the-modern-psychedelic-industry/2025-06-29T17:48:27.000Z https://psychedelicinvest.com/cybin-announces-date-of-annual-and-special-meeting-of-shareholders/2023-09-21T21:49:41.000Z https://psychedelicinvest.com/trascend-therapeutics-and-yale-awarded-us-department-of-defense-grant/2023-09-21T21:37:46.000Z https://psychedelicinvest.com/silo-pharma-announces-positive-data-on-spc-15-for-ptsd-2/2023-09-21T14:58:06.000Z https://psychedelicinvest.com/cybin-completes-enrollment-in-phase-2-study-of-cyb003-in-major-depressive-disorder/2023-09-21T14:48:47.000Z https://psychedelicinvest.com/filament-health-and-jaguar-health-import-coca-leaf-to-canada/2023-09-21T16:12:29.000Z https://psychedelicinvest.com/lucy-scientific-discovery-navigating-growth-and-diversification-in-the-psychedelic-industry/2025-06-29T17:48:27.000Z https://psychedelicinvest.com/interview-with-red-light-holland-ceo-todd-shapiro/2023-09-20T16:13:10.000Z https://psychedelicinvest.com/silo-pharma-announces-positive-data-on-spc-15-for-ptsd/2023-09-20T14:29:19.000Z https://psychedelicinvest.com/mydecine-innovations-announces-closing-of-prospectus-supplement/2023-09-20T14:24:14.000Z https://psychedelicinvest.com/pharmadrug-announces-amendment-to-shareholder-meeting-matter/2023-09-20T14:18:50.000Z https://psychedelicinvest.com/the-healing-company-to-present-at-investor-event/2023-09-19T22:58:27.000Z https://psychedelicinvest.com/origin-therapeutics-announces-results-of-annual-general-and-special-meeting/2023-09-19T22:22:40.000Z https://psychedelicinvest.com/numinus-takes-actions-to-accelerate-its-path-to-profitability/2023-09-19T22:13:40.000Z https://psychedelicinvest.com/compass-pathways-appoints-daphne-karydas-to-board-of-directors/2023-09-18T21:44:31.000Z https://psychedelicinvest.com/fsd-pharma-announces-interim-results-from-first-in-human-clinical-trial/2023-09-18T21:17:54.000Z https://psychedelicinvest.com/clearmind-medicine-closes-2-5-public-offering/2023-09-18T21:11:02.000Z https://psychedelicinvest.com/reunion-neuroscience-announces-fda-clearance-of-ind-application/2023-09-18T16:23:11.000Z https://psychedelicinvest.com/mydecine-innovations-group-files-prospectus-supplement/2023-09-18T16:17:47.000Z https://psychedelicinvest.com/psilocybin-study-shows-it-combats-stress-by-triggering-rise-in-stress-hormone/2023-09-15T15:12:19.000Z https://psychedelicinvest.com/maps-phase-iii-trial-results-mark-a-paradigm-shift-in-mental-health/2023-12-08T01:51:18.000Z https://psychedelicinvest.com/betterlife-pharma-to-host-investors-update-call-2023/2023-09-14T17:37:59.000Z https://psychedelicinvest.com/maps-publishes-results-from-phase-3-study-of-mdma-assisted-therapy/2023-09-14T17:30:26.000Z https://psychedelicinvest.com/biomind-labs-completes-the-development-of-the-first-5-meo-dmt-organic-synthesis-scheme/2023-09-14T17:26:22.000Z https://psychedelicinvest.com/clearmind-medicine-announces-pricing-of-public-offering/2023-09-14T14:28:38.000Z https://psychedelicinvest.com/atai-life-sciences-to-participate-in-the-2023-cantor-fitzgerald-global-conference/2023-09-14T14:25:41.000Z https://psychedelicinvest.com/beckley-waves-raises-3-3-million-funding-round/2023-09-14T14:22:47.000Z https://psychedelicinvest.com/pharmadrug-provides-update-on-pd-001/2023-09-14T14:18:04.000Z https://psychedelicinvest.com/lusaris-therapeutics-from-promising-psychedelic-startu-to-vanishing-act/2025-06-29T17:48:27.000Z https://psychedelicinvest.com/clearmind-medicine-condensed-interim-consolidated-financial-statements/2023-09-13T17:48:19.000Z https://psychedelicinvest.com/fsd-pharma-announces-analyst-coverage-initiated-by-singular-research/2023-09-13T17:20:32.000Z https://psychedelicinvest.com/psyched-wellness-lists-calm-at-central-market-locations/2023-09-13T14:31:52.000Z https://psychedelicinvest.com/psychedelic-drug-market-revenue-to-exceed-12-billion-by-2023/2023-09-12T17:26:56.000Z https://psychedelicinvest.com/silo-pharma-initiates-feasibility-study-of-spc-15/2023-09-12T14:07:20.000Z https://psychedelicinvest.com/betterlife-obtains-favorable-animal-safety-data/2023-09-12T14:02:16.000Z https://psychedelicinvest.com/lucy-scientific-discovery-announces-aquisition-of-bluesky-wellness/2023-09-12T13:55:47.000Z https://psychedelicinvest.com/safe-supply-and-origin-therapeutics-to-list-on-cse/2023-09-12T13:47:03.000Z https://psychedelicinvest.com/core-one-labs-announces-non-brokered-private-placement/2023-09-12T13:41:16.000Z https://psychedelicinvest.com/psychedelic-laws-in-vermont/2023-09-11T21:43:01.000Z https://psychedelicinvest.com/interview-with-psychedelic-athlete-ian-mccall/2023-09-11T21:30:19.000Z https://psychedelicinvest.com/california-legislation-tackles-addiction-mental-health-and-psychedelics/2023-12-08T01:52:14.000Z https://psychedelicinvest.com/pharmala-biotech-ceo-letter-to-shareholders/2023-09-11T13:44:54.000Z https://psychedelicinvest.com/incannex-to-participate-at-annual-global-investment-conference/2023-09-08T18:49:45.000Z https://psychedelicinvest.com/colorado-seeks-public-views-on-implementing-psychedelic-program/2023-09-08T18:43:49.000Z https://psychedelicinvest.com/top-10-psychedelic-companies-that-should-be-on-your-radar/2025-06-29T17:48:27.000Z https://psychedelicinvest.com/lucy-scientific-acquires-high-times-intellectual-property/2023-09-07T16:41:09.000Z https://psychedelicinvest.com/the-healing-company-appoints-biotech-visionaries-as-advisors/2023-09-07T13:36:28.000Z https://psychedelicinvest.com/optimi-health-granted-amendment-to-dealers-licence-by-health-canada/2023-09-07T13:30:19.000Z https://psychedelicinvest.com/atai-life-sciences-to-participate-in-september-investor-conferences/2023-09-06T22:04:48.000Z https://psychedelicinvest.com/awakn-life-sciences-submits-clinical-trial-application/2023-09-06T16:31:00.000Z https://psychedelicinvest.com/clearmind-medicine-clinical-research-collaboration-with-johns-hopkins/2023-09-06T16:26:09.000Z https://psychedelicinvest.com/pharmala-biotech-begins-trading-on-otcqb/2023-09-06T16:21:41.000Z https://psychedelicinvest.com/american-psychedelic-practitioners-assossiation/2023-09-06T16:16:29.000Z https://psychedelicinvest.com/psychedelic-harm-reduction-and-integration/2025-06-29T17:48:27.000Z https://psychedelicinvest.com/compass-pathways-announces-publication-of-study-evaluating-ai-and-psilocybin/2023-09-06T15:22:02.000Z https://psychedelicinvest.com/pharmather-submits-new-drug-application-for-ketarx/2023-09-06T15:16:06.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-announces-grant-of-us-patnent/2023-09-06T15:16:50.000Z https://psychedelicinvest.com/origin-therapeutics-announces-results-of-annual-general-and-special-shareholder-meeting/2023-09-05T20:46:08.000Z https://psychedelicinvest.com/betterlife-pharma-closes-private-placement/2023-09-05T19:11:36.000Z https://psychedelicinvest.com/optimi-health-announces-second-tranche-of-cad-1-million/2023-09-05T13:42:24.000Z https://psychedelicinvest.com/cybin-announces-grant-of-us-patent-covering-deutierated-tryptamines/2023-09-05T13:37:24.000Z https://psychedelicinvest.com/mindbio-bio-therapeutics-genetic-discover-in-microdosing-research/2023-09-05T15:08:31.000Z https://psychedelicinvest.com/california-psychedelic-decriminalization-bill-clears-appropriations-committee/2023-09-01T20:48:55.000Z https://psychedelicinvest.com/consolidation-continues-in-the-psychedelic-industry/2025-06-29T17:48:27.000Z https://psychedelicinvest.com/peyote-cultivation-company-lists-to-cse/2023-08-31T16:11:42.000Z https://psychedelicinvest.com/psyc-acquires-stock-day-media-to-grow-revenue/2023-08-31T16:06:30.000Z https://psychedelicinvest.com/fiilament-health-enters-licensing-agreement-with-reset-pharma/2023-08-31T17:39:08.000Z https://psychedelicinvest.com/otsuka-pharmaceutical-to-aquire-mindset-pharma/2023-08-31T15:51:25.000Z https://psychedelicinvest.com/maps-launches-online-video-session-from-psychedelic-science-2023/2023-08-31T15:42:52.000Z https://psychedelicinvest.com/mydecine-announces-gains-approval-cse-listing/2023-08-31T15:35:31.000Z https://psychedelicinvest.com/decriminalize-nature-president-steps-down/2023-12-08T01:54:14.000Z https://psychedelicinvest.com/oscillate-interim-loss-widens-amid-investment-loss/2023-08-30T17:26:59.000Z https://psychedelicinvest.com/compass-pathways-to-participate-in-investor-conferences/2023-08-30T14:55:48.000Z https://psychedelicinvest.com/psyc-corporation-enters-strategic-partnership-with-target-media/2023-08-29T16:45:16.000Z https://psychedelicinvest.com/silo-wellness-to-aquire-nuglkaya/2023-08-29T16:37:26.000Z https://psychedelicinvest.com/red-light-holland-microdosing-capsules/2023-08-28T15:47:08.000Z https://psychedelicinvest.com/cybin-to-aquire-small-pharma/2023-08-28T15:20:05.000Z https://psychedelicinvest.com/irwin-naturals-q2-financial-results/2023-08-28T15:12:38.000Z https://psychedelicinvest.com/canadian-survey-people-arent-talking-to-doctors-about-psychedelics/2023-08-25T18:59:03.000Z https://psychedelicinvest.com/should-psychedelic-therapists-do-psychedelics/2025-06-29T17:48:27.000Z https://psychedelicinvest.com/sunstone-therapies-psilocybin-assisted-therapy-study/2023-08-25T15:14:15.000Z https://psychedelicinvest.com/societal-cdmo-announces-public-offering/2023-08-25T15:24:43.000Z https://psychedelicinvest.com/incannex-pepares-fda-ind-application/2023-08-24T18:28:02.000Z https://psychedelicinvest.com/core-one-labs-study-studies-psychedelics-for-pain/2023-08-24T18:16:14.000Z https://psychedelicinvest.com/cybin-renews-market-equity-program/2023-08-24T18:09:31.000Z https://psychedelicinvest.com/mindbio-takehome-lsd-microdosing-trial/2023-08-24T18:02:42.000Z https://psychedelicinvest.com/diamond-equity-research-initiates-coverage-on-enveric-biosciencewse/2023-08-24T17:45:18.000Z https://psychedelicinvest.com/gh-research-q2-2023-financial-results/2023-08-23T20:14:43.000Z https://psychedelicinvest.com/atai-life-sciences-state-of-the-company/2025-06-29T17:48:28.000Z https://psychedelicinvest.com/revive-therapeutics-announces-initiation-of-novel-bucillamine-formulation/2023-08-22T14:03:51.000Z https://psychedelicinvest.com/psyence-group-announces-private-placement/2023-08-21T22:25:10.000Z https://psychedelicinvest.com/how-crowdfunding-isfueling-growth-in-the-psychedelic-industry/2025-06-29T17:48:28.000Z https://psychedelicinvest.com/novel-combination-of-oral-ketamine-and-aspirin-is-safe-form-of-pain-medication-after-total-knee-replacement-surgery/2023-08-17T15:41:45.000Z https://psychedelicinvest.com/compass-pathways-announces-up-to-285-million-private-placement-financing-joined-by-leading-healthcare-investors/2023-08-17T15:37:55.000Z https://psychedelicinvest.com/mind-cure-health-inc-to-be-renamed-lng-energy-group-corp-announces-completion-of-business-combination-transaction/2023-08-17T15:49:54.000Z https://psychedelicinvest.com/melissa-lavasani-advocates-for-psychedelic-medicines-podcast-episode-34/2023-08-16T18:22:50.000Z https://psychedelicinvest.com/cybin-financial-analysis-q1-2023/2025-06-29T17:48:28.000Z https://psychedelicinvest.com/compass-pathways-q2-financial-analysis/2025-06-29T17:48:28.000Z https://psychedelicinvest.com/mydecine-reports-financial-results-for-the-second-quarter-of-fiscal-year-2023/2023-08-15T15:58:37.000Z https://psychedelicinvest.com/filament-health-and-nasdaq-listed-spac-jupiter-acquisition-corp-announce-filing-of-sec-registration-statement/2023-08-15T16:24:39.000Z https://psychedelicinvest.com/mindmed-secures-50-0-million-credit-facility-with-k2-healthventures/2023-08-14T17:12:32.000Z https://psychedelicinvest.com/enveric-biosciences-reports-second-quarter-2023-corporate-and-financial-results/2023-08-14T17:08:45.000Z https://psychedelicinvest.com/cybin-reports-first-quarter-financial-results-and-recent-business-highlights/2023-08-14T17:02:51.000Z https://psychedelicinvest.com/clearmind-medicine-announces-collaboration-with-cts-ltd-a-leading-pharmaceutical-and-consumer-products-company/2023-08-14T16:54:19.000Z https://psychedelicinvest.com/nrx-pharmaceuticals-announces-the-licensure-of-a-us-patent-to-support-use-of-nrx-101-for-chronic-pain/2023-08-14T16:48:07.000Z https://psychedelicinvest.com/psychedelics-and-artificial-intelligence/2025-06-29T17:48:28.000Z https://psychedelicinvest.com/apex-labs-announces-the-appointment-of-chief-medical-officer-chief-commercial-officer/2023-08-11T13:21:40.000Z https://psychedelicinvest.com/optimi-health-announces-cad-3000000-senior-debt-financing/2023-08-11T13:17:28.000Z https://psychedelicinvest.com/atai-life-sciences-reports-second-quarter-2023-financial-results-and-operational-highlights-and-announces-clinical-data-from-the-phase-1-study-of-dmx-1002-ibogaine/2023-08-11T13:12:01.000Z https://psychedelicinvest.com/silo-pharma-engages-clarivate-for-intellectual-property-and-patent-management/2023-08-11T13:06:44.000Z https://psychedelicinvest.com/enthea-reports-clinical-results-from-first-year-of-psychedelic-healthcare-benefit-for-employees-of-leading-california-based-soap-company/2023-08-11T13:01:54.000Z https://psychedelicinvest.com/psychedelic-legalization-is-happening-here/2025-06-29T17:49:11.000Z https://psychedelicinvest.com/numinus-to-participate-in-a-water-tower-research-fireside-chat-on-thursday-august-17-2023/2023-08-10T13:03:06.000Z https://psychedelicinvest.com/atai-life-sciences-announces-results-from-the-phase-1-iv-to-subcutaneous-bridging-study-of-pcn-101-r-ketamine/2023-08-10T13:00:04.000Z https://psychedelicinvest.com/bright-minds-biosciences-announces-positive-qeeg-quantitative-electroencephalogram-data-from-its-first-in-human-phase-1-study-of-lead-compound-bmb-101/2023-08-08T18:30:33.000Z https://psychedelicinvest.com/silo-pharma-reaches-positive-milestone-with-nasal-formulation-of-spc-15-for-anxiety-ptsd-and-stress-related-disorders/2023-08-08T18:26:22.000Z https://psychedelicinvest.com/filament-health-announces-fda-approval-of-two-clinical-trials-studying-its-botanical-psilocybin-drug-candidate-pex010/2023-08-08T19:51:28.000Z https://psychedelicinvest.com/algernon-neuroscience-announces-40-patient-phase-2-psychedelic-drug-dmt-stroke-study/2023-08-08T18:06:37.000Z https://psychedelicinvest.com/mind-cure-announces-closing-of-lng-energys-subscription-receipt-financing/2023-08-08T19:46:10.000Z https://psychedelicinvest.com/braxia-scientific-financial-report-analysis/2025-06-29T17:49:11.000Z https://psychedelicinvest.com/the-science-on-psychedelics-and-ssris/2025-06-29T17:49:11.000Z https://psychedelicinvest.com/cybin-initiates-dosing-of-final-cohort-of-its-phase-2-trial-of-cyb003-in-major-depressive-disorder/2023-08-04T16:28:30.000Z https://psychedelicinvest.com/mindmed-reports-second-quarter-2023-financial-results-and-business-highlights/2023-08-04T16:24:06.000Z https://psychedelicinvest.com/cybin-announces-closing-of-overnight-marketed-public-offering-of-units/2023-08-04T16:20:46.000Z https://psychedelicinvest.com/mindmed-announces-exclusive-license-agreement-with-catalent-for-its-patented-zydis-fast-dissolve-technology-for-use-with-mm-120/2023-08-04T16:17:41.000Z https://psychedelicinvest.com/fsd-pharma-signs-definitive-agreement-to-launch-unbuzzd-a-revolutionary-rapid-alcohol-detoxification-drink/2023-08-04T16:12:49.000Z https://psychedelicinvest.com/the-trip-report-by-beckley-waves-launches-the-trip-report-podcast/2023-08-04T16:06:23.000Z https://psychedelicinvest.com/compass-pathways-announces-second-quarter-2023-financial-results-and-business-highlights/2023-08-03T16:26:50.000Z https://psychedelicinvest.com/psyence-group-announces-sec-registration-filing-with-nasdaq-spac-newcourt-and-signing-of-amended-and-restated-business-combination-agreement/2023-08-03T16:19:46.000Z https://psychedelicinvest.com/reunion-neuroscience-inc-and-mpm-bioimpact-announce-completion-of-plan-of-arrangement/2023-08-03T16:12:59.000Z https://psychedelicinvest.com/clearmind-medicine-files-patent-application-with-uspto-for-the-treatment-of-dyskinesia-further-strengthens-its-already-robust-ip-portfolio/2023-08-03T16:09:19.000Z https://psychedelicinvest.com/optimi-completes-proprietary-natural-psilocybin-extraction-process-and-files-u-s-provisional-patent/2023-08-03T16:00:27.000Z https://psychedelicinvest.com/fraser-johnston-inspires-healthy-and-cooperative-communities-podcast-episode-33/2023-08-02T18:25:56.000Z https://psychedelicinvest.com/cybin-raises-capital-with-public-offering/2023-12-08T01:56:53.000Z https://psychedelicinvest.com/psychedelic-access-is-coming-to-california/2025-06-29T17:49:12.000Z https://psychedelicinvest.com/psilocybin-potency-the-missing-link-for-magic-mushroom-safety-oaklands-psychedelic-mushroom-church-announces-groundbreaking-information-for-safe-use-of-psilocybin-mushrooms/2023-07-31T18:09:51.000Z https://psychedelicinvest.com/pharmala-files-patent-for-novel-mdxx-molecule-pharmala-1/2023-07-31T18:04:45.000Z https://psychedelicinvest.com/compass-pathways-plc-to-announce-second-quarter-2023-financial-results-on-august-3-2023/2023-07-31T17:56:09.000Z https://psychedelicinvest.com/incannex-healthcare-june-2023-quarterly-activities-report-and-appendix-4c-cash-flow-statement/2023-07-28T15:41:53.000Z https://psychedelicinvest.com/revive-therapeutics-announces-filing-of-patent-for-bucillamine-in-the-treatment-of-exposure-to-chemical-warfare-agents/2023-07-28T15:36:42.000Z https://psychedelicinvest.com/mind-cure-announces-lng-energy-group-credit-agreement-in-the-amount-of-u-s-70-million-to-acquire-lewis-energy-colombia-inc/2023-07-28T16:52:47.000Z https://psychedelicinvest.com/optimi-health-announces-receipt-of-purported-termination-notice/2023-07-28T15:29:15.000Z https://psychedelicinvest.com/small-pharma-reports-fiscal-first-quarter-2024-highlights/2023-07-28T15:25:19.000Z https://psychedelicinvest.com/numinus-earnings-report-analysis/2025-06-29T17:49:12.000Z https://psychedelicinvest.com/treat-nicotine-addiction-with-magic-mushrooms/2025-06-29T17:49:12.000Z https://psychedelicinvest.com/treating-anorexia-with-psychedelics/2023-12-08T01:57:54.000Z https://psychedelicinvest.com/mydecine-innovations-group-provides-corporate-update/2023-07-25T23:33:45.000Z https://psychedelicinvest.com/pharmala-received-guidance-on-ala-002-from-mhra-launches-clinical-program-with-university-of-sydney-2/2023-07-25T23:25:25.000Z https://psychedelicinvest.com/psychedelic-science-advancement-with-kernel-flow/2025-06-29T17:49:12.000Z https://psychedelicinvest.com/first-clinical-study-results-of-psilocybin-treatment-in-anorexia-nervosa-published-in-nature-medicine/2023-07-25T17:58:11.000Z https://psychedelicinvest.com/filament-health-announces-upsizing-and-closing-of-2500000-non-brokered-private-placement-financing/2023-07-25T18:51:08.000Z https://psychedelicinvest.com/samuel-becht-monitors-the-progress-of-proper-dosing-podcast-episode-32/2023-07-25T15:58:29.000Z https://psychedelicinvest.com/the-truth-about-chemical-imbalance-theory/2025-06-29T17:49:12.000Z https://psychedelicinvest.com/psybio-therapeutics-awarded-approval-to-manufacture-biosynthetic-tryptamines-at-scale/2023-07-21T15:41:33.000Z https://psychedelicinvest.com/kernels-revolutionary-neuroimaging-technology-flow1-validated-in-published-feasibility-study-on-measuring-psychedelic-effects/2023-07-20T14:44:16.000Z https://psychedelicinvest.com/filament-health-corp-to-list-on-nasdaq-through-business-combination-with-jupiter-acquisition-corporation/2023-07-20T15:16:48.000Z https://psychedelicinvest.com/arbitration-panel-finds-that-syneos-health-nasdaq-synh-failed-to-use-commercially-reasonable-efforts-in-conducting-its-trial-for-fsd-201/2023-07-20T14:31:00.000Z https://psychedelicinvest.com/mushrooms-inc-ceo-kimberly-carlson-discusses-exciting-potential-of-industrial-mushroom-industry-on-psychedelic-spotlight-podcast/2023-07-20T14:27:15.000Z https://psychedelicinvest.com/bright-minds-biosciences-announces-positive-topline-data-for-its-first-in-human-phase-1-study-of-lead-compound-bmb-101/2023-07-20T14:25:01.000Z https://psychedelicinvest.com/pharmala-received-guidance-on-ala-002-from-mhra-launches-clinical-program-with-university-of-sydney/2023-07-20T14:20:32.000Z https://psychedelicinvest.com/filament-health-corp-announces-non-brokered-private-placement-unit-offering-of-up-to-c2000000/2023-07-20T15:11:07.000Z https://psychedelicinvest.com/data-on-psychedelic-legalization/2025-06-29T17:49:12.000Z https://psychedelicinvest.com/kentucky-considers-ibogaine-for-opioid-epidemic/2025-06-29T17:49:13.000Z https://psychedelicinvest.com/pharmather-announces-positive-research-results-for-pharmapatch-with-nn-dimethyltryptamine-dmt-and-strategic-investment-into-sairiyo-therapeutics/2023-07-18T16:54:35.000Z https://psychedelicinvest.com/numinus-wellness-inc-reports-q3-2023-results/2023-07-18T16:50:38.000Z https://psychedelicinvest.com/clearmind-medicine-announces-share-based-payment-for-the-companys-consultants/2023-07-18T16:44:05.000Z https://psychedelicinvest.com/incannex-announces-intention-to-redomicile-to-united-states-list-all-shares-on-nasdaq/2023-07-17T16:46:26.000Z https://psychedelicinvest.com/compass-pathways-announces-publication-of-positive-data-from-treatment-resistant-depression-phase-2-clinical-trial-of-comp360-psilocybin-alongside-antidepressants-in-nature-journal-neuropsychopharmac/2023-07-17T16:32:25.000Z https://psychedelicinvest.com/filament-health-announces-change-of-auditor/2023-07-17T16:47:03.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-announces-private-placement-and-issuance-of-shares-in-connection-with-financial-advisory-agreement/2023-07-17T16:23:25.000Z https://psychedelicinvest.com/reunion-neuroscience-inc-obtains-final-court-order-for-proposed-plan-of-arrangement/2023-07-17T16:19:47.000Z https://psychedelicinvest.com/tryp-therapeutics-receives-confirmation-from-fda-to-proceed-with-phase-2a-clinical-trial-in-patients-with-ibs-at-massachusetts-general-hospital/2023-07-14T11:25:16.000Z https://psychedelicinvest.com/beckley-retreats-advances-research-to-combat-veteran-suicide-through-psychedelic-retreats/2023-07-14T15:31:44.000Z https://psychedelicinvest.com/opinion-paper-calls-for-clarity-on-the-definition-of-psychedelic-assisted-therapy-using-psilocybin/2023-07-14T11:12:52.000Z https://psychedelicinvest.com/betterlife-highlights-american-college-of-physicians-updated-guidelines-for-treating-depression-and-announces-closing-of-private-placement/2023-07-14T11:06:58.000Z https://psychedelicinvest.com/breaking-boundaries-transforming-markets-a-comprehensive-mid-year-review-of-the-psychedelic-sector-pro-report/2023-10-25T20:04:15.000Z https://psychedelicinvest.com/legal-battles-and-investor-concerns-fsd-pharma-psychedelic-stock/2023-07-13T15:41:02.000Z https://psychedelicinvest.com/cybin-announces-the-development-of-a-scalable-psychedelic-facilitation-training-program-embarkct/2023-07-12T17:42:31.000Z https://psychedelicinvest.com/lucy-scientific-discovery-inc-unveils-new-sleep-aid-product-twilight-by-lucy/2023-07-12T17:32:54.000Z https://psychedelicinvest.com/psyence-group-corporate-update/2023-07-12T17:18:28.000Z https://psychedelicinvest.com/psyence-appoints-intellectual-property-expert-to-its-board-of-directors/2023-07-11T12:55:21.000Z https://psychedelicinvest.com/dr-fatima-cody-stanford-associate-professor-of-medicine-and-pediatrics-at-harvard-medical-school-joins-clearmind-medicines-scientific-advisory-board/2023-07-11T12:48:13.000Z https://psychedelicinvest.com/numinus-to-present-at-the-small-cap-growth-virtual-investor-conference-on-july-13-2023-2/2023-07-11T12:41:09.000Z https://psychedelicinvest.com/bright-minds-announces-effective-date-of-share-consolidation/2023-07-11T12:37:27.000Z https://psychedelicinvest.com/american-medical-association-releases-language-of-first-new-current-procedural-terminology-code-for-psychedelic-therapies/2023-07-11T00:00:46.000Z https://psychedelicinvest.com/the-healing-company-uplists-to-the-otcqb-venture-market-and-secures-new-strategic-investors/2023-07-10T23:49:05.000Z https://psychedelicinvest.com/numinus-to-present-at-the-small-cap-growth-virtual-investor-conference-on-july-13-2023/2023-07-10T23:05:07.000Z https://psychedelicinvest.com/webinar-trials-and-triumphs-of-operating-a-ketamine-clinic/2023-07-26T16:27:13.000Z https://psychedelicinvest.com/pharmala-biotech-holdings-inc-cortexa-makes-first-drug-order-for-australian-commercial-market/2023-07-07T13:46:44.000Z https://psychedelicinvest.com/mydecine-reports-its-special-meeting-results/2023-07-07T13:36:47.000Z https://psychedelicinvest.com/revive-therapeutics-announces-results-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19/2023-07-07T13:32:42.000Z https://psychedelicinvest.com/compass-pathways-secures-term-loan-facility-for-up-to-50-million-from-hercules-capital/2023-07-07T13:26:24.000Z https://psychedelicinvest.com/filament-health-to-supply-psilocybin-for-recipients-of-the-canadian-institutes-of-health-research-psilocybin-operating-grants/2023-07-07T16:42:49.000Z https://psychedelicinvest.com/carina-cunha-helps-you-find-the-right-psychedelic-experiences-podcast-episode-31/2023-10-10T18:02:32.000Z https://psychedelicinvest.com/aion-therapeutic-announces-proposed-non-brokered-private-placement-offering-of-units/2023-07-05T16:09:58.000Z https://psychedelicinvest.com/small-pharma-announces-management-team-change/2023-07-05T16:05:47.000Z https://psychedelicinvest.com/small-pharma-announces-spl028-rd-strategy-update/2023-07-05T15:59:51.000Z https://psychedelicinvest.com/wesana-health-announces-closing-of-previously-announced-sana-013-asset-sale/2023-07-05T15:55:03.000Z https://psychedelicinvest.com/fsd-pharma-inc-announces-results-of-annual-general-and-special-meeting-of-shareholders/2023-07-03T20:21:17.000Z https://psychedelicinvest.com/cybin-to-participate-in-psych-symposium-london-2023/2023-06-30T14:44:37.000Z https://psychedelicinvest.com/cybin-inc-announces-appointment-of-aaron-bartlone-as-chief-operating-officer/2023-06-30T14:39:44.000Z https://psychedelicinvest.com/filament-health-enters-exclusive-licensing-agreement-with-neolumina-bioscience-inc/2023-07-02T00:47:02.000Z https://psychedelicinvest.com/numinus-to-host-q3-2023-results-conference-call-on-july-17-2023/2023-06-30T14:25:35.000Z https://psychedelicinvest.com/reunion-neuroscience-reports-fiscal-fourth-quarter-and-full-year-2023-financial-results-and-provides-a-corporate-update/2023-06-29T17:38:48.000Z https://psychedelicinvest.com/small-pharma-reports-financial-results-for-the-fiscal-year-ended-february-28-2023-and-recent-business-highlights/2023-06-29T17:33:17.000Z https://psychedelicinvest.com/insurance-coverage-for-psychedelic-treatment-breaking-down-the-costs-and-access/2025-06-29T17:49:13.000Z https://psychedelicinvest.com/betterlife-fast-tracks-its-us-patent-for-betr-001-and-other-lsd-derivatives/2023-06-27T16:35:15.000Z https://psychedelicinvest.com/cybin-announces-appointment-of-sanford-r-climan-as-strategic-advisor/2023-06-27T16:31:07.000Z https://psychedelicinvest.com/lobe-sciences-initiates-phase-1-clinical-trial-of-l-130/2023-06-27T16:24:57.000Z https://psychedelicinvest.com/pharmather-initiates-filing-of-abbreviated-new-drug-application-for-ketarx-racemic-ketamine-to-the-fda/2023-06-27T16:16:39.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-engages-maxim-group-to-explore-spin-off-of-its-ifenprodil-phase-2-chronic-cough-drug-development-program/2023-06-27T16:11:16.000Z https://psychedelicinvest.com/seelos-therapeutics-announces-the-close-of-enrollment-of-its-registration-directed-study-of-sls-002-intranasal-racemic-ketamine-for-acute-suicidal-ideation-and-behavior-asib-in-adults-with-major-d/2023-06-27T16:06:46.000Z https://psychedelicinvest.com/fsd-pharma-inc-featured-in-investmentpitch-media-video/2023-06-23T17:16:15.000Z https://psychedelicinvest.com/incannex-announces-participation-at-the-h-c-wainwright-4th-annual-neuropsychiatry-virtual-conference-june-26-2023/2023-06-23T17:11:00.000Z https://psychedelicinvest.com/betterlife-to-present-betr-001-preclinical-data-at-the-32nd-annual-meeting-of-the-international-behavioural-neuroscience-society-ibns-in-niagara-falls-ontario-canada/2023-06-22T17:43:43.000Z https://psychedelicinvest.com/bjorn-hansen-nathaniel-morris-are-enhancing-sexual-wellness-with-technology-podcast-episode-30/2023-06-22T17:40:26.000Z https://psychedelicinvest.com/bright-minds-announces-proposed-share-consolidation/2023-06-22T17:39:24.000Z https://psychedelicinvest.com/numinus-announces-agreement-with-healingmaps-to-drive-strategic-clinic-growth/2023-06-22T17:35:39.000Z https://psychedelicinvest.com/silo-pharmas-spu-21-treatment-for-autoimmune-disease-awarded-u-s-patent/2023-06-22T17:30:37.000Z https://psychedelicinvest.com/whats-next-predictions-for-what-happens-after-mdma-is-approved/2025-06-29T17:49:13.000Z https://psychedelicinvest.com/pharmather-and-vitruvias-enter-into-collaboration-agreement-for-commercialization-of-ketarx-racemic-ketamine-in-the-u-s/2023-06-20T19:07:56.000Z https://psychedelicinvest.com/delix-therapeutics-announces-completion-of-1st-cohort-dosing-dose-escalation-approval-in-phase-i-trial-for-novel-compound-dlx-001/2023-06-20T18:59:17.000Z https://psychedelicinvest.com/delix-therapeutics-appoints-aaron-koenig-md-as-chief-medical-officer-2/2023-06-16T18:35:33.000Z https://psychedelicinvest.com/nue-life-health-announces-1-9m-financing-opening-of-its-app-to-support-all-patients-undergoing-ketamine-therapies-and-the-appointment-of-dr-drummond-as-cmo/2023-06-16T18:31:16.000Z https://psychedelicinvest.com/clearmind-medicine-and-scisparc-to-conduct-study-evaluating-combination-treatment-for-obesity-and-metabolic-syndrome/2023-06-16T13:26:11.000Z https://psychedelicinvest.com/compass-pathways-to-participate-in-upcoming-cantor-fitzgerald-and-hc-wainwright-investor-conferences/2023-06-16T13:18:43.000Z https://psychedelicinvest.com/numinus-announces-partnership-with-maps-to-support-therapist-psychedelic-experiential-training/2023-06-16T13:12:36.000Z https://psychedelicinvest.com/optimi-health-to-supply-mdma-for-therapist-experiential-training-program-at-numinus-supported-by-maps/2023-06-16T13:08:03.000Z https://psychedelicinvest.com/breaking-political-boundaries-the-surprising-political-consensus-on-psychedelics/2025-06-29T17:49:13.000Z https://psychedelicinvest.com/silo-pharma-signs-agreement-to-develop-first-in-class-ketamine-implant-therapeutic-2/2023-06-14T16:21:11.000Z https://psychedelicinvest.com/pharmala-biotech-announces-non-brokered-private-placement-offering-of-up-to-an-aggregate-of-5000000/2023-06-14T16:17:03.000Z https://psychedelicinvest.com/numinus-appoints-new-chief-financial-officer/2023-06-14T16:12:17.000Z https://psychedelicinvest.com/silo-pharma-signs-agreement-to-develop-first-in-class-ketamine-implant-therapeutic/2023-06-14T16:01:22.000Z https://psychedelicinvest.com/exploring-intersections-a-comparative-analysis-of-the-psychedelic-and-cannabis-industries/2025-06-29T17:49:13.000Z https://psychedelicinvest.com/pharmather-holdings-provides-corporate-update/2023-06-12T13:53:58.000Z https://psychedelicinvest.com/delix-therapeutics-appoints-aaron-koenig-md-as-chief-medical-officer/2023-06-12T13:48:15.000Z https://psychedelicinvest.com/wesana-health-announces-voting-results-of-agsm/2023-06-12T13:41:41.000Z https://psychedelicinvest.com/apex-labs-receives-approval-for-us-based-secondary-gmp-psilocybin-supplier-by-health-canada/2023-06-12T13:37:26.000Z https://psychedelicinvest.com/clearmind-medicine-to-host-virtual-investor-conference-on-psychedelics-for-obesity-2/2023-06-09T14:50:45.000Z https://psychedelicinvest.com/mind-cure-and-lng-energy-group-provide-update-on-previously-announced-business-combination-transaction/2023-06-09T15:45:17.000Z https://psychedelicinvest.com/numinus-to-participate-in-the-healthcare-virtual-conference-presented-by-maxim-group-llc-and-hosted-by-m-vest-on-june-20-22-2023/2023-06-09T14:40:34.000Z https://psychedelicinvest.com/betterlife-continues-progress-on-betr-001-ind-enabling-studies/2023-06-09T14:37:33.000Z https://psychedelicinvest.com/enveric-biosciences-announces-two-poster-presentations-at-the-canadian-chemistry-conference-and-exhibition-csc-2023/2023-06-07T15:18:04.000Z https://psychedelicinvest.com/psycs-psychedelic-spotlight-continues-ascent-as-a-top-ranking-multimedia-platform-for-the-psychedelics-sector/2023-06-07T15:07:04.000Z https://psychedelicinvest.com/compass-pathways-key-patents-upheld-by-the-us-patent-and-trademark-office/2023-06-07T14:56:09.000Z https://psychedelicinvest.com/cedar-clinical-research-by-numinus-the-top-enrolling-clinical-research-site-for-mindmeds-phase-2b-study-evaluating-mm-120/2023-06-07T14:48:52.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-to-present-phase-2-ifenprodil-cough-data-at-the-2023-american-cough-conference/2023-06-07T14:44:32.000Z https://psychedelicinvest.com/tripping-around-the-world-the-global-legal-landscape-of-psychedelics/2025-06-29T17:49:13.000Z https://psychedelicinvest.com/algernon-neuroscience-announces-successful-completion-of-highest-planned-single-dose-in-dmt-phase-1-trial-accelerates-plans-for-phase-2-stroke-and-tbi-studies/2023-06-05T14:47:46.000Z https://psychedelicinvest.com/silo-pharma-announces-participation-on-webull-corporate-communications-service-platform/2023-06-05T14:42:56.000Z https://psychedelicinvest.com/numinus-to-participate-in-a-water-tower-research-fireside-chat-on-wednesday-june-7-2023/2023-06-05T14:37:15.000Z https://psychedelicinvest.com/psychedelic-search-trends-insights-into-the-rising-popularity-and-geographic-preferences-of-mind-altering-experiences/2025-06-29T17:49:13.000Z https://psychedelicinvest.com/reunion-neuroscience-announces-us13-1-million-take-private-transaction-with-mpm-bioimpact/2023-06-01T16:52:16.000Z https://psychedelicinvest.com/atai-life-sciences-to-participate-in-upcoming-june-investor-conferences/2023-06-01T16:47:12.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-receives-notice-of-allowance-from-the-japanese-patent-office-for-repirinast-and-the-treatment-of-ckd/2023-06-01T16:44:11.000Z https://psychedelicinvest.com/compass-pathways-co-founder-ekaterina-malievskaia-to-step-down-as-chief-innovation-officer/2023-06-01T16:39:01.000Z https://psychedelicinvest.com/numinus-to-research-comp360-psilocybin-therapy-in-treatment-resistant-depression-as-part-of-large-phase-3-study/2023-06-01T16:33:21.000Z https://psychedelicinvest.com/silo-pharma-commences-study-of-novel-joint-homing-peptide-spu-21/2023-06-01T16:28:23.000Z https://psychedelicinvest.com/breaking-kentucky-to-invest-in-ibogaine-treatment-for-addiction/2025-06-29T17:49:13.000Z https://psychedelicinvest.com/filament-health-announces-interim-results-from-phase-i-clinical-trial-at-the-university-of-california-san-francisco/2023-05-30T14:29:00.000Z https://psychedelicinvest.com/compass-pathways-to-participate-in-upcoming-jefferies-healthcare-conference/2023-05-30T12:40:31.000Z https://psychedelicinvest.com/psilera-unveils-novel-non-hallucinogenic-psilocybin-derivative-psil-006-as-lead-clinical-candidate/2023-05-30T12:35:40.000Z https://psychedelicinvest.com/mindmed-releases-investor-presentation-highlighting-how-the-company-is-unlocking-the-power-of-psychedelics-for-patients-and-shareholders/2023-05-26T14:35:47.000Z https://psychedelicinvest.com/mindmed-publishes-report-by-leading-fda-experts-validating-mindmeds-mm-120-drug-development-strategy/2023-05-26T14:29:42.000Z https://psychedelicinvest.com/enveric-biosciences-receives-notice-of-allowance-from-uspto-for-c4-carboxylic-acid-substituted-tryptamine-derivatives-for-next-generation-psilocin-prodrug/2023-05-26T14:23:21.000Z https://psychedelicinvest.com/cybin-initiates-first-in-human-dosing-of-cyb004-in-phase-1-clinical-trial/2023-05-26T14:17:42.000Z https://psychedelicinvest.com/mindmed-to-present-data-on-the-preclinical-activity-of-mm-402-at-the-american-society-of-clinical-psychopharmacology-ascp-2023-annual-meeting/2023-05-26T14:13:16.000Z https://psychedelicinvest.com/fsd-pharma-appoints-former-ontario-minister-of-health-doctor-eric-hoskins-to-board-of-directors/2023-05-26T14:05:33.000Z https://psychedelicinvest.com/irwin-naturals-reports-year-end-2022-financial-results-and-recent-events/2023-05-26T14:00:55.000Z https://psychedelicinvest.com/sunstone-therapies-presents-data-at-asco-showing-positive-long-term-follow-up-results-from-psilocybin-therapy-in-cancer-patients-with-major-depressive-disorder-mdd/2023-05-26T13:56:23.000Z https://psychedelicinvest.com/small-pharma-announces-significant-developments-in-intellectual-property-portfolio/2023-05-26T13:51:55.000Z https://psychedelicinvest.com/numinus-aligns-business-initiatives-to-prepare-for-future-approval-of-mdma-assisted-therapy/2023-05-26T13:45:18.000Z https://psychedelicinvest.com/peter-grinspoon-sees-through-the-smoke-podcast-episode-29/2023-05-25T18:22:50.000Z https://psychedelicinvest.com/maps-sponsored-global-psychedelic-survey-gathers-data-for-a-crucial-view-into-psychedelic-use/2023-05-23T17:40:39.000Z https://psychedelicinvest.com/clearmind-medicine-announces-first-us-site-for-its-phase-i-iia-clinical-trial-evaluating-cmnd-100-in-patients-with-alcohol-use-disorder/2023-05-23T17:35:31.000Z https://psychedelicinvest.com/clearmind-medicine-announces-receipt-of-nasdaq-minimum-bid-price-notification/2023-05-23T17:30:30.000Z https://psychedelicinvest.com/unleashing-the-full-potential-of-psychedelic-therapy/2025-06-29T17:49:14.000Z https://psychedelicinvest.com/mindmed-announces-enrollment-milestone-in-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder-gad/2023-05-19T15:33:31.000Z https://psychedelicinvest.com/revitalist-fails-to-make-interest-payment-on-promissory-note/2023-05-19T15:26:25.000Z https://psychedelicinvest.com/have-a-good-trip-benefit-show-to-celebrate-maps-and-psychedelic-medicine/2023-05-19T15:20:29.000Z https://psychedelicinvest.com/filament-health-announces-first-ever-nagoya-protocol-compliant-shipment-of-iboga-from-gabon/2023-05-19T04:34:44.000Z https://psychedelicinvest.com/clearmind-medicine-to-host-virtual-investor-conference-on-psychedelics-for-obesity/2023-05-18T16:54:36.000Z https://psychedelicinvest.com/optimi-health-completes-harvest-of-psilocybe-cubensis-for-delivery-to-the-australian-medical-market/2023-05-18T16:50:30.000Z https://psychedelicinvest.com/fsd-pharma-announces-receipt-of-court-action-and-update-on-spin-out-and-distribution/2023-05-16T17:09:51.000Z https://psychedelicinvest.com/incannex-company-presentation-presentation-of-psychennex-psychedelic-therapies-subsidiary-company/2023-05-16T17:06:49.000Z https://psychedelicinvest.com/pharmala-biotech-and-shaman-pharma-granted-first-ever-special-access-program-authorization-for-mdma/2023-05-16T17:02:39.000Z https://psychedelicinvest.com/filament-health-announces-first-quarter-2023-financial-results-and-operational-highlights/2023-05-16T16:57:32.000Z https://psychedelicinvest.com/fsd-pharma-awarded-2-81-million-in-cost-awards-from-dr-raza-bokhari/2023-05-12T14:50:07.000Z https://psychedelicinvest.com/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease-2/2023-05-12T14:46:34.000Z https://psychedelicinvest.com/fsd-pharma-completes-dosing-of-first-cohort-in-phase-i-clinical-trial-of-lucid-ms-a-new-drug-candidate-for-the-treatment-of-multiple-sclerosis-safety-review-committee-recommends-commencing-dosing-of/2023-05-12T14:42:29.000Z https://psychedelicinvest.com/clearmind-medicine-announces-irb-approval-to-conduct-clinical-trial-on-alcohol-use-disorder/2023-05-12T14:35:58.000Z https://psychedelicinvest.com/gh-research-reports-first-quarter-2023-financial-results-and-provides-business-highlights/2023-05-11T18:15:00.000Z https://psychedelicinvest.com/compass-pathways-announces-first-quarter-2023-financial-results-and-business-highlights/2023-05-11T18:09:13.000Z https://psychedelicinvest.com/atai-life-sciences-reports-first-quarter-2023-financial-results-and-announces-pipeline-highlights-and-updates/2023-05-11T18:02:07.000Z https://psychedelicinvest.com/sunstone-therapies-to-present-data-on-the-long-term-efficacy-of-psilocybin-therapy-in-cancer-patients-with-major-depressive-disorder-mdd-at-the-asco-2023-annual-meeting/2023-05-11T17:56:23.000Z https://psychedelicinvest.com/mind-cure-closes-previously-announced-private-placement/2023-05-12T04:18:05.000Z https://psychedelicinvest.com/clearmind-medicine-retains-crescendo-communications-llc-for-investor-relations-and-announces-granting-of-stock-and-warrants/2023-05-11T17:49:32.000Z https://psychedelicinvest.com/optimi-health-granted-natural-health-product-site-licence-by-health-canada/2023-05-11T17:45:55.000Z https://psychedelicinvest.com/is-the-american-medical-association-ready-for-psychedelics/2025-06-29T17:49:14.000Z https://psychedelicinvest.com/silo-pharmas-spc-15-awarded-u-s-patent-protecting-ongoing-rd-of-therapeutic-for-stress-induced-affective-disorder-and-alzheimers-disease/2023-05-09T18:17:22.000Z https://psychedelicinvest.com/delix-therapeutics-initiates-phase-i-trial-for-novel-compound-dlx-001/2023-05-09T18:09:57.000Z https://psychedelicinvest.com/filament-health-to-host-virtual-investor-update-2/2023-05-08T15:56:11.000Z https://psychedelicinvest.com/clearmind-medicine-strengthens-scientific-advisory-board-with-appointment-of-prof-joseph-tam/2023-05-08T15:52:48.000Z https://psychedelicinvest.com/mind-cure-and-lng-energy-group-enter-into-arrangement-agreement-with-respect-to-previously-announced-business-combination-transaction/2023-05-08T15:48:07.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-announces-closing-of-rights-offering/2023-05-08T15:42:52.000Z https://psychedelicinvest.com/first-patient-dosed-in-beckley-psytechs-phase-iia-study-of-bpl-003-for-treatment-resistant-depression/2023-05-05T14:29:04.000Z https://psychedelicinvest.com/optimi-health-announces-cad1-2-million-gmp-psilocybin-supply-agreement-for-clinical-research-and-development/2023-05-04T19:13:28.000Z https://psychedelicinvest.com/compass-pathways-plc-to-announce-first-quarter-2023-financial-results-on-11-may-2023/2023-05-04T19:07:04.000Z https://psychedelicinvest.com/small-pharma-to-present-at-upcoming-cinp-world-congress-of-neuropsychopharmacology/2023-05-04T19:02:33.000Z https://psychedelicinvest.com/atai-life-sciences-to-participate-in-upcoming-may-investor-conference/2023-05-04T18:58:58.000Z https://psychedelicinvest.com/state-of-the-psychedelic-industry-2023-q1-pro-report/2023-10-25T20:32:30.000Z https://psychedelicinvest.com/oregons-psilocybin-marketplace-could-be-facing-a-serious-bottleneck/2025-06-29T17:49:14.000Z https://psychedelicinvest.com/blackhawk-and-mindbio-therapeutics-corp-formerly-1286409-b-c-ltd-announce-completion-of-plan-of-arrangement/2023-05-02T21:00:46.000Z https://psychedelicinvest.com/incannex-announces-final-results-from-phase-1-clinical-trial-assessing-safety-and-pharmacokinetics-of-ihl-675a/2023-05-02T21:23:25.000Z https://psychedelicinvest.com/update-on-release-of-the-2022-year-end-financials-and-board-of-directors/2023-05-02T19:32:24.000Z https://psychedelicinvest.com/pharmather-holdings-submits-fast-track-application-to-fda-for-ketarx-ketamine-for-the-treatment-of-parkinsons-disease/2023-05-02T19:27:59.000Z https://psychedelicinvest.com/clearmind-medicine-announces-clinical-supply-agreement-for-its-upcoming-clinical-trial/2023-05-02T19:22:59.000Z https://psychedelicinvest.com/revive-therapeutics-announces-data-safety-monitoring-board-meeting-date-on-phase-3-clinical-study-of-bucillamine-in-the-treatment-of-covid-19/2023-05-02T19:18:15.000Z https://psychedelicinvest.com/cybin-to-participate-at-the-26th-annual-milken-institute-global-conference/2023-04-28T16:31:02.000Z https://psychedelicinvest.com/atai-life-sciences-presents-pharmacodynamic-data-on-grx-917-in-a-late-breaking-poster-presentation-at-the-2023-sobp-annual-meeting/2023-04-28T16:22:00.000Z https://psychedelicinvest.com/nucleuss-community-round-surpasses-500000-raised/2023-04-28T14:55:07.000Z https://psychedelicinvest.com/psyc-explores-the-boundaries-of-psychedelics-and-society-with-new-video-series-psyc-taboo/2023-04-27T17:29:33.000Z https://psychedelicinvest.com/clearmind-medicine-forms-a-data-and-safety-monitoring-board-to-oversee-its-first-in-human-clinical-trial/2023-04-27T17:23:11.000Z https://psychedelicinvest.com/mindbloom-announces-partnership-with-shift-to-offer-affordable-at-home-ketamine-therapy-to-its-employees/2023-04-26T20:32:31.000Z https://psychedelicinvest.com/biomind-labs-announces-the-start-of-the-first-ever-clinical-trial-targeting-depression-and-anxiety-in-alzheimers-disease-with-a-proprietary-formulation-based-on-5-meo-dmt/2023-04-26T20:25:23.000Z https://psychedelicinvest.com/mindset-pharma-files-two-patent-applications-for-its-non-hallucinogenic-non-tryptamine-compounds/2023-04-26T20:17:53.000Z https://psychedelicinvest.com/moon-equity-holdings-to-sell-bitgift-asset-to-silo-wellness-in-exchange-for-a-dividend/2023-04-26T20:12:45.000Z https://psychedelicinvest.com/eric-david-rahn-offer-insurance-coverage-for-psychedelic-businesses-podcast-episode-28/2023-04-26T19:54:59.000Z https://psychedelicinvest.com/reunion-neuroscience-announces-presentation-at-2023-bloom-burton-co-healthcare-investor-conference/2023-04-25T17:57:29.000Z https://psychedelicinvest.com/filament-health-announces-spring-2023-event-and-media-appearances/2023-04-25T18:06:54.000Z https://psychedelicinvest.com/betterlife-to-present-betr-001-preclinical-data-at-the-2023-annual-meeting-of-the-society-of-biological-psychiatry-sobp-in-san-diego-california/2023-04-25T17:49:37.000Z https://psychedelicinvest.com/silo-pharma-to-present-at-psychedelic-drug-development-conference/2023-04-25T17:45:09.000Z https://psychedelicinvest.com/apex-labs-granted-approval-for-160-patient-macrodose-multi-dose-psilocybin-clinical-trial-by-health-canada-2/2023-04-24T13:58:20.000Z https://psychedelicinvest.com/mindcure-announces-financial-results-for-the-third-quarter-of-fiscal-2023/2023-04-24T13:52:15.000Z https://psychedelicinvest.com/clearmind-medicine-expanding-ip-portfolio-with-new-us-patent-application-for-treatment-of-depression/2023-04-24T13:49:32.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-reminds-shareholders-of-previously-announced-rights-offering-and-approaching-cut-off-date-and-time/2023-04-21T12:39:38.000Z https://psychedelicinvest.com/pharmala-biotech-to-supply-clinical-psychedelic-lab-at-monash-university-clinical-trial-with-laneo-mdma/2023-04-21T12:34:23.000Z https://psychedelicinvest.com/apex-labs-granted-approval-for-160-patient-macrodose-multi-dose-psilocybin-clinical-trial-by-health-canada/2023-04-21T12:25:37.000Z https://psychedelicinvest.com/clearmind-medicine-engages-experienced-contract-research-organization-to-support-its-first-in-human-clinical-trial/2023-04-21T11:23:45.000Z https://psychedelicinvest.com/mydecine-innovations-group-announces-closing-under-share-subscription-agreement-4/2023-04-21T15:44:21.000Z https://psychedelicinvest.com/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders/2023-04-21T11:14:23.000Z https://psychedelicinvest.com/bright-minds-biosciences-receives-a-favorable-written-opinion-from-the-international-searching-authority-for-bmb-202/2023-04-21T11:08:54.000Z https://psychedelicinvest.com/yuriy-blokhin-is-empowering-modern-coaches-and-therapists-podcast-episode-27/2023-04-20T14:48:01.000Z https://psychedelicinvest.com/ways-your-psychedelic-business-can-avoid-insurance-landmines/2025-06-29T17:49:42.000Z https://psychedelicinvest.com/weekly-extractions-featuring-intelgenx-mindmed-and-atai-life-sciences/2023-04-18T16:29:11.000Z https://psychedelicinvest.com/fsd-pharma-achieves-milestone-in-completion-of-dosing-of-sentinel-subjects-in-first-in-human-clinical-trial-of-lucid-ms-lucid-21-302-for-multiple-sclerosis/2023-04-17T18:06:16.000Z https://psychedelicinvest.com/numinus-to-participate-in-a-water-tower-research-fireside-chat-on-wednesday-april-19-2023/2023-04-17T17:58:11.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-announces-notice-of-allowance-for-method-of-use-u-s-patent-application/2023-04-17T17:53:25.000Z https://psychedelicinvest.com/nucleus-to-close-crowdfunding-campaign-in-less-than-two-weeks/2023-04-17T17:22:36.000Z https://psychedelicinvest.com/fsd-pharma-inc-provides-update-on-spin-out-plan-announces-shareholder-meeting/2023-04-14T15:09:22.000Z https://psychedelicinvest.com/pharmala-biotech-and-filament-health-announce-release-of-gmp-mdma-capsules/2023-04-14T15:04:04.000Z https://psychedelicinvest.com/psyc-set-to-relaunch-bonfire-with-psychedelics-for-beginners-online-course/2023-04-14T14:58:40.000Z https://psychedelicinvest.com/sunstone-therapies-announces-publication-of-positive-data-on-use-of-psilocybin-therapy-for-patients-with-cancer-and-major-depression-disorder-in-jama-oncology/2023-04-14T14:51:37.000Z https://psychedelicinvest.com/numinus-launches-new-website-to-enhance-its-client-experience/2023-04-14T14:46:07.000Z https://psychedelicinvest.com/numinus-wellness-inc-reports-q2-2023-results/2023-04-14T14:33:51.000Z https://psychedelicinvest.com/atai-life-sciences-announces-first-subject-dosed-in-the-phase-1-iv-to-subcutaneous-bridging-study-of-pcn-101-r-ketamine/2023-04-14T14:26:40.000Z https://psychedelicinvest.com/what-can-the-industry-learn-from-field-trip-healths-downfall/2025-06-29T17:49:42.000Z https://psychedelicinvest.com/jeremy-gardner-has-expanded-from-crypto-to-psychedelics-podcast-episode-26/2023-04-12T20:24:29.000Z https://psychedelicinvest.com/filament-health-and-pharmala-biotech-announce-release-of-gmp-mdma-capsules/2023-04-11T20:51:51.000Z https://psychedelicinvest.com/nucleus-ceo-publishes-letter-from-the-captain-summarizes-q1-progress/2023-04-11T16:36:15.000Z https://psychedelicinvest.com/numinus-launches-new-clinic-licensing-platform-the-numinus-network-to-accelerate-expansion/2023-04-11T16:07:17.000Z https://psychedelicinvest.com/mydecine-innovations-group-files-prospectus-supplement-and-announces-closing-under-share-subscription-agreement-4/2023-04-11T16:26:24.000Z https://psychedelicinvest.com/compass-pathways-to-participate-in-upcoming-22nd-annual-needham-virtual-healthcare-conference/2023-04-11T15:10:43.000Z https://psychedelicinvest.com/bright-minds-biosciences-to-present-at-the-20th-international-meeting-of-the-international-society-for-serotonin-research/2023-04-11T15:07:06.000Z https://psychedelicinvest.com/psychedelics-and-eating-disorders/2025-06-29T17:49:42.000Z https://psychedelicinvest.com/psycs-psychedelic-spotlight-closes-strong-q1-with-new-kpi-records-in-march/2023-04-07T15:08:52.000Z https://psychedelicinvest.com/maps-pbc-announces-positive-topline-results-from-long-term-observational-follow-up-study-on-mdma-assisted-therapy-for-treatment-of-ptsd-2/2023-04-07T15:00:34.000Z https://psychedelicinvest.com/clearmind-medicine-closes-us3-5-million-public-offering/2023-04-07T14:51:34.000Z https://psychedelicinvest.com/small-pharma-announces-positive-six-month-data-from-phase-iia-trial-of-spl026/2023-04-07T14:47:04.000Z https://psychedelicinvest.com/top-5-kpis-ketamine-clinics-need-to-track/2025-06-29T17:49:42.000Z https://psychedelicinvest.com/olivia-mannix-is-dedicated-to-female-focused-medicines-podcast-episode-25/2023-04-05T21:01:52.000Z https://psychedelicinvest.com/mindmed-bullish-vs-bearish-episode-8/2023-10-06T03:26:40.000Z https://psychedelicinvest.com/clearmind-medicine-announces-pricing-of-us3-5-million-public-offering/2023-04-04T15:46:04.000Z https://psychedelicinvest.com/algernon-neuroscience-announces-successful-dosing-of-2nd-cohort-in-phase-1-dmt-clinical-study/2023-04-04T15:42:44.000Z https://psychedelicinvest.com/first-avenue-ventures-life-science-fund-i-invests-in-diamond-therapeutics-to-accelerate-innovation-in-mental-health/2023-04-04T15:37:13.000Z https://psychedelicinvest.com/psyence-group-announces-closing-of-fourth-tranche-of-private-placement-and-conversion-of-convertible-debt-note/2023-04-04T15:32:09.000Z https://psychedelicinvest.com/algernon-neuroscience-announces-u-s-sec-qualification-of-regulation-a-tier-ii-offering-to-raise-up-to-usd-10m/2023-04-03T16:21:10.000Z https://psychedelicinvest.com/revive-therapeutics-advances-mdma-transdermal-patch-development-with-purchase-of-mdma-supply-from-pharmala-biotech/2023-04-03T16:15:17.000Z https://psychedelicinvest.com/reunion-neuroscience-appoints-dr-fred-grossman-to-board-of-directors/2023-04-03T16:10:48.000Z https://psychedelicinvest.com/seelos-therapeutics-announces-business-update-on-its-key-programs/2023-04-03T16:03:29.000Z https://psychedelicinvest.com/mindset-pharma-to-participate-in-the-sequire-cannabis-psychedelics-conference-on-wednesday-april-5-2023/2023-04-03T15:59:31.000Z https://psychedelicinvest.com/filament-health-reports-q4-and-year-end-2022-financial-results-and-operational-highlights/2023-04-03T16:25:16.000Z https://psychedelicinvest.com/apex-labs-meets-endpoints-in-first-of-its-kind-take-home-microdose-psilocybin-clinical-trial-2/2023-04-03T15:47:31.000Z https://psychedelicinvest.com/numinus-to-host-q2-2023-results-conference-call-on-april-13-2023/2023-03-31T14:13:12.000Z https://psychedelicinvest.com/apex-labs-meets-endpoints-in-first-of-its-kind-take-home-microdose-psilocybin-clinical-trial/2023-03-31T14:09:55.000Z https://psychedelicinvest.com/betterlifes-non-hallucinogenic-lsd-betr-001-for-treating-mood-disorders-highlighted-in-drug-discovery-development-article/2023-03-31T14:05:24.000Z https://psychedelicinvest.com/pharmather-holdings-announces-update-of-type-c-meeting-with-the-fda-for-ketarx-ketamine-in-parkinsons-disease/2023-03-31T14:00:54.000Z https://psychedelicinvest.com/nrx-pharmaceuticals-announces-positive-recommendation-to-continue-enrollment-in-the-ongoing-trial-of-nrx-101-in-patients-with-suicidal-treatment-resistant-bipolar-depression/2023-03-31T13:49:33.000Z https://psychedelicinvest.com/protecting-your-ketamine-clinic-key-questions-answered-about-business-liability-insurance/2023-03-30T17:46:44.000Z https://psychedelicinvest.com/joel-brierre-calls-to-those-seeking-transformation-podcast-episode-24/2023-03-29T21:00:32.000Z https://psychedelicinvest.com/psycs-ceo-to-moderate-panel-at-film-screening-for-espns-upcoming-documentary-peace-of-mind/2023-03-29T13:03:55.000Z https://psychedelicinvest.com/mindset-pharma-ceo-james-lanthier-issues-letter-to-shareholders-discussing-expansion-of-drug-discovery-efforts-into-novel-non-hallucinogenic-therapeutics/2023-03-29T12:35:16.000Z https://psychedelicinvest.com/revive-therapeutics-provides-update-on-psilocybin-clinical-study-for-methamphetamine-use-disorder/2023-03-29T12:30:39.000Z https://psychedelicinvest.com/psychedelics-trip-experiences-and-the-potential-of-ai/2023-03-27T18:41:27.000Z https://psychedelicinvest.com/silo-pharma-announces-filing-of-patent-for-treatment-of-fibromyalgia/2023-03-27T15:15:30.000Z https://psychedelicinvest.com/reunion-neuroscience-abstract-accepted-for-poster-presentation-at-2023-ascp-annual-meeting/2023-03-27T15:09:57.000Z https://psychedelicinvest.com/numinus-launches-the-practitioner-certification-pathway-a-complete-psychedelic-assisted-therapy-training-program/2023-03-27T15:04:35.000Z https://psychedelicinvest.com/weekly-extractions-featuring-atai-and-field-trip/2023-03-24T21:14:59.000Z https://psychedelicinvest.com/fsd-pharma-inc-subsidiary-receives-official-approval-to-move-forward-with-phase-1-clinical-trial/2023-03-24T18:08:59.000Z https://psychedelicinvest.com/irwin-naturals-acquires-ketamine-media/2023-03-24T18:03:09.000Z https://psychedelicinvest.com/atai-life-sciences-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-clinical-pipeline-highlights/2023-03-24T14:25:01.000Z https://psychedelicinvest.com/psyence-group-announces-cantheon-capital-private-placement/2023-03-24T14:18:16.000Z https://psychedelicinvest.com/field-trip-health-wellness-obtains-ccaa-protection/2023-03-23T12:52:42.000Z https://psychedelicinvest.com/promise-of-betterlifes-non-hallucinogenic-lsd-betr-001-for-treating-mood-disorders-highlighted-in-medical-xpress-article/2023-03-23T12:48:45.000Z https://psychedelicinvest.com/diamond-therapeutics-announces-fda-authorized-clinical-trial-of-low-dose-psilocybin-in-collaboration-with-university-of-alabama-at-birmingham-2/2023-03-23T15:16:45.000Z https://psychedelicinvest.com/numinus-to-participate-in-the-sequire-cannabis-psychedelics-conference-on-wednesday-april-5-2023/2023-03-23T12:40:01.000Z https://psychedelicinvest.com/numinus-announces-four-peer-reviewed-publications-from-its-chief-clinical-officer-in-2023/2023-03-21T19:56:22.000Z https://psychedelicinvest.com/psyence-partners-with-ingenu-for-palliative-care-clinical-trial-in-australia/2023-03-21T19:51:32.000Z https://psychedelicinvest.com/wesana-health-announces-sale-of-sana-13-assets-to-lucy-scientific-discovery/2023-03-21T19:34:26.000Z https://psychedelicinvest.com/diamond-therapeutics-announces-fda-authorized-clinical-trial-of-low-dose-psilocybin-in-collaboration-with-university-of-alabama-at-birmingham/2023-03-21T19:25:13.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-announces-launch-of-rights-offering/2023-03-21T19:19:36.000Z https://psychedelicinvest.com/first-patient-dosed-in-europe-in-clairvoyants-phase-2b-clinical-trial-exploring-psilocybin-therapy-as-a-treatment-for-alcohol-use-disorder/2023-03-21T17:48:03.000Z https://psychedelicinvest.com/george-mcbride-cco-of-clerkenwell-health-sits-in-the-investor-hotseat-on-march-30/2023-10-06T03:32:21.000Z https://psychedelicinvest.com/ra-psyins-announces-strategic-partnership-with-nucleus-to-provide-the-psychedelic-industry-insurance-coverage/2023-03-16T19:59:04.000Z https://psychedelicinvest.com/silo-pharma-announces-positive-results-from-ind-enabling-study-of-sp-26-for-fibromyalgia/2023-03-15T17:22:58.000Z https://psychedelicinvest.com/field-trip-health-wellness-to-close-clinics-in-5-locations/2023-03-15T17:19:00.000Z https://psychedelicinvest.com/filament-health-announces-fda-approval-of-phase-ii-clinical-trial-studying-psilocybin-for-methamphetamine-use-disorder/2023-03-16T14:01:47.000Z https://psychedelicinvest.com/betterlife-closes-1857143-of-private-placement/2023-03-15T17:09:07.000Z https://psychedelicinvest.com/clearmind-medicine-appoints-professor-henry-r-kranzler-m-d-to-scientific-advisory-board/2023-03-15T17:03:48.000Z https://psychedelicinvest.com/mindset-pharma-to-defend-against-lawsuit-filed-by-reunion-neurosciences/2023-03-15T16:56:18.000Z https://psychedelicinvest.com/reunion-neuroscience-files-lawsuit-against-mindset-pharma/2023-03-15T16:50:49.000Z https://psychedelicinvest.com/betterlife-files-amended-and-restated-offering-document-for-offering-of-units/2023-03-15T16:45:12.000Z https://psychedelicinvest.com/the-benefits-of-psychedelics-for-cancer-patients/2023-03-15T14:57:57.000Z https://psychedelicinvest.com/why-alts-co-invested-in-the-psychedelics-industry-live-event/2023-03-10T17:22:03.000Z https://psychedelicinvest.com/betterlife-publishes-promising-results-from-a-study-titled-a-non-hallucinogenic-lsd-analog-with-therapeutic-potential-for-mood-disorders/2023-03-10T16:54:01.000Z https://psychedelicinvest.com/betterlife-announces-pricing-of-proposed-offering-of-units/2023-03-09T13:55:05.000Z https://psychedelicinvest.com/revive-therapeutics-provides-update-from-type-c-meeting-with-fda-for-amended-protocol-agreement-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19/2023-03-09T13:51:10.000Z https://psychedelicinvest.com/numinus-wellness-inc-executives-to-present-on-panel-at-upcoming-south-by-southwest-conference/2023-03-08T19:30:26.000Z https://psychedelicinvest.com/small-pharma-announces-further-positive-data-from-spl026-phase-iia-trial-in-major-depressive-disorder-strengthening-topline-efficacy-results/2023-03-08T19:24:48.000Z https://psychedelicinvest.com/reunion-neuroscience-to-participate-in-the-oppenheimer-annual-healthcare-conference/2023-03-08T19:18:30.000Z https://psychedelicinvest.com/apex-labs-pioneers-take-home-psychedelic-treatment/2023-12-08T02:08:40.000Z https://psychedelicinvest.com/safe-supply-and-origin-therapeutics-announces-engagement-of-research-capital-and-upsizing-of-brokered-financing-to-4-million/2023-03-07T19:32:13.000Z https://psychedelicinvest.com/incannex-engages-catalent-for-development-and-cgmp-manufacture-of-psilocybin-drug-product-for-clinical-trials-and-potential-commercial-use-2/2023-03-06T23:58:50.000Z https://psychedelicinvest.com/mydecine-announces-debt-settlements/2023-03-06T23:51:34.000Z https://psychedelicinvest.com/mindset-pharma-and-pharmala-complete-first-sale-of-pharmaceutical-grade-psilocybin-into-growing-australian-market-via-sales-partnership/2023-03-06T23:40:59.000Z https://psychedelicinvest.com/atai-life-sciences-announces-key-clinical-pipeline-and-corporate-updates/2023-03-06T23:33:21.000Z https://psychedelicinvest.com/pangenomic-health-provides-corporate-update/2023-03-03T14:46:58.000Z https://psychedelicinvest.com/pharmala-biotech-named-exclusive-mdma-supply-partner-to-awakn-life-sciences/2023-03-03T14:41:55.000Z https://psychedelicinvest.com/incannex-engages-catalent-for-development-and-cgmp-manufacture-of-psilocybin-drug-product-for-clinical-trials-and-potential-commercial-use/2023-03-03T14:35:30.000Z https://psychedelicinvest.com/gh-research-reports-full-year-2022-financial-results-and-provides-business-updates/2023-03-03T14:30:01.000Z https://psychedelicinvest.com/compass-pathways-to-participate-in-upcoming-cowen-43rd-annual-health-care-conference-oppenheimer-33rd-annual-healthcare-conference-and-loop-capital-investor-conference/2023-03-03T14:21:43.000Z https://psychedelicinvest.com/algernon-neuroscience-appoints-global-tbi-expert-and-former-nfl-neurological-player-care-safety-director-dr-david-brody-to-advisory-board/2023-03-03T14:17:43.000Z https://psychedelicinvest.com/atai-life-sciences-to-participate-in-the-cowen-43rd-annual-health-care-conference/2023-03-03T14:12:28.000Z https://psychedelicinvest.com/small-pharma-to-present-at-cowens-43rd-annual-health-care-conference/2023-03-03T14:07:47.000Z https://psychedelicinvest.com/optimi-health-enters-australian-medical-mdma-and-psilocybin-market-with-mind-medicine-australia-distribution-agreement/2023-03-03T14:01:03.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-announces-4-for-1-forward-share-split/2023-03-03T13:51:49.000Z https://psychedelicinvest.com/field-trip-health-wellness-provides-business-update-and-reports-fiscal-third-quarter-2023-results/2023-02-28T23:22:25.000Z https://psychedelicinvest.com/original-shark-and-iconic-entrepreneur-kevin-harrington-joins-fsd-pharma-advisory-board/2023-02-28T19:17:31.000Z https://psychedelicinvest.com/cybin-announces-positive-data-from-its-cyb003-phase-1-2a-trial-and-provides-update-on-its-cyb004-development-program/2023-02-28T19:12:26.000Z https://psychedelicinvest.com/enosis-therapeutics-announces-its-response-to-australian-tga-decision-plans-to-present-at-sxsw-2023/2023-02-28T19:03:46.000Z https://psychedelicinvest.com/compass-pathways-announces-fourth-quarter-and-year-end-2022-financial-results-and-business-highlights/2023-02-28T18:58:16.000Z https://psychedelicinvest.com/facing-a-down-round-dont-panic/2023-02-27T19:46:16.000Z https://psychedelicinvest.com/bright-minds-biosciences-provides-clinical-program-updates-and-outlines-anticipated-milestones-for-2023/2023-02-27T16:16:00.000Z https://psychedelicinvest.com/compass-pathways-plc-to-announce-fourth-quarter-and-year-end-2022-financial-results-on-28-february-2023/2023-02-27T16:04:53.000Z https://psychedelicinvest.com/numinus-to-participate-in-a-water-tower-research-fireside-chat-on-tuesday-february-28-2023/2023-02-24T15:52:11.000Z https://psychedelicinvest.com/fsd-pharma-presenting-two-scientific-posters-on-preclinical-toxicology-and-efficacy-data-of-lucid-21-302/2023-02-23T21:08:50.000Z https://psychedelicinvest.com/cybin-announces-streamlined-clinical-alignment/2023-02-23T21:03:30.000Z https://psychedelicinvest.com/psly-com-inc-ei-ventures-inc-and-mycotopia-therapies-inc-terminate-agreement-and-plan-of-merger/2023-02-23T20:57:03.000Z https://psychedelicinvest.com/patent-application-published-for-pharmala-biotechs-mdma-analogs/2023-02-23T20:49:33.000Z https://psychedelicinvest.com/investing-in-the-building-blocks-of-psychedelics/2025-06-29T17:49:42.000Z https://psychedelicinvest.com/psychedelics-and-grief-processing-trauma-rewiring-the-brain/2023-02-22T16:59:23.000Z https://psychedelicinvest.com/beckley-psytech-receives-fda-investigational-new-drug-ind-approval-for-phase-iib-study-of-bpl-003-a-novel-synthetic-formulation-of-5-meo-dmt-mebufotenin/2023-02-21T17:11:54.000Z https://psychedelicinvest.com/irwin-naturals-closes-acquisition-of-leading-kentucky-clinic-adding-3-million-in-projected-ebitda-company-delivering-on-ambitious-strategy-to-build-largest-global-network-of-mental-health-clinics/2023-02-21T17:05:09.000Z https://psychedelicinvest.com/field-trip-health-wellness-ltd-to-release-fiscal-2023-third-quarter-financial-results-on-tuesday-february-28-2023/2023-02-21T16:55:51.000Z https://psychedelicinvest.com/algernon-neuroscience-initiates-traumatic-brain-injury-research-program-with-dmt-appoints-global-tbi-expert-as-advisor/2023-02-21T16:48:50.000Z https://psychedelicinvest.com/numinus-expands-research-capabilities-with-new-phoenix-clinical-research-site/2023-02-17T16:09:52.000Z https://psychedelicinvest.com/cybin-inc-reports-third-quarter-financial-results-and-recent-business-highlights/2023-02-17T15:57:33.000Z https://psychedelicinvest.com/fsd-pharma-inc-receives-confirmation-of-nasdaq-compliance/2023-02-17T15:51:36.000Z https://psychedelicinvest.com/fsd-pharma-inc-launches-new-program-targeting-unmet-medical-needs-for-alcohol-misuse/2023-02-17T15:48:30.000Z https://psychedelicinvest.com/scisparc-and-clearmind-collaboration-strengthens-ip-portfolio-with-three-provisional-patent-applications-in-the-us/2023-02-17T15:41:43.000Z https://psychedelicinvest.com/bright-minds-biosciences-announces-non-executive-director-appointment/2023-02-17T15:32:14.000Z https://psychedelicinvest.com/pioneering-delix-therapeutics-study-published-in-science-elucidates-the-mechanism-of-psychedelic-induced-neuroplasticity/2023-02-17T15:20:16.000Z https://psychedelicinvest.com/algernon-neuroscience-provides-update-on-phase-1-dmt-clinical-study-drug-found-safe-to-proceed-to-next-phase/2023-02-17T15:15:20.000Z https://psychedelicinvest.com/numinus-wellness-announces-voting-results-from-its-annual-general-and-special-meeting-of-shareholders/2023-02-17T15:09:40.000Z https://psychedelicinvest.com/israel-based-clearmind-medicine-strengthening-ip-portfolio-with-three-provisional-patent-applications-in-the-us/2023-02-17T15:03:15.000Z https://psychedelicinvest.com/first-subject-dosed-in-small-pharmas-first-in-human-phase-i-clinical-trial-with-spl028/2023-02-17T14:58:21.000Z https://psychedelicinvest.com/seelos-therapeutics-announces-completion-of-enrollment-of-its-phase-ii-iii-trial-of-sls-005-in-amyotrophic-lateral-sclerosis-on-the-healey-als-platform/2023-02-17T14:52:17.000Z https://psychedelicinvest.com/delix-therapeutics-partners-with-cellectricon-expressive-neuroscience-and-expands-science-team-to-accelerate-drug-discovery-and-translatability/2023-02-17T14:47:24.000Z https://psychedelicinvest.com/cody-shandraw-founder-of-healing-reit-sits-in-the-investor-hotseat-on-february-23rd/2023-10-06T03:32:30.000Z https://psychedelicinvest.com/real-estate-for-psychedelics/2025-06-29T17:49:43.000Z https://psychedelicinvest.com/filament-health-announces-second-psilocybin-supply-agreement-with-the-centre-for-addiction-and-mental-health/2023-02-14T17:04:35.000Z https://psychedelicinvest.com/israel-based-clearmind-medicine-to-present-at-the-ourcrowd-global-investor-summit-sponsored-by-greenberg-traurig-tel-aviv/2023-02-14T13:49:06.000Z https://psychedelicinvest.com/pharmala-biotech-closes-purchase-order-with-emyria-ltd-completes-filing-of-laneo-trademark-in-australia/2023-02-14T13:44:40.000Z https://psychedelicinvest.com/reunion-neuroscience-provides-business-update-and-reports-fiscal-third-quarter-2023-financial-results/2023-02-14T13:39:33.000Z https://psychedelicinvest.com/silo-pharma-announces-filing-of-patent-for-treatment-of-alzheimers/2023-02-14T13:28:26.000Z https://psychedelicinvest.com/mydecine-innovations-group-announces-closing-under-share-subscription-agreement-3/2023-02-10T22:11:26.000Z https://psychedelicinvest.com/silo-pharma-inc-partnering-to-transform-health-care-improve-patient-outcomes/2023-02-10T20:51:59.000Z https://psychedelicinvest.com/fsd-pharma-inc-receipt-of-no-objection-letter-from-health-canada-is-focus-of-recent-investmentpitch-media-video/2023-02-10T20:42:39.000Z https://psychedelicinvest.com/bright-minds-biosciences-announces-receipt-of-nasdaq-deficiency-letter-regarding-independent-director-and-audit-committee-requirements/2023-02-10T20:33:56.000Z https://psychedelicinvest.com/israeli-based-clearmind-medicine-to-host-virtual-investor-conference-on-psychedelics-for-obesity/2023-02-10T20:27:41.000Z https://psychedelicinvest.com/whats-bringing-crypto-bros-into-the-psychedelics-space/2023-02-10T17:00:40.000Z https://psychedelicinvest.com/microdosing-is-now-legal-in-oregon-what-does-it-mean-for-the-psilocybin-community/2023-02-09T18:40:09.000Z https://psychedelicinvest.com/2022-industry-reports-webinar-with-charley-rose/2023-02-08T18:58:31.000Z https://psychedelicinvest.com/optimi-health-submits-phase-i-clinical-trial-application-combining-the-use-of-proprietary-psilocybin-and-mdma-drug-candidates-in-healthy-therapists/2023-02-08T14:08:28.000Z https://psychedelicinvest.com/pharmather-submits-fda-meeting-package-to-discuss-505b2-pathway-for-new-drug-application-of-ketarx-ketamine-on-body-pump-system/2023-02-08T13:59:30.000Z https://psychedelicinvest.com/revive-therapeutics-secures-mdma-supply-from-pharmala-biotech-for-mdma-transdermal-patch-development/2023-02-08T13:52:02.000Z https://psychedelicinvest.com/lobe-sciences-congratulates-australia-for-becoming-the-first-nation-to-approve-the-medicinal-use-of-psilocybin-and-mdma/2023-02-06T14:43:42.000Z https://psychedelicinvest.com/pharmala-named-exclusive-mdma-supplier-to-revive-therapeutics/2023-02-06T14:37:27.000Z https://psychedelicinvest.com/optimi-health-completes-first-production-of-novel-mdma-drug-candidate-opti-mhcl/2023-02-06T14:30:33.000Z https://psychedelicinvest.com/seelos-therapeutics-doses-first-patients-in-an-ethnobridging-study-with-sls-002-intranasal-racemic-ketamine/2023-02-06T14:22:58.000Z https://psychedelicinvest.com/ehave-provides-progress-update-on-its-hppd-study-with-university-of-melbourne/2023-02-03T20:21:12.000Z https://psychedelicinvest.com/silo-pharma-announces-expansion-of-intellectual-property-portfolio/2023-02-03T20:14:52.000Z https://psychedelicinvest.com/revive-therapeutics-enters-into-research-collaboration-agreement-with-pharmather-for-development-of-mdma-transdermal-patch/2023-02-03T20:06:19.000Z https://psychedelicinvest.com/numinus-receives-clinical-trial-application-approval-from-health-canada-for-experiential-psychedelic-assisted-therapy-training-using-psilocybe-cubensis-tea/2023-02-03T19:53:47.000Z https://psychedelicinvest.com/reunion-neuroscience-schedules-fiscal-third-quarter-2023-conference-call-for-tuesday-february-14-2023-at-830-a-m-et/2023-02-03T19:43:41.000Z https://psychedelicinvest.com/pharmather-holdings-submits-fda-meeting-package-to-discuss-phase-3-program-and-fast-track-designation-for-ketarx-ketamine-in-parkinsons-disease/2023-02-03T19:37:31.000Z https://psychedelicinvest.com/small-pharma-announces-update-on-intellectual-property-portfolio/2023-02-03T20:11:04.000Z https://psychedelicinvest.com/pharmather-holdings-submits-for-fda-orphan-drug-designation-for-ketamine-to-treat-rett-syndrome/2023-02-03T19:17:07.000Z https://psychedelicinvest.com/psyence-and-eden-labs-announce-extraction-and-product-development-collaboration/2023-02-03T19:06:24.000Z https://psychedelicinvest.com/apex-labs-granted-approval-for-294-patient-take-home-psilocybin-clinical-trial-2/2023-02-03T18:58:03.000Z https://psychedelicinvest.com/2023-psychedelic-industry-predictions-w-dustin-robinson-of-iter-investments/2023-02-01T21:05:40.000Z https://psychedelicinvest.com/psyc-provides-shareholders-with-key-corporate-updates-and-highlights-objectives-for-2023/2023-02-01T00:31:50.000Z https://psychedelicinvest.com/the-future-of-ketamine-telehealth-when-biden-ends-the-covid-19-emergencies-in-may-2023/2023-01-31T21:19:50.000Z https://psychedelicinvest.com/silo-pharma-announces-stock-repurchase-program/2023-01-31T15:22:32.000Z https://psychedelicinvest.com/israeli-biotech-clearmind-medicine-announces-positive-pre-clinical-results-treating-major-depression-with-a-novel-ketamine-based-compound/2023-01-31T15:15:58.000Z https://psychedelicinvest.com/betterlife-announces-engagement-of-bloom-burton-securities-inc-and-provides-summary-of-2022-accomplishments/2023-01-30T17:00:23.000Z https://psychedelicinvest.com/fsd-pharma-inc-commences-recruitment-in-fsd201-phase-2-clinical-trial/2023-01-30T16:51:40.000Z https://psychedelicinvest.com/bright-minds-biosciences-announces-receipt-of-nasdaq-notification-letter-regarding-minimum-bid-price-deficiency/2023-01-30T16:42:56.000Z https://psychedelicinvest.com/irwin-naturals-signs-letter-of-intent-to-acquire-braxia-scientific/2023-01-30T16:38:06.000Z https://psychedelicinvest.com/cybin-inc-announces-virtual-rd-day/2023-01-26T17:37:55.000Z https://psychedelicinvest.com/hebrew-university-yissum-and-israeli-biotech-clearmind-medicines-psychedelic-derived-obesity-treatment/2023-01-26T17:30:57.000Z https://psychedelicinvest.com/small-pharma-reports-fiscal-third-quarter-2023-highlights/2023-01-26T17:24:34.000Z https://psychedelicinvest.com/is-now-the-best-time-to-invest-in-equity-crowdfunding-campaigns-we-think-so/2023-01-25T16:33:30.000Z https://psychedelicinvest.com/gh-research-provides-business-updates-and-highlights-key-upcoming-milestones/2023-01-25T15:46:19.000Z https://psychedelicinvest.com/small-pharma-to-announce-results-of-spl026-phase-iia-trial-for-major-depressive-disorder-and-host-conference-call-on-wednesday-january-25/2023-01-25T15:41:50.000Z https://psychedelicinvest.com/diamond-therapeutics-announces-health-canada-approval-of-phase-2-clinical-trial-with-low-dose-psilocybin/2023-01-25T15:37:59.000Z https://psychedelicinvest.com/reunion-neuroscience-appoints-robert-alexander-as-chief-medical-officer/2023-01-25T15:33:08.000Z https://psychedelicinvest.com/legal-aspects-of-setting-up-a-ketamine-clinic-in-florida/2024-07-22T14:23:30.000Z https://psychedelicinvest.com/weekly-extractions-january-20-2023/2023-01-23T06:13:17.000Z https://psychedelicinvest.com/apex-labs-granted-approval-for-294-patient-take-home-psilocybin-clinical-trial/2023-01-20T15:45:50.000Z https://psychedelicinvest.com/israel-based-clearmind-successfully-completed-two-rd-projects-with-the-hebrew-university-of-jerusalems-tech-transfer-company-yissum/2023-01-20T15:39:15.000Z https://psychedelicinvest.com/filament-health-announces-clinical-trial-approval-in-partnership-with-psychiatric-centre-copenhagen/2023-01-20T15:55:24.000Z https://psychedelicinvest.com/mydecine-innovations-group-files-prospectus-supplement-and-announces-closing-under-share-subscription-agreement-3/2023-01-20T15:53:47.000Z https://psychedelicinvest.com/revive-therapeutics-submits-updated-briefing-package-in-support-of-upcoming-type-c-meeting-granted-by-fda-for-amended-protocol-agreement-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-c/2023-01-20T15:22:43.000Z https://psychedelicinvest.com/numinus-wellness-inc-reports-q1-2023-results/2023-01-20T15:51:29.000Z https://psychedelicinvest.com/the-complete-2022-stock-market-analysis-pro-report/2023-01-18T22:00:03.000Z https://psychedelicinvest.com/technology-in-psychedelics/2025-06-29T17:49:43.000Z https://psychedelicinvest.com/the-public-psychedelic-companies-report-pro-report/2023-01-18T21:14:45.000Z https://psychedelicinvest.com/the-exhaustive-ketamine-clinic-industry-report-pro-report/2023-01-18T21:07:58.000Z https://psychedelicinvest.com/psychedelics-around-the-world/2023-01-18T20:42:39.000Z https://psychedelicinvest.com/core-one-labs-acquires-gmp-drug-inc-positioning-itself-as-a-full-cycle-psychedelics-supply-chain-solution-for-clinicians-researchers-and-other-drug-developers/2023-01-18T15:51:37.000Z https://psychedelicinvest.com/fsd-pharma-submits-its-phase-1-clinical-trial-application-for-lucid-ms-lucid-21-302-for-first-in-human-safety-and-tolerability-investigation/2023-01-18T15:44:47.000Z https://psychedelicinvest.com/optimi-health-expands-functional-mushroom-sales-network-with-additional-brokers-distribution-agreements/2023-01-18T15:35:34.000Z https://psychedelicinvest.com/algernon-neuroscience-doses-first-subject-in-phase-1-dmt-clinical-stroke-study/2023-01-18T15:29:31.000Z https://psychedelicinvest.com/israel-based-clearmind-announces-additional-positive-results-from-the-third-part-of-its-pre-clinical-study-for-cocaine-addiction-treatment/2023-01-18T15:22:55.000Z https://psychedelicinvest.com/the-future-of-psychedelics/2025-06-29T17:49:43.000Z https://psychedelicinvest.com/psychedelic-research-in-2022-pro-report/2023-01-18T18:15:55.000Z https://psychedelicinvest.com/2022-psychedelic-investment-landscape-pro-report/2023-01-20T16:58:36.000Z https://psychedelicinvest.com/fsd-pharma-inc-board-authorized-share-repurchase-program/2023-01-16T15:20:52.000Z https://psychedelicinvest.com/mindbloom-partners-with-this-is-jane-project-to-offer-affordable-at-home-ketamine-therapy-to-trauma-survivors/2023-01-16T15:15:57.000Z https://psychedelicinvest.com/atai-life-sciences-company-gaba-therapeutics-announces-positive-final-results-from-phase-1-single-and-multiple-ascending-dose-trial-of-grx-917/2023-01-16T14:58:23.000Z https://psychedelicinvest.com/bright-minds-biosciences-announces-resignation-of-board-member/2023-01-16T14:53:18.000Z https://psychedelicinvest.com/greg-mayes-ceo-of-reunion-sits-in-the-investor-hotseat-on-january-16th/2023-10-06T03:32:38.000Z https://psychedelicinvest.com/jaguar-health-and-filament-health-with-funding-from-one-small-planet-form-joint-venture-magdalena-biosciences-to-develop-botanical-pharmaceutical-drug-candidates-for-mental-health-illnesses/2023-01-12T17:29:25.000Z https://psychedelicinvest.com/cybin-inc-selects-generalized-anxiety-disorder-as-target-indication-for-cyb004/2023-01-12T17:20:05.000Z https://psychedelicinvest.com/field-trip-health-wellness-ltd-announces-launch-of-online-therapy/2023-01-12T17:13:52.000Z https://psychedelicinvest.com/revive-therapeutics-ltd-closes-4-3-million-offering/2023-01-12T16:57:40.000Z https://psychedelicinvest.com/irwin-naturals-and-braxia-scientific-announce-partnership-for-in-human-clinical-studies-supporting-pharmaceutical-companies-in-the-us/2023-01-10T23:53:30.000Z https://psychedelicinvest.com/israel-based-clearmind-medicine-successfully-completes-production-of-cmnd-100-drug-candidate-for-clinical-trial/2023-01-10T23:44:53.000Z https://psychedelicinvest.com/silo-pharma-advances-clinical-study-analyzing-effects-of-psilocybin-on-inflammation/2023-01-10T23:39:57.000Z https://psychedelicinvest.com/optimi-health-announces-re-appointments-to-board-of-directors/2023-01-10T23:33:13.000Z https://psychedelicinvest.com/2022-the-year-in-psychedelics-pro-report/2023-01-20T16:57:57.000Z https://psychedelicinvest.com/chad-harman-ceo-of-psycheceutical-sits-in-the-investor-hotseat-on-january-12th/2023-10-06T03:32:46.000Z https://psychedelicinvest.com/reunion-neuroscience-inc-completes-interim-data-analysis-for-phase-1-clinical-trial-with-novel-serotonergic-psychedelic-re104/2023-01-09T16:12:55.000Z https://psychedelicinvest.com/psyence-signs-letter-of-intent-with-australian-cro-ingenu/2023-01-09T16:02:36.000Z https://psychedelicinvest.com/first-patient-dosed-in-small-pharmas-phase-i-study-exploring-intramuscular-administration-of-spl026/2023-01-09T15:53:53.000Z https://psychedelicinvest.com/pharmather-announces-fda-orphan-drug-designation-granted-to-ketamine-for-prevention-of-ischemia-reperfusion-injury-from-organ-transplantation-2/2023-01-09T15:46:28.000Z https://psychedelicinvest.com/gh-research-reports-third-quarter-2022-financial-results-and-provides-business-updates/2023-01-09T15:40:17.000Z https://psychedelicinvest.com/atai-life-sciences-announces-results-from-phase-2a-trial-of-pcn-101-r-ketamine-for-treatment-resistant-depression/2023-01-09T15:35:46.000Z https://psychedelicinvest.com/maps-pbc-announces-positive-results-from-confirmatory-phase-3-mapp2-trial-of-mdma-assisted-therapy-for-treatment-of-ptsd/2023-01-09T15:30:51.000Z https://psychedelicinvest.com/weekly-extractions-atai-life-sciences-january-6-2023/2023-01-09T22:25:17.000Z https://psychedelicinvest.com/filament-health-announces-ceo-year-end-letter-and-change-to-board-of-directors/2023-01-06T17:39:51.000Z https://psychedelicinvest.com/tryp-therapeutics-announces-interim-results-for-its-phase-ii-clinical-trial-for-the-treatment-of-binge-eating-disorder-with-psilocybin-assisted-psychotherapy/2023-01-05T18:05:52.000Z https://psychedelicinvest.com/psybio-announces-closing-of-first-tranche-of-private-placement-and-provides-corporate-update/2023-01-05T18:00:07.000Z https://psychedelicinvest.com/psychedelicnewsbreaks-universal-ibogaine-inc-recaps-2022-eyes-2023-as-pivotal-year/2023-01-05T17:53:08.000Z https://psychedelicinvest.com/revive-therapeutics-announces-type-c-meeting-request-granted-by-fda-for-amended-protocol-agreement-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19/2023-01-05T17:49:07.000Z https://psychedelicinvest.com/israel-based-clearmind-medicine-shows-efficacy-of-psychedelic-derived-obesity-treatment-in-pre-clinical-trial/2023-01-05T17:44:24.000Z https://psychedelicinvest.com/scisparc-ltd-announces-efficacy-of-psychedelic-based-obesity-treatment-of-clearmind-medicine-inc-in-pre-clinical-trial/2023-01-05T17:39:48.000Z https://psychedelicinvest.com/reset-pharmaceuticals-appoints-innes-meldrum-as-president-and-chief-executive-officer/2023-01-05T17:32:54.000Z https://psychedelicinvest.com/numinus-to-host-q1-2023-results-conference-call-on-january-16-2023/2023-01-04T16:08:25.000Z https://psychedelicinvest.com/reunion-neuroscience-inc-provides-2023-corporate-update/2023-01-04T16:03:32.000Z https://psychedelicinvest.com/tryp-therapeutics-and-massachusetts-general-hospital-sign-letter-of-intent-for-clinical-study-investigating-the-use-of-psilocybin-assisted-psychotherapy-for-the-treatment-of-patients-suffering-from-ir/2023-01-03T16:30:03.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-forms-private-subsidiary-to-advance-companys-psychedelic-dmt-stroke-program-files-form-1-a-offering-statement-with-u-s-sec-for-regulation-a-offering/2023-01-03T16:21:45.000Z https://psychedelicinvest.com/silo-pharma-announces-positive-study-results-of-spu-21-for-arthritis/2022-12-30T16:27:15.000Z https://psychedelicinvest.com/highlights-from-the-psychedelics-industry-in-2022/2022-12-29T16:47:04.000Z https://psychedelicinvest.com/clearmind-medicine-announces-shareholders-meeting-results/2022-12-29T15:32:57.000Z https://psychedelicinvest.com/israel-based-clearmind-medicine-announces-first-clinical-center-to-join-its-clinical-trial-for-alcohol-use-disorder/2022-12-28T16:58:01.000Z https://psychedelicinvest.com/biomind-labs-announces-the-completion-of-the-first-sublingual-psychedelic-formulation-for-its-drug-candidate-bmnd08-for-depression-and-anxiety-in-alzheimers-disease/2022-12-28T16:53:05.000Z https://psychedelicinvest.com/wellbeing-subsidiary-kgk-science-receives-approval-for-first-of-its-kind-psylocibin-clinical-trial/2022-12-26T16:07:40.000Z https://psychedelicinvest.com/pangenomic-health-issues-letter-to-shareholders/2022-12-26T18:57:21.000Z https://psychedelicinvest.com/small-pharma-announces-completion-of-spl026-phase-iia-trial-and-secures-new-intellectual-property/2022-12-26T15:53:25.000Z https://psychedelicinvest.com/beckley-psytech-launches-phase-iia-study-of-lead-candidate-bpl-003-a-novel-benzoate-formulation-of-5-meo-dmt-for-treatment-resistant-depression/2022-12-22T17:41:33.000Z https://psychedelicinvest.com/cybin-inc-ceo-highlights-2022-as-momentous-year/2022-12-20T16:36:04.000Z https://psychedelicinvest.com/wesana-health-announces-receipt-of-short-term-loan/2022-12-20T16:29:15.000Z https://psychedelicinvest.com/gilgamesh-pharmaceuticals-raises-39-million-series-b-to-advance-mental-health-treatments/2022-12-20T15:08:16.000Z https://psychedelicinvest.com/first-patient-dosed-in-small-pharmas-drug-interaction-study/2022-12-19T20:36:17.000Z https://psychedelicinvest.com/the-atai-fellowship-fund-in-psychedelic-neuroscience-announces-its-first-cohort-at-massachusetts-general-hospital/2022-12-19T20:29:58.000Z https://psychedelicinvest.com/israeli-based-biotech-company-clearmind-medicine-incs-ceo-dr-adi-zuloff-shani-issues-letter-to-shareholders/2022-12-19T20:17:27.000Z https://psychedelicinvest.com/mydecine-innovations-group-announces-closing-under-share-subscription-agreement-2/2022-12-19T20:56:56.000Z https://psychedelicinvest.com/revive-therapeutics-ltd-expands-life-offering-to-quebec/2022-12-19T20:06:57.000Z https://psychedelicinvest.com/coming-soon-2022-year-in-review-industry-reports/2025-06-29T17:49:43.000Z https://psychedelicinvest.com/pharmather-announces-fda-orphan-drug-designation-granted-to-ketamine-for-prevention-of-ischemia-reperfusion-injury-from-organ-transplantation/2022-12-15T20:11:18.000Z https://psychedelicinvest.com/fda-grants-ehave-consent-to-proceed-with-its-clinical-study-on-intravenous-ketamine-infusion-for-major-depressive-disorder/2022-12-15T20:06:58.000Z https://psychedelicinvest.com/filament-health-and-psyence-announce-worldwide-licensing-agreement-of-psilocybin-capsule-for-palliative-care/2022-12-15T20:16:10.000Z https://psychedelicinvest.com/mind-cure-enters-into-binding-letter-of-intent-with-lng-energy-group/2022-12-15T20:14:52.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-receives-u-s-fda-orphan-drug-designation-for-ifenprodil-for-the-treatment-of-idiopathic-pulmonary-fibrosis/2022-12-15T18:17:30.000Z https://psychedelicinvest.com/video-interview-a-psychedelic-conversation-with-doug-drysdale-ceo-of-cybin/2025-06-29T17:49:43.000Z https://psychedelicinvest.com/mindbloom-announces-rollout-of-ketamine-telehealth-employee-benefits-program-with-kennedy-care-15five/2022-12-14T18:53:04.000Z https://psychedelicinvest.com/core-one-labs-subsidiary-vocan-biotechnologies-achieves-development-milestones/2022-12-14T18:08:25.000Z https://psychedelicinvest.com/numinus-to-participate-in-the-kcsa-mental-health-virtual-investor-conference-on-december-15-2022/2022-12-14T17:56:03.000Z https://psychedelicinvest.com/field-trip-health-wellness-to-webcast-live-at-the-kcsa-mental-health-conference-on-december-15th/2022-12-14T17:48:44.000Z https://psychedelicinvest.com/psyence-group-announces-closing-of-second-tranche-of-private-placement-and-appointment-of-strategic-advisor/2022-12-14T17:44:19.000Z https://psychedelicinvest.com/small-pharma-to-support-university-college-london-research-project-on-neuroplasticity/2022-12-14T17:36:07.000Z https://psychedelicinvest.com/palo-alto-iv-ketamine-depression-therapy-launched-by-soft-reboot-wellness/2022-12-14T17:28:34.000Z https://psychedelicinvest.com/tryp-therapeutics-announces-fiscal-year-2022-financial-results-and-reports-corporate-highlights/2022-12-14T17:21:49.000Z https://psychedelicinvest.com/exploring-psychedelics-and-autism-spectrum-disorder/2022-12-14T03:31:12.000Z https://psychedelicinvest.com/israeli-based-biotech-company-clearmind-completes-ind-enabling-studies-for-cmnd-100/2022-12-13T16:05:40.000Z https://psychedelicinvest.com/psyc-provides-shareholders-with-a-year-end-company-review-for-2022/2022-12-13T15:49:10.000Z https://psychedelicinvest.com/filament-health-to-present-live-at-virtualinvestorconferences-com-december-15th/2022-12-13T15:37:43.000Z https://psychedelicinvest.com/awakn-life-sciences-phase-iii-trial-to-be-delivered-in-the-uk-national-health-service/2022-12-13T15:27:29.000Z https://psychedelicinvest.com/atai-life-sciences-strengthens-leadership-team-with-appointment-of-dr-sahil-v-kirpekar-as-chief-business-officer/2022-12-13T14:31:57.000Z https://psychedelicinvest.com/pangenomic-health-completes-acquisition-of-mindleap-health/2022-12-12T16:42:09.000Z https://psychedelicinvest.com/lusaris-therapeutics-launches-with-60-million-series-a-financing-to-redefine-the-treatment-of-severe-neuropsychiatric-and-neurological-disorders-2/2022-12-09T21:07:59.000Z https://psychedelicinvest.com/sensorium-therapeutics-closes-30-million-series-a-to-transform-mental-health-treatment-with-nature-inspired-psychoactive-medicines/2022-12-09T21:02:35.000Z https://psychedelicinvest.com/psychedelic-stock-market-update-november-2022/2025-06-29T17:49:43.000Z https://psychedelicinvest.com/israeli-biotech-clearmind-medicine-appoints-ex-red-bull-executive-special-advisor-for-developing-meai-as-alcohol-substitute/2022-12-09T20:47:01.000Z https://psychedelicinvest.com/small-pharma-to-participate-in-upcoming-canaccord-genuity-investor-symposium/2022-12-09T16:46:12.000Z https://psychedelicinvest.com/the-addition-of-three-mental-health-clinics-to-irwin-naturals-florida-footprint-solidifies-the-companies-impact-as-one-of-the-fastest-growing-chains-of-mental-health-clinics/2022-12-09T16:36:54.000Z https://psychedelicinvest.com/the-2022-psychedelic-holiday-gift-guide/2022-12-12T16:47:14.000Z https://psychedelicinvest.com/how-can-i-get-involved-in-the-psychedelics-industry-mindshifting-moments-20/2023-10-06T03:29:41.000Z https://psychedelicinvest.com/diamond-therapeutics-completes-phase-i-clinical-study-of-low-dose-psilocybin-in-healthy-human-subjects/2022-12-08T16:04:32.000Z https://psychedelicinvest.com/psybio-therapeutics-takes-initial-step-to-help-protect-the-sonoran-desert-toad-as-it-files-three-new-provisional-patent-applications-including-intellectual-property-protection-for-the-biosynthetic-pr/2022-12-08T15:58:34.000Z https://psychedelicinvest.com/numinus-submits-clinical-trial-application-to-health-canada-for-experiential-psilocybin-assisted-therapy-training-research/2022-12-08T15:39:57.000Z https://psychedelicinvest.com/nova-mentis-psilocybin-preclinical-study-published-in-international-science-journal/2022-12-08T15:34:00.000Z https://psychedelicinvest.com/comp360-psilocybin-therapy-shows-potential-in-open-label-study-in-type-ii-bipolar-disorder-presented-at-acnp/2022-12-08T15:27:47.000Z https://psychedelicinvest.com/red-light-hollands-wholly-owned-subsidiary-radix-motion-receives-favorable-international-preliminary-report-on-patentability-on-its-patent-application-utilizing-3d-movement-data-for-psychedelic-t/2022-12-07T18:12:36.000Z https://psychedelicinvest.com/ehave-shareholder-from-ceo-ben-kaplan-and-corporate-update/2022-12-07T18:05:10.000Z https://psychedelicinvest.com/betterlife-announces-closing-of-private-placement/2022-12-07T19:36:22.000Z https://psychedelicinvest.com/reunion-neuroscience-inc-to-participate-in-upcoming-investor-conferences-in-december/2022-12-07T17:47:26.000Z https://psychedelicinvest.com/mindset-pharma-to-participate-in-upcoming-conferences-in-december-2022/2022-12-07T17:43:46.000Z https://psychedelicinvest.com/irwin-naturals-files-q3-2022-financials/2022-12-07T17:39:20.000Z https://psychedelicinvest.com/enthea-announces-nationwide-rollout-to-offer-psychedelic-therapy-as-a-workplace-benefit/2022-12-06T20:34:47.000Z https://psychedelicinvest.com/psybio-therapeutics-files-four-u-s-patent-cooperation-treaty-pct-patent-applications-further-expanding-its-patent-portfolio/2022-12-06T18:07:36.000Z https://psychedelicinvest.com/joseph-tucker-ceo-of-enveric-biosciences-sits-in-the-investor-hotseat-on-december-8th/2023-10-06T03:32:54.000Z https://psychedelicinvest.com/4-tips-to-invest-in-equity-crowdfunding-like-a-pro/2022-12-05T16:29:33.000Z https://psychedelicinvest.com/psybio-therapeutics-announces-non-brokered-private-placement-financing/2022-12-02T13:15:18.000Z https://psychedelicinvest.com/silo-pharma-issues-letter-to-shareholders-detailing-progress-on-pipeline-assets-combining-traditional-therapeutics-with-psychedelic-medicine/2022-12-02T13:08:44.000Z https://psychedelicinvest.com/awakn-life-sciences-receives-regulatory-approval-for-flagship-clinic-in-london-to-begin-delivering-treatments-2/2022-12-02T14:31:09.000Z https://psychedelicinvest.com/cannabis-and-psychedelics-join-forces-at-the-arcview-access-cannabis-investment-summit/2022-12-01T20:11:32.000Z https://psychedelicinvest.com/what-is-nucleus-a-webinar-w-ceo-logan-lenz/2022-12-01T04:11:43.000Z https://psychedelicinvest.com/what-does-oregons-legalization-mean-for-me-mindshifting-moments-19/2023-10-06T03:28:43.000Z https://psychedelicinvest.com/lobe-sciences-provides-an-update-to-clinical-development-plans-for-its-proprietary-psilocin-product-l-130/2022-11-30T23:40:24.000Z https://psychedelicinvest.com/wellbeing-subsidiary-kgk-science-submits-cta-for-phase-iia-clinical-trial/2022-11-30T23:34:15.000Z https://psychedelicinvest.com/fsd-pharma-inc-announces-changes-to-the-board-of-directors/2022-11-30T23:23:09.000Z https://psychedelicinvest.com/goodmind-available-for-sale-in-the-united-kingdom-and-europe-exclusive-distribution-agreement-concluded-with-this-works/2022-11-30T23:16:01.000Z https://psychedelicinvest.com/mindset-pharma-ceo-james-lanthier-issues-letter-to-shareholders-2/2022-11-30T23:02:58.000Z https://psychedelicinvest.com/revive-therapeutics-ltd-announces-offering-of-up-to-5-million/2022-11-30T22:55:50.000Z https://psychedelicinvest.com/irwin-naturals-leverages-household-brand-status-in-effort-to-be-worlds-largest-chain-of-psychedelic-mental-health-clinics/2022-11-30T20:45:31.000Z https://psychedelicinvest.com/filament-health-announces-new-united-states-patent-issuances/2022-11-30T20:56:39.000Z https://psychedelicinvest.com/braxia-scientific-reports-q2-2023-financial-results-focused-on-growing-clinic-and-telemedicine-delivery-of-novel-mental-health-treatments-in-north-america/2022-11-30T20:31:58.000Z https://psychedelicinvest.com/numinus-wellness-inc-reports-q4-2022-and-annual-results/2022-11-30T20:24:17.000Z https://psychedelicinvest.com/psyrise-launches-the-first-end-to-end-marketing-platform-for-ketamine-clinics-retreats-and-psychedelic-assisted-therapists/2022-11-30T16:55:05.000Z https://psychedelicinvest.com/wellbeing-subsidiary-mindscape-treats-its-1000th-patient/2022-11-29T20:53:40.000Z https://psychedelicinvest.com/psybio-therapeutics-reports-third-quarter-2022-financial-results/2022-11-29T20:42:22.000Z https://psychedelicinvest.com/core-one-labs-announces-appointment-of-bf-borgers-cpa-pc-as-its-new-auditor/2022-11-29T03:32:00.000Z https://psychedelicinvest.com/bright-minds-biosciences-announces-non-brokered-private-placement/2022-11-28T16:23:59.000Z https://psychedelicinvest.com/field-trip-health-wellness-ltd-announces-updated-time-for-fiscal-second-quarter-2023-financial-results-and-conference-call/2022-11-28T16:03:36.000Z https://psychedelicinvest.com/jeffrey-finkle-ceo-of-arcview-sits-in-the-investor-hotseat-on-november-30th/2023-10-06T03:33:04.000Z https://psychedelicinvest.com/albert-labs-announces-private-placement/2022-11-27T12:51:47.000Z https://psychedelicinvest.com/revive-therapeutics-announces-fda-recommendation-for-type-c-meeting-to-discuss-amended-protocol-agreement-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19/2022-11-27T12:44:52.000Z https://psychedelicinvest.com/clearmind-announces-initiation-of-cmnd-100-manufacturing-program-to-address-its-upcoming-clinical-trial/2022-11-27T12:37:49.000Z https://psychedelicinvest.com/bright-minds-biosciences-appoints-drug-development-executive-mark-a-smith-m-d-ph-d-as-chief-medical-officer/2022-11-27T12:31:07.000Z https://psychedelicinvest.com/examining-the-intersection-of-psychedelics-memory-and-cognition/2022-11-23T04:44:56.000Z https://psychedelicinvest.com/mind-medicine-bullish-vs-bearish-episode-7/2023-10-06T03:26:51.000Z https://psychedelicinvest.com/field-trip-health-wellness-ltd-strengthens-leadership-team-with-two-executive-appointments-schedules-fiscal-second-quarter-2023-conference-call/2022-11-22T13:05:44.000Z https://psychedelicinvest.com/kaya-holdings-inc-managements-discussion-and-analysis-of-financial-condition-and-results-of-operations-form-10-q/2022-11-22T12:45:10.000Z https://psychedelicinvest.com/numinus-to-participate-in-a-water-tower-research-fireside-chat-on-thursday-december-8-2022/2022-11-22T12:34:22.000Z https://psychedelicinvest.com/nirvana-life-sciences-inc-announces-agreement-to-acquire-the-licensed-distributor-of-a-patented-who-approved-herbal-treatment-for-opiate-addiction/2022-11-22T12:27:03.000Z https://psychedelicinvest.com/core-one-labs-prepares-for-commercial-production-of-api-grade-psilocybin-plans-initial-production-run-at-gmp-facility-in-january/2022-11-21T20:22:34.000Z https://psychedelicinvest.com/mydecine-innovations-group-files-prospectus-supplement-and-announces-closing-under-share-subscription-agreement-2/2022-11-21T20:05:25.000Z https://psychedelicinvest.com/wellbeing-digital-announces-resignation-of-directors/2022-11-21T14:05:28.000Z https://psychedelicinvest.com/wellbeing-subsidiary-kgk-science-enters-into-research-contract-with-nova-mentis-for-phase-ii-a-clinical-trial/2022-11-21T13:59:57.000Z https://psychedelicinvest.com/reunion-neuroscience-puts-in-place-at-the-market-equity-facility/2022-11-21T13:46:56.000Z https://psychedelicinvest.com/silo-pharma-initiates-study-of-novel-joint-homing-peptide-in-human-tissue/2022-11-21T13:41:36.000Z https://psychedelicinvest.com/atai-life-sciences-and-massachusetts-general-hospital-announce-initiation-of-clinical-study-investigating-neuroplasticity-biomarkers-in-treatment-resistant-depression-patients-undergoing-ketamine-trea/2022-11-18T12:15:14.000Z https://psychedelicinvest.com/silo-wellness-wins-amendment-to-proposed-land-use-ordinance-for-oregon-psychedelic-ranch-corporate-update-shareholder-faqs/2022-11-18T12:08:03.000Z https://psychedelicinvest.com/awakn-life-sciences-signs-its-third-licensing-partnership-agreement-in-north-america-and-first-in-new-york-2/2022-11-18T11:53:58.000Z https://psychedelicinvest.com/nova-mentis-enters-into-research-contract-with-kgk-science-for-phase-ii-a-clinical-trial/2022-11-18T11:45:34.000Z https://psychedelicinvest.com/neil-markey-ceo-of-beckley-retreats-sits-in-the-investor-hotseat-on-november-23rd/2023-10-06T03:33:19.000Z https://psychedelicinvest.com/international-psychedelic-regulations-and-politics/2023-01-18T18:19:41.000Z https://psychedelicinvest.com/clearmind-medicine-announces-closing-of-us7-5-million-public-offering-and-uplisting-to-the-nasdaq-capital-market/2022-11-17T23:06:31.000Z https://psychedelicinvest.com/maps-pbc-completes-second-phase-3-mapp2-trial-of-mdma-assisted-therapy-for-treatment-of-ptsd/2022-11-17T22:49:50.000Z https://psychedelicinvest.com/filament-health-announces-psilocybin-supply-agreement-with-the-centre-for-addiction-and-mental-health/2022-11-18T02:07:22.000Z https://psychedelicinvest.com/albert-labs-signs-letter-of-intent-loi-with-ingenu-cro-for-first-in-human-clinical-studies/2022-11-17T22:21:23.000Z https://psychedelicinvest.com/telehealth-supports-rapid-growth-of-the-psychedelics-industry/2025-06-29T17:49:43.000Z https://psychedelicinvest.com/atai-life-sciences-bullish-vs-bearish-episode-6/2023-10-06T03:26:57.000Z https://psychedelicinvest.com/numinus-to-host-q4-and-year-end-2022-results-conference-call-on-november-29-2022/2022-11-16T23:23:31.000Z https://psychedelicinvest.com/freedom-biosciences-appoints-dr-david-hough-as-chief-medical-officer/2022-11-16T23:16:04.000Z https://psychedelicinvest.com/mindset-pharma-and-pharmala-biotech-enter-into-exclusive-sales-agreement/2022-11-16T23:04:07.000Z https://psychedelicinvest.com/what-is-psilacetin/2022-11-16T17:10:00.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-screens-first-subject-in-phase-1-dmt-human-stroke-study/2022-11-16T16:34:29.000Z https://psychedelicinvest.com/what-does-oregons-legalization-mean-for-me-mindshifting-moments-18/2023-10-06T03:28:52.000Z https://psychedelicinvest.com/the-influence-of-shamans-on-the-psychedelic-industry/2025-06-29T17:49:44.000Z https://psychedelicinvest.com/cybin-inc-presents-cyb003-preclinical-data-at-neuroscience-2022/2022-11-15T14:44:26.000Z https://psychedelicinvest.com/field-trip-announces-the-launch-of-freedom-by-field-trip-a-first-of-its-kind-ketamine-therapy-program/2022-11-15T14:39:02.000Z https://psychedelicinvest.com/beckley-psytech-successfully-completes-phase-i-clinical-study-of-lead-candidate-bpl-003-a-novel-benzoate-formulation-of-5-meo-dmt/2022-11-15T14:33:27.000Z https://psychedelicinvest.com/cybin-inc-reports-second-quarter-financial-results-and-recent-business-highlights/2022-11-15T14:27:40.000Z https://psychedelicinvest.com/colorado-votes-yes-on-psychedelics/2025-06-29T17:49:44.000Z https://psychedelicinvest.com/mindset-pharma-presents-poster-at-neuroscience-2022-highlighting-preclinical-data-on-msp-1014-its-psilocybin-like-lead-drug-candidate/2022-11-14T17:37:02.000Z https://psychedelicinvest.com/pharmather-announces-poster-presentation-of-positive-efficacy-and-safety-data-from-phase-1-2-clinical-study-of-ketamine-in-the-treatment-of-levodopa-induced-dyskinesia-in-parkinsons-disease-a/2022-11-14T17:29:46.000Z https://psychedelicinvest.com/reunion-neuroscience-inc-provides-business-update-and-reports-fiscal-second-quarter-2023-financial-results/2022-11-14T15:47:18.000Z https://psychedelicinvest.com/revitalist-and-wake-network-announce-joint-venture-partnership-to-open-psychedelic-clinics-and-retreats-in-the-united-states/2022-11-14T14:39:11.000Z https://psychedelicinvest.com/psychedelic-assisted-therapy-company-better-u-creates-military-liaison-officer-position-to-help-expand-access-to-veterans/2022-11-14T14:24:48.000Z https://psychedelicinvest.com/tripsitter-clinic-ltd-announces-the-closing-of-assets-acquisition-deal-with-reconcious-medical-and-appointment-of-dr-mark-braunstein-as-chairman/2022-11-14T14:18:55.000Z https://psychedelicinvest.com/psychedelic-stock-market-update-october-2022/2025-06-29T17:49:44.000Z https://psychedelicinvest.com/placebos-in-psychedelic-studies/2025-06-29T17:49:44.000Z https://psychedelicinvest.com/intelgenx-reports-third-quarter-2022-financial-results/2022-11-11T14:03:31.000Z https://psychedelicinvest.com/small-pharma-to-participate-in-november-investor-and-healthcare-conferences/2022-11-11T13:55:17.000Z https://psychedelicinvest.com/silo-pharma-achieves-new-milestone-for-sp-26-therapeutic-initiates-ind-enabling-study-of-topical-ketamine-formulation/2022-11-11T13:50:53.000Z https://psychedelicinvest.com/relmada-therapeutics-provides-corporate-update-and-reports-third-quarter-2022-financial-results/2022-11-11T13:38:11.000Z https://psychedelicinvest.com/filament-health-announces-third-quarter-2022-financial-results-and-operational-highlights/2022-11-10T22:43:57.000Z https://psychedelicinvest.com/psyence-group-announces-strategic-private-placement/2022-11-11T16:27:52.000Z https://psychedelicinvest.com/mindmed-reports-third-quarter-2022-financial-results-and-business-highlights/2022-11-10T22:04:52.000Z https://psychedelicinvest.com/goodcap-pharmaceuticals-and-the-university-of-toronto-awarded-nserc-alliance-grant-for-ongoing-research-of-low-dose-psilocybin-drug-formulas-targeting-inflammation-and-depressive-disorders/2022-11-10T21:34:52.000Z https://psychedelicinvest.com/video-the-mindmed-chronicles-whats-the-latest/2025-06-29T17:49:44.000Z https://psychedelicinvest.com/cybin-provides-progress-update-on-its-cyb004-e-phase-1-trial/2022-11-10T19:45:31.000Z https://psychedelicinvest.com/tryp-therapeutics-announces-poster-presentations-on-the-reduction-of-chronic-pain-in-a-rodent-model-with-psilocybin-and-intravenous-psilocybin-alters-brain-network-dynamics-in-rats-at-the-2022-society/2022-11-10T19:33:16.000Z https://psychedelicinvest.com/the-rise-of-the-psilocybin-retail-market/2025-06-29T17:49:44.000Z https://psychedelicinvest.com/awakn-life-sciences-signs-its-third-licensing-partnership-agreement-in-north-america-and-first-in-new-york/2022-11-10T16:58:54.000Z https://psychedelicinvest.com/irwin-naturals-looks-to-add-pacific-northwest-ketamine-clinic-to-its-national-footprint/2022-11-10T16:41:07.000Z https://psychedelicinvest.com/lobe-sciences-to-present-at-moneyshow-virtual-expo-november-10-2022/2022-11-09T13:44:37.000Z https://psychedelicinvest.com/beckley-psytech-announces-first-participant-dosed-in-phase-i-trial-of-ele-101-a-novel-intravenous-formulation-of-psilocin/2022-11-09T13:40:27.000Z https://psychedelicinvest.com/pharmala-submits-pre-ind-dossier-for-novel-mdma-analog-to-fda-2/2022-11-09T13:33:58.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-advancing-dmt-into-a-phase-1-clinical-trial-ceo-clips-video/2022-11-09T13:23:50.000Z https://psychedelicinvest.com/universal-ibogaine-announces-formation-of-advisory-board/2022-11-08T21:11:06.000Z https://psychedelicinvest.com/george-tziras-ceo-of-small-pharma-sits-in-the-investor-hotseat-on-november-10th/2023-10-06T03:33:29.000Z https://psychedelicinvest.com/how-could-psychedelics-help-ukranian-civilians-mindshifting-moments-17/2023-10-06T03:29:05.000Z https://psychedelicinvest.com/the-mindmed-chronicles-live-qa-with-jake-freeman-of-freeman-capital-part-3/2025-06-29T17:49:44.000Z https://psychedelicinvest.com/aion-therapeutic-files-financials/2022-11-07T22:54:45.000Z https://psychedelicinvest.com/reunion-neuroscience-schedules-fiscal-second-quarter-2023-conference-call-for-monday-november-14-2022-at-830-a-m-et/2022-11-07T22:33:26.000Z https://psychedelicinvest.com/revitalist-ceo-awarded-professional-service-practitioner-of-the-year-by-microdose/2022-11-07T12:04:34.000Z https://psychedelicinvest.com/women-in-psychedelics-announces-atai-as-platinum-sponsors/2022-11-04T19:11:39.000Z https://psychedelicinvest.com/biomind-labs-announces-positive-initial-results-from-its-phase-ii-trial-on-its-bmnd01-candidate-for-treatment-resistant-depression/2022-11-04T18:16:20.000Z https://psychedelicinvest.com/beckley-psytech-to-attend-and-present-at-the-jefferies-london-healthcare-conference-november-15-17-2022/2022-11-04T18:07:30.000Z https://psychedelicinvest.com/compass-pathways-announces-third-quarter-2022-financial-results-and-business-highlights/2022-11-04T18:03:17.000Z https://psychedelicinvest.com/fluence-moves-to-withdraw-trademark/2025-06-29T17:49:44.000Z https://psychedelicinvest.com/cybin-to-participate-in-the-jefferies-london-healthcare-conference-and-upcoming-investor-events/2022-11-03T21:19:29.000Z https://psychedelicinvest.com/mindmed-to-host-earnings-call-to-discuss-third-quarter-2022-financial-results-and-provide-business-update/2022-11-03T21:11:41.000Z https://psychedelicinvest.com/first-patient-dosed-in-clairvoyants-phase-2-clinical-trial-exploring-psilocybin-as-a-treatment-for-alcohol-use-disorder/2022-11-03T16:23:52.000Z https://psychedelicinvest.com/compass-pathways-announces-publication-of-phase-2b-study-of-comp360-psilocybin-therapy-for-treatment-resistant-depression-in-the-new-england-journal-of-medicine/2022-11-03T12:32:28.000Z https://psychedelicinvest.com/silo-wellness-breaking-news-jackson-county-oregons-proposed-tpm-restrictions-put-rural-psilocybin-retreat-therapy-centers-at-risk/2022-11-03T12:18:20.000Z https://psychedelicinvest.com/how-can-businesses-take-advantage-of-psychedelic-retreats-mindshifting-moments-16/2023-10-06T03:29:14.000Z https://psychedelicinvest.com/revitalist-releases-supplement-line-to-enhance-the-results-of-psychedelic-medicines/2022-11-02T21:59:53.000Z https://psychedelicinvest.com/pharmala-submits-pre-ind-dossier-for-novel-mdma-analog-to-fda/2022-11-02T21:53:27.000Z https://psychedelicinvest.com/lusaris-therapeutics-launches-with-60-million-series-a-financing-to-redefine-the-treatment-of-severe-neuropsychiatric-and-neurological-disorders/2022-11-02T17:56:53.000Z https://psychedelicinvest.com/atai-life-sciences-to-participate-in-november-investor-events-healthcare-conferences/2022-11-02T16:21:24.000Z https://psychedelicinvest.com/braxia-scientific-announces-voting-results-from-the-annual-general-and-special-meeting-of-shareholders/2022-11-02T16:17:45.000Z https://psychedelicinvest.com/revitalist-increases-patient-access-making-care-more-affordable-by-financing-the-cost-with-m-lend-financial/2022-11-01T21:17:11.000Z https://psychedelicinvest.com/cybin-announces-scientific-presentation-at-the-5th-annual-neuropsychiatric-psychedelics-drug-development-summit/2022-11-01T21:10:51.000Z https://psychedelicinvest.com/pharmather-enters-into-exclusive-option-agreement-with-case-western-reserve-university-to-develop-and-commercialize-ketamine-for-rett-syndrome/2022-11-01T21:05:17.000Z https://psychedelicinvest.com/irwin-naturals-looks-to-add-to-florida-foothold-expanding-chain-of-healthcare-clinics/2022-11-01T20:06:58.000Z https://psychedelicinvest.com/apex-labs-granted-approval-for-north-americas-first-take-home-psilocybin-clinical-trial/2022-11-01T19:48:34.000Z https://psychedelicinvest.com/numinus-re-launches-psychedelic-therapy-frontiers-podcast-with-additional-hosts-and-topics/2022-11-01T18:57:23.000Z https://psychedelicinvest.com/reunion-neuroscience-to-present-at-upcoming-november-conferences/2022-11-01T17:32:02.000Z https://psychedelicinvest.com/psilera-to-sponsor-and-present-at-wonderland-miami-november-3-5-2022/2022-11-01T17:21:44.000Z https://psychedelicinvest.com/psychedelics-a-tool-for-innovation-creativity-and-leadership/2022-11-01T17:08:51.000Z https://psychedelicinvest.com/field-trip-health-wellness-to-participate-in-upcoming-november-conferences/2022-10-31T20:58:51.000Z https://psychedelicinvest.com/enosis-therapeutics-and-ovid-clinics-announce-partnership-to-launch-worlds-first-in-clinic-application-of-virtual-reality-modulated-psychedelic-augmented-psychotherapy/2022-10-31T18:17:49.000Z https://psychedelicinvest.com/better-u-expanding-psychedelic-assisted-therapies-to-9-states-with-immersive-healing-centers/2022-10-31T18:11:10.000Z https://psychedelicinvest.com/small-pharma-receives-approval-for-first-in-human-phase-i-clinical-trial-with-spl028/2022-10-31T17:36:45.000Z https://psychedelicinvest.com/numinus-to-participate-in-wonderland-miami-on-november-3-5-2022/2022-10-31T17:24:54.000Z https://psychedelicinvest.com/silo-wellness-to-testify-on-oregon-psilocybin-therapy-land-use-restrictions-at-jackson-county-planning-commissions-thursday-hearing-other-corporate-updates/2022-10-31T17:20:22.000Z https://psychedelicinvest.com/soft-reboot-wellness-ketamine-depression-treatment-now-available-for-los-altos/2022-10-31T17:12:14.000Z https://psychedelicinvest.com/mindcure-announces-financial-results-for-the-first-quarter-of-fiscal-2023-usa/2022-10-30T21:34:45.000Z https://psychedelicinvest.com/clairvoyants-phase-2-psilocybin-therapy-trial-for-alcohol-use-disorder-obtains-regulatory-approval-and-initiates-1st-clinical-site-in-finland-2/2022-10-30T19:41:03.000Z https://psychedelicinvest.com/love-pharma-johns-hopkins-university-psilocybin-trial-advances-toward-launch-in-2022-2/2022-10-30T19:35:23.000Z https://psychedelicinvest.com/mindset-pharma-announces-poster-presentations-at-two-upcoming-scientific-conferences/2022-10-30T19:29:25.000Z https://psychedelicinvest.com/numinus-launches-psychedelic-assisted-therapy-for-chronic-and-serious-medical-illness/2022-10-30T19:20:08.000Z https://psychedelicinvest.com/compass-pathways-plc-to-announce-third-quarter-2022-financial-results-on-3-november-2022/2022-10-29T16:36:11.000Z https://psychedelicinvest.com/havn-life-announces-retail-listing-with-loblaws-company-ltd/2022-10-29T12:18:06.000Z https://psychedelicinvest.com/seelos-therapeutics-to-sponsor-and-participate-in-wonderland-the-worlds-leading-psychedelic-event/2022-10-27T14:39:57.000Z https://psychedelicinvest.com/cybins-embark-program-announces-graduation-of-facilitators/2022-10-27T14:33:07.000Z https://psychedelicinvest.com/wellbeing-announces-dfinitive-agreement-to-divest-irp-health/2022-10-27T14:26:36.000Z https://psychedelicinvest.com/delic-labs-president-and-cso-dr-markus-roggen-to-discuss-the-importance-of-rd-for-business-growth-at-mjbizcon/2022-10-27T14:18:41.000Z https://psychedelicinvest.com/mindcure-announces-financial-results-for-the-first-quarter-of-fiscal-2023/2022-10-27T12:38:33.000Z https://psychedelicinvest.com/silo-wellness-announces-subsidiarys-branding-licensing-agreement-terminated/2022-10-26T21:13:38.000Z https://psychedelicinvest.com/wellbeing-digital-to-participate-at-this-years-wonderland-miami-conference/2022-10-26T16:44:43.000Z https://psychedelicinvest.com/reunion-neuroscience-opens-the-market/2022-10-27T23:41:08.000Z https://psychedelicinvest.com/silo-pharma-to-discuss-mainstream-pharma-and-psychedelics-at-wonderland-miami-conference/2022-10-26T15:19:46.000Z https://psychedelicinvest.com/logan-lenz-builds-psychedelics-brands-and-tools-podcast-episode-23/2022-10-26T15:18:51.000Z https://psychedelicinvest.com/what-are-some-of-the-most-common-misconceptions-about-psychedelics-mindshifting-moments-15/2023-10-06T03:29:23.000Z https://psychedelicinvest.com/aion-therapeutic-provides-default-status-update/2022-10-25T21:47:27.000Z https://psychedelicinvest.com/core-one-labs-takes-next-steps-to-prepare-for-potential-takeover-opportunities/2022-10-25T20:07:45.000Z https://psychedelicinvest.com/awakn-life-sciences-secures-funding-to-expand-nordic-commercial-operations/2022-10-25T19:52:22.000Z https://psychedelicinvest.com/silo-pharma-distinctive-with-ground-breaking-research-commitment-to-developing-innovative-solutions/2022-10-25T18:21:16.000Z https://psychedelicinvest.com/intelgenx-receives-fda-gdufa-date-for-xiromed-partnered-development-candidate-buprenorphine-buccal-film/2022-10-25T16:51:50.000Z https://psychedelicinvest.com/atai-life-sciences-company-perception-neuroscience-completes-enrollment-for-phase-2a-clinical-trial-of-pcn-101-r-ketamine-for-treatment-resistant-depression/2022-10-25T15:58:37.000Z https://psychedelicinvest.com/albert-labs-provides-corporate-update/2022-10-25T15:49:28.000Z https://psychedelicinvest.com/nutritional-mushrooms-and-cannabinoids-for-optimal-health/2022-10-25T15:40:17.000Z https://psychedelicinvest.com/reunion-neuroscience-appoints-chief-financial-officer-and-vice-president-medical-affairs/2022-10-24T20:00:38.000Z https://psychedelicinvest.com/beckley-psytech-strengthens-pipeline-and-development-team-with-acquisition-of-eleusis-therapeutics-limited/2022-10-24T17:34:42.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-enters-into-a-clinical-trial-agreement-with-yale-university-for-a-dmt-phase-2-depression-study/2022-10-24T15:41:17.000Z https://psychedelicinvest.com/atai-life-sciences-announces-rd-day-agenda/2022-10-21T23:35:55.000Z https://psychedelicinvest.com/albert-labs-files-new-international-pct-patent-application-for-scalable-api-manufacturing/2022-10-20T17:28:53.000Z https://psychedelicinvest.com/silo-wellness-announces-loi-for-potentially-largest-psilocybin-retreat-center-in-oregon-and-the-world-if-novembers-election-is-favorable-and-an-oregon-real-estate-law-and-psilocybin-industry-prim/2022-10-20T17:14:52.000Z https://psychedelicinvest.com/death-and-psychedelics-end-of-life-applications-for-mind-altering-compounds/2022-10-20T15:09:36.000Z https://psychedelicinvest.com/second-united-states-patent-granted-for-small-pharmas-psychedelics-portfolio/2022-10-19T21:16:08.000Z https://psychedelicinvest.com/origin-therapeutics-portfolio-company-clairvoyant-approved-for-phase-2-psilocybin-therapy-trial-first-clinical-site-initiated-in-finland/2022-10-19T17:23:17.000Z https://psychedelicinvest.com/tim-schlidt-is-funding-a-new-paradigm-in-wellbeing-podcast-episode-22/2022-10-19T17:20:52.000Z https://psychedelicinvest.com/atais-pipeline-update-weekly-extractions-october-19-2022/2022-10-19T15:07:59.000Z https://psychedelicinvest.com/what-does-the-future-of-psychedelics-look-like-a-mindshifting-moments-special-event/2023-10-06T03:29:33.000Z https://psychedelicinvest.com/atai-life-sciences-announces-initiation-of-phase-1-proof-of-concept-clinical-trial-for-its-sol-gel-based-direct-to-brain-drug-delivery-technology/2022-10-18T15:44:49.000Z https://psychedelicinvest.com/silo-pharma-extends-research-pact-for-alzheimers-and-stress-induced-anxiety-therapeutics/2022-10-18T15:39:13.000Z https://psychedelicinvest.com/silo-pharma-stock-higher-after-investors-appraise-innovative-treatment-for-nerve-pain-and-neurological-disorders/2022-10-18T15:33:01.000Z https://psychedelicinvest.com/silo-wellness-closes-acquisition-of-dyscovry-science-and-its-psilocybin-pharmaceutical-biosynthesis-and-research-portfolio/2022-10-18T15:27:12.000Z https://psychedelicinvest.com/wellbeing-digital-subsidiary-kgk-to-participate-in-the-supply-side-west-conference/2022-10-18T15:19:08.000Z https://psychedelicinvest.com/spravato-drug-approvals-and-international-questioning/2022-10-17T18:36:15.000Z https://psychedelicinvest.com/european-university-to-fund-core-one-labs-akome-advanced-neurogenesis-stimulation-studies/2022-10-17T18:05:20.000Z https://psychedelicinvest.com/small-pharma-reports-fiscal-second-quarter-2023-highlights/2022-10-16T13:27:38.000Z https://psychedelicinvest.com/revive-therapeutics-announces-finalization-of-amended-phase-3-covid-19-study-protocol-to-fda/2022-10-16T13:14:39.000Z https://psychedelicinvest.com/psychedelic-stock-market-update-september-2022/2022-10-14T19:53:14.000Z https://psychedelicinvest.com/what-has-been-going-on-with-mindmed-lately/2022-10-14T17:12:27.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-announces-dr-rick-strassman-author-of-dmt-the-spirit-molecule-to-join-ceo-christopher-j-moreau-for-keynote-science-address-at-wonderland-conference/2022-10-14T14:07:02.000Z https://psychedelicinvest.com/clearmind-medicine-announces-share-based-payment-for-one-of-the-companys-consultants-2/2022-10-14T14:00:46.000Z https://psychedelicinvest.com/wellbeing-digital-and-subsidiary-kgk-science-applauds-the-government-of-albertas-move-to-regulate-the-use-of-psychedelics/2022-10-14T13:50:11.000Z https://psychedelicinvest.com/love-pharma-johns-hopkins-university-psilocybin-trial-advances-toward-launch-in-2022/2022-10-13T19:13:11.000Z https://psychedelicinvest.com/psycs-spotlight-media-highlights-revenue-growth-and-other-operational-achievements-met-in-q3/2022-10-13T18:52:59.000Z https://psychedelicinvest.com/intelgenx-says-atai-life-sciences-collaboration-leads-to-start-of-first-in-human-clinical-study-of-oral-thin-film-psychedelic-drug-candidate/2022-10-13T18:18:29.000Z https://psychedelicinvest.com/pharmala-appoints-dr-leah-mayo-to-scientific-advisory-board/2022-10-13T16:21:42.000Z https://psychedelicinvest.com/relmada-therapeutics-announces-top-line-results-from-phase-3-reliance-iii-trial-for-rel-1017-as-a-monotherapy-for-the-treatment-of-major-depressive-disorder/2022-10-13T12:59:40.000Z https://psychedelicinvest.com/field-trip-announces-relaunch-and-refresh-of-its-award-winning-psychedelic-app/2022-10-13T12:52:09.000Z https://psychedelicinvest.com/clairvoyants-phase-2-psilocybin-therapy-trial-for-alcohol-use-disorder-obtains-regulatory-approval-and-initiates-1st-clinical-site-in-finland/2022-10-13T12:45:29.000Z https://psychedelicinvest.com/compass-pathways-announces-phase-3-pivotal-program-design-for-comp360-in-treatment-resistant-depression-at-capital-markets-day/2022-10-12T17:00:02.000Z https://psychedelicinvest.com/atai-life-sciences-announces-positive-initial-results-for-phase-1-trial-of-kur-101-an-oral-formulation-of-mitragynine-for-oud/2022-10-12T16:52:32.000Z https://psychedelicinvest.com/what-have-we-learned-so-far-mindshifting-moments-14/2023-10-06T03:29:53.000Z https://psychedelicinvest.com/anand-shahi-compares-psychedelics-and-cannabis-investing-podcast-episode-21/2022-10-12T15:43:23.000Z https://psychedelicinvest.com/enveric-biosciences-announces-poster-presentations-of-lead-programs-at-the-2022-international-neurology-brain-disorders-conference/2022-10-12T14:53:51.000Z https://psychedelicinvest.com/reunion-neuroscience-ceo-to-participate-on-panel-at-2022-horizons-perspectives-on-psychedelics-conference/2022-10-12T14:16:19.000Z https://psychedelicinvest.com/filament-health-to-host-virtual-investor-update/2022-10-12T14:48:54.000Z https://psychedelicinvest.com/pharmala-contracts-with-clerkenwell-to-bring-safer-mdma-analogue-to-us-uk/2022-10-11T22:07:50.000Z https://psychedelicinvest.com/who-controls-the-psychedelics-industry/2022-10-11T15:49:45.000Z https://psychedelicinvest.com/psybio-therapeutics-reaches-agreement-to-conduct-initial-psilocybin-clinical-trial/2022-10-11T13:17:59.000Z https://psychedelicinvest.com/cybin-the-chopra-foundation-recognize-world-mental-health-day/2022-10-10T23:43:01.000Z https://psychedelicinvest.com/silo-pharmas-mission-to-merge-traditional-pharmaceuticals-with-psychedelic-compounds-can-be-a-treatment-game-changer-for-neurological-disorders/2022-10-10T15:34:44.000Z https://psychedelicinvest.com/core-one-labs-nearing-gmp-production-as-canadas-province-of-alberta-announces-game-changing-legislation/2022-10-10T15:23:41.000Z https://psychedelicinvest.com/altrd-tvs-open-minds-documentary-explores-the-promising-future-of-psychedelic-medicine/2022-10-10T14:01:32.000Z https://psychedelicinvest.com/silo-pharma-initiates-toxicity-study-of-its-proprietary-ketamine-formulation-for-treatment-of-fibromyalgia/2022-10-10T13:55:54.000Z https://psychedelicinvest.com/reunion-neuroscience-inc-announces-executive-changes/2022-10-10T12:52:48.000Z https://psychedelicinvest.com/the-mindmed-chronicles-an-interview-with-robert-barrow-the-ceo-of-mindmed/2022-10-08T03:38:06.000Z https://psychedelicinvest.com/numinus-to-participate-in-a-water-tower-research-fireside-chat-on-thursday-october-13-2022/2022-10-07T18:27:13.000Z https://psychedelicinvest.com/evan-levine-ceo-of-psybio-therapeutics-sits-in-the-investor-hotseat-on-october-13th/2023-10-06T03:33:38.000Z https://psychedelicinvest.com/cybin-provides-update-on-its-intellectual-property-portfolio/2022-10-07T12:15:18.000Z https://psychedelicinvest.com/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19-3/2022-10-07T12:01:16.000Z https://psychedelicinvest.com/pharmala-biotech-ready-to-assist-alberta-government-with-clinical-mdma-supply/2022-10-06T23:36:33.000Z https://psychedelicinvest.com/the-mindmed-chronicles-part-2-of-the-interview-with-jake-freeman-of-freeman-capital/2022-10-06T20:06:59.000Z https://psychedelicinvest.com/silo-pharma-to-present-at-the-dawson-james-small-cap-growth-conference-on-october-12/2022-10-06T19:25:20.000Z https://psychedelicinvest.com/alberta-puts-patients-first-by-regulating-psychedelic-therapy-optimi-health/2022-10-06T19:19:59.000Z https://psychedelicinvest.com/wellbeing-subsidiary-kgk-science-announces-psilocybin-microdose-capsule-formulation-to-be-submitted-to-health-canada-for-phase-2a-trial/2022-10-06T19:08:44.000Z https://psychedelicinvest.com/creso-pharma-unit-completes-enrollment-for-phase-2-psychedelic-trial/2022-10-06T18:57:08.000Z https://psychedelicinvest.com/the-birth-and-rise-of-integrative-medicine/2022-10-05T19:53:58.000Z https://psychedelicinvest.com/atai-life-sciences-announces-first-subject-dosed-in-phase-1-trial-of-buccal-and-iv-vls-01-a-synthetic-form-of-dmt/2022-10-05T14:38:17.000Z https://psychedelicinvest.com/gregory-roufa-and-david-glowacki-are-building-digital-group-therapeutics-podcast-episode-20/2022-10-05T14:34:11.000Z https://psychedelicinvest.com/universal-ibogaine-announces-results-of-annual-general-meeting/2022-10-05T14:31:54.000Z https://psychedelicinvest.com/pharmather-holdings-announces-grant-of-u-s-patent-covering-ketamine-for-parkinsons-disease/2022-10-05T14:14:18.000Z https://psychedelicinvest.com/mindset-pharma-selects-lead-clinical-candidates-from-family-2-of-its-next-generation-psychedelic-drug-portfolio/2022-10-05T14:04:24.000Z https://psychedelicinvest.com/numinus-develops-mushroom-tea-for-use-in-psychedelic-research/2022-10-05T13:57:21.000Z https://psychedelicinvest.com/lobe-sciences-announces-the-expansion-of-its-patent-portfolio-with-international-filings/2022-10-04T22:48:34.000Z https://psychedelicinvest.com/psyc-corporation-discusses-significance-of-expansion-into-cannabis-and-precious-metals-sectors-with-the-stock-day-podcast/2022-10-04T22:30:25.000Z https://psychedelicinvest.com/irwin-naturals-agrees-to-add-idaho-clinic-to-its-national-chain-of-psychedelic-mental-health-clinics/2022-10-04T22:11:19.000Z https://psychedelicinvest.com/mindmed-collaborators-initiate-phase-1-comparative-pk-pd-trial-of-r-s-and-racemic-mdma/2022-10-04T21:59:05.000Z https://psychedelicinvest.com/why-are-female-focused-therapeutics-so-important-mindshifting-moments-13/2023-10-06T03:30:04.000Z https://psychedelicinvest.com/pasithea-therapeutics-to-call-special-meeting-of-stockholders/2022-10-04T20:36:50.000Z https://psychedelicinvest.com/wellbeing-digital-signs-loi-manage-additional-clinics/2022-10-04T20:20:27.000Z https://psychedelicinvest.com/pharmala-biotech-to-supply-university-of-california-clinical-trial-with-laneo-mdma/2022-10-04T18:54:21.000Z https://psychedelicinvest.com/ketamd-expands-access-to-breakthrough-ketamine-therapy-in-florida-to-battle-the-growing-mental-health-crisis-and-shortage-of-mental-health-care-providers/2022-10-04T16:20:11.000Z https://psychedelicinvest.com/universal-ibogaine-undertaking-offering-of-convertible-debt-securities-and-common-shares/2022-10-04T16:02:43.000Z https://psychedelicinvest.com/pharmadrug-advances-programs-in-oncology-and-infectious-disease-through-completion-of-cgmp-drug-substance-manufacturing/2022-10-04T15:53:11.000Z https://psychedelicinvest.com/tryp-therapeutics-announces-publication-of-international-pct-patent-application-for-the-intravenous-administration-of-psilocin-and-psilocybin/2022-10-04T15:44:05.000Z https://psychedelicinvest.com/revitalist-non-profit-community-change-foundation-receives-1m-grant-to-address-adolescent-mental-health-and-school-violence/2022-10-03T22:06:17.000Z https://psychedelicinvest.com/silo-pharma-initiates-fda-pre-investigational-new-drug-package-for-time-released-ketamine-technology/2022-10-03T18:47:33.000Z https://psychedelicinvest.com/core-one-labs-announces-breakthrough-with-proprietary-isolation-and-purification-method-of-psilocybin-from-mushrooms-prepares-patent-application/2022-10-01T19:39:52.000Z https://psychedelicinvest.com/silo-pharma-announces-closing-of-5-75-million-public-offering-of-common-stock-nasdaq-listing-and-full-exercise-of-underwriters-over-allotment-option/2022-10-01T19:30:51.000Z https://psychedelicinvest.com/mindmed-board-is-trippin-significant-investor-calls-for-termination-of-highly-dilutive-equity-offering-and-pledges-to-hold-board-and-management-accountable-through-activist-campaign/2022-09-30T22:36:27.000Z https://psychedelicinvest.com/supermind-platforms-inc-acquires-psychedelics-com-and-closes-pre-seed-financing/2022-09-30T17:12:06.000Z https://psychedelicinvest.com/reunion-neuroscience-inc-announces-results-of-annual-general-and-special-shareholder-meeting/2022-09-30T14:17:24.000Z https://psychedelicinvest.com/irwin-naturals-acquiring-ketamine-media/2022-09-30T14:10:58.000Z https://psychedelicinvest.com/pharmather-provides-business-highlights-and-releases-audited-annual-financials-for-fiscal-year-ended-may-31-2022/2022-09-30T14:04:35.000Z https://psychedelicinvest.com/psyence-group-completes-export-of-psilocybin-mushrooms-to-portugal/2022-09-29T17:19:14.000Z https://psychedelicinvest.com/nova-mentis-psilocybin-microdose-capsule-formulation-to-be-submitted-in-health-canada-phase-2a-clinical-trial-application/2022-09-29T17:06:35.000Z https://psychedelicinvest.com/biomind-and-queens-university-of-belfast-receive-controlled-substances-license-to-commence-the-production-of-a-novel-transdermal-drug-delivery-system/2022-10-25T16:38:08.000Z https://psychedelicinvest.com/reunion-neuroscience-inc-appoints-greg-mayes-as-president-and-chief-executive-officer/2022-09-29T15:41:47.000Z https://psychedelicinvest.com/mindmed-announces-pricing-of-public-offering-of-common-shares-and-warrants/2022-09-29T15:23:35.000Z https://psychedelicinvest.com/the-mindmed-chronicles-a-conversation-with-jake-freeman-of-freeman-capital/2022-09-29T01:21:29.000Z https://psychedelicinvest.com/the-top-5-psychedelic-stocks-to-watch-right-now/2022-09-28T17:44:31.000Z https://psychedelicinvest.com/mindmed-announces-proposed-public-offering-of-common-shares/2022-09-28T12:15:48.000Z https://psychedelicinvest.com/betterlife-files-comprehensive-patent-for-betr-001-and-other-lsd-derivatives/2022-09-28T12:05:58.000Z https://psychedelicinvest.com/silo-pharma-announces-uplisting-to-nasdaq-capital-market-and-pricing-of-5-million-public-offering-of-common-stock/2022-09-28T12:18:15.000Z https://psychedelicinvest.com/atai-life-sciences-announces-initiation-of-phase-1-trial-for-its-mdma-derivative-emp-01/2022-09-28T11:18:59.000Z https://psychedelicinvest.com/silo-wellness-executes-definitive-agreement-to-acquire-dyscovry-science-and-its-psilocybin-pharmaceutical-biosynthesis-and-research-portfolio/2022-09-28T11:43:00.000Z https://psychedelicinvest.com/cybin-obtains-exclusive-license-to-a-novel-catalog-of-psychedelic-based-compounds/2022-09-28T11:03:46.000Z https://psychedelicinvest.com/jordan-tishler-is-a-physician-educator-and-patient-advocate-podcast-episode-19/2022-09-28T03:50:33.000Z https://psychedelicinvest.com/the-mindmed-chronicles-new-shelf-offering-on-september-27-2022/2022-09-28T02:56:18.000Z https://psychedelicinvest.com/what-are-the-concerns-with-self-administering-psychedelics-mindshifting-moments-12/2023-10-06T03:30:12.000Z https://psychedelicinvest.com/genetics-psychedelics-do-you-inherit-your-trip/2022-09-28T00:14:25.000Z https://psychedelicinvest.com/payton-nyquvest-ceo-of-numinus-sits-in-the-investor-hotseat-on-september-29th/2023-10-06T03:33:46.000Z https://psychedelicinvest.com/tryp-therapeutics-strengthens-intellectual-property-portfolio-with-provisional-patent-applications-for-fibromyalgia-treatment-and-for-crystalline-forms-of-trp-8803/2022-09-27T00:19:00.000Z https://psychedelicinvest.com/wellbeing-subsidiary-kgk-science-opens-new-clinical-research-center-to-reimagine-a-healthier-future/2022-09-26T23:29:20.000Z https://psychedelicinvest.com/universal-ibogaine-featured-in-psychedelics-tonight-documentary-series/2022-09-26T22:57:06.000Z https://psychedelicinvest.com/clearmind-announces-notice-of-proposed-stock-consolidation/2022-09-25T23:23:50.000Z https://psychedelicinvest.com/irwin-naturals-inc-announces-normal-course-issuer-bid-for-subordinate-voting-shares-of-the-corporation/2022-09-24T13:43:42.000Z https://psychedelicinvest.com/optimi-health-atma-journey-centers-to-proceed-with-phase-i-natural-psilocybin-and-mdma-clinical-trial-application-to-health-canada/2022-09-24T13:31:58.000Z https://psychedelicinvest.com/core-one-labs-signs-letter-of-intent-with-gmp-manufacturing-partner-for-production-of-proprietary-psychedelic-compounds/2022-09-24T13:22:15.000Z https://psychedelicinvest.com/mydecine-innovations-group-announces-closing-under-share-subscription-agreement-and-welcomes-new-cfo/2022-09-26T16:32:45.000Z https://psychedelicinvest.com/psychedelic-sector-news-weekly-extractions-september-23-2022/2022-09-24T02:37:55.000Z https://psychedelicinvest.com/delix-therapeutics-expands-world-class-team-with-first-head-of-rd/2022-09-23T18:10:26.000Z https://psychedelicinvest.com/clearmind-applies-for-patent-to-treat-obesity-and-metabolic-syndrome/2022-09-22T22:56:11.000Z https://psychedelicinvest.com/origin-therapeutics-portfolio-company-xpira-pharmaceuticals-receives-fda-approval-for-psilocybin-trial-ind-application/2022-09-22T22:35:39.000Z https://psychedelicinvest.com/nirvana-life-sciences-inc-deuterates-7-hydroxymitragynine-to-create-d7-h-an-analogue-that-may-improve-research-and-formulations-using-kratom-derivatives/2022-09-22T22:25:30.000Z https://psychedelicinvest.com/caamtech-creates-two-new-prodrugs-of-4-ho-dipt/2022-09-22T20:42:11.000Z https://psychedelicinvest.com/ketamine-wellness-centers-kwc-partners-with-veterans-administration-community-care-network-va-ccn-to-expand-spravato-coverage/2022-09-22T19:58:02.000Z https://psychedelicinvest.com/psyence-group-completes-export-of-psilocybin-mushrooms-to-canada/2022-09-22T19:49:33.000Z https://psychedelicinvest.com/numinus-expands-ketamine-therapy-for-mental-health-in-montreal-and-announces-new-brand-awareness-initiatives/2022-09-22T19:41:04.000Z https://psychedelicinvest.com/colorado-votes-for-psilocybin-access/2022-09-22T14:49:48.000Z https://psychedelicinvest.com/universal-ibogaine-announces-kelburn-reopening-date/2022-09-22T13:59:20.000Z https://psychedelicinvest.com/braxia-scientific-announces-board-appointment/2022-09-22T13:51:50.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-announces-receipt-of-cdn-450k-cash-refund-from-australian-research-program/2022-09-21T23:59:35.000Z https://psychedelicinvest.com/robbie-bent-is-building-the-future-of-emotional-wellness-podcast-episode-18/2022-09-21T20:19:26.000Z https://psychedelicinvest.com/biomind-labs-announces-completion-of-dosing-in-phase-ii-trial-of-its-dmt-based-inhaled-formulation-bmnd01-for-treatment-resistant-depression/2022-10-25T16:38:06.000Z https://psychedelicinvest.com/cybin-achieves-research-and-development-milestones-ahead-of-projected-timelines/2022-09-21T14:19:21.000Z https://psychedelicinvest.com/compass-pathways-to-participate-in-upcoming-jefferies-innovation-in-mental-health-summit/2022-09-21T14:01:43.000Z https://psychedelicinvest.com/havn-life-provides-corporate-update/2022-09-20T23:59:51.000Z https://psychedelicinvest.com/bexson-biomedical-announces-renowned-scientist-engineer-and-inventor-robert-s-langer-scd-joins-its-scientific-advisory-board/2022-09-20T23:52:56.000Z https://psychedelicinvest.com/mindmed-collaborators-dose-first-patient-in-phase-1-investigator-initiated-trial-of-mdma-like-substances/2022-09-20T23:44:07.000Z https://psychedelicinvest.com/optimind-acquires-mindsetting-institute-to-integrate-three-pronged-approach-to-its-business-and-become-industry-leader-in-psychedelic-enhanced-psychotherapy/2022-09-20T23:28:13.000Z https://psychedelicinvest.com/san-francisco-decriminalization-what-does-it-mean/2022-09-20T20:00:53.000Z https://psychedelicinvest.com/why-do-we-need-a-women-in-psychedelics-network-mindshifting-moments-11/2023-10-06T03:30:20.000Z https://psychedelicinvest.com/psyc-completes-acquisition-of-media-assets-from-technical420-llc/2022-09-20T14:23:42.000Z https://psychedelicinvest.com/xphyto-files-patent-application-for-library-of-novel-psychedelic-compounds/2022-09-20T14:08:35.000Z https://psychedelicinvest.com/psyence-group-receives-phase-iia-clinical-trial-approval-from-the-uk-medicines-and-healthcare-products-regulatory-agency/2022-09-19T20:14:34.000Z https://psychedelicinvest.com/tryp-therapeutics-appoints-jim-oneill-as-chief-financial-officer/2022-09-19T19:53:27.000Z https://psychedelicinvest.com/small-pharma-completes-enrollment-in-phase-iia-dmt-assisted-psychotherapy-clinical-trial-in-patients-with-major-depressive-disorder/2022-09-19T15:31:10.000Z https://psychedelicinvest.com/numinus-now-offers-ketamine-assisted-therapy-in-toronto/2022-09-19T15:17:45.000Z https://psychedelicinvest.com/psybio-therapeutics-latest-u-s-pct-non-provisional-patent-application-accepted/2022-09-19T15:10:55.000Z https://psychedelicinvest.com/core-one-labs-akome-move-psychedelic-drug-formulations-to-next-stage-of-development-initiating-phase-2-analysis-of-therapeutic-potential/2022-09-19T14:54:36.000Z https://psychedelicinvest.com/braxia-scientific-announces-court-approval-of-class-action-settlement-in-canada/2022-09-19T14:45:14.000Z https://psychedelicinvest.com/clearmind-medicine-announces-share-based-payment-for-one-of-the-companys-consultants/2022-09-19T14:38:54.000Z https://psychedelicinvest.com/bexson-biomedical-granted-uspto-patent-allowance-on-proprietary-formulation-technology-sevalent/2022-09-19T14:32:43.000Z https://psychedelicinvest.com/psychedelic-sector-news-weekly-extractions-september-16-2022/2022-09-16T18:30:16.000Z https://psychedelicinvest.com/pharmather-announces-presentation-of-positive-efficacy-and-safety-data-from-phase-1-2-clinical-study-of-ketamine/2022-09-16T14:03:42.000Z https://psychedelicinvest.com/revive-therapeutics-provides-update-on-the-psilocybin-clinical-study-for-methamphetamine-use-disorder-and-oral-psilocybin-thin-film-strip-program/2022-09-16T13:44:42.000Z https://psychedelicinvest.com/awakn-life-sciences-reports-strong-q2-2022-results/2022-09-16T13:35:20.000Z https://psychedelicinvest.com/innovation1-biotech-appoints-frederick-e-pierce-ii-to-its-board-of-directors/2022-09-16T13:23:00.000Z https://psychedelicinvest.com/blackhawks-mindbio-therapeutics-announces-reveal-date-for-presentation-of-phase-1-clinical-trial-data/2022-09-15T23:46:13.000Z https://psychedelicinvest.com/healingmaps-announces-1-million-in-seed-funding-to-power-growth-in-psychedelic-therapy-industry/2022-09-15T23:28:33.000Z https://psychedelicinvest.com/nova-mentis-completes-production-of-psilocybin-microdose-capsules/2022-09-15T21:43:14.000Z https://psychedelicinvest.com/psychedelic-stock-market-update-august-2022-etf-edition/2022-09-15T21:20:42.000Z https://psychedelicinvest.com/silo-pharma-announces-implementation-of-1-for-50-reverse-stock-split-in-preparation-for-planned-uplisting-to-nasdaq/2022-09-15T18:48:51.000Z https://psychedelicinvest.com/psyc-nucleus-form-new-partnership-to-develop-and-launch-psychedelic-finder/2022-09-15T15:54:12.000Z https://psychedelicinvest.com/psychedelic-analogues-solve-the-problems-of-limiting-psychedelic-treatment-model/2022-09-15T15:58:42.000Z https://psychedelicinvest.com/wellbeing-digital-reports-financial-results-for-the-fourth-fiscal-quarter/2022-09-15T14:48:12.000Z https://psychedelicinvest.com/mydecine-innovations-group-files-prospectus-supplement-and-announces-closing-under-share-subscription-agreement/2022-09-15T12:28:25.000Z https://psychedelicinvest.com/mindcure-announces-financial-results-for-fiscal-2022/2022-09-15T00:52:08.000Z https://psychedelicinvest.com/caamtech-publishes-fundamental-research-on-aeruginascin-derivatives/2022-09-14T22:40:05.000Z https://psychedelicinvest.com/sunstone-therapies-collaborates-with-maps-to-conduct-clinical-trial-of-mdma-assisted-therapy-for-ptsd/2022-09-14T22:06:20.000Z https://psychedelicinvest.com/psilera-receives-first-patent-allowance-for-transdermal-patch-formulations/2022-09-14T16:45:50.000Z https://psychedelicinvest.com/health-canada-provides-a-no-objection-letter-to-atmas-n500-phase-ii-clinical-trial-application-paving-the-way-for-the-largest-psilocybin-trial-to-date/2022-09-14T16:10:21.000Z https://psychedelicinvest.com/mindset-pharma-receives-scientific-advice-from-uk-regulator-facilitating-advancement-of-phase-1-first-in-human-clinical-trial-plan-for-its-lead-clinical-candidate-msp-1014/2022-09-14T15:54:36.000Z https://psychedelicinvest.com/mindmed-announces-compliance-with-nasdaq-listing-requirements/2022-09-14T14:47:53.000Z https://psychedelicinvest.com/small-pharma-enters-into-automatic-share-purchase-plan/2022-09-14T12:37:34.000Z https://psychedelicinvest.com/itzhak-beery-is-a-modern-day-shaman-podcast-episode-17/2022-09-14T03:37:38.000Z https://psychedelicinvest.com/tryp-therapeutics-retains-ims-investor-relations/2022-09-13T22:44:47.000Z https://psychedelicinvest.com/nature-biotechnology-selects-delix-therapeutics-as-a-leading-biotech-start-up/2022-09-13T20:59:26.000Z https://psychedelicinvest.com/what-can-psychedelics-learn-from-the-cannabis-industry-mindshifting-moments-10/2023-10-06T03:30:28.000Z https://psychedelicinvest.com/numinus-provides-update-on-acquisition-integration-and-announces-new-client-financing-options/2022-09-13T15:51:29.000Z https://psychedelicinvest.com/seelos-therapeutics-announces-the-participation-of-acadia-healthcare-in-the-registration-directed-study-of-sls-002-intranasal-racemic-ketamine-for-acute-suicidal-ideation-and-behavior-in-patients-wi/2022-09-13T14:40:43.000Z https://psychedelicinvest.com/revitalist-and-wake-network-enter-joint-venture-offering-national-and-international-access-to-psychedelics-for-veterans/2022-09-13T12:40:34.000Z https://psychedelicinvest.com/dreams-psychedelics-and-linking-hallucinations/2022-09-13T13:07:40.000Z https://psychedelicinvest.com/psychedelic-sector-news-weekly-extractions-september-13-2022/2022-09-13T03:36:46.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-receives-approval-for-groundbreaking-phase-1-dmt-human-stroke-study/2022-09-12T15:00:41.000Z https://psychedelicinvest.com/braxia-scientific-launches-ketamd-in-florida-first-patients-complete-initial-virtual-ketamine-treatments-at-home/2022-09-12T14:42:43.000Z https://psychedelicinvest.com/awakn-life-sciences-signs-drug-development-agreement-with-catalent-for-zydisr-technology-to-conduct-feasibility-studies-to-improve-differentiation-of-its-mdma-program/2022-09-12T14:31:44.000Z https://psychedelicinvest.com/josh-bartch-ceo-of-mydecine-innovations-group-interview/2022-09-09T01:32:52.000Z https://psychedelicinvest.com/lobe-sciences-announces-closing-of-private-placement/2022-09-08T19:19:35.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-secures-lead-sponsorship-of-2022-wonderland-psychedelic-conference-in-miami/2022-09-08T14:56:04.000Z https://psychedelicinvest.com/optimi-health-completes-largest-legal-natural-psilocybin-harvest-in-canadian-history/2022-09-08T14:36:12.000Z https://psychedelicinvest.com/mindmed-announces-positive-results-from-collaborators-placebo-controlled-investigator-initiated-trial-published-in-peer-reviewed-journal/2022-09-08T13:56:04.000Z https://psychedelicinvest.com/psyence-group-announces-amendment-and-closing-of-previously-announced-private-placement/2022-09-08T00:25:00.000Z https://psychedelicinvest.com/douglas-finkelstein-develops-community-around-psychedelics-podcast-episode-16/2022-09-08T02:47:17.000Z https://psychedelicinvest.com/nirvana-life-sciences-inc-announces-a-method-for-producing-mdma-that-reduces-manufacturing-time-by-two-thirds/2022-09-12T14:52:54.000Z https://psychedelicinvest.com/what-is-the-mind-army-mindshifting-moments-9/2023-10-06T03:30:37.000Z https://psychedelicinvest.com/mindset-pharma-files-national-patents-protecting-family-1-application-in-16-different-countries/2022-09-07T19:34:33.000Z https://psychedelicinvest.com/optimi-health-signs-first-international-mushroom-supply-agreement-with-uk-based-avida-global/2022-09-07T19:20:39.000Z https://psychedelicinvest.com/pharmather-announces-completion-of-ind-enabling-pharmacokinetic-and-tolerability-study-with-ketarx-ketamine-patch/2022-09-07T15:34:35.000Z https://psychedelicinvest.com/psybio-therapeutics-to-present-at-upcoming-investor-events-in-september-2022/2022-09-07T13:28:56.000Z https://psychedelicinvest.com/delic-announces-postponement-of-meet-delic-conference/2022-09-07T13:11:52.000Z https://psychedelicinvest.com/psychedelic-sector-news-weekly-extractions-september-6-2022/2022-09-07T04:20:57.000Z https://psychedelicinvest.com/irwin-naturals-emergence-to-add-ohio-ketamine-clinic/2022-09-06T18:10:08.000Z https://psychedelicinvest.com/mydecine-repositions-for-a-successful-future/2022-09-06T18:59:15.000Z https://psychedelicinvest.com/core-one-labs-scientists-successfully-complete-breakthrough-first-step-in-producing-api-grade-dmt/2022-09-03T18:51:56.000Z https://psychedelicinvest.com/cybin-announces-final-adelia-milestone-achievement/2022-09-03T15:41:07.000Z https://psychedelicinvest.com/core-one-rolls-out-commercial-sales-strategy-for-its-revolutionary-api-grade-biosynthetic-psilocybin/2022-09-02T21:55:35.000Z https://psychedelicinvest.com/cure-pharmaceutical-reports-second-quarter-2022-results/2022-09-02T17:25:57.000Z https://psychedelicinvest.com/lobe-sciences-and-cantheon-capital-enter-into-exclusive-investment-agreement-to-fund-1-5m-usd-toward-clinical-trials-in-australia/2022-09-01T21:01:51.000Z https://psychedelicinvest.com/pangenomic-health-inc-signs-a-non-binding-letter-of-intent-for-the-acquisition-of-mindleap-health-inc/2022-09-01T20:34:34.000Z https://psychedelicinvest.com/optimi-health-provides-progress-report-on-year-of-commercialization/2022-09-01T17:01:57.000Z https://psychedelicinvest.com/filament-health-and-atma-journey-centers-announce-14-subjects-dosed-in-health-canada-approved-psilocybin-clinical-trial/2022-09-01T16:28:48.000Z https://psychedelicinvest.com/bright-minds-biosciences-initiates-dosing-in-phase-i-clinical-trial-of-bmb-101-for-dravet-syndrome/2022-08-31T23:21:25.000Z https://psychedelicinvest.com/pharmala-biotech-to-supply-university-of-sydney-clinical-trial-with-laneo-mdma/2022-09-12T16:03:13.000Z https://psychedelicinvest.com/psyc-completes-and-publishes-2021-audited-financials-will-begin-audit-of-q1-q2-2022/2022-08-31T18:26:33.000Z https://psychedelicinvest.com/mindset-pharma-further-expands-its-ip-portfolio-with-three-additional-non-tryptamine-families-of-next-generation-psychedelic-compounds/2022-08-31T17:40:21.000Z https://psychedelicinvest.com/bright-minds-biosciences-announces-closing-of-4-million-unit-offering/2022-08-31T16:43:22.000Z https://psychedelicinvest.com/the-1960s-vs-today-psychedelic-use-and-common-trends/2022-08-31T04:52:25.000Z https://psychedelicinvest.com/amanda-reiman-plants-seeds-for-the-growth-of-plant-medicines-podcast-episode-15/2022-08-31T03:56:31.000Z https://psychedelicinvest.com/doug-drysdale-ceo-of-cybin-sits-in-the-investor-hotseat-on-september-1st/2023-10-06T03:33:55.000Z https://psychedelicinvest.com/wellbeing-ceo-joins-benzingas-psychedelic-advisory-board/2022-09-12T16:33:35.000Z https://psychedelicinvest.com/seelos-therapeutics-to-participate-in-two-upcoming-psychedelic-conferences/2022-08-30T18:02:11.000Z https://psychedelicinvest.com/optimi-health-enters-into-international-collaborative-research-and-supply-agreement-with-promises-innovative-recovery-center/2022-08-30T18:00:07.000Z https://psychedelicinvest.com/field-trip-health-wellness-ltd-reports-fiscal-first-quarter-2023-financial-and-operating-results%ef%bf%bc/2022-10-04T22:20:15.000Z https://psychedelicinvest.com/braxia-scientific-reports-q1-2023-financial-results-launches-ketamd-in-u-s-increasing-treatment-access-for-mental-health-patients/2022-08-30T17:36:55.000Z https://psychedelicinvest.com/mydecine-innovations-group-announces-common-share-subscription-agreement%ef%bf%bc/2022-08-30T17:15:03.000Z https://psychedelicinvest.com/wesana-announces-second-quarter-2022-financial-results/2022-08-30T16:34:39.000Z https://psychedelicinvest.com/thailand-is-reconsidering-magic-mushroom-laws/2022-08-30T15:07:23.000Z https://psychedelicinvest.com/how-can-the-future-of-psychedelics-respect-its-past-mindshifting-moments-8/2023-10-06T03:30:45.000Z https://psychedelicinvest.com/wellbeing-subsidiary-kgk-science-announces-akl-no-objection-status-for-progo-branded-ingredient-from-fda/2022-09-12T16:33:35.000Z https://psychedelicinvest.com/pharmala-biotech-completes-filing-of-patent-application-for-6-mdma-analogs%ef%bf%bc/2022-09-12T16:03:13.000Z https://psychedelicinvest.com/mindmed-completes-1-for-15-reverse-share-split%ef%bf%bc/2022-08-29T16:40:10.000Z https://psychedelicinvest.com/love-pharma-delivers-letter-to-shareholders/2022-08-29T16:37:24.000Z https://psychedelicinvest.com/core-one-labs-engages-in-talks-with-gmp-manufacturing-partner-for-commercial-scale-production-of-proprietary-biosynthetic-psilocybin/2022-08-29T16:16:49.000Z https://psychedelicinvest.com/psybio-therapeutics-reports-second-quarter-2022-financial-results/2022-08-29T15:57:36.000Z https://psychedelicinvest.com/psychedelic-sector-news-weekly-extractions-august-27-2022/2022-08-27T18:57:48.000Z https://psychedelicinvest.com/b-more-receives-fda-investigational-new-drug-approval-for-psilocybin-alcohol-use-disorder-program-phase-2b-clinical-trial/2022-08-26T17:06:06.000Z https://psychedelicinvest.com/filament-health-appoints-new-members-to-board-of-directors-and-advisory-council/2022-08-26T16:54:51.000Z https://psychedelicinvest.com/pharmadrug-advances-psychedelics-pharmaceutical-program-focused-on-dmt-and-dmt-analogues/2022-08-26T16:51:07.000Z https://psychedelicinvest.com/awakn-life-sciences-signs-agreement-with-a-leading-drug-development-company-to-deepen-ip-moat-for-its-lead-program/2022-08-26T16:46:14.000Z https://psychedelicinvest.com/scisparc-ltd-announces-additional-positive-results-for-the-cocaine-addiction-treatment-of-its-psychedelic-based-pharma-collaboration-with-clearmind-medicine-inc/2022-08-26T16:42:55.000Z https://psychedelicinvest.com/psycs-bonfire-platform-development-progresses-will-host-free-virtual-community-event-on-august-29th%ef%bf%bc/2022-08-26T16:43:16.000Z https://psychedelicinvest.com/psyc-appoints-coo-for-wholly-owned-subsidiary-spotlight-media-corp/2022-08-26T16:33:43.000Z https://psychedelicinvest.com/cybin-clinilabs-granted-schedule-i-dea-license-for-cyb003-phase-1-2a-first-in-human-clinical-trial-form-6-k/2022-08-26T16:29:05.000Z https://psychedelicinvest.com/betterlife-lead-drug-betr-001-promotes-structural-neural-plasticity-with-possible-nootropic-effects-similar-to-that-of-lsd-without-hallucinogenic-side-effects/2022-08-25T17:22:10.000Z https://psychedelicinvest.com/mindmed-announces-first-patient-dosed-in-phase-2b-trial-of-mm-120-in-generalized-anxiety-disorder/2022-08-25T17:02:26.000Z https://psychedelicinvest.com/optimi-health-announces-canadian-retail-and-e-commerce-distribution-agreements-for-functional-mushroom-supplements-and-appoints-chief-financial-officer-to-its-board-of-directors/2022-08-25T16:16:01.000Z https://psychedelicinvest.com/psychedelic-sector-news-weekly-extractions-august-24-2022/2022-08-24T21:30:01.000Z https://psychedelicinvest.com/freedom-biosciences-emerges-from-stealth-with-10-5-million-seed-financing-to-develop-next-generation-ketamine-and-psychedelic-based-mental-health-treatments/2022-08-24T18:47:24.000Z https://psychedelicinvest.com/love-pharma-announces-strategic-acquisition-of-doc-hygiene-pharmaceuticals-inc/2022-08-24T18:45:30.000Z https://psychedelicinvest.com/innovation1-biotech-announces-filing-of-patent-application-for-novel-combination-therapy-targeting-addiction/2022-08-24T18:42:33.000Z https://psychedelicinvest.com/nrx-pharmaceuticals-provides-business-update-and-reports-second-quarter-2022-results-focusing-on-reactivation-advancement-of-its-psychiatry-franchise/2022-08-24T18:36:27.000Z https://psychedelicinvest.com/gh-research-reports-second-quarter-2022-financial-results-and-provides-business-updates/2022-08-24T18:32:40.000Z https://psychedelicinvest.com/clearmind-medicine-announces-additional-positive-pre-clinical-results-for-its-cocaine-addiction-treatment/2022-08-24T19:15:28.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-largest-shareholder-alphanorth-asset-management-increases-ownership-position/2022-08-24T18:16:27.000Z https://psychedelicinvest.com/announces-results-of-shareholders-meeting-form-6-k/2022-08-24T17:49:41.000Z https://psychedelicinvest.com/neil-markey-offers-real-change-in-a-retreat-setting-podcast-episode-14/2022-08-24T02:47:54.000Z https://psychedelicinvest.com/core-one-labs-akome-achieves-significant-research-milestone-with-positive-neurogenesis-stimulation-studies-results/2022-08-23T18:26:28.000Z https://psychedelicinvest.com/how-can-we-exercise-our-mind-mindshifting-moments-7/2023-10-06T03:30:54.000Z https://psychedelicinvest.com/field-trip-health-wellness-ltd-schedules-fiscal-first-quarter-2023-conference-call-for-tuesday-august-30-2022-at-830-a-m-et/2022-10-04T22:20:21.000Z https://psychedelicinvest.com/another-public-company-first-silo-wellness-opens-jamaican-ecotourism-psilocybin-microdosing-resort-for-the-psychedelic-curious-shareholder-discounts-for-psychedelic-vacations-available/2022-09-12T16:15:11.000Z https://psychedelicinvest.com/cybin-corporate-presentation-august-2022/2022-08-23T18:13:57.000Z https://psychedelicinvest.com/small-pharma-announces-tsxv-approval-of-normal-course-issuer-bid-2/2022-08-23T19:02:52.000Z https://psychedelicinvest.com/mydecine-innovations-group-announces-private-placement-interim-changes-to-management-and-board-of-directors/2022-08-23T18:04:07.000Z https://psychedelicinvest.com/awakn-life-sciences-signs-second-licensing-partnership-agreement-and-expands-commercial-operations-into-canada/2022-09-12T15:01:35.000Z https://psychedelicinvest.com/bright-minds-announces-overnight-marketed-offering-of-units/2022-08-23T17:57:14.000Z https://psychedelicinvest.com/the-shifting-landscape-of-psychedelic-biotechnology-investments/2022-08-23T16:52:27.000Z https://psychedelicinvest.com/universal-ibogaine-provides-update-on-kelburn-recovery-center-2/2022-09-12T16:26:19.000Z https://psychedelicinvest.com/lobe-sciences-announces-update-on-corporate-slide-deck-highlighting-its-psilocin-compounds-and-development-plans/2022-08-22T15:48:36.000Z https://psychedelicinvest.com/core-one-labs-akome-achieves-another-milestone-in-development-of-its-psychedelic-drug-formulas-and-announces-positive-results-from-neuro-pharmacokinetics-studies/2022-08-22T15:41:42.000Z https://psychedelicinvest.com/pharmala-biotech-to-supply-major-australian-research-institute-with-laneo-mdma-for-phase-3-clinical-trial/2022-09-12T16:03:14.000Z https://psychedelicinvest.com/how-psilocybin-can-invigorate-your-life/2022-08-22T04:21:46.000Z https://psychedelicinvest.com/havn-life-announces-the-close-of-the-first-tranche-of-its-previously-announced-financing-commitment-by-alpha-blue-ocean-and-warrant-amendments-and-the-issuance-of-shares-for-debt/2022-08-19T14:39:32.000Z https://psychedelicinvest.com/small-pharma-announces-tsxv-approval-of-normal-course-issuer-bid/2022-08-19T14:35:05.000Z https://psychedelicinvest.com/bright-minds-biosciences-comments-on-recent-trading-activity/2022-08-19T14:32:18.000Z https://psychedelicinvest.com/phillips-lytle-launches-psychedelic-mental-health-therapies-practice/2022-08-19T14:29:56.000Z https://psychedelicinvest.com/universal-ibogaine-provides-update-on-kelburn-recovery-center/2022-09-12T16:26:20.000Z https://psychedelicinvest.com/reunion-neuroscience-inc-to-commences-trading-on-the-toronto-stock-exchange-on-august-17-2022/2022-08-18T23:01:41.000Z https://psychedelicinvest.com/pharmala-biotech-first-publicly-traded-company-to-produce-gmp-mdma/2022-09-12T16:03:14.000Z https://psychedelicinvest.com/the-freeman-chronicles-an-interview-with-the-former-cmo-of-mindmed-part-2-of-2/2022-08-17T19:18:53.000Z https://psychedelicinvest.com/core-one-labs-vocan-successfully-converts-psilocin-precursor-into-psilocybin/2022-08-17T17:04:04.000Z https://psychedelicinvest.com/dustin-robinson-is-forging-the-path-for-psychedelics-psychedelic-investors/2022-08-17T17:40:00.000Z https://psychedelicinvest.com/delic-announces-two-key-executive-appointments/2022-08-17T16:59:44.000Z https://psychedelicinvest.com/filament-health-announces-eighth-patent-issuance/2022-08-17T16:55:39.000Z https://psychedelicinvest.com/psychedelics-as-a-non-habit-forming-anxiety-treatment/2022-08-17T03:27:03.000Z https://psychedelicinvest.com/how-does-at-home-ketamine-therapy-work-mindshifting-moments-6/2023-10-06T03:31:02.000Z https://psychedelicinvest.com/filament-health-announces-second-quarter-2022-financial-results-and-operational-highlights/2022-08-16T17:11:38.000Z https://psychedelicinvest.com/awakn-life-sciences-expands-commercial-operations-into-the-u-s-first-licensing-partnership-agreement-with-revitalist/2022-09-12T15:01:34.000Z https://psychedelicinvest.com/health-canada-grants-mdma-production-and-distribution-amendment-to-optimi-health/2022-08-16T17:02:26.000Z https://psychedelicinvest.com/the-freeman-chronicles-an-interview-with-the-former-cmo-of-mindmed-part-1-of-2/2022-08-16T16:10:59.000Z https://psychedelicinvest.com/atai-life-sciences-secures-term-loan-facility-for-up-to-175-million-from-hercules-capital/2022-09-15T20:08:27.000Z https://psychedelicinvest.com/irwin-naturals-emergence-adds-new-england-clinic-to-its-national-footprint/2022-08-15T16:45:49.000Z https://psychedelicinvest.com/small-pharma-receives-approval-for-dmt-assisted-psychotherapy-and-ssri-drug-interaction-study/2022-08-15T16:41:02.000Z https://psychedelicinvest.com/awakn-life-sciences-receives-regulatory-approval-for-flagship-clinic-in-london-to-begin-delivering-treatments/2022-08-15T16:15:53.000Z https://psychedelicinvest.com/core-one-labs-subsidiaries-successfully-produce-psilocin-precursor-for-production-to-psilocybin/2022-08-15T16:11:01.000Z https://psychedelicinvest.com/psychedelic-sector-news-weekly-extractions-august-13-2022/2022-08-15T03:05:57.000Z https://psychedelicinvest.com/psychedelic-stock-market-update-july-2022%ef%bf%bc/2022-09-12T16:12:15.000Z https://psychedelicinvest.com/mindmed-strengthens-board-with-appointment-of-two-new-independent-directors/2022-08-12T19:48:17.000Z https://psychedelicinvest.com/relmada-therapeutics-provides-corporate-update-and-reports-second-quarter-2022-financial-results/2022-09-12T16:12:13.000Z https://psychedelicinvest.com/roger-mcintyre-ceo-of-braxia-scientific-sits-in-the-investor-hotseat-on-august-18th/2023-10-06T03:34:04.000Z https://psychedelicinvest.com/mindmed-reports-second-quarter-2022-financial-results-and-business-highlights/2022-08-11T21:56:05.000Z https://psychedelicinvest.com/mindmed-co-founder-dr-scott-freeman-proposes-value-enhancement-plan/2022-08-11T18:30:18.000Z https://psychedelicinvest.com/psybio-therapeutics-strengthens-ip-portfolio-through-filing-of-data-to-support-previously-submitted-provisional-biosynthetic-production-patent-application/2022-08-11T17:24:32.000Z https://psychedelicinvest.com/new-study-could-lead-to-paradigm-shift-in-the-treatment-of-depression/2022-08-11T17:31:18.000Z https://psychedelicinvest.com/red-light-holland-2022-financial-results-bullish-vs-bearish-episode-5/2023-10-06T03:27:04.000Z https://psychedelicinvest.com/lobe-sciences-enters-into-an-exclusive-agreement-with-ingenu-to-conduct-clinical-trials-in-australia/2022-08-11T17:12:39.000Z https://psychedelicinvest.com/optimi-health-unveils-canadas-first-natural-therapeutic-psilocybin-product-for-approved-patients/2022-08-10T18:55:28.000Z https://psychedelicinvest.com/mindset-pharma-ceo-james-lanthier-issues-letter-to-shareholders/2022-08-10T15:42:17.000Z https://psychedelicinvest.com/psileras-new-compounds-show-potential-for-significant-treatment-improvement-in-depression-and-neurodegenerative-disorders/2022-08-10T15:38:27.000Z https://psychedelicinvest.com/jordan-youkilis-provides-capital-to-next-generation-industries-psychedelic-investors-2/2022-08-10T03:54:14.000Z https://psychedelicinvest.com/compass-pathways-q2-2022-financial-results-bullish-vs-bearish-episode-4/2023-10-06T03:27:10.000Z https://psychedelicinvest.com/psybio-therapeutics-announces-expansion-of-patent-portfolio-with-additional-global-patent-applications/2022-08-09T20:40:15.000Z https://psychedelicinvest.com/pharmala-biotech-named-exclusive-mdma-supplier-to-intervivo-solutions/2022-09-12T16:03:15.000Z https://psychedelicinvest.com/revitalist-announces-release-of-three-proprietary-service-lines-advancing-their-comprehensive-footprint-in-the-mental-health-and-psychedelic-wellness-space/2022-09-12T15:01:34.000Z https://psychedelicinvest.com/optimi-health-to-launch-therapeutic-psilocybin-product-in-partnership-with-patient-advocate-thomas-hartle/2022-08-09T17:19:22.000Z https://psychedelicinvest.com/cybin-inc-reports-first-quarter-financial-results-and-recent-business-highlights/2022-08-09T17:15:33.000Z https://psychedelicinvest.com/irwin-naturals-completes-georgia-acquisition-adds-two-ketamine-clinics-to-national-chain/2022-08-09T17:23:01.000Z https://psychedelicinvest.com/relmada-therapeutics-receives-fda-fast-track-designation-for-rel-1017-as-a-monotherapy-for-the-treatment-of-major-depressive-disorder/2022-09-12T16:12:14.000Z https://psychedelicinvest.com/treating-opioid-addiction-with-ibogaine-could-this-be-the-future/2022-09-12T16:26:21.000Z https://psychedelicinvest.com/segal-trials-and-psychedelic-research-in-south-florida/2022-08-08T21:14:57.000Z https://psychedelicinvest.com/psychedelic-sector-news-weekly-extractions-august-5-2022/2022-08-05T14:38:23.000Z https://psychedelicinvest.com/mindmed-board-of-directors-approves-reverse-share-split/2022-08-05T00:56:43.000Z https://psychedelicinvest.com/psychedelics-could-disrupt-the-42-billion-a-year-rehab-industry/2022-08-04T19:29:55.000Z https://psychedelicinvest.com/mindmed-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference/2022-08-04T17:21:14.000Z https://psychedelicinvest.com/retreats-and-the-transformative-effects-of-ketamine/2022-08-03T21:20:48.000Z https://psychedelicinvest.com/psyc-corps-psychedelic-spotlight-surpasses-one-million-page-views-for-third-consecutive-month/2022-08-03T19:07:36.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-invited-to-present-phase-2-ipf-and-chronic-cough-study-data-at-9th-american-cough-conference/2022-08-03T19:02:26.000Z https://psychedelicinvest.com/canadian-patent-grant-strengthens-small-pharmas-international-position/2022-08-03T18:48:02.000Z https://psychedelicinvest.com/braxia-scientific-enters-u-s-telemedicine-industry-acquires-ketamd-a-mental-health-platform-providing-beneficial-ketamine-treatments-in-florida-with-plans-to-expand-across-the-u-s/2022-08-03T18:23:20.000Z https://psychedelicinvest.com/cody-shandraw-invests-in-entrepreneurs-obsessed-with-impacting-and-improving-lives-psychedelic-investors-1/2022-08-03T17:22:41.000Z https://psychedelicinvest.com/kaya-holdings-to-seek-licenses-for-first-ever-state-legal-psilocybin-manufacturing-and-facilitation-service-centers-in-oregon/2022-08-03T19:05:45.000Z https://psychedelicinvest.com/many-counties-are-voting-to-opt-out-but-that-doesnt-mean-the-end-of-measure-109/2022-08-02T20:37:10.000Z https://psychedelicinvest.com/compass-pathways-to-participate-in-upcoming-btig-biotechnology-conference-and-canaccord-annual-growth-conference/2022-08-02T17:41:14.000Z https://psychedelicinvest.com/atai-life-sciences-to-announce-second-quarter-2022-financial-results-and-business-update/2022-08-02T17:26:48.000Z https://psychedelicinvest.com/unlimited-sciences-announces-groundbreaking-new-study-to-observe-ayahuascas-effects-on-trauma/2022-08-02T17:10:31.000Z https://psychedelicinvest.com/braxia-scientific-reports-fourth-quarter-and-fy-2022-financial-results/2022-08-01T16:54:25.000Z https://psychedelicinvest.com/delic-completes-offering-of-debentures/2022-08-01T16:43:22.000Z https://psychedelicinvest.com/investment-opportunities-in-measure-109/2022-08-01T15:45:48.000Z https://psychedelicinvest.com/psychedelic-sector-news-weekly-extractions-july-29-2022/2022-07-29T20:17:36.000Z https://psychedelicinvest.com/are-magic-mushrooms-the-gateway-psychedelic-mindshifting-moments-stream-5/2023-10-06T03:31:09.000Z https://psychedelicinvest.com/incannex-healthcare-quarterly-activities-report-and-appendix-4c-cash-flow-statement/2022-07-28T21:04:01.000Z https://psychedelicinvest.com/hemplucid-becomes-first-startup-to-provide-psychedelic-therapy-as-employee-healthcare-benefit/2022-07-28T21:02:56.000Z https://psychedelicinvest.com/is-this-the-end-of-the-psychedelic-pr-crisis/2022-07-28T20:17:27.000Z https://psychedelicinvest.com/u-s-patent-grant-to-strengthen-small-pharmas-dmt-patent-strategy-with-injectable-formulation/2022-07-28T19:38:46.000Z https://psychedelicinvest.com/silo-pharma-announces-positive-results-from-its-topically-administered-formulation-of-ketamine/2022-09-12T16:18:25.000Z https://psychedelicinvest.com/filament-health-announces-participation-in-project-solace/2022-07-28T17:14:36.000Z https://psychedelicinvest.com/compass-pathways-launches-phase-ii-clinical-trial-of-psilocybin-therapy-in-anorexia-nervosa/2022-07-28T17:01:47.000Z https://psychedelicinvest.com/braxia-scientific-bolsters-leadership-with-strategic-hires-adds-chief-information-officer-and-global-pharmaceutical-industry-leader-as-vp-rd-and-growth/2022-07-27T16:36:04.000Z https://psychedelicinvest.com/camh-receives-first-canadian-federal-cihr-grant-to-study-psilocybin/2022-07-27T16:01:32.000Z https://psychedelicinvest.com/gregory-roufa-ceo-of-anuma-sits-in-the-investor-hotseat-on-august-4th/2023-10-06T03:34:12.000Z https://psychedelicinvest.com/compass-pathways-to-announce-second-quarter-2022-financial-results-on-august-4-2022/2022-07-26T16:39:33.000Z https://psychedelicinvest.com/silo-wellness-organizes-jamaican-psilocybin-retreat-team-and-advocates-to-speak-to-lane-county-commissioners-regarding-bm109-optout-vote-lane-county-declines-to-refer-a-psilocybin-ban-to-voters/2022-09-12T16:15:12.000Z https://psychedelicinvest.com/fto-files-requests-for-reconsideration-of-u-s-patent-trial-and-appeal-boards-decisions-concerning-petitions-for-post-grant-review-of-compass-patents/2022-07-25T17:42:48.000Z https://psychedelicinvest.com/havn-life-announces-financing-commitment-of-c9000000-through-the-issuance-of-convertible-debentures-and-warrants/2022-07-25T17:28:34.000Z https://psychedelicinvest.com/field-trip-announces-first-dosings-in-phase-i/2022-07-22T19:41:09.000Z https://psychedelicinvest.com/enveric-biosciences-announces-formation-of-scientific-advisory-board-to-drive-further-growth-of-next-generation-mental-health-medicines/2022-07-22T19:30:49.000Z https://psychedelicinvest.com/lobe-sciences-files-patent-application-covering-the-preparation-of-stable-psilocin-prodrugs-and-analogues-and-their-uses-further-strengthening-its-intellectual-property-portfolio/2022-07-22T17:26:52.000Z https://psychedelicinvest.com/psychedelic-sector-news-weekly-extractions-july-22-2022/2022-07-22T15:07:11.000Z https://psychedelicinvest.com/relmada-therapeutics-appoints-biopharmaceutical-marketing-and-commercial-planning-veteran-john-hixon-as-head-of-commercial/2022-09-12T16:12:14.000Z https://psychedelicinvest.com/psychedelic-invest-pro-industry-reports/2022-07-21T19:10:16.000Z https://psychedelicinvest.com/delic-2021-revenue-shows-strong-growth-as-nations-largest-ketamine-clinic-chain-continues-expansion-of-mental-health-wellness-services/2022-07-21T16:22:09.000Z https://psychedelicinvest.com/mydecine-files-full-patent-application-covering-myco-006-family-of-novel-short-acting-mdma-analogs/2022-07-21T00:39:29.000Z https://psychedelicinvest.com/how-can-psilocybin-help-executives-mindshifting-moments-stream-4/2023-10-06T03:31:18.000Z https://psychedelicinvest.com/delic-labs-president-and-cso-dr-markus-roggen-named-to-cannabis-scientist-power-list-for-third-consecutive-year/2022-07-20T15:39:03.000Z https://psychedelicinvest.com/clairvoyant-therapeutics-clairvoyant-initiates-first-site-for-phase-2-psilocybin-therapy-clinical-trial-for-alcohol-use-disorder/2022-07-20T15:16:16.000Z https://psychedelicinvest.com/compass-pathways-appoints-kabir-nath-as-chief-executive-officer/2022-07-19T16:36:55.000Z https://psychedelicinvest.com/george-tziras-to-succeed-peter-rands-as-small-pharma-chief-executive-officer/2022-07-19T15:42:13.000Z https://psychedelicinvest.com/awakn-life-sciences-provides-a-business-and-corporate-update/2022-07-19T15:53:53.000Z https://psychedelicinvest.com/numinus-wellness-q3-2022-earnings-report-analysis-bullish-vs-bearish-episode-3/2023-10-06T03:27:17.000Z https://psychedelicinvest.com/enveric-biosciences-announces-reverse-stock-split/2022-07-18T15:56:54.000Z https://psychedelicinvest.com/iter-investments-announces-the-closing-of-first-fund/2022-07-15T15:33:12.000Z https://psychedelicinvest.com/tom-feegel-ceo-of-beond-sits-in-the-investor-hotseat-on-july-21st/2023-10-06T03:34:24.000Z https://psychedelicinvest.com/psychedelic-sector-news-weekly-extractions-july-13-2022/2022-07-13T21:17:36.000Z https://psychedelicinvest.com/albert-labs-files-us-provisional-patent-application-for-psilocybe-and-other-mycelia/2022-07-13T17:24:00.000Z https://psychedelicinvest.com/filament-health-issued-third-patent-by-united-states-patent-and-trademark-office/2022-07-13T17:18:53.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-provides-update-on-its-planned-phase-1-repirinast-chronic-kidney-disease-study/2022-07-12T20:32:57.000Z https://psychedelicinvest.com/cybin-completes-acquisition-of-phase-1-dmt-study-from-entheon-biomedical/2022-07-11T19:46:38.000Z https://psychedelicinvest.com/season-one-of-the-psychedelic-invest-podcast-is-now-available-on-youtube/2022-07-11T18:53:20.000Z https://psychedelicinvest.com/psychedelic-stock-market-update-june-2022/2022-07-08T22:00:35.000Z https://psychedelicinvest.com/clairvoyant-initiates-first-site-for-phase-2-psilocybin-therapy-clinical-trial-for-alcohol-use-disorder/2022-07-08T18:29:12.000Z https://psychedelicinvest.com/filament-health-announces-first-dosing-in-fda-approved-psilocin-clinical-trial/2022-07-08T16:54:16.000Z https://psychedelicinvest.com/lobe-sciences-ltd-announces-regulatory-and-clinical-development-plans-for-2022-and-early-2023/2022-07-07T17:00:07.000Z https://psychedelicinvest.com/how-would-i-use-stem-cell-rejuvenation-mindshifting-moments-stream-3/2023-10-06T03:31:30.000Z https://psychedelicinvest.com/caamtech-collaborates-with-the-alexander-shulgin-research-institute-to-study-shulgin-compounds/2022-07-06T19:32:40.000Z https://psychedelicinvest.com/psychedelic-sector-news-weekly-extractions-july-5-2022/2022-07-06T19:25:37.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-discloses-novel-dmt-salt-patent-strategy-includes-bioactive-nicotinate-and-pamoate/2022-07-05T17:12:34.000Z https://psychedelicinvest.com/field-trips-2022-financial-and-pipeline-analysis-bullish-vs-bearish-episode-2/2023-10-06T03:27:24.000Z https://psychedelicinvest.com/atai-life-sciences-company-kures-therapeutics-appoints-dr-chad-beyer-as-chief-executive-officer/2022-07-01T16:09:12.000Z https://psychedelicinvest.com/mindset-pharma-announces-development-of-novel-optimized-intranasal-formulation/2022-06-30T22:44:24.000Z https://psychedelicinvest.com/pharmather-announces-positive-results-from-study-for-ketamine-microneedle-patch/2022-06-29T16:39:41.000Z https://psychedelicinvest.com/becca-williams-guides-the-release-of-emotional-turmoil-using-psychedelics-podcast-episode-10/2022-06-29T02:50:06.000Z https://psychedelicinvest.com/damian-kettlewell-ceo-of-clairvoyant-therapeutics-sits-in-the-investor-hotseat/2023-10-06T03:34:34.000Z https://psychedelicinvest.com/optimi-health-initiates-agreement-with-sabi-mind-for-therapeutic-supplies-of-psilocybin-mdma/2022-06-28T17:54:40.000Z https://psychedelicinvest.com/cybin-receives-fda-ind-clearance-for-phase-1-2a-clinical-trial-for-cyb003/2022-06-27T16:35:10.000Z https://psychedelicinvest.com/psychedelic-patent-news-weekly-extractions-june-24-2022/2022-07-06T19:25:37.000Z https://psychedelicinvest.com/cybin-reports-fiscal-year-2022-financial-results-and-recent-business-highlights/2022-06-24T15:42:08.000Z https://psychedelicinvest.com/cybins-fiscal-year-2022-financial-results-bullish-vs-bearish-episode-1/2023-10-06T03:27:31.000Z https://psychedelicinvest.com/silo-pharma-expands-license-agreement-and-patent-portfolio/2022-09-12T16:18:35.000Z https://psychedelicinvest.com/numinus-applies-for-international-patent-filing-of-psychedelics-production-process/2022-06-22T18:11:20.000Z https://psychedelicinvest.com/kimberly-stuck-supports-businesses-in-tightly-regulated-industries-podcast-episode-9/2022-06-22T14:24:54.000Z https://psychedelicinvest.com/why-choose-ibogaine-for-healing-mindshifting-moments-stream-2/2023-10-06T03:31:51.000Z https://psychedelicinvest.com/lobe-sciences-and-clearway-global-enter-into-agreement-to-manage-lobe-sciences-global-regulatory-and-development-strategy-and-implementation/2022-06-21T17:22:36.000Z https://psychedelicinvest.com/optimi-health-requests-approval-to-manufacture-mdma-other-synthetic-psychedelics/2022-06-20T16:37:55.000Z https://psychedelicinvest.com/u-s-fda-clears-myco-001-for-multi-site-government-funded-trial-in-smoking-cessation/2022-06-17T17:37:45.000Z https://psychedelicinvest.com/photos-from-our-investor-event-in-san-francisco/2022-06-17T16:46:17.000Z https://psychedelicinvest.com/dr-molly-maloof-ceo-of-adamo-bioscience-sits-in-the-investor-hotseat-on-june-23rd/2023-10-06T03:34:42.000Z https://psychedelicinvest.com/nova-mentis-files-patent-on-diagnosing-monitoring-and-treating-neurological-diseases-with-psychoactive-tryptamine-derivatives/2022-06-16T17:38:06.000Z https://psychedelicinvest.com/pro-elon-musk-ark-numinus-and-more-video/2022-06-16T16:23:17.000Z https://psychedelicinvest.com/braxia-scientific-expands-clinic-footprint-in-canada-providing-greater-access-to-network-of-specialists-delivering-ketamine-and-psilocybin-treatments-for-mental-health-disorders/2022-06-15T16:13:53.000Z https://psychedelicinvest.com/jay-godfrey-and-richard-meloff-are-unleashing-the-power-of-psychedelic-therapy-podcast-episode-8/2022-06-15T16:39:04.000Z https://psychedelicinvest.com/filament-health-cultivates-70th-variety-of-psilocybin-containing-mushrooms-at-vancouver-facility%ef%bf%bc/2022-06-14T18:38:11.000Z https://psychedelicinvest.com/eugene-shteyngarts-of-floresta-retreats-mindshifting-moments-stream-1/2023-10-06T03:32:04.000Z https://psychedelicinvest.com/mindset-pharma-receives-notice-of-allowance-for-patent-application-for-psilocin-derivatives%ef%bf%bc/2022-06-13T17:26:40.000Z https://psychedelicinvest.com/nova-mentis-and-university-of-central-florida-to-develop-saliva-serotonin-assay/2022-06-10T16:34:38.000Z https://psychedelicinvest.com/chris-witowski-ceo-of-psilera-bioscience-to-sit-in-the-investor-hotseat-on-june-9th/2023-10-06T03:34:51.000Z https://psychedelicinvest.com/tryp-therapeutics-announces-results-of-first-patient-dosed-in-phase-ii-clinical-trial-for-binge-eating-disorder/2022-06-09T17:32:01.000Z https://psychedelicinvest.com/a-closer-look-at-awakn-life-sciences/2022-07-06T19:25:37.000Z https://psychedelicinvest.com/nova-mentis-receives-controlled-substances-export-approval-from-dea-for-proprietary-psilocybin-drug/2022-06-08T17:31:51.000Z https://psychedelicinvest.com/charles-patti-was-healed-through-ketamine-assisted-therapy-podcast-episode-7/2022-06-08T03:13:00.000Z https://psychedelicinvest.com/cybin-acquires-dmt-clinical-study-from-entheon-biomedical/2022-06-07T19:35:14.000Z https://psychedelicinvest.com/optimi-health-enters-into-psilocybin-supply-agreement-with-filament-health/2022-06-06T16:17:46.000Z https://psychedelicinvest.com/mycomedica-life-sciences-secures-60-million/2022-06-03T21:37:33.000Z https://psychedelicinvest.com/stock-market-update-may-2022/2022-06-03T21:39:02.000Z https://psychedelicinvest.com/scisparc-and-clearmind-collaboration-yields-another-patent-application-for-proprietary-psychedelic-combination/2022-06-03T16:58:20.000Z https://psychedelicinvest.com/psychedelics-big-3-financial-and-pipeline-analysis-of-atai-cmps-and-mnmd/2022-06-02T19:58:55.000Z https://psychedelicinvest.com/awakn-life-sciences-initiates-follow-on-behavioral-study-to-focus-on-gambling-disorder/2022-06-02T17:09:36.000Z https://psychedelicinvest.com/clearmind-medicine-granted-patent-approval-for-psychedelic-based-alcohol-substitute-in-india%ef%bf%bc/2022-06-01T17:04:04.000Z https://psychedelicinvest.com/hadas-alterman-adriana-kertzer-are-humanizing-the-legal-process-for-psychedelics-podcast-episode-6/2022-06-07T16:11:57.000Z https://psychedelicinvest.com/mydecine-announces-closing-of-overnight-marketed-public-offering-of-units/2022-05-30T18:58:03.000Z https://psychedelicinvest.com/small-pharma-shares-business-update-ahead-of-annual-financial-results%ef%bf%bc/2022-05-30T18:10:21.000Z https://psychedelicinvest.com/anthony-tennyson-ceo-of-awakn-life-sciences-sits-in-the-investor-hotseat/2023-10-06T03:34:59.000Z https://psychedelicinvest.com/optimi-health-signs-psilocybin-supply-agreement-with-halucenex-life-sciences-inc/2022-05-27T18:30:56.000Z https://psychedelicinvest.com/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19-2/2022-05-26T19:03:50.000Z https://psychedelicinvest.com/pharmather-to-develop-and-commercialize-novel-wearable-ketamine-delivery-device-in-collaboration-with-ccbio/2022-05-25T16:49:01.000Z https://psychedelicinvest.com/danny-motyka-manufactures-psychedelics-for-the-masses-podcast-episode-5/2022-05-25T04:06:53.000Z https://psychedelicinvest.com/pro-mind-medicine-earnings-report-breakdown/2022-05-25T03:04:09.000Z https://psychedelicinvest.com/clearmind-medicine-and-scisparc-collaboration-yields-positive-results-for-its-psychedelic-combination-treatment/2022-05-24T16:42:38.000Z https://psychedelicinvest.com/braxia-scientific-receives-health-canada-special-access-program-approval-to-provide-psilocybin-assisted-therapy-for-depression-in-ontario/2022-05-23T15:25:57.000Z https://psychedelicinvest.com/emotional-intelligence-ventures-and-mycotopia-enter-a-definitive-agreement-on-382m-merger-transaction/2022-05-20T17:38:13.000Z https://psychedelicinvest.com/atai-q1-2022-earnings/2022-05-20T01:03:47.000Z https://psychedelicinvest.com/novamind-launches-group-psychedelic-treatment-for-frontline-workers/2022-05-19T17:18:13.000Z https://psychedelicinvest.com/filament-health-issued-second-u-s-patent-and-reports-q1-results/2022-05-18T16:10:14.000Z https://psychedelicinvest.com/jason-hein-researches-design-development-and-efficiencies-podcast-episode-4/2022-05-18T04:07:28.000Z https://psychedelicinvest.com/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19/2022-05-17T16:19:21.000Z https://psychedelicinvest.com/albert-labs-granted-health-canada-license/2022-05-16T20:57:47.000Z https://psychedelicinvest.com/field-trip-and-nue-life-are-collaborating-to-bring-psychedelic-therapy-into-the-home/2022-05-13T18:00:58.000Z https://psychedelicinvest.com/osmind-raises-40m-series-b-round-led-by-dfj-growth-to-expand-platform-for-breakthrough-mental-health-research-and-treatment/2022-05-12T18:23:09.000Z https://psychedelicinvest.com/pro-rapid-reactions-to-compass-pathways-earning-report/2022-05-12T17:45:10.000Z https://psychedelicinvest.com/mindmed-collaborators-prof-liechti-and-dr-holze-announce-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders/2022-05-11T17:59:52.000Z https://psychedelicinvest.com/nanea-reeves-is-creating-unique-experiences-for-well-being-podcast-episode-3/2022-05-11T14:10:18.000Z https://psychedelicinvest.com/pro-a-deeper-dive-into-gh-research/2022-05-11T03:02:01.000Z https://psychedelicinvest.com/novamind-to-host-bionomics-prevail-trial-for-acute-treatment-of-social-anxiety-disorder/2022-05-10T14:43:09.000Z https://psychedelicinvest.com/compass-pathways-to-fund-study-of-comp360-psilocybin-in-autistic-adults/2022-05-09T17:21:27.000Z https://psychedelicinvest.com/mydecine-innovations-group-announces-closing-under-share-subscription-agreement/2022-05-06T17:02:48.000Z https://psychedelicinvest.com/pharmather-announces-grant-of-u-s-patent-on-formulation-and-production-process-of-ketamine-and-ketamine-analogs/2022-05-05T16:55:33.000Z https://psychedelicinvest.com/nova-mentis-psilocybin-manufacturer-receives-approved-health-canada-importation-permit/2022-05-04T17:49:26.000Z https://psychedelicinvest.com/psychedelic-stock-market-update-april-2022/2022-09-12T16:12:15.000Z https://psychedelicinvest.com/chris-witowski-is-reimagining-natural-products-podcast-episode-2/2022-05-06T03:59:57.000Z https://psychedelicinvest.com/comp360-psilocybin-therapy-shows-potential-in-exploratory-open-label-studies-for-anorexia-nervosa-and-severe-treatment-resistant-depression/2022-05-03T15:53:03.000Z https://psychedelicinvest.com/pro-last-week-in-review-field-trip-oregon-psilocybin-and-more/2022-05-02T17:25:05.000Z https://psychedelicinvest.com/field-trip-health-ltd-announces-intention-to-separate-the-field-trip-discovery-and-field-trip-health-divisions-into-two-independent-public-companies/2022-05-02T17:11:50.000Z https://psychedelicinvest.com/allied-corp-announces-purchase-order-continuing-into-monthly-supply-agreement-for-brazilian-specialty-cancer-care-hospital/2022-04-29T17:01:01.000Z https://psychedelicinvest.com/filament-health-announces-fourth-patent-issuance/2022-04-28T16:37:43.000Z https://psychedelicinvest.com/phyto-partners-launches-neurowellness-focused-venture-capital-fund/2022-04-27T17:27:13.000Z https://psychedelicinvest.com/zappy-zapolin-wants-to-change-the-world-with-psychedelics-podcast-episode-1/2022-04-29T14:23:49.000Z https://psychedelicinvest.com/biomind-labs-doses-first-subject-in-phase-i-iia-clinical-trial-of-its-dmt-based-inhaled-formulation-bmnd01-for-treatment-resistant-depression/2022-10-25T16:38:06.000Z https://psychedelicinvest.com/mindset-pharma-strengthens-ip-portfolio-with-another-new-provisional-patent-application-covering-its-dmt-and-5-meo-dmt-drug-candidate-compounds/2022-04-25T17:04:26.000Z https://psychedelicinvest.com/deep-dive-into-cybin-cybn/2022-04-22T22:37:14.000Z https://psychedelicinvest.com/filament-health-and-psyence-enter-into-exclusive-licensing-agreement-for-natural-psilocybin-products/2022-04-22T15:58:11.000Z https://psychedelicinvest.com/atai-intelgenx-partnership-breakdown/2022-04-21T21:41:04.000Z https://psychedelicinvest.com/cybin-partners-with-clinilabs-drug-development-corporation-for-phase-1-2a-trial-evaluating-cyb003-for-the-treatment-of-major-depressive-disorder/2022-04-21T16:55:49.000Z https://psychedelicinvest.com/nue-life-health-a-next-gen-mental-wellness-platform-announces-a-23m-financing-led-by-obvious-ventures-and-western-technology-investment/2022-04-20T18:31:55.000Z https://psychedelicinvest.com/wesana-is-exploring-broadening-sana-013-lead-indication-to-treat-major-depressive-disorder/2022-04-19T16:51:57.000Z https://psychedelicinvest.com/revive-therapeutics-announces-publication-of-research-data-with-bucillamine-in-covid-19/2022-04-18T15:22:15.000Z https://psychedelicinvest.com/numinus-novamind-merger/2022-04-21T21:41:13.000Z https://psychedelicinvest.com/neonmind-announces-plan-to-launch-10-clinics-for-innovative-treatments-as-mental-health-crisis-grows/2022-04-15T16:18:41.000Z https://psychedelicinvest.com/gilgamesh-will-soon-complete-series-b-funding-as-it-boosts-team-pipeline-and-tech/2022-04-14T18:32:18.000Z https://psychedelicinvest.com/awakn-life-sciences-provides-shareholder-update-on-three-operational-ketamine-assisted-therapy-clinics-in-the-uk-and-norway/2022-04-14T17:37:43.000Z https://psychedelicinvest.com/delic-labs-receives-health-canada-56-exemption-to-conduct-research-on-mdma-lsd-and-other-psychedelic-compounds/2022-04-13T16:41:41.000Z https://psychedelicinvest.com/numinus-to-acquire-novamind-creating-the-north-american-industry-leader-in-psychedelic-therapy-and-research/2022-04-12T15:33:26.000Z https://psychedelicinvest.com/cybin-announces-publication-of-international-pct-patent-application-for-inhalation-delivery-of-multiple-psychedelic-molecules/2022-04-11T18:44:25.000Z https://psychedelicinvest.com/comparing-the-largest-psychedelic-companies-post-earnings/2022-04-21T21:41:31.000Z https://psychedelicinvest.com/homecoming-closes-4-million-seed-funding-round-to-scale-psychedelic-therapy-companion-tools/2022-04-08T21:53:46.000Z https://psychedelicinvest.com/nova-mentis-to-produce-psilocybin-capsules-for-phase-2a-clinical-study%ef%bf%bc/2022-04-07T19:01:49.000Z https://psychedelicinvest.com/pharmadrug-advances-dmt-analogue-program-for-glaucoma-with-production-of-medical-device-designed-to-provide-sustained-control-of-elevated-intraocular-pressure/2022-04-07T18:35:43.000Z https://psychedelicinvest.com/core-one-labs-upgrades-to-otcqb-venture-market/2022-04-06T16:29:30.000Z https://psychedelicinvest.com/field-trip-health-ltd-granted-us-patent-covering-novel-psychedelic-molecule-ft-104/2022-04-05T18:03:20.000Z https://psychedelicinvest.com/multiple-psychedelics-companies-come-together-in-a-watershed-moment-for-psilocybin-therapy/2022-04-05T07:16:41.000Z https://psychedelicinvest.com/health-canada-approves-first-special-access-program-requests-for-psilocybin/2022-04-04T17:16:21.000Z https://psychedelicinvest.com/atai-life-sciences-2021-financial-results/2022-04-21T21:41:42.000Z https://psychedelicinvest.com/novamind-partner-to-acquire-specialized-ibogaine-group-in-brazil/2022-04-01T15:58:35.000Z https://psychedelicinvest.com/cybin-announces-initiation-of-kernel-flow-feasibility-study-measuring-psychedelic-effects-on-the-brain/2022-03-31T15:49:14.000Z https://psychedelicinvest.com/albert-labs-files-u-s-provisional-patent-application-for-a-cultivation-process-for-the-production-of-psilocybe-mycelia-as-well-as-other-fungi-species/2022-03-30T19:14:36.000Z https://psychedelicinvest.com/cybin-announces-successful-completion-of-in-vivo-preclinical-studies-for-its-deuterated-psilocybin-analog-cyb003-supporting-advancement-into-phase-1-2a-clinical-trial/2022-03-29T20:02:46.000Z https://psychedelicinvest.com/mindmed-2021-earnings-rapid-reactions/2022-04-21T21:41:55.000Z https://psychedelicinvest.com/mindmed-reports-full-year-2021-financial-results-and-business-highlights/2022-03-28T17:05:55.000Z https://psychedelicinvest.com/biomind-labs-to-commence-commercial-clinical-trial-on-its-proprietary-mescaline-candidate-bmnd06/2022-10-25T16:38:07.000Z https://psychedelicinvest.com/compass-pathways-and-partners-launch-the-centre-for-mental-health-research-and-innovation-in-the-uk%ef%bf%bc/2022-03-24T18:01:04.000Z https://psychedelicinvest.com/havn-life-expands-supply-agreement-with-mycotopia-therapies-inc/2022-03-23T20:02:09.000Z https://psychedelicinvest.com/awakn-life-sciences-announces-closing-of-private-placement/2022-03-23T18:54:17.000Z https://psychedelicinvest.com/wesana-health-announces-new-findings-indicating-psilocybin-potentiates-impact-of-an-anti-depressant/2022-03-22T19:17:57.000Z https://psychedelicinvest.com/core-one-labs-to-investigate-soliciting-investment-and-potential-takeover-opportunities%ef%bf%bc/2022-03-21T19:08:39.000Z https://psychedelicinvest.com/pro-companies-focused-on-dmt-video/2022-10-25T16:38:08.000Z https://psychedelicinvest.com/optimi-health-begins-cultivation-of-natural-psilocybin-for-use-in-clinical-trials/2022-03-18T16:40:27.000Z https://psychedelicinvest.com/awakn-life-sciences-receives-regulatory-to-begin-delivering-treatments-in-london-clinic/2022-03-17T17:44:51.000Z https://psychedelicinvest.com/whats-going-on-with-mindcure/2022-03-17T14:09:16.000Z https://psychedelicinvest.com/novamind-to-host-mindmed-phase-iib-trial-for-lsd-and-anxiety/2022-03-16T17:40:34.000Z https://psychedelicinvest.com/bright-minds-biosciences-announces-successful-completion-of-28-day-toxicology-studies-and-advancement-to-first-in-human-clinical-trial/2022-03-15T20:50:46.000Z https://psychedelicinvest.com/numinus-expands-natural-psychedelic-research-with-new-biosecurity-license/2022-03-14T15:47:00.000Z https://psychedelicinvest.com/a-deeper-dive-into-seelos-therapeutics/2022-04-21T21:42:14.000Z https://psychedelicinvest.com/albert-labs-closes-4-7m-private-placement-begins-trading-on-the-canadian-securities-exchange/2022-03-11T18:57:34.000Z https://psychedelicinvest.com/small-pharma-expands-commerical-portfolio-with-dmt/2022-03-11T22:58:13.000Z https://psychedelicinvest.com/novamind-to-conduct-phase-ii-psilocybin-trial-for-major-depressive-disorder/2022-03-09T18:39:49.000Z https://psychedelicinvest.com/clearmind-medicine-scisparc-launch-a-psychedelic-pharma-collaboration/2022-03-08T17:55:20.000Z https://psychedelicinvest.com/seelos-therapeutics-announces-year-end-2021-business-and-clinical-update/2022-03-07T20:17:29.000Z https://psychedelicinvest.com/magellan-rx-management-releases-clinical-insights-on-the-use-of-psychedelics-in-treating-mental-health-conditions%ef%bf%bc/2022-03-04T23:19:28.000Z https://psychedelicinvest.com/love-pharma-updates-microdoz-proposed-acquisition-with-global-leader-in-psychedelic-research%ef%bf%bc/2022-03-04T17:36:00.000Z https://psychedelicinvest.com/a-deeper-dive-into-novaminds-q2-financial-results/2022-04-21T21:42:24.000Z https://psychedelicinvest.com/the-scientific-community-is-investing-heavily-in-the-god-molecule/2022-03-03T21:53:57.000Z https://psychedelicinvest.com/field-trip-health-and-cerebral-partner-to-provide-end-to-end-mental-health-care/2022-03-03T17:52:18.000Z https://psychedelicinvest.com/novamind-reports-fiscal-q2-2022-financial-results-and-operating-highlights/2022-03-02T19:26:50.000Z https://psychedelicinvest.com/havn-life-sciences-health-products-listed-on-amazon/2022-02-28T19:35:50.000Z https://psychedelicinvest.com/havn-life-secures-purchase-order-for-controlled-substance-sale-to-revive-therapeutics-ltd-for-use-in-clinical-research%ef%bf%bc/2022-02-25T18:39:48.000Z https://psychedelicinvest.com/compass-pathways-announces-financial-results-for-the-fourth-quarter-and-full-year-2021-and-business-highlights%ef%bf%bc/2022-02-25T22:17:29.000Z https://psychedelicinvest.com/pharmadrug-receives-positive-results-for-dmt-analogue-program-to-treat-glaucoma/2022-02-23T17:31:30.000Z https://psychedelicinvest.com/worlds-first-clinical-trial-for-dmt-assisted-therapy-in-major-depressive-disorder-shows-consistent-quality-of-psychedelic-response-in-phase-i/2022-02-22T21:28:21.000Z https://psychedelicinvest.com/nova-mentis-study-confirms-oral-microdose-psilocybin-treatment-of-autism%ef%bf%bc/2022-02-25T22:05:17.000Z https://psychedelicinvest.com/field-trip-health-earnings-review/2022-02-19T00:01:25.000Z https://psychedelicinvest.com/awakn-life-sciences-drug-discovery-program-files-patent-application-for-a-new-class-of-entactogen-like-molecules/2022-02-18T20:06:58.000Z https://psychedelicinvest.com/mydecine-announces-myco-005-family-of-improved-safety-microdose-novel-molecules/2022-02-17T17:03:50.000Z https://psychedelicinvest.com/fluence-raises-3-million-to-scale-psychedelic-therapy-training/2022-02-16T16:00:12.000Z https://psychedelicinvest.com/betterlife-lead-drug-betr-001-promotes-structural-neural-plasticity-in-preclinical-model%ef%bf%bc/2022-02-15T16:50:14.000Z https://psychedelicinvest.com/psychedelic-invest-pro-video-weekly-content-teaser/2022-04-21T21:42:35.000Z https://psychedelicinvest.com/revive-therapeutics-provides-update-on-phase-3-clinical-trial-for-bucillamine-in-covid-19%ef%bf%bc/2022-02-14T19:36:42.000Z https://psychedelicinvest.com/havn-life-enters-into-distribution-agreement-with-mycrodose-therapeutics-for-u-s-market/2022-02-12T00:40:12.000Z https://psychedelicinvest.com/psychedelics-in-2022-iter-investments-and-industry-predictions/2022-02-14T05:20:58.000Z https://psychedelicinvest.com/elemental-advisors-launches-psyk-etf-focused-on-the-medical-psychedelics-industry/2022-02-10T18:08:11.000Z https://psychedelicinvest.com/ehave-expands-its-ketadash-brand-and-begins-producing-revenue-with-the-purchase-of-california-based-rejuv-iv/2022-02-09T21:26:36.000Z https://psychedelicinvest.com/mydecines-exclusive-dealer-identified-as-licensed-psilocybin-and-mdma-supplier-in-canada/2022-02-08T18:28:30.000Z https://psychedelicinvest.com/sierra-sage-herbs-acquired-by-creso-pharma/2022-02-07T18:31:34.000Z https://psychedelicinvest.com/psychedelic-stock-market-update-january-2022/2022-07-06T19:25:38.000Z https://psychedelicinvest.com/tryp-therapeutics-announces-2000000-financing-and-changes-in-management-board-of-directors/2022-02-04T20:15:32.000Z https://psychedelicinvest.com/entheon-biomedical-announces-the-approval-of-dmt-clinical-trial/2022-02-03T18:51:46.000Z https://psychedelicinvest.com/mydecine-submits-pre-investigational-new-drug-briefing-package-to-the-fda-for-myco-001/2022-02-02T18:18:01.000Z https://psychedelicinvest.com/pharmadrug-announces-filing-of-us-provisional-patent-for-cepharanthine-to-treat-prostate-cancer/2022-02-01T19:19:51.000Z https://psychedelicinvest.com/filament-health-subsidiary-psilo-scientific-announces-inclusion-in-health-canada-list-of-licensed-psilocybin-producers/2022-01-31T18:46:17.000Z https://psychedelicinvest.com/atai-life-sciences-launches-invyxis-to-accelerate-discovery-of-next-generation-mental-health-treatments/2022-01-29T00:43:05.000Z https://psychedelicinvest.com/awakn-life-sciences-files-patent-application-for-a-new-class-of-entactogen-like-molecules-to-treat-a-broad-range-of-addictions/2022-01-29T00:39:57.000Z https://psychedelicinvest.com/video-the-psychedelics-industry-in-2021/2022-01-26T15:57:35.000Z https://psychedelicinvest.com/mindset-pharma-enters-manufacturing-agreement-to-produce-next-generation-psilocybin-drug-candidate-msp-1014/2022-01-25T18:46:05.000Z https://psychedelicinvest.com/g2-acquires-lophos-pharma-a-peyote-focused-psychedelics-company/2022-01-24T17:44:31.000Z https://psychedelicinvest.com/psychedelic-science-leader-eleusis-to-become-public-company-in-merger-with-silver-spike-acquisition-corp-ii/2022-01-21T20:22:01.000Z https://psychedelicinvest.com/betterlife-receives-fda-response-on-its-pre-ind-application-for-major-depressive-disorder-treatment/2022-01-20T20:27:59.000Z https://psychedelicinvest.com/nucleus-a-data-driven-psychedelics-platform-begins-to-orbit-the-mental-health-crisis-logan-lenz-to-captain-the-ship/2022-01-19T19:04:43.000Z https://psychedelicinvest.com/survey-finds-majority-of-affected-americans-approve-of-psychedelics-as-an-alternative-treatment-to-address-anxiety-depression-and-ptsd/2022-01-19T01:24:26.000Z https://psychedelicinvest.com/over-730m-were-invested-in-psychedelics-in-2021/2022-01-19T15:12:08.000Z https://psychedelicinvest.com/mynd-life-sciences-announces-collaborative-research-agreement-with-the-university-of-british-columbia/2022-01-14T17:32:44.000Z https://psychedelicinvest.com/mydecine-to-launch-special-access-support-and-supply-program-in-canada-expanding-access-to-psychedelic-assisted-psychotherapy-for-patients/2022-01-13T19:47:34.000Z https://psychedelicinvest.com/atai-life-sciences-announces-fda-investigational-new-drug-ind-clearance-for-pcn-101-r-ketamine-program/2022-01-12T18:57:02.000Z https://psychedelicinvest.com/wesana-health-granted-us-fda-pre-ind-meeting-for-sana-013/2022-01-11T18:30:29.000Z https://psychedelicinvest.com/cybin-announces-additional-adelia-milestone-achievement/2022-01-10T19:46:31.000Z https://psychedelicinvest.com/australian-government-pledges-to-donate-14-8-million-for-pyschedelic-medicine-research/2022-01-07T18:26:55.000Z https://psychedelicinvest.com/numinus-to-follow-tsx-upgrade-with-us-listing-in-2022-ceo/2022-01-07T17:56:59.000Z https://psychedelicinvest.com/is-this-the-end-of-patents-on-psilocybin/2022-01-07T17:26:26.000Z https://psychedelicinvest.com/field-trip-announces-intention-to-make-applications-on-behalf-of-patients-to-health-canadas-special-access-program-sap-for-access-to-psilocybin-and-mdma-assisted-therapies/2022-01-07T17:03:11.000Z https://psychedelicinvest.com/red-light-holland-expands-imicrodose-branded-product-offerings-and-launches-the-sale-of-all-in-one-mushroom-fruiting-extracts-capsules-and-tinctures/2022-01-05T20:44:28.000Z https://psychedelicinvest.com/pharmather-announces-publication-of-research-data-for-ketabet/2022-01-04T19:48:31.000Z https://psychedelicinvest.com/awakn-life-sciences-reports-fiscal-third-quarter-2021-financial-results-and-business-highlights/2022-01-03T18:28:04.000Z https://psychedelicinvest.com/2021-the-year-in-psychedelics/2022-01-01T22:05:46.000Z https://psychedelicinvest.com/mindset-pharma-recaps-2021-milestones-and-highlights/2022-04-27T13:10:33.000Z https://psychedelicinvest.com/mindmed-announces-transitions-to-management-team/2021-12-29T19:20:44.000Z https://psychedelicinvest.com/mindset-pharma-announces-filing-of-international-patent-application-covering-its-family-3-microdose-compounds/2021-12-29T16:13:50.000Z https://psychedelicinvest.com/revive-therapeutics-expands-bucillamine-research-to-treat-omicron-variant-and-adds-inflammatory-markers-to-fda-phase-3-clinical-trial/2021-12-28T18:03:06.000Z https://psychedelicinvest.com/tryp-therapeutics-announces-advancement-of-phase-2a-clinical-trial-in-binge-eating-disorder/2021-12-27T16:53:31.000Z https://psychedelicinvest.com/novamind-signs-definitive-agreement-to-acquire-arizona-based-clinics/2021-12-23T15:00:19.000Z https://psychedelicinvest.com/tryp-therapeutics-announces-fiscal-year-2021-financial-results-and-reports-on-corporate-highlights/2021-12-22T18:23:55.000Z https://psychedelicinvest.com/optimi-health-receives-dealers-license-inspection-and-introduces-quality-assurance-department/2021-12-21T17:46:52.000Z https://psychedelicinvest.com/havn-life-enters-into-definitive-agreement-to-acquire-spore-life-sciences-inc/2021-12-20T21:44:41.000Z https://psychedelicinvest.com/pharmather-enters-into-process-development-agreement-with-lts-lohmann-for-ketamine-microneedle-patch/2021-12-20T19:48:23.000Z https://psychedelicinvest.com/compass-selected-for-addition-to-nasdaq-biotechnology-index/2021-12-17T18:19:59.000Z https://psychedelicinvest.com/mynd-life-sciences-acquires-rights-for-the-use-of-psychedelics-to-treat-alzheimers-disease-and-other-dementias/2021-12-17T18:21:57.000Z https://psychedelicinvest.com/entheon-biomedical-announces-eeg-patent-application-provides-research-update/2021-12-17T18:19:25.000Z https://psychedelicinvest.com/apeiron-and-other-key-shareholders-of-atai-life-sciences-reinforce-support-by-entering-into-extended-voluntary-share-lock-up-agreements/2021-12-15T20:18:35.000Z https://psychedelicinvest.com/atai-life-sciences-has-been-selected-for-addition-to-the-nasdaq-biotechnology-index/2021-12-14T19:52:15.000Z https://psychedelicinvest.com/pharmather-announces-positive-research-results-for-lsd-microneedle-patch/2021-12-14T18:44:58.000Z https://psychedelicinvest.com/numinus-wellness-inc-reports-q4-and-year-end-2021-results/2021-12-13T20:47:02.000Z https://psychedelicinvest.com/a-new-cross-sector-partnership-means-a-huge-step-forward-for-mdma-therapy/2021-12-10T19:18:54.000Z https://psychedelicinvest.com/how-to-effectively-market-your-psychedelic-brand/2021-12-10T19:13:07.000Z https://psychedelicinvest.com/cybin-confirms-scientific-advice-meeting-with-uk-medical-and-healthcare-products-regulatory-agency-for-lead-candidate-cyb003/2021-12-10T16:30:27.000Z https://psychedelicinvest.com/mydecine-secures-financing-and-provides-company-update-on-clinical-trials-drug-development-and-technology-initiatives/2021-12-10T16:15:18.000Z https://psychedelicinvest.com/atai-life-sciences-launches-new-bioprospecting-platform-tryptagenix/2021-12-09T21:00:55.000Z https://psychedelicinvest.com/mindmed-engages-in-productive-pre-submission-meeting-with-fda-for-development-of-the-mindmed-session-monitoring-system/2021-12-09T18:23:36.000Z https://psychedelicinvest.com/algernon-pharmaceuticals-completes-manufacturing-of-dmt-appoints-uk-stroke-experts-for-phase-2/2021-12-08T18:34:50.000Z https://psychedelicinvest.com/mycotopia-and-ei-ventures-sign-loi-to-explore-merger-and-formation-of-psly-com-a-360-million-transaction-and-will-apply-to-list-shares-on-nasdaq/2021-12-07T21:22:12.000Z https://psychedelicinvest.com/psybio-therapeutics-successfully-completes-first-pre-ind-meeting-with-fda/2021-12-07T21:02:36.000Z https://psychedelicinvest.com/mydecine-files-full-patent-application-covering-multiple-families-of-psilocin-analogs/2021-12-06T17:55:14.000Z https://psychedelicinvest.com/awakn-life-sciences-strengthens-executive-leadership-team/2021-12-03T18:20:00.000Z https://psychedelicinvest.com/tryp-therapeutics-receives-confirmation-from-fda-to-proceed-with-phase-2a-study-in-fibromyalgia/2021-12-02T19:50:31.000Z https://psychedelicinvest.com/seelos-therapeutics-raises-20-million-in-private-placement-of-senior-secured-convertible-note/2021-12-02T19:13:51.000Z https://psychedelicinvest.com/mindmed-and-liechti-lab-publish-first-human-data-on-the-interacting-effects-of-an-ssri-and-psilocybin/2021-12-01T18:12:57.000Z https://psychedelicinvest.com/clairvoyant-therapeutics-raises-more-than-3-million-in-seed-financing-adds-bench-strength-to-senior-leadership-team/2021-11-30T19:19:36.000Z https://psychedelicinvest.com/atai-life-sciences-increases-its-ownership-position-in-compass-pathways/2021-12-01T20:22:29.000Z https://psychedelicinvest.com/albert-labs-receive-conditional-approval-for-cse-listing-appoint-chrystal-capital-partners-to-advise-on-european-listing/2021-11-29T20:05:29.000Z https://psychedelicinvest.com/biomind-labs-announces-design-of-a-pharmaceutical-form-for-psychedelic-drug-delivery-using-3d-printing/2022-10-25T16:38:07.000Z https://psychedelicinvest.com/compass-pathways-granted-fifth-us-patent-for-crystalline-psilocybin/2021-11-23T19:42:15.000Z https://psychedelicinvest.com/field-trip-health-ltd-reports-second-fiscal-quarter-2022-financial-results-and-provides-business-update/2021-11-22T19:26:17.000Z https://psychedelicinvest.com/wesana-health-clinics-surpass-4000-administered-ketamine-treatments/2021-11-19T20:28:16.000Z https://psychedelicinvest.com/tryp-therapeutics-provides-update-on-clinical-hold-for-phase-2a-study-for-eating-disorders/2021-11-19T18:17:14.000Z https://psychedelicinvest.com/filament-health-announces-co-development-and-exclusive-licensing-agreement-with-entheotech-bioscience/2021-11-18T20:47:41.000Z https://psychedelicinvest.com/silo-pharma-and-strategic-partner-zylo-therapeutics-begin-development-process-for-novel-ketamine-loaded-z-pods/2022-09-12T16:18:39.000Z https://psychedelicinvest.com/compass-pathways-november-2021-results/2021-11-17T21:23:05.000Z https://psychedelicinvest.com/mindmed-announces-financial-results-for-the-third-quarter-2021-and-business-highlights/2021-11-16T21:36:51.000Z https://psychedelicinvest.com/finding-value-in-the-clinical-space-a-conversation-with-iter-investments-founder-dustin-robinson/2021-11-16T21:17:05.000Z https://psychedelicinvest.com/atai-life-sciences-reports-third-quarter-2021-financial-results-and-corporate-update/2021-11-15T18:11:27.000Z https://psychedelicinvest.com/mynd-executes-loi-to-enter-into-a-clinical-research-collaboration-with-revitalist/2022-09-12T15:01:35.000Z https://psychedelicinvest.com/silo-pharma-reports-third-quarter-results-and-operating-highlights/2022-09-12T16:18:43.000Z https://psychedelicinvest.com/alto-neuroscience-announces-publication-in-nature-neuroscience-highlighting-superiority-of-data-driven-framework-for-mapping-human-neurobiology-domains/2021-11-11T19:14:08.000Z https://psychedelicinvest.com/monsenso-has-signed-an-agreement-with-awakn-life-sciences/2021-11-10T19:04:07.000Z https://psychedelicinvest.com/braxia-scientific-ceo-dr-roger-mcintyre-to-deliver-keynote-address-at-wonderland-miami/2021-11-08T19:09:19.000Z https://psychedelicinvest.com/cybin-announces-positive-cyb003-data-demonstrating-significant-advantages-over-oral-psilocybin-for-treatment-of-mental-health/2021-11-08T18:24:15.000Z https://psychedelicinvest.com/cybin-granted-dea-schedule-i-manufacturing-license/2021-11-05T21:08:39.000Z https://psychedelicinvest.com/novamind-reports-fy2021-financial-results-and-operating-highlights/2022-07-06T19:23:50.000Z https://psychedelicinvest.com/bright-minds-biosciences-commences-trading-on-the-nasdaq-under-the-ticker-symbol-drug/2021-11-04T17:56:24.000Z https://psychedelicinvest.com/compass-pathways-to-launch-phase-ii-trial-of-comp360-psilocybin-therapy-for-post-traumatic-stress-disorder/2021-11-03T17:15:23.000Z https://psychedelicinvest.com/u-s-fda-approves-nova-mentis-orphan-drug-application/2021-11-02T19:29:26.000Z https://psychedelicinvest.com/tryp-therapeutics-submits-ind-application-for-phase-2a-clinical-trial-in-fibromyalgia/2021-11-02T16:27:54.000Z https://psychedelicinvest.com/mydecine-to-participate-in-wonderland-miami-on-november-8-9-2021/2021-11-01T19:55:54.000Z https://psychedelicinvest.com/cybin-announces-launch-of-embark-psychedelic-facilitator-training-program/2021-11-01T18:21:27.000Z https://psychedelicinvest.com/mindcure-signs-loi-with-awakn-life-sciences-to-distribute-ketamine-protocol-for-alcohol-use-disorder-into-clinics-across-united-states-and-canada-through-istrym-mindcures-digital-therapeutics-platf/2021-10-29T23:06:55.000Z https://psychedelicinvest.com/psychedelics-venture-capital-firm-iter-investments-to-exhibit-host-events-at-wonderland-miami-by-microdose-from-nov-8-9-2021/2021-10-29T23:15:57.000Z https://psychedelicinvest.com/awakn-life-sciences-identifies-new-chemical-series-via-its-drug-discovery-program/2021-10-29T22:56:14.000Z https://psychedelicinvest.com/cybin-announces-fda-investigational-new-drug-authorization-of-cybins-sponsored-feasibility-study-using-kernel-flow-technology/2021-10-29T19:34:37.000Z https://psychedelicinvest.com/mindmed-expands-its-drug-development-pipeline-with-launch-of-r-mdma-program/2021-10-29T17:24:15.000Z https://psychedelicinvest.com/psychedelic-laws-in-michigan/2021-10-26T23:18:13.000Z https://psychedelicinvest.com/small-pharma-granted-fast-track-designation-from-u-k-regulator-for-dmt-assisted-therapy-for-major-depressive-disorder/2021-10-22T21:52:12.000Z https://psychedelicinvest.com/levitee-labs-enters-into-credit-facility-for-up-to-12-million/2021-10-21T19:44:25.000Z https://psychedelicinvest.com/numinus-advances-phase-1-trial-on-proprietary-psilocybin-product/2021-10-20T19:46:00.000Z https://psychedelicinvest.com/pharmadrug-commences-trading-on-the-otcqb-market-in-the-united-states/2021-10-20T19:20:53.000Z https://psychedelicinvest.com/open-label-study-of-comp360-psilocybin-therapy-for-depression-in-cancer-patients-demonstrates-feasibility-of-simultaneous-psilocybin-administration-in-small-groups/2021-10-20T14:46:56.000Z https://psychedelicinvest.com/cybin-announces-completion-of-74-pre-clinical-psychedelic-molecule-studies/2021-10-20T12:52:06.000Z https://psychedelicinvest.com/mycrodose-therapeutics-and-nova-mentis-announce-loi-to-co-develop-advanced-drug-delivery-system/2021-10-19T19:30:00.000Z https://psychedelicinvest.com/clearmind-partners-with-clinipace-fda-approval/2021-10-18T19:37:41.000Z https://psychedelicinvest.com/levitee-signs-letter-of-intent-acquire-calgary-addiction-and-compounding-pharmacy/2021-10-15T17:16:02.000Z https://psychedelicinvest.com/tryp-inclusion-advisorshares-psychedelics-etf/2021-10-14T20:43:08.000Z https://psychedelicinvest.com/mindmed-joins-clinical-trials-transformation-initiative/2021-10-13T19:59:35.000Z https://psychedelicinvest.com/cybin-files-an-international-patent-application-covering-psychedelic-delivery-methods/2021-10-12T19:02:28.000Z https://psychedelicinvest.com/atai-life-sciences-announces-launch-of-psyprotix/2021-10-11T20:00:34.000Z https://psychedelicinvest.com/observing-world-mental-health-day-2021/2021-10-08T22:57:00.000Z https://psychedelicinvest.com/numinus-upgrades-psychedelics-lab-to-increase-research-service-capabilities/2021-10-08T20:35:47.000Z https://psychedelicinvest.com/tryp-therapeutics-to-collaborate-with-researchers-at-the-university-of-wisconsin-madison/2021-10-08T02:00:34.000Z https://psychedelicinvest.com/psygen-psilocybin-patent-pending-formula-clinical-trial/2021-10-07T17:48:19.000Z https://psychedelicinvest.com/pharmather-phase-2-ketamine-clinical-trial-parkinsons/2021-10-06T21:20:44.000Z https://psychedelicinvest.com/lobe-sciences-and-the-world-boxing-association-announce-initiative-targeting-mtbi-and-ptsd/2021-10-05T19:47:03.000Z https://psychedelicinvest.com/cybin-announces-appointment-of-dr-amir-inamdar-as-chief-medical-officer-for-european-operations-and-dr-geoff-varty-as-the-head-of-research-and-development/2021-10-04T18:39:29.000Z https://psychedelicinvest.com/mydecine-completes-spin-out-cannabis-assets/2021-10-01T18:05:46.000Z https://psychedelicinvest.com/braxia-reports-results-ketamine-study/2021-11-17T20:05:56.000Z https://psychedelicinvest.com/havn-acquires-bennetts-choice-brain-health-recovery/2021-11-17T20:07:07.000Z https://psychedelicinvest.com/betterlife-pharma-alpha2b-covid-trial/2021-09-28T21:33:57.000Z https://psychedelicinvest.com/the-meteoric-rise-of-the-worlds-first-psychedelic-beverage/2021-11-17T20:15:19.000Z https://psychedelicinvest.com/mindcure-launces-desire-project-hsdd/2021-09-27T20:13:19.000Z https://psychedelicinvest.com/delix-therapeutics-closes-70-million-series-a-financing-to-advance-pipeline-of-novel-psychoplastogen-therapeutics-to-treat-brain-disorders/2021-09-27T17:32:12.000Z https://psychedelicinvest.com/mindmed-provide-results-from-psilocybin-r-and-d/2021-09-24T18:13:08.000Z https://psychedelicinvest.com/numinus-completes-acquisition-of-neurology-centre-of-toronto/2021-09-23T19:58:12.000Z https://psychedelicinvest.com/fsd-pharma-acquires-lucid/2021-09-22T19:17:25.000Z https://psychedelicinvest.com/mindset-preclinical-data-dmt-inspired-candidate/2021-09-20T19:43:04.000Z https://psychedelicinvest.com/delic-acuqires-ketamine-wellness-clinic-becomes-largest-ketamine-healthcare-provider/2021-09-20T18:07:50.000Z https://psychedelicinvest.com/enveric-acquires-mindmed/2021-09-17T16:01:06.000Z https://psychedelicinvest.com/compass-pathways-acquires-psychedelic-ip/2021-09-16T18:57:20.000Z https://psychedelicinvest.com/awakn-acquire-ketamine-clinic-norway/2021-09-16T15:40:18.000Z https://psychedelicinvest.com/nova-mentis-patent-psilocybin-fragile-x-syndrome/2021-09-15T19:19:01.000Z https://psychedelicinvest.com/perception-neuroscience-initiates-phase2a-rketamine-study/2021-09-15T16:08:26.000Z https://psychedelicinvest.com/dr-ilya-reznik-joins-cannabics/2021-09-14T16:38:29.000Z https://psychedelicinvest.com/pharmather-provides-product-pipeline-updates/2021-09-13T17:50:35.000Z https://psychedelicinvest.com/hamilton-morriss-joins-compass-pathways/2021-09-10T16:09:14.000Z https://psychedelicinvest.com/field-trip-health-treatment-resistant-depression/2021-09-09T16:38:28.000Z https://psychedelicinvest.com/ketamineone-enters-agreement-for-two-ketamine-clinics-in-texas/2021-09-08T20:06:12.000Z https://psychedelicinvest.com/journey-colab-series-a-funding-for-alcohol-use-disorder/2021-09-08T18:17:42.000Z https://psychedelicinvest.com/field-trip-opens-first-psychedelic-therapy-healthcare-facility/2021-09-07T19:05:37.000Z https://psychedelicinvest.com/filament-to-begin-trading-on-otc/2021-09-07T17:42:02.000Z https://psychedelicinvest.com/mindcure-announces-financial-results-for-fiscal-2021/2021-09-03T21:55:06.000Z https://psychedelicinvest.com/filament-health-files-20th-patent-application-including-three-international-pct-applications/2021-09-03T21:54:17.000Z https://psychedelicinvest.com/field-trip-health-announces-kap-program/2021-09-03T16:52:59.000Z https://psychedelicinvest.com/mindmed-bioxcel-patent-agiitation/2021-09-02T18:49:18.000Z https://psychedelicinvest.com/ketamine-one-to-deploy-integrated-cognitive-assesment-tool/2021-09-01T18:54:03.000Z https://psychedelicinvest.com/red-light-successfully-exports-psilocybe-mushrooms/2021-09-01T17:34:40.000Z https://psychedelicinvest.com/psychedelic-laws-new-york-state/2021-08-31T19:25:34.000Z https://psychedelicinvest.com/small-pharma-announces-lyne-fortin-as-chair-of-the-board/2021-08-30T18:16:59.000Z https://psychedelicinvest.com/braxia-scientific-comments-on-class-action-complaint/2021-08-27T16:55:35.000Z https://psychedelicinvest.com/awakn-initiates-first-ketamine-treatment-study-for-gambling-addiction/2021-08-26T19:13:46.000Z https://psychedelicinvest.com/pharmadrug-announces-clinical-research-collaboration-with-johns-hopkins-university/2021-08-26T15:45:19.000Z https://psychedelicinvest.com/mycelial-gallery-blends-crypto-and-psychedelics/2021-08-26T17:57:34.000Z https://psychedelicinvest.com/tryp-completes-psychotherapy-training-for-phase-2a-study-at-uf/2021-08-25T15:21:54.000Z https://psychedelicinvest.com/mindmed-announces-collaboration-with-florian/2021-08-24T19:14:09.000Z https://psychedelicinvest.com/mindset-files-new-dmt-patents/2021-08-24T16:54:48.000Z https://psychedelicinvest.com/ketamine-one-established-medical-advisory-board/2021-08-23T16:20:34.000Z https://psychedelicinvest.com/silo-wellness-announces-3-million-distribution-partnership/2022-09-12T16:15:12.000Z https://psychedelicinvest.com/cybin-files-two-additional-patents/2021-08-19T16:35:18.000Z https://psychedelicinvest.com/core-one-labs-acquires-mycology/2021-08-18T15:53:16.000Z https://psychedelicinvest.com/mydecine-innovations-finishes-q2-with-c7m-cash/2021-08-17T19:57:58.000Z https://psychedelicinvest.com/beckley-psytech-completes-oversubscribed-80m-fundraise-to-develop-portfolio-of-psychedelic-medicine-breakthroughs/2021-08-17T15:39:54.000Z https://psychedelicinvest.com/ketamine-one-subsidiary-working-to-secure-new-contracts/2021-08-16T17:39:11.000Z https://psychedelicinvest.com/atai-releases-q2-financial-update/2021-08-16T15:57:58.000Z https://psychedelicinvest.com/psychedelics-stocks-vs-psychedelic-focused-etfs/2021-08-13T20:28:33.000Z https://psychedelicinvest.com/core-one-labs-submit-application-to-treat-patient-with-psilocybin/2021-08-13T17:07:09.000Z https://psychedelicinvest.com/awakn-begins-trading-on-otcqb-market/2021-08-12T16:46:44.000Z https://psychedelicinvest.com/novamind-divests-non-core-retreat-investment/2022-07-06T19:23:50.000Z https://psychedelicinvest.com/mynd-life-sciences-announces-dtc-eligibility/2021-08-11T16:47:41.000Z https://psychedelicinvest.com/revive-therapeutics-provides-update-on-development-pipeline/2021-08-10T18:39:37.000Z https://psychedelicinvest.com/mindmed-appoints-dr-robert-dworkin-to-scientific-advisory-board/2022-07-06T19:25:38.000Z https://psychedelicinvest.com/ketamine-one-starts-vr-platform/2021-08-09T16:37:39.000Z https://psychedelicinvest.com/compass-to-announce-second-quarter-finance-results-on-august-11/2021-08-06T16:29:49.000Z https://psychedelicinvest.com/pharmadrug-collaborates-with-terasaki-institute-to-research-dmt-for-eye-disease/2021-08-05T18:12:21.000Z https://psychedelicinvest.com/cybin-to-begin-trading-on-nyse/2021-08-05T15:34:19.000Z https://psychedelicinvest.com/awakn-announces-plans-for-london-clinic/2021-08-04T18:40:56.000Z https://psychedelicinvest.com/tryp-to-present-at-canaccord-conference/2021-08-03T19:02:18.000Z https://psychedelicinvest.com/mindmed-joins-digital-medicine-society/2021-08-03T16:51:16.000Z https://psychedelicinvest.com/wesana-announces-listing-on-otcqb-venture-market/2021-08-02T20:08:34.000Z https://psychedelicinvest.com/bionomics-announces-plans-for-ipo/2021-08-02T17:14:33.000Z https://psychedelicinvest.com/nova-mentis-files-u-s-patent-application-for-psilocybin-based-therapeutics/2021-07-30T21:08:15.000Z https://psychedelicinvest.com/entheon-biomedical-corp-acquires-lobo-genetics-inc/2021-07-30T21:05:10.000Z https://psychedelicinvest.com/tryp-announces-q3-financial-results/2021-07-29T21:38:30.000Z https://psychedelicinvest.com/levitee-acquires-blockmd/2021-07-29T18:13:55.000Z https://psychedelicinvest.com/cybin-receives-final-approval-to-commence-trading-on-the-nyse-american-on-or-about-august-5/2021-07-29T17:55:00.000Z https://psychedelicinvest.com/field-trip-health-to-list-on-nasdaq/2021-07-27T20:51:46.000Z https://psychedelicinvest.com/awakn-commences-trading-on-otc/2021-07-27T13:58:41.000Z https://psychedelicinvest.com/field-trip-gets-conditional-approval-to-list-on-nasdaq/2021-07-23T17:02:34.000Z https://psychedelicinvest.com/cybin-announces-conditional-listing-approval-from-nyse-american/2021-07-22T18:14:13.000Z https://psychedelicinvest.com/psilocybin-vs-dmt/2021-07-22T17:50:12.000Z https://psychedelicinvest.com/novamind-applies-to-trade-on-otcqb/2022-07-06T19:23:50.000Z https://psychedelicinvest.com/levitee-labs-to-commence-trading-on-the-canadian-securities-exchange-under-the-ticker-symbol-lvt/2021-07-20T17:20:25.000Z https://psychedelicinvest.com/knowde-group-enters-partnership-with-lmc-manna/2021-07-19T23:06:19.000Z https://psychedelicinvest.com/global-wellness-strategies-acquires-shanti-therapeutics/2021-07-19T18:06:27.000Z https://psychedelicinvest.com/jackie-von-salm-psilera/2021-07-16T19:19:46.000Z https://psychedelicinvest.com/nova-mentis-appoints-new-chief-science-officer/2021-07-16T16:27:41.000Z https://psychedelicinvest.com/red-light-holland-expected-merger-partner-creso-pharma-completes-acquisition-of-halucenex-life-sciences-inc/2021-07-15T19:33:31.000Z https://psychedelicinvest.com/awakn-initiates-research-program-to-further-develop-ketamine-assisted-therapies/2021-07-15T15:35:49.000Z https://psychedelicinvest.com/clearmind-announces-new-senior-management-staff/2021-07-14T19:43:01.000Z https://psychedelicinvest.com/red-light-holland-sells-350000grams-of-magic-truffles/2021-07-14T16:03:28.000Z https://psychedelicinvest.com/wesana-health-to-acquire-psytech-in-all-stock-deal/2021-07-13T15:16:22.000Z https://psychedelicinvest.com/research-is-the-emerging-psychedelics-framework/2021-07-09T19:04:17.000Z https://psychedelicinvest.com/cybin-expands-to-europe-with-ireland-subsidiary/2021-07-09T17:17:42.000Z https://psychedelicinvest.com/horizon-etfs-rebalances-psychedelics-etf/2021-07-07T19:18:36.000Z https://psychedelicinvest.com/braxia-scientific0announces-participation-at-psych-investor-summit/2021-07-06T18:33:50.000Z https://psychedelicinvest.com/seelos-theraputics-doses-first-patient-in-2nd-part-of-study/2021-07-06T16:15:50.000Z https://psychedelicinvest.com/cybin-announces-promising-preclinical-results/2021-07-05T19:26:40.000Z https://psychedelicinvest.com/compass-partners-to-advance-uk-mental-health-models/2021-07-05T15:58:00.000Z https://psychedelicinvest.com/osmind-closes-15-million-series-a-roun/2021-07-02T15:10:59.000Z https://psychedelicinvest.com/index-update-july-2021/2021-11-17T20:11:19.000Z https://psychedelicinvest.com/is-tripping-necessary/2021-07-01T16:16:56.000Z https://psychedelicinvest.com/tryp-therapeutics-partners-with-alcami-for-proprietary-formulations/2021-06-29T15:43:36.000Z https://psychedelicinvest.com/understanding-legalization-v-decriminalization-in-the-psychedelics-industry/2021-07-05T19:23:44.000Z https://psychedelicinvest.com/compass-pathways-completes-comp360-for-216-patients/2021-07-02T21:28:49.000Z https://psychedelicinvest.com/speakeasy-to-acquire-karolos/2021-06-25T16:53:17.000Z https://psychedelicinvest.com/filament-health-corp-announces-approval-for-listing-on-the-neo-exchange/2021-06-24T18:23:14.000Z https://psychedelicinvest.com/psychedelics-biotech-company-awakn-life-sciences-goes-public-on-the-neo-exchange/2022-07-06T19:20:50.000Z https://psychedelicinvest.com/red-light-holland-to-partner-with-leading-fresh-and-dried-mushroom-producers-on-east-coast-facility/2021-06-22T20:03:34.000Z https://psychedelicinvest.com/atai-life-sciences-goes-public/2021-06-18T17:12:06.000Z https://psychedelicinvest.com/atai-life-sciences-announces-pricing-of-upsized-initial-public-offering/2021-06-18T15:33:22.000Z https://psychedelicinvest.com/mydecine-innovations-kicks-off-machine-learning-based-drug-discovery-program-with-the-university-of-alberta/2021-06-17T18:12:17.000Z https://psychedelicinvest.com/as-a-public-company-wesana-health-aims-to-solve-traumatic-brain-injury/2021-06-22T16:17:25.000Z https://psychedelicinvest.com/mindmed-appoints-dr-peter-bergethon-to-advisory-board/2021-06-17T16:56:34.000Z https://psychedelicinvest.com/cure-pharmaceuticals-to-present-at-hc-wainwright-conference/2021-06-15T21:15:54.000Z https://psychedelicinvest.com/field-trip-health-ltd-announces-completion-of-dmpk-studies-engineering-batch-for-ft-104-its-novel-psychedelic-compound/2021-06-15T16:00:58.000Z https://psychedelicinvest.com/mindset-pharma-announces-first-data-set/2021-06-14T16:05:12.000Z https://psychedelicinvest.com/pharmather-announces-update/2021-06-11T19:19:24.000Z https://psychedelicinvest.com/red-light-holland-closes-acquisition-of-happy-caps/2021-06-11T14:26:57.000Z https://psychedelicinvest.com/gh-research-files-to-go-public-only-two-months-after-raising-125-million/2021-06-10T16:47:24.000Z https://psychedelicinvest.com/goodness-growth-to-expand-intellectual-properties/2021-06-10T16:16:32.000Z https://psychedelicinvest.com/american-journal-of-psychiatry-publishes-ketamine-guidelines/2021-06-09T19:05:40.000Z https://psychedelicinvest.com/mindmed-ceo-steps-down/2021-06-09T16:34:57.000Z https://psychedelicinvest.com/the-new-health-club/2021-06-09T17:28:15.000Z https://psychedelicinvest.com/leading-psychedelic-wellness-company-delic-signs-definitive-agreement-to-acquire-ketamine-infusion-centers-llc/2021-06-08T16:07:53.000Z https://psychedelicinvest.com/mindset-selects-lead-clinical-candidate/2021-06-07T19:39:42.000Z https://psychedelicinvest.com/pharmadrug-launches-online-retail-platform-in-the-netherlands/2021-06-07T16:50:10.000Z https://psychedelicinvest.com/compass-publish-cognition-results-from-comp360/2021-06-04T17:57:18.000Z https://psychedelicinvest.com/mindcure-completes-first-stage-of-manufacturing-synthetic-ibogaine/2021-06-03T15:08:58.000Z https://psychedelicinvest.com/small-pharma-inc-appoints-mac-clinical-research-to-assisnt-in-clinical-trial/2021-06-02T16:07:31.000Z https://psychedelicinvest.com/pharmather-and-trsl-enter-into-agreement-for-microneedle-patch/2021-06-01T15:42:45.000Z https://psychedelicinvest.com/mynd-life-sciences-establishes-scientific-advisory-board/2021-05-28T22:28:23.000Z https://psychedelicinvest.com/defiance-etfs-launches-psy-the-first-u-s-listed-etf-focused-on-psychedelics/2021-06-11T20:49:44.000Z https://psychedelicinvest.com/neonmind-to-commence-trading-on-the-otcqb-venture-market/2021-05-28T14:49:14.000Z https://psychedelicinvest.com/a-second-psychedelics-etf-prepares-to-trade-here-are-the-top-10-holdings/2021-06-11T20:49:49.000Z https://psychedelicinvest.com/a-major-dilemma-for-those-looking-to-invest-in-psychedelic-stocks/2022-09-12T16:19:29.000Z https://psychedelicinvest.com/delic-acquires-biotech-company-discover-ventures/2021-05-27T15:55:21.000Z https://psychedelicinvest.com/field-trip-health-ltd-receives-conditional-approval-to-up-list-to-the-toronto-stock-exchange/2021-05-27T15:52:28.000Z https://psychedelicinvest.com/mindmed-publish-first-lsd-data/2021-05-26T18:23:12.000Z https://psychedelicinvest.com/mynd-life-sciences-inc-announces-public-listing-on-the-cse/2021-05-26T15:53:43.000Z https://psychedelicinvest.com/pharmather-files-for-fda-orphan-drug-designation-for-ketamine/2021-05-25T17:42:55.000Z https://psychedelicinvest.com/finding-the-derivative-with-dr-joseph-tucker/2021-05-24T18:26:04.000Z https://psychedelicinvest.com/enveric-biosciences-announces-agreement-to-acquire-magicmed/2021-05-25T15:00:02.000Z https://psychedelicinvest.com/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system/2021-05-24T15:34:28.000Z https://psychedelicinvest.com/braxia-scientific-changes-otc-symbol/2021-05-21T17:13:17.000Z https://psychedelicinvest.com/the-chopra-foundation-and-mindmed-to-partner-on-the-future-of-psychedelic-medicines-mental-wellbeing/2021-05-21T15:05:07.000Z https://psychedelicinvest.com/mindmed-announces-the-approval-of-mescaline-study/2021-05-20T16:28:40.000Z https://psychedelicinvest.com/awakn-life-sciences-inc-enter-into-binding-agreement-for-reverse-takeover-transaction/2022-07-06T19:20:50.000Z https://psychedelicinvest.com/silo-wellness-reaches-agreement-for-dmt-expansion/2022-09-12T16:15:13.000Z https://psychedelicinvest.com/mindcure-appoints-dr-john-brownstein-as-company-advisor/2021-05-19T19:14:11.000Z https://psychedelicinvest.com/mindmed-receives-fda-type-c-meeting-response-for-project-lucy-phase-2b-clinical-trial/2021-05-19T14:52:48.000Z https://psychedelicinvest.com/havn-life-enters-into-agreement-to-acquire-clinical-stage-ip-for-development-of-lsd-derived-api-for-cluster-headaches/2021-05-18T15:35:22.000Z https://psychedelicinvest.com/revive-enters-agreement-to-develop-psilocybin-strip/2021-05-18T14:57:11.000Z https://psychedelicinvest.com/the-world-boxing-council-and-wesana-health-announce-joint-efforts-to-research-the-impact-of-psychedelics-on-traumatic-brain-injury/2021-05-17T14:44:27.000Z https://psychedelicinvest.com/the-growth-of-psychedelic-content-on-clubhouse/2021-05-14T21:18:36.000Z https://psychedelicinvest.com/mindmed-announces-2021-q1-financial-results/2021-05-14T15:46:15.000Z https://psychedelicinvest.com/mindmed-bolsters-management-team/2021-05-14T15:02:24.000Z https://psychedelicinvest.com/delics-acquisition-target-ketamine-infusion-centers-announces-proposal-to-acquire-2-additional-clinic-locations/2021-05-12T15:40:09.000Z https://psychedelicinvest.com/index-update-may-2021/2021-05-11T23:56:58.000Z https://psychedelicinvest.com/wesana-health-commences-trading-on-the-cse/2021-05-11T20:04:38.000Z https://psychedelicinvest.com/braxia-scientific-introduces-braxia-health-a-growing-network-of-clinics-leading-psychedelic-research/2021-05-11T20:08:32.000Z https://psychedelicinvest.com/gilgamesh-pharmaceuticals-closes-on-27-million-series-a-round/2021-05-06T19:07:10.000Z https://psychedelicinvest.com/speakeasy-to-enter-psychedelics-sector-with-narcotics-dealers-licence/2021-05-06T15:40:38.000Z https://psychedelicinvest.com/private-psychedelics-companies-continue-to-perform/2021-05-05T21:20:56.000Z https://psychedelicinvest.com/psychedelic-laws-in-kentucky/2023-11-29T16:22:59.000Z https://psychedelicinvest.com/novamind-doubles-in-size-adds-four-new-psychedelic-mental-health-clinics/2021-05-05T14:29:08.000Z https://psychedelicinvest.com/core-one-labs-completes-milestone-acquisition-of-akome-biotech/2021-05-04T20:36:47.000Z https://psychedelicinvest.com/field-trip-health-ltd-announces-opening-of-psychedelic-enhanced-therapy-center-in-houston/2021-05-04T20:18:08.000Z https://psychedelicinvest.com/mycotopia-therapies-inc-begins-trading-under-symbol-myco/2021-05-04T19:49:12.000Z https://psychedelicinvest.com/psychedelic-laws-in-maine/2021-05-03T16:37:05.000Z https://psychedelicinvest.com/creating-a-sustainable-psychedelics-ecosystem/2021-06-11T20:24:14.000Z https://psychedelicinvest.com/numinus-wellness-q2-2021-results-highlighted-by-17-25-million-financing/2021-04-30T14:59:16.000Z https://psychedelicinvest.com/psychedelic-laws-in-indiana/2021-04-29T20:10:13.000Z https://psychedelicinvest.com/mindset-pharma-announces-positive-preclinical-results-of-its-proprietary-next-generation-dmt-5-meo-dmt-compounds/2021-04-29T15:33:33.000Z https://psychedelicinvest.com/mindmed-surpasses-compass-pathways-as-largest-publicly-traded-psychedelic-company/2021-04-30T18:28:03.000Z https://psychedelicinvest.com/compass-pathways-launches-proposed-public-offering/2021-04-28T15:27:31.000Z https://psychedelicinvest.com/psychedelic-laws-in-georgia/2021-04-27T16:44:14.000Z https://psychedelicinvest.com/mindmed-begins-trading-on-nasdaq/2022-07-06T19:25:38.000Z https://psychedelicinvest.com/silo-wellness-announces-five-new-psychedelic-wellness-retreats-in-jamaica/2022-09-12T16:15:13.000Z https://psychedelicinvest.com/mindmed-to-commence-trading-on-nasdaq/2022-07-06T19:25:38.000Z https://psychedelicinvest.com/psychedelic-laws-in-massachusetts/2021-04-23T16:00:38.000Z https://psychedelicinvest.com/ehave-inc-engages-legal-counsel-on-launch-of-ketadash-in-the-u-s/2021-04-23T15:21:16.000Z https://psychedelicinvest.com/better-plant-launches-jusu-labs-for-influencer-and-celebrity-partnerships/2021-04-22T15:04:38.000Z https://psychedelicinvest.com/psychedelic-laws-in-washington-dc/2021-04-21T17:18:57.000Z https://psychedelicinvest.com/nova-mentis-organizes-autism-data-bank-in-north-america/2021-04-21T15:07:31.000Z https://psychedelicinvest.com/pharmather-announces-submission-application-with-the-fda-for-ketamine-in-the-treatment-of-parkinsons-disease/2021-04-20T14:36:27.000Z https://psychedelicinvest.com/cybin-establishes-clinical-advisory-board-of-renowned-physicians/2021-04-19T15:25:40.000Z https://psychedelicinvest.com/ehave-prepares-to-launch-ketamine-clinical-trials-using-brain-scientifics-brain-mapping-technology/2021-04-16T13:35:59.000Z https://psychedelicinvest.com/silo-wellness-expands-to-latin-america/2022-09-12T16:15:14.000Z https://psychedelicinvest.com/new-research-confirms-multi-billion-dollar-investment-opportunity-in-psychedelic-medicine/2022-07-06T19:25:39.000Z https://psychedelicinvest.com/mindset-pharma-announces-closing-of-7-5-million-bought-deal-public-offering/2021-04-15T14:10:05.000Z https://psychedelicinvest.com/mydecine-announces-launch-of-cutting-edge-therapeutic-compound-screening/2021-04-14T14:47:59.000Z https://psychedelicinvest.com/novamind-increases-strategic-investment-in-bionomics/2021-04-13T15:30:38.000Z https://psychedelicinvest.com/mindcure-announces-partnership-with-speak-ai-to-enhance-istrym/2021-04-13T15:14:37.000Z https://psychedelicinvest.com/silo-wellness-expands-to-europe/2022-09-12T16:15:14.000Z https://psychedelicinvest.com/psybio-therapeutics-announces-application-to-list-on-otcqx/2021-04-12T14:56:24.000Z https://psychedelicinvest.com/visualizing-the-psychedelics-investment-ecosystem/2022-07-06T19:25:39.000Z https://psychedelicinvest.com/the-ultimate-guide-to-ketamine-for-investors/2021-04-09T21:08:51.000Z https://psychedelicinvest.com/new-wave-subsidiary-way-of-will-inc-confirms-plans-to-expand-brand-presence-on-walmart-com/2021-04-12T17:43:29.000Z https://psychedelicinvest.com/entheon-biomedical-corp-launches-psychedelics-genetic-test/2021-04-08T14:49:48.000Z https://psychedelicinvest.com/psychedelic-laws-in-washington-state/2021-04-06T19:52:02.000Z https://psychedelicinvest.com/better-plants-jusu-juice-now-available-at-whole-foods-in-canada/2021-04-06T13:35:10.000Z https://psychedelicinvest.com/mindmed-announces-the-publication-of-new-data-on-personalized-mdma-dosing/2022-07-06T19:25:40.000Z https://psychedelicinvest.com/mapping-psychedelic-ecosystem/2021-04-30T18:20:19.000Z https://psychedelicinvest.com/way-of-will-announces-plans-to-expand-brand-presence-on-amazon/2021-04-01T20:19:41.000Z https://psychedelicinvest.com/global-post-traumatic-stress-disorder-treatment-market-to-surpass-us-1380-0-million-by-2028-says-coherent-market-insights-cmi/2021-11-17T20:14:27.000Z https://psychedelicinvest.com/better-plant-expands-jusu-juice-home-delivery-to-vancouver-and-launches-new-online-ordering-platform/2021-04-01T14:27:21.000Z https://psychedelicinvest.com/mindcure-files-provisional-patent-application-for-istrym/2021-03-31T14:24:01.000Z https://psychedelicinvest.com/noetic-launches-venture-studio-to-build-psychedelic-biotechnology-companies/2021-03-30T22:10:40.000Z https://psychedelicinvest.com/mindmed-announces-2020-year-end-financial-results/2022-07-06T19:25:40.000Z https://psychedelicinvest.com/mindmed-announces-stanford-university-neuroscientist-as-chair-of-the-scientific-advisory-board/2022-07-06T19:25:40.000Z https://psychedelicinvest.com/new-wave-subsidiary-way-of-will-inc-announces-launch-of-functional-mushroom-capsules-and-functional-mushroom-powder-as-part-of-new-emerging-mushroom-collection/2021-03-29T14:43:44.000Z https://psychedelicinvest.com/psygen-industries-ltd-and-larose-ventures-ltd-announce-reverse-takeover/2021-03-25T16:08:57.000Z https://psychedelicinvest.com/pharmather-advancing-research-for-novel-microneedle-delivery-of-ketamine/2021-03-30T14:17:07.000Z https://psychedelicinvest.com/neonmind-ceo-provides-update/2021-03-30T14:17:34.000Z https://psychedelicinvest.com/psychedelic-laws-in-new-mexico/2021-03-23T15:58:10.000Z https://psychedelicinvest.com/compass-pathways-granted-two-us-patents/2021-03-23T15:28:57.000Z https://psychedelicinvest.com/mindmed-announces-inclusion-in-ftse-russell-indexes/2022-07-06T19:25:40.000Z https://psychedelicinvest.com/red-light-holland-closes-acquisition-of-sr-wholesale-becoming-a-leader-in-distribution-of-psychedelics/2021-03-19T15:15:42.000Z https://psychedelicinvest.com/tryp-therapeutics-announces-patent-filing-for-improved-administration-of-psychedelics/2021-03-18T14:41:43.000Z https://psychedelicinvest.com/world-leading-depression-researcher-dr-maurizio-fava-joins-pharmather-as-scientific-and-clinical-advisor/2021-03-30T14:18:10.000Z https://psychedelicinvest.com/red-light-holland-successfully-completes-sale-and-import-of-imicrodose-psychedelic-truffles-into-canada-under-a-health-canada-approved-psilocybin-import-permit/2021-03-30T14:18:31.000Z https://psychedelicinvest.com/numinus-wellness-inc-announces-30-million-bought-deal-public-offering/2021-03-15T14:47:57.000Z https://psychedelicinvest.com/family-of-bob-marley-and-silo-wellness-collaborate-to-debut-exclusive-worldwide-functional-psychedelic-mushroom-brand/2022-09-12T16:15:15.000Z https://psychedelicinvest.com/neonmind-engages-certara-to-advance-its-synthetic-psilocybin-drug-candidates-for-obesity/2021-03-30T14:18:51.000Z https://psychedelicinvest.com/demerx-receives-mhra-approval-for-dmx-1002-ibogaine-phase-1-2a-clinical-trial/2021-03-10T17:12:13.000Z https://psychedelicinvest.com/nova-mentis-upgrades-u-s-listing-to-the-otcqb-venture-market/2021-03-10T15:55:50.000Z https://psychedelicinvest.com/awakn-acquires-proprietary-next-generation-mdma-and-ketamine-data-from-prof-david-nutt/2022-07-06T19:20:50.000Z https://psychedelicinvest.com/better-plant-appoints-branding-expert-perry-chua-as-chief-creative-officer/2021-03-09T16:18:54.000Z https://psychedelicinvest.com/another-etf-to-invest-in-psychedelics/2021-04-30T18:29:12.000Z https://psychedelicinvest.com/mindmed-announces-c19-5-million-bought-deal-private-placement-offering/2022-07-06T19:25:41.000Z https://psychedelicinvest.com/silo-wellness-commences-trading-on-the-canadian-securities-exchange-under-ticker-symbol-silo/2022-09-12T16:15:15.000Z https://psychedelicinvest.com/psychedelic-laws-in-texas/2021-03-04T17:27:57.000Z https://psychedelicinvest.com/psyence-group-launches-its-functional-mushroom-brand-goodmind/2021-03-04T15:17:12.000Z https://psychedelicinvest.com/cybin-inc-announces-uplisting-to-otcqb-venture-market/2021-03-03T14:59:33.000Z https://psychedelicinvest.com/atai-life-sciences-157-million-series-d/2021-03-30T14:20:41.000Z https://psychedelicinvest.com/investing-in-psychedelic-medicine-and-sustainable-solutions-for-mental-health-and-well-being/2021-03-03T19:33:06.000Z https://psychedelicinvest.com/therapsil-launches-beta-version-of-health-canada-approved-psilocybin-therapy-training-program/2021-03-02T15:03:14.000Z https://psychedelicinvest.com/mindmed-closes-acquisition-of-healthmode-a-leading-machine-learning-digital-medicine-company/2022-07-06T19:25:41.000Z https://psychedelicinvest.com/psybio-therapeutics-corp-begins-trading-on-the-tsx-venture-exchange/2021-02-26T15:20:23.000Z https://psychedelicinvest.com/pharmadrug-files-for-fda-orphan-drug-designation-for-dmt-in-kidney-transplantation-and-expands-on-its-psychedelics-strategy/2021-02-25T15:18:55.000Z https://psychedelicinvest.com/neonmind-purchases-synthetic-psilocybin-from-psygen-labs-human-clinical-trial/2021-03-30T14:21:04.000Z https://psychedelicinvest.com/pharmather-announces-research-collaboration-with-terasaki-institute-for-novel-microneedle-delivery-of-psychedelic-pharmaceuticals/2021-03-30T14:21:24.000Z https://psychedelicinvest.com/awakn-chief-medical-officer-dr-ben-sessa-announces-results-of-the-worlds-first-mdma-in-alcohol-use-disorder-clinical-trial/2022-07-06T19:20:50.000Z https://psychedelicinvest.com/atai-life-sciences-partners-with-bionomics/2021-04-30T18:29:42.000Z https://psychedelicinvest.com/mindset-pharma-added-to-north-american-psychedelics-index/2021-02-19T15:35:25.000Z https://psychedelicinvest.com/revive-therapeutics-acquires-unique-psilocybin-assets/2021-02-18T15:29:58.000Z https://psychedelicinvest.com/psychedelic-laws-in-california/2021-02-17T17:29:09.000Z https://psychedelicinvest.com/mindmeds-lsd-neutralizer-study-begins/2022-07-06T19:25:41.000Z https://psychedelicinvest.com/mydecine-innovations-group-announces-closing-of-17250000-bought-deal-public-offering-including-full-exercise-of-the-over-allotment-option/2021-02-15T16:25:57.000Z https://psychedelicinvest.com/how-the-pandemic-has-highlighted-the-need-for-mental-health-alternatives/2021-02-12T18:54:28.000Z https://psychedelicinvest.com/pharmadrug-files-for-fda-orphan-drug-designation-for-dmt-in-stroke/2021-02-12T15:58:24.000Z https://psychedelicinvest.com/mindmed-signs-partnership-with-mindshift/2022-07-06T19:25:41.000Z https://psychedelicinvest.com/psychedelic-laws-in-oregon/2023-08-22T14:45:45.000Z https://psychedelicinvest.com/psychedelic-laws-in-colorado/2023-08-21T20:39:22.000Z https://psychedelicinvest.com/xphyto-adds-mescaline-production-to-psychedelic-medicine-programs/2021-02-10T16:55:03.000Z https://psychedelicinvest.com/dr-barker-pharmadrug/2021-02-12T19:19:39.000Z https://psychedelicinvest.com/what-oregons-measure-109-means-for-hopeful-entrepreneurs-and-investors/2021-04-30T18:57:35.000Z https://psychedelicinvest.com/tryp-therapeutics-plans-phase-2a-eating-disorder-clinical-trial-with-dr-jennifer-miller/2021-02-09T15:35:54.000Z https://psychedelicinvest.com/bright-minds-biosciences-announces-listing-on-canadian-stock-exchange/2021-02-08T15:20:46.000Z https://psychedelicinvest.com/mindset-files-multiple-final-patent-applications-on-its-novel-psilocybin-inspired-compounds/2021-02-05T14:35:20.000Z https://psychedelicinvest.com/dr-robin-carhart-harris-joins-osmind-as-a-scientific-advisor/2021-02-04T22:47:23.000Z https://psychedelicinvest.com/champignon-brands-new-rapid-mood-screener-rms-screens-for-manic-symptoms-and-bipolar-i-disorder-features-to-address-unmet-clinical-need/2022-07-06T19:27:19.000Z https://psychedelicinvest.com/mindmed-streamlines-leadership-with-further-emphasis-on-integrating-psychedelic-drug-development-with-digital-medicines-and-therapeutics/2022-07-06T19:25:42.000Z https://psychedelicinvest.com/pharmather-signs-exclusive-worldwide-license-agreement-for-patented-microneedle-delivery-technology-to-deliver-ketamine/2021-02-01T16:13:27.000Z https://psychedelicinvest.com/ehave-inc-utilizes-artificial-intelligence-and-machine-learning-for-big-data-management-in-mental-healthcare/2021-01-29T16:05:14.000Z https://psychedelicinvest.com/otc-markets-group-welcomes-field-trip-health-ltd-to-otcqx/2021-01-28T16:28:52.000Z https://psychedelicinvest.com/mydecine-innovations-group-files-application-to-list-to-the-nasdaq/2021-01-27T15:58:13.000Z https://psychedelicinvest.com/field-trip-health-ltd-announces-opening-of-field-trip-health-center-in-atlanta-ga-as-it-continues-expansion-in-the-us/2021-01-26T15:41:17.000Z https://psychedelicinvest.com/champignon-brands-canadian-rapid-treatment-center-of-excellence-opens-first-community-based-centre-in-ottawa-to-provide-ketamine-treatment-for-adults-with-depression/2022-07-06T19:27:19.000Z https://psychedelicinvest.com/pharmather-signs-license-agreement-for-patented-ketamine-treatment/2021-02-02T17:35:38.000Z https://psychedelicinvest.com/january-2021-update/2021-04-30T18:32:36.000Z https://psychedelicinvest.com/mydecine-innovations-group-included-in-first-ever-psychedelics-etf/2021-01-28T17:31:54.000Z https://psychedelicinvest.com/revive-therapeutics-announces-10-million-bought-deal-offering-of-units/2021-02-03T17:40:27.000Z https://psychedelicinvest.com/mindmed-announces-the-start-of-the-first-ever-clinical-trial-combining-mdma-and-lsd/2022-07-06T19:26:03.000Z https://psychedelicinvest.com/better-plant-affiliate-neonmind-lists-on-the-frankfurt-stock-exchange-fse-6uf/2021-01-28T17:32:57.000Z https://psychedelicinvest.com/cybin-announces-cdn20-million-bought-deal-offering/2021-02-03T16:58:38.000Z https://psychedelicinvest.com/journey-colab-sutton-king/2021-01-25T19:00:04.000Z https://psychedelicinvest.com/seelos-therapeutics-announces-dosing-of-the-first-patients-in-a-study-of-sls-002-intranasal-racemic-ketamine-for-acute-suicidal-ideation-and-behavior-in-patients-with-major-depressive-disorder/2021-02-04T16:29:10.000Z https://psychedelicinvest.com/mindmed-adds-chief-development-officer-with-fda-phase-2-psilocybin-clinical-trial-experience/2022-07-06T19:26:03.000Z https://psychedelicinvest.com/novamind-expands-psychedelic-medicine-access-in-utah/2021-01-28T17:34:50.000Z https://psychedelicinvest.com/pharmather-approved-to-trade-on-the-otcqb-venture-market/2021-02-02T17:37:06.000Z https://psychedelicinvest.com/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/2022-07-06T19:26:03.000Z https://psychedelicinvest.com/cybin-partners-with-kernel-to-leverage-its-breakthrough-neuroimaging-technology-for-psychedelic-therapeutics/2021-02-03T16:58:43.000Z https://psychedelicinvest.com/fluence-training-the-next-generation-of-psychedelic-treatment-professionals/2021-01-28T17:35:55.000Z https://psychedelicinvest.com/compass-pathways-establishes-centre-of-excellence-with-sheppard-pratt-to-accelerate-research-and-improve-patient-experience-in-mental-health-care/2021-01-28T17:36:05.000Z https://psychedelicinvest.com/mindmed-closes-upsized-financing-of-cad-92-1m-usd-72-7m-to-meet-high-investor-demand/2022-07-06T19:26:04.000Z https://psychedelicinvest.com/mind-cure-announces-build-out-of-digital-therapeutics-istrym-a-technology-platform-for-mental-wellness-optimization-psychedelic-research/2021-01-28T17:36:23.000Z https://psychedelicinvest.com/novamind-goes-public/2021-03-02T21:34:08.000Z https://psychedelicinvest.com/neonmind-commences-trading-under-cse-ticker-symbol-neon/2021-01-05T15:06:16.000Z https://psychedelicinvest.com/psychedelic-stock-index-december-performance/2022-07-06T19:27:19.000Z https://psychedelicinvest.com/ehave-inc-files-to-list-on-the-canadian-stock-exchange-and-applies-to-upgrade-to-otcqb-exchange/2021-02-04T22:33:49.000Z https://psychedelicinvest.com/leiio-wellness/2021-04-30T19:08:53.000Z https://psychedelicinvest.com/pharmather-announces-application-for-otcqb-listing/2021-02-02T17:36:27.000Z https://psychedelicinvest.com/better-plants-subsidiary-neonmind-to-complete-fully-subscribed-ipo-and-commence-trading-on-monday-january-4-2021-under-the-symbol-neon/2021-02-03T23:50:45.000Z https://psychedelicinvest.com/mindset-further-expands-portfolio-of-psychedelic-drug-candidates-with-third-u-s-provisional-patent-application-50-total-new-psychedelic-patent-pending-compounds-synthesized/2021-02-04T22:36:16.000Z https://psychedelicinvest.com/red-light-holland-announces-exercise-of-warrants-for-gross-proceeds-of-over-5-million/2021-02-03T17:44:09.000Z https://psychedelicinvest.com/caamtech-utilizing-the-entourage-effect-to-transform-psychedelic-medicine/2021-02-03T17:04:38.000Z https://psychedelicinvest.com/mindset-pharma-to-commence-trading-on-the-cse-on-december-23-2020-under-the-symbol-mset/2021-02-04T22:36:16.000Z https://psychedelicinvest.com/magicmed-industries-announces-the-establishment-of-psilocybin-derivatives-portfolio-and-launch-of-candidate-selection-program/2020-12-22T14:45:23.000Z https://psychedelicinvest.com/betterlife-closes-acquisition-of-second-generation-psychedelic-assets-of-transcend-biodynamics-llc/2021-02-04T21:29:15.000Z https://psychedelicinvest.com/revive-therapeutics-announces-loi-to-acquire-pharmathers-psilocybin-program/2021-02-03T17:42:17.000Z https://psychedelicinvest.com/back-of-the-yard-algae-sciences-toward-the-first-vertically-integrated-psychedelic-producer/2021-01-28T17:40:09.000Z https://psychedelicinvest.com/tryp-therapeutics-goes-public-heres-everything-you-need-to-know/2021-04-30T18:30:55.000Z https://psychedelicinvest.com/magicmed-industries-announces-closing-of-upsized-and-oversubscribed-8-1-million-private-placement-of-units-led-by-gravitas-securities-due-to-significant-investor-demand/2020-12-18T15:02:05.000Z https://psychedelicinvest.com/a-new-fund-dedicated-to-psychedelic-investments-has-launched-in-the-uk/2021-04-30T18:31:04.000Z https://psychedelicinvest.com/tryp-therapeutics-completes-initial-public-offering/2021-02-03T17:04:00.000Z https://psychedelicinvest.com/numinus-completes-first-extraction-of-its-psilocybe-mushrooms/2020-12-17T15:35:31.000Z https://psychedelicinvest.com/atai-life-sciences-appoints-new-cfo-and-cmo-in-preparation-for-ipo/2021-04-30T18:31:13.000Z https://psychedelicinvest.com/ehave-inc-announces-ketadash-for-ketamine-home-delivery-and-purchase-of-curedash-assets/2021-02-04T16:17:45.000Z https://psychedelicinvest.com/florida-psychedelic-laws/2021-02-04T19:17:12.000Z https://psychedelicinvest.com/pharmather-files-u-s-patent-for-novel-combinations-of-psilocybin-and-fda-approved-drugs-to-treat-neurological-disorders/2021-02-02T17:36:33.000Z https://psychedelicinvest.com/christian-angermayer-this-will-be-the-best-performing-asset-class-over-the-next-20-years/2022-12-09T20:50:25.000Z https://psychedelicinvest.com/seelos-therapeutics-raises-10-million-in-private-placement-of-senior-secured-convertible-note/2021-02-04T16:29:16.000Z https://psychedelicinvest.com/mindmed-closes-upsized-financing-of-cad-34-5m-gross-proceeds-raised-since-company-founding-now-total-cad-121-4m-usd-94-8m/2022-07-06T19:26:04.000Z https://psychedelicinvest.com/greenway-dna-interview/2021-01-28T17:40:54.000Z https://psychedelicinvest.com/better-plant-subsidiary-neonmind-announces-filing-of-final-prospectus-in-connection-with-an-initial-public-offering/2021-02-03T23:50:39.000Z https://psychedelicinvest.com/tryp-therapeutics-files-final-prospectus-and-announces-initial-public-offering/2021-02-03T17:04:00.000Z https://psychedelicinvest.com/red-light-holland-announces-intention-to-acquire-controlling-interest-in-psychedelic-insights-providing-psychological-guidance-of-psychedelic-experiences-with-truffles-in-the-netherlands/2021-02-03T17:44:14.000Z https://psychedelicinvest.com/entheon-biomedical-announces-dmt-drug-supply-agreement-with-psygen-labs-inc-completion-of-initial-dmt-research-drug-batch/2021-02-03T23:32:08.000Z https://psychedelicinvest.com/17-canadian-healthcare-professionals-approved-to-use-psilocybin-for-professional-training-therapsil/2021-02-04T19:20:10.000Z https://psychedelicinvest.com/champignon-brands-appoints-christopher-hobbs-as-interim-chief-financial-officer/2022-07-06T19:27:20.000Z https://psychedelicinvest.com/mindmed-files-final-prospectus-in-connection-with-bought-deal-equity-financing-2/2022-07-06T19:26:05.000Z https://psychedelicinvest.com/mydecine-innovations-group-to-make-first-commercial-export-of-legal-psilocybin-mushrooms/2021-02-03T23:29:58.000Z https://psychedelicinvest.com/cybin-signs-definitive-agreement-to-acquire-adelia-therapeutics-as-part-of-its-commitment-to-strategic-growth/2021-02-03T16:58:53.000Z https://psychedelicinvest.com/unilock-to-acquire-small-pharma-as-qt/2020-12-10T17:37:08.000Z https://psychedelicinvest.com/psybio-therapeutics-and-leo-acquisitions-announce-closing-of-cad14-5-million-oversubscribed-private-placement/2020-12-04T20:18:43.000Z https://psychedelicinvest.com/field-trip-health-ltd-provides-operational-and-investor-update-announces-expanded-hours-at-its-field-trip-health-center-in-toronto-plus-rollout-of-portal-field-trips-proprietary-digital-me/2021-02-02T18:58:02.000Z https://psychedelicinvest.com/bo-tandrup-lophora-a-new-version-of-psilocybin/2021-01-28T17:41:36.000Z https://psychedelicinvest.com/entheon-biomedical-announces-corporate-update-including-investment-in-wonder-scientific/2021-02-03T23:32:12.000Z https://psychedelicinvest.com/epidemiologist-dr-joel-moody-joins-revive-therapeutics-as-medical-and-clinical-advisor/2021-02-03T17:40:34.000Z https://psychedelicinvest.com/caamtech-collaborates-with-the-leibniz-institute-for-natural-product-research-to-investigate-psychedelic-mushrooms/2020-12-03T15:03:23.000Z https://psychedelicinvest.com/numinus-and-maps-public-benefit-corporation-announce-collaboration-agreement-to-seek-approval-of-mdma-assisted-psychotherapy-for-ptsd-single-arm-open-label-trial/2020-12-02T15:55:10.000Z https://psychedelicinvest.com/heres-where-field-trip-health-is-opening-locations-next/2021-04-30T18:31:49.000Z https://psychedelicinvest.com/field-trip-health-ltd-reports-second-fiscal-quarter-2021-financial-results-announces-two-new-field-trip-health-center-locations/2021-02-02T18:58:08.000Z https://psychedelicinvest.com/new-wave-enters-into-partnership-with-the-university-of-west-indies-mona-jamaica-for-medicinal-drug-discovery/2020-11-30T15:13:48.000Z https://psychedelicinvest.com/david-nikzad-psilly/2021-01-28T17:42:49.000Z https://psychedelicinvest.com/entheon-biomedical-to-begin-trading-on-the-frankfurt-exchange/2021-02-03T23:32:17.000Z https://psychedelicinvest.com/champignon-brands-updates-investors-on-changes-at-the-top/2022-07-06T19:27:20.000Z https://psychedelicinvest.com/mindmed-to-launch-albert-a-digital-medicine-division-for-psychedelic-medicines/2022-07-06T19:26:05.000Z https://psychedelicinvest.com/atai-life-sciences-announces-closing-of-125-million-series-c-financing-round/2021-02-04T21:20:03.000Z https://psychedelicinvest.com/pharmadrug-positions-for-eurozone-psychedelic-distribution-as-germany-begins-psilocybin-depression-study/2021-02-04T16:33:09.000Z https://psychedelicinvest.com/red-light-holland-and-halo-labs-announce-intention-to-enter-oregon-medicinal-psilocybin-market/2020-11-25T16:00:11.000Z https://psychedelicinvest.com/field-trip-health-ltd-and-whoop-announce-partnership-to-measure-effect-of-psychedelic-therapies-on-physiology-and-mental-health/2021-02-02T18:58:14.000Z https://psychedelicinvest.com/rritual-president-dr-mike-hart/2021-01-28T17:42:45.000Z https://psychedelicinvest.com/neonmind-commences-preclinical-trial-to-examine-psilocybin-for-weight-loss-better-plant-sciences/2021-02-03T23:50:31.000Z https://psychedelicinvest.com/revive-therapeutics-announces-research-collaboration-with-pharmather-for-development-of-psilocybin-in-cancer-and-discovery-of-novel-uses-of-psychedelics/2021-02-03T17:40:39.000Z https://psychedelicinvest.com/field-trip-health-ltd-announces-expansion-to-the-netherlands-and-launch-of-proprietary-truffle-program/2021-02-02T18:58:20.000Z https://psychedelicinvest.com/navy-seal-foundation-contributes-50000-to-support-major-ptsd-study/2020-11-16T19:00:31.000Z https://psychedelicinvest.com/mindmed-receives-approval-of-protocol-design-to-evaluate-microdoses-of-lsd-for-adult-adhd-in-phase-2a-clinical-trial-from-swiss-and-dutch-health-authorities/2022-07-06T19:26:05.000Z https://psychedelicinvest.com/five-psychedelic-law-firms-you-should-have-on-your-radar/2021-04-30T18:31:54.000Z https://psychedelicinvest.com/entheon-biomedical-corp-commences-trading-on-the-canadian-securities-exchange/2021-02-03T23:32:03.000Z https://psychedelicinvest.com/lucid-news/2021-01-28T17:44:39.000Z https://psychedelicinvest.com/compass-pathways-plc-announces-financial-results-for-third-quarter-2020/2020-11-12T15:57:14.000Z https://psychedelicinvest.com/neonmind-obtains-health-canada-approval-to-advance-psilocybin-research-better-plant-sciences/2021-02-03T23:51:24.000Z https://psychedelicinvest.com/european-synthetic-biology-company-octarine-raises-1-8m-usd-in-funding-and-enters-pre-clinical-studies-with-novel-improved-cannabinoid-and-psychedelic-derivatives/2021-02-04T19:37:53.000Z https://psychedelicinvest.com/revive-therapeutics-provides-update-on-oral-thin-film-product-with-psilocybin/2021-02-03T17:40:43.000Z https://psychedelicinvest.com/red-light-holland-to-acquire-wholesale-distribution-company-in-the-netherlands-providing-access-to-over-1000-retail-outlets-in-multiple-eu-countries/2021-02-03T17:44:18.000Z https://psychedelicinvest.com/cybin-goes-public-on-neo-exchange/2021-02-03T17:00:17.000Z https://psychedelicinvest.com/mind-cure-announces-hiring-of-award-winning-experimental-scientist-dr-ryan-hartwell-as-chief-science-officer/2020-11-10T15:07:28.000Z https://psychedelicinvest.com/10-psychedelic-companies-investors-should-have-on-their-radar/2022-07-06T19:27:20.000Z https://psychedelicinvest.com/compass-pathways-joins-the-psychiatry-consortium/2020-11-09T15:16:15.000Z https://psychedelicinvest.com/havn-life-sciences-supplying-the-compounds-to-support-the-future-of-psychedelic-medicine/2021-01-28T17:44:36.000Z https://psychedelicinvest.com/field-trip-health-to-expand-to-psilocybin-treatment-in-the-us/2021-04-30T18:32:05.000Z https://psychedelicinvest.com/mydecine-innovations-group-retains-kcsa-strategic-communications/2020-11-06T14:55:05.000Z https://psychedelicinvest.com/cybin-completes-reverse-take-over-transaction/2021-02-03T17:01:55.000Z https://psychedelicinvest.com/what-decriminalization-in-oregon-and-dc-means-for-psychedelic-investors/2021-01-28T17:44:27.000Z https://psychedelicinvest.com/nova-mentis-life-science-acquisition-target-pilz-bioscience-corp-signs-psilocybin-manufacturing-agreement/2020-11-05T14:47:33.000Z https://psychedelicinvest.com/mapping-psilocybin-reform/2021-10-08T22:22:47.000Z https://psychedelicinvest.com/oregon-becomes-the-first-state-to-legalize-psilocybin-for-therapy/2020-11-04T18:39:51.000Z https://psychedelicinvest.com/mindmed-raises-28-million/2022-07-06T19:26:06.000Z https://psychedelicinvest.com/mindmed-announces-the-completion-of-phase-1-study-measuring-dosing-effects-of-lsd/2022-07-06T19:26:06.000Z https://psychedelicinvest.com/atai-life-sciences-valuation/2021-06-11T21:16:17.000Z https://psychedelicinvest.com/mindmed-closes-upsized-financing-of-cad-28-75m-with-strong-institutional-demand-for-psychedelic-medicines/2022-07-06T19:26:06.000Z https://psychedelicinvest.com/better-plant-receives-health-canada-approval-for-plant-based-antiseptic-skin-ointment/2021-02-03T23:51:29.000Z https://psychedelicinvest.com/atai-life-sciences-has-massively-oversubscribed-series-c/2021-02-12T16:55:54.000Z https://psychedelicinvest.com/mindmed-files-final-prospectus-in-connection-with-bought-deal-equity-financing/2022-07-06T19:26:06.000Z https://psychedelicinvest.com/osmind-lucia-huang-jimmy-qian/2021-01-28T18:11:44.000Z https://psychedelicinvest.com/atai-life-sciences-announces-neuronasal-completes-pilot-study-receives-ind-clearance/2021-02-04T21:20:03.000Z https://psychedelicinvest.com/field-trip-health-ltd-continues-expansion-with-psychedelic-enhanced-therapy-center-in-chicago/2021-02-02T18:58:26.000Z https://psychedelicinvest.com/kevin-oleary-psychedelics-are-my-highest-return-this-year/2022-07-06T19:26:07.000Z https://psychedelicinvest.com/mr-psychedelic-law/2021-01-28T18:11:49.000Z https://psychedelicinvest.com/numinus-first-canadian-public-company-to-complete-legal-harvest-of-psilocybe-mushrooms/2020-10-22T13:43:05.000Z https://psychedelicinvest.com/pharmather-files-for-fda-orphan-drug-designation-for-ketamine-in-parkinsons-disease/2021-02-02T17:36:37.000Z https://psychedelicinvest.com/mindmed-ceo-jr-rahn-pledges-stock-for-loan-not-sale/2022-07-06T19:26:07.000Z https://psychedelicinvest.com/psychedelic-stock-index-update-october/2022-09-12T16:19:48.000Z https://psychedelicinvest.com/vc-mindset/2021-04-30T19:00:25.000Z https://psychedelicinvest.com/revive-therapeutics-signs-supply-agreement-with-havn-life-sciences-for-psychedelic-compounds/2021-02-04T19:44:43.000Z https://psychedelicinvest.com/cybin-and-clarmin-announce-closing-of-cdn45-million-oversubscribed-private-placement/2021-02-03T17:01:59.000Z https://psychedelicinvest.com/mindmed-files-preliminary-prospectus-in-connection-with-bought-deal-equity-financing/2022-07-06T19:26:07.000Z https://psychedelicinvest.com/universal-ibogaine-retains-westmount-park-investments-for-corporate-financial-advisory-services/2022-09-12T16:26:21.000Z https://psychedelicinvest.com/mind-cure-announces-geoff-belair-as-chief-technology-officer/2020-10-15T19:40:24.000Z https://psychedelicinvest.com/pharmather-announces-exclusive-license-agreement-with-the-university-of-arizona-for-the-commercialization-of-ketamine-in-the-treatment-of-parkinsons-disease/2021-02-02T17:36:22.000Z https://psychedelicinvest.com/silo-pharma-inc-silo-announces-successful-uplisting-to-the-otcqb-venture-market/2022-09-12T16:18:47.000Z https://psychedelicinvest.com/study-mdma-assisted-psychotherapy-will-be-more-cost-effective-than-other-treatments-for-ptsd/2020-10-16T17:20:08.000Z https://psychedelicinvest.com/psilera-bioscience-developing-the-next-generation-of-safer-targeted-psychedelic-therapies/2021-01-28T18:11:51.000Z https://psychedelicinvest.com/osmind-raises-2m-seed-round-to-revolutionize-mental-health/2020-10-14T14:25:58.000Z https://psychedelicinvest.com/better-plant-sciences-completes-acquisition-of-jusu/2021-02-03T23:51:35.000Z https://psychedelicinvest.com/new-wave-to-provide-sponsorship-for-the-documentary-the-world-on-drugs/2020-10-13T13:46:28.000Z https://psychedelicinvest.com/nova-mentis-life-science-signs-agreement-to-acquire-100-of-psychedelic-focused-autism-research-company-pilz-bioscience-corp/2020-10-12T14:08:13.000Z https://psychedelicinvest.com/new-mindmed-warrants-strikes-buying-opportunity/2022-07-06T19:26:07.000Z https://psychedelicinvest.com/mindmed-announces-25-million-bought-deal-public-offering/2022-07-06T19:26:07.000Z https://psychedelicinvest.com/cb-therapeutics-sher-butt/2021-01-28T18:11:54.000Z https://psychedelicinvest.com/minerco-searches-for-domestic-home-in-ann-arbor-michigan/2020-10-08T15:34:31.000Z https://psychedelicinvest.com/field-trip-adds-acclaimed-physician-dr-andrew-weil-to-medical-advisory-board/2021-02-02T18:58:30.000Z https://psychedelicinvest.com/mydecine-innovations-group-announces-filing-of-provisional-patent-for-the-treatment-of-ptsd-with-psilocybin/2020-10-07T14:43:38.000Z https://psychedelicinvest.com/mindmed-share-price-nears-all-time-high/2022-07-06T19:26:08.000Z https://psychedelicinvest.com/field-trip-health-roadmap/2021-04-30T18:33:03.000Z https://psychedelicinvest.com/red-light-holland-reaches-a-distribution-arrangement-for-imicrodose-packs-with-three-3-house-of-smart-locations/2021-02-03T17:44:27.000Z https://psychedelicinvest.com/field-trip-health-commence-trading-cse-ticker-symbol-ftrp/2021-02-02T18:58:36.000Z https://psychedelicinvest.com/mindmed-partners-with-nyu-langone-medical-center-to-launch-groundbreaking-training-program-for-psychedelic-therapies-and-medicines/2022-07-06T19:26:16.000Z https://psychedelicinvest.com/dr-roger-mcintyre-elected-board-chair-of-champignon-brands-inc/2022-07-06T19:27:21.000Z https://psychedelicinvest.com/imicrodose-packs-smartshop-oss/2021-02-03T17:44:22.000Z https://psychedelicinvest.com/compass-pathways-ipo-proves-psychedelic-medicine-investment-thesis/2020-10-02T14:06:39.000Z https://psychedelicinvest.com/speak-ai-tyler-bryden/2021-01-28T18:11:56.000Z https://psychedelicinvest.com/mydecine-innovations-group-announces-the-official-mindleap-health-mobile-app/2020-10-01T14:18:13.000Z https://psychedelicinvest.com/nutritional-highs-psychedelic-sciences-prepares-for-clinical-trials-with-rangsit-university/2020-09-30T15:57:56.000Z https://psychedelicinvest.com/lsu-health-foundation-new-orleans-and-foundation-board-of-directors-announce-strategic-investment-to-support-prevention-and-treatment-of-inflammatory-eye-disease/2021-02-04T20:12:33.000Z https://psychedelicinvest.com/field-trip-psychedelics-inc-announces-successful-glp-synthesis-results/2021-02-04T22:35:23.000Z https://psychedelicinvest.com/better-plant-sciences-subsidiary-neonmind-signs-psilocybin-supply-agreement/2021-02-03T23:51:40.000Z https://psychedelicinvest.com/red-light-holland-reaches-distribution-agreement-for-imicrodose-packs/2021-02-03T17:44:33.000Z https://psychedelicinvest.com/psychedelic-medicine-faces-its-next-challenge/2021-02-12T16:57:58.000Z https://psychedelicinvest.com/mindmed-and-liechti-lab-announce-rd-collaboration-on-psilocybin/2022-07-06T19:26:16.000Z https://psychedelicinvest.com/havn-life-sciences-submits-range-of-natural-health-products-to-health-canada/2021-02-03T23:36:04.000Z https://psychedelicinvest.com/compass-pathways-announces-closing-of-initial-public-offering-of-american-depositary-shares/2020-09-23T13:42:40.000Z https://psychedelicinvest.com/ehave-inc-launches-premier-psychedelic-retreat-centers-partnership/2021-02-04T16:17:49.000Z https://psychedelicinvest.com/mindmed-submits-application-for-nasdaq-up-listing-appoints-canaccord-genuity-as-financial-advisor/2022-07-06T19:26:16.000Z https://psychedelicinvest.com/mind-cure-announces-commencement-of-trading-on-the-cse/2020-09-21T16:12:27.000Z https://psychedelicinvest.com/compass-pathways-ipo-begins-trading/2021-04-30T18:33:16.000Z https://psychedelicinvest.com/compass-pathways-trading-begins/2020-09-18T15:09:12.000Z https://psychedelicinvest.com/mind-cure-announces-closing-of-oversubscribed-upsized-initial-public-offering/2020-09-21T15:40:18.000Z https://psychedelicinvest.com/field-trip-health-interview/2021-01-28T18:12:02.000Z https://psychedelicinvest.com/psychedelic-medicine-association-announced-globally/2020-09-17T15:59:12.000Z https://psychedelicinvest.com/red-light-holland-announces-imicrodose-launch-party-on-september-25th-2020-and-engages-leading-european-experiential-creative-agency-to-host-the-premiere-event-in-amsterdam/2021-02-03T17:44:37.000Z https://psychedelicinvest.com/jaguar-health-establishes-world-class-scientific-strategy-team-to-support-newly-launched-mental-health-entheogen-therapeutics-initiative/2020-09-16T22:53:36.000Z https://psychedelicinvest.com/champignon-provides-update-on-disclosure-review/2022-07-06T19:27:21.000Z https://psychedelicinvest.com/mydecine-innovations-group-shareholder-value/2020-09-15T15:38:06.000Z https://psychedelicinvest.com/mindset-pharma-inc-and-north-sur-complete-combination/2021-02-04T22:36:16.000Z https://psychedelicinvest.com/seelos-announces-issuance-of-a-new-patent-and-an-additional-notice-of-allowance-in-japan-for-intranasal-racemic-ketamine-sls-002/2021-02-04T16:29:04.000Z https://psychedelicinvest.com/compass-pathways-ipo/2021-02-12T16:59:12.000Z https://psychedelicinvest.com/havn-life-sciences-granted-section-56-exemption-to-begin-scientific-work-with-psilocybin/2021-02-03T23:36:09.000Z https://psychedelicinvest.com/behold-retreats-jonathan-de-potter/2021-01-28T18:12:13.000Z https://psychedelicinvest.com/better-plant-sciences-ready-for-sales-of-its-fda-listed-gel-based-hand-sanitizer/2021-02-03T23:51:44.000Z https://psychedelicinvest.com/ehave-announces-plans-to-enter-the-30-billion-patient-medical-records-industry/2021-02-04T16:17:54.000Z https://psychedelicinvest.com/psychedelics-company-havn-life-announces-public-trading-on-the-cse/2021-02-03T23:36:13.000Z https://psychedelicinvest.com/thoughtful-brands-q2-2020/2021-02-04T17:50:45.000Z https://psychedelicinvest.com/mydecine-innovations-group-completes-acquisition-of-neuropharm-inc/2020-09-07T14:00:18.000Z https://psychedelicinvest.com/ehave-signs-licensing-agreement-to-enhance-its-telemedicine-platform/2021-02-04T16:17:58.000Z https://psychedelicinvest.com/havn-life-sciences-announced-filing-of-final-prospectus/2021-02-03T23:40:50.000Z https://psychedelicinvest.com/better-plant-sciences-announces-otc-ticker-symbol-change-to-veggf/2021-02-03T23:51:50.000Z https://psychedelicinvest.com/numinus-announces-filing-of-final-short-form-prospectus-for-offering/2020-09-03T14:01:08.000Z https://psychedelicinvest.com/beckley-foundation-launches-study-microdosing-pain-management/2021-04-30T18:33:39.000Z https://psychedelicinvest.com/opportune-therapeutics-will-krawszik/2021-01-28T18:12:15.000Z https://psychedelicinvest.com/magicmed-industries-closes-oversubscribed-private-placement-for-1642880/2020-09-02T14:55:50.000Z https://psychedelicinvest.com/revive-therapeutics-enters-into-clinical-agreement-to-evaluate-psilocybin-for-methamphetamine-use/2021-02-03T17:40:49.000Z https://psychedelicinvest.com/better-plant-sciences-adds-ecommerce-sales-of-200-plant-based-products/2021-02-03T23:52:26.000Z https://psychedelicinvest.com/mindset-pharma-announces-promising-test-results-of-psilocybin-inspired-compounds/2021-02-04T22:36:06.000Z https://psychedelicinvest.com/champignon-to-begin-offering-esketamine-treatment/2022-07-06T19:27:21.000Z https://psychedelicinvest.com/new-wave-holdings-announces-definitive-agreement-to-acquire-additional-shares-in-anahit-therapeutics/2020-08-28T14:46:40.000Z https://psychedelicinvest.com/novamind-new-cmo/2021-02-04T22:39:02.000Z https://psychedelicinvest.com/better-plant-sciences-announces-website-launch-and-plan-to-grow-direct-sales/2021-02-03T23:52:32.000Z https://psychedelicinvest.com/revive-therapeutics-announces-irb-approval-bucillamine/2021-02-03T17:40:56.000Z https://psychedelicinvest.com/mydecine-innovations-group-announces-extended-lock-up-arrangement/2020-08-26T14:08:57.000Z https://psychedelicinvest.com/psyc-continuing-its-path-of-becoming-content-leader-in-the-psychedelic-space-through-key-interviews/2021-02-04T16:19:08.000Z https://psychedelicinvest.com/two-psychedelic-companies-present-at-y-combinator-demo-day-2020/2021-04-30T18:33:47.000Z https://psychedelicinvest.com/mindmed-announces-first-ever-clinical-trial-combining-mdma-and-lsd/2022-07-06T19:26:17.000Z https://psychedelicinvest.com/ehave-dashboard-accelerating/2021-02-04T16:18:02.000Z https://psychedelicinvest.com/field-trip-psychedelics-inc-announces-closing-of-11-0-million-financing/2021-02-04T22:35:23.000Z https://psychedelicinvest.com/atai-and-intelgenx-enter-into-agreement-to-develop-pharmaceutical-psychedelic-medicines/2021-02-04T21:20:03.000Z https://psychedelicinvest.com/capstone-campaign-maps-tim-ferris/2020-08-21T11:56:05.000Z https://psychedelicinvest.com/mimosa-psychedelics-jim-keim/2021-01-28T18:12:16.000Z https://psychedelicinvest.com/neonmind-ready-to-launch-four-mushroom-coffee-blends-better-plant-sciences/2021-02-03T23:52:35.000Z https://psychedelicinvest.com/psyc-establishes-new-partnership-with-industry-leader-microdose-psychedelic-insights/2021-02-04T16:19:13.000Z https://psychedelicinvest.com/better-plant-sciences-jusu-bar/2021-02-03T23:52:40.000Z https://psychedelicinvest.com/mydecine-innovations-group-exercises-ability-to-legally-produce-and-sell-psilocybin/2020-08-18T13:43:22.000Z https://psychedelicinvest.com/yield-growth-corp-urban-juve-amazon/2020-08-18T03:24:33.000Z https://psychedelicinvest.com/nutritional-high-completes-acquisition-of-psychedelic-science-corp/2020-09-03T00:04:27.000Z https://psychedelicinvest.com/bright-minds-ian-mcdonald/2021-01-28T18:12:18.000Z https://psychedelicinvest.com/mind-medicine-expanding-into-europe-adds-dr-wernli-as-president/2022-07-06T19:26:17.000Z https://psychedelicinvest.com/mydecine-innovations-announced-neuropharm-was-recently-covered-in-forbes/2020-08-13T14:09:39.000Z https://psychedelicinvest.com/yield-growth-corp-name-change/2021-02-03T23:53:06.000Z https://psychedelicinvest.com/ghp-noetic-announces-ipo-completion/2021-02-04T20:25:45.000Z https://psychedelicinvest.com/mydecine-innovations-group-gives-corporate-update-august-2020/2020-08-12T15:13:14.000Z https://psychedelicinvest.com/psilera-bioscience-tampa-bay-technology-incubator/2020-08-11T18:40:22.000Z https://psychedelicinvest.com/revive-therapeutics-announce-first-film-strip-psilocybin-prototype/2021-02-03T17:41:01.000Z https://psychedelicinvest.com/cybin-corp-applauds-therapsil-for-psilocybin-therapy-use-in-palliative-care/2021-02-03T17:01:51.000Z https://psychedelicinvest.com/neonmind-submits-application-to-health-canada-for-controlled-substances-exemption/2020-08-10T14:40:52.000Z https://psychedelicinvest.com/top-shroom-stocks-sectors/2022-07-06T19:27:21.000Z https://psychedelicinvest.com/mindmed-adds-dr-peter-gasser-to-lsd-experiential-therapy-program/2022-07-06T19:26:17.000Z https://psychedelicinvest.com/watch-60-minutes-report-on-psilocybin-therapy/2021-04-30T18:33:59.000Z https://psychedelicinvest.com/nutritional-high-announces-update-on-acquisition-for-psychedelic-sciences-corp/2020-08-05T15:18:53.000Z https://psychedelicinvest.com/red-light-holland-commences-magic-truffles-growth-operation-in-the-netherlands-months-ahead-of-schedule/2021-02-03T17:44:41.000Z https://psychedelicinvest.com/mindleap-health-expands-its-digital-mental-health-programs/2020-08-04T14:26:58.000Z https://psychedelicinvest.com/usona-institute/2021-02-04T20:38:15.000Z https://psychedelicinvest.com/how-to-buy-stocks-on-the-neo-stock-exchange/2020-10-13T22:03:43.000Z https://psychedelicinvest.com/revive-therapeutics-gets-fda-approval-for-bucillamine-covid-trial/2021-02-03T17:40:22.000Z https://psychedelicinvest.com/novamind-closes-the-acquisition-of-cedar-psychiatry/2021-02-04T22:39:03.000Z https://psychedelicinvest.com/numinus-wellness-partners-with-together-we-can-addiction-recovery/2020-07-30T13:16:47.000Z https://psychedelicinvest.com/cybin-corp-to-deliver-psychedelic-medicines-targeting-conditions-failed-by-big-pharma/2021-11-17T20:09:02.000Z https://psychedelicinvest.com/numinus-wellness-issues-units-for-compassionate-access/2020-07-30T13:14:02.000Z https://psychedelicinvest.com/mind-medicine-phase-1-opioid-addiction-study-results/2022-07-06T19:26:18.000Z https://psychedelicinvest.com/mindset-pharma-provisional-process-synthesize-psilocybin/2021-02-04T22:36:06.000Z https://psychedelicinvest.com/empower-clinics-2019-fiscal-reports/2021-02-04T18:02:40.000Z https://psychedelicinvest.com/mota-ventures-corp-joint-venture-franchise-cannabis-corp/2021-02-04T20:49:17.000Z https://psychedelicinvest.com/atai-launches-viridia-life-sciences/2021-02-04T21:20:03.000Z https://psychedelicinvest.com/lundquist-institute-anonymous-donation/2021-02-04T20:52:08.000Z https://psychedelicinvest.com/mydecine-mindleap-brightmind/2020-08-04T20:15:32.000Z https://psychedelicinvest.com/cybin-announces-board-of-directors/2021-02-03T17:01:44.000Z https://psychedelicinvest.com/what-is-psilocybin-companies-how-to-invest/2022-07-06T19:27:22.000Z https://psychedelicinvest.com/awakn-life-sciences-partners-with-drug-science-in-the-uk/2022-07-06T19:20:51.000Z https://psychedelicinvest.com/wuhan-general-group-signs-moa-for-the-acquisition-of-tsime-pharmaceuticals-pty-limited/2021-02-04T17:53:54.000Z https://psychedelicinvest.com/psychedelic-investors-war-on-drugs/2021-02-12T17:01:59.000Z https://psychedelicinvest.com/psychedelic-invest-releases-free-investor-guidebook/2021-02-04T20:55:05.000Z https://psychedelicinvest.com/psychedelics-vancouver/2021-02-04T21:10:46.000Z https://psychedelicinvest.com/german-cannabis-distributor-signs-loi-to-acquire-dutch-psychedelic-company/2020-05-21T12:13:39.000Z https://psychedelicinvest.com/psychedelic-company-numinus-to-go-public/2020-05-18T16:19:04.000Z https://psychedelicinvest.com/canadian-cannabis-company-set-to-acquire-german-psychedelic-facility/2020-05-15T15:46:02.000Z https://psychedelicinvest.com/this-danish-psychedelic-company-turns-yeast-into-psilocybin/2020-05-14T13:20:48.000Z https://psychedelicinvest.com/the-future-of-treating-mental-health-with-psychedelics/2020-04-17T23:43:11.000Z https://psychedelicinvest.com/former-red-bull-exec-joins-psychedelic-company/2020-04-17T09:34:05.000Z https://psychedelicinvest.com/mindmed-gets-upgraded-trading-status/2020-04-17T09:15:44.000Z https://psychedelicinvest.com/patent-filed-on-psilly-a-unique-psilocybin-blend/2021-04-30T18:34:19.000Z https://psychedelicinvest.com/origins-of-the-1960s-psychedelic-designs/2020-04-13T15:55:37.000Z https://psychedelicinvest.com/the-arrival-of-virtual-psychedelic-therapy/2020-04-06T04:53:06.000Z https://psychedelicinvest.com/why-kevin-oleary-is-investing-in-psychedelics/2020-04-01T19:56:43.000Z https://psychedelicinvest.com/can-psychedelics-make-you-a-better-parent/2020-03-31T19:36:24.000Z https://psychedelicinvest.com/street-names-hurt-credibility-of-psychedelic-therapy/2020-03-30T10:38:34.000Z https://psychedelicinvest.com/the-toad-that-naturally-produces-dmt/2020-03-30T10:37:47.000Z https://psychedelicinvest.com/top-5-at-home-uses-for-psychedelics/2020-03-30T10:34:40.000Z https://psychedelicinvest.com/the-human-bond-between-psychedelics-and-nature/2020-03-09T14:03:24.000Z https://psychedelicinvest.com/re-branding-of-ketamine-in-psychotherapy/2020-03-09T11:48:32.000Z https://psychedelicinvest.com/knowledge-gap-between-psychologists-and-psychedelics/2020-03-04T16:16:10.000Z https://psychedelicinvest.com/will-california-decriminalize-psychedelic-mushrooms/2020-03-02T21:01:45.000Z https://psychedelicinvest.com/mindmed-raises-24-million-prior-to-ipo/2022-07-06T19:26:18.000Z https://psychedelicinvest.com/is-lsd-a-remedy-for-alzheimers/2020-02-25T14:18:22.000Z https://psychedelicinvest.com/psychedelic-company-buys-rights-for-mushroom-extraction/2020-02-24T16:21:35.000Z https://psychedelicinvest.com/similarities-of-cannabis-edibles-and-psychedelic-mushrooms/2020-02-21T15:29:13.000Z https://psychedelicinvest.com/americas-capital-prepares-to-vote-on-psychedelics/2020-02-20T09:49:02.000Z https://psychedelicinvest.com/boulder-colorado-next-in-line-for-psychedelics/2020-02-19T09:00:12.000Z https://psychedelicinvest.com/what-is-psychedelic-microdosing/2019-07-22T10:45:00.000Z https://psychedelicinvest.com/treating-ptsd-with-psychedelics-what-we-know-so-far/2019-07-17T09:22:05.000Z https://psychedelicinvest.com/what-is-sananga/2020-07-30T14:52:53.000Z https://psychedelicinvest.com/natural-plants-that-alter-the-human-brain/2019-07-02T14:04:28.000Z https://psychedelicinvest.com/can-psychedelics-treat-depression-effectively/2019-07-01T09:28:08.000Z https://psychedelicinvest.com/do-psychedelics-increase-neuroplasticity/2019-07-01T08:57:58.000Z https://psychedelicinvest.com/420-for-cannabis-419-for-lsd/2019-06-27T14:34:38.000Z https://psychedelicinvest.com/best-books-about-psychedelics/2021-06-22T22:23:26.000Z https://psychedelicinvest.com/entrepreneurs-are-microdosing-to-unlock-their-potential/2021-02-04T20:56:37.000Z https://psychedelicinvest.com/dont-mix-psychedelics-with-maois/2019-06-26T10:45:50.000Z https://psychedelicinvest.com/nootropics-cannabis-and-psychedelics/2019-06-22T21:40:08.000Z https://psychedelicinvest.com/is-it-legal-to-grow-psychedelic-mushrooms-at-home/2023-12-21T20:20:59.000Z https://psychedelicinvest.com/the-cia-ruined-psychedelics-now-thats-changing/2019-06-18T10:11:14.000Z https://psychedelicinvest.com/where-can-i-find-psychedelic-mushrooms-growing-naturally/2019-06-17T07:21:43.000Z https://psychedelicinvest.com/how-does-ketamine-fight-depression/2019-06-17T07:08:47.000Z https://psychedelicinvest.com/how-many-different-types-of-psychedelic-mushrooms-are-there/2019-06-15T09:45:39.000Z https://psychedelicinvest.com/iboga-drug-addictions/2022-09-12T16:26:22.000Z https://psychedelicinvest.com/silicon-valley-is-using-psychedelics-as-a-quick-fix-to-hack-their-lives/2019-06-14T08:42:50.000Z https://psychedelicinvest.com/do-psychedelic-mushrooms-grow-on-poop/2023-12-21T20:16:45.000Z